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Introduction: Over the past decades, considerable advances in understanding of 
cell biology at genetic, epigenetic and proteomic levels led to development of new 
strategies for better outcome of cancer therapy. One of these new strategies is targeting 
the class I PI3K/Akt/mTOR signaling pathway, in that this pathway plays a key role in 
regulation of many cellular functions, including proliferation, survival, metabolism, 
autophagy and motility. Dysregulation of the class I PI3K/Akt/mTOR pathway has been 
documented in a variety of human tumours and inhibition of this pathway has been 
observed to hamper tumour proliferation in vitro and prevent tumour progression in vivo 
and in clinic. More recently, emerging evidence suggests that the class I 
PI3K/Akt/mTOR pathway is associated with Cancer Stem Cell (CSC) biology, in light 
of maintenance, viability and conventional therapy resistance of CSCs. The CSC theory 
conceptualizes that a subset of tumour cells with Stem Cell-like properties, including 
self-renewal, multipotency, differentiation, and resistance to chemotherapy and 
radiotherapy, can recapitulate new tumours and resistance to cancer therapy.    
Materials and Methods: To explore class I PI3K/Akt/mTOR signaling pathway 
and CSCs as therapeutic targets in canine oncology, in one series of experiments, small-
molecular inhibitors Wortmannin, ZSTK474, KP372-1 and Rapamycin, which 
selectively target pan-class I PI3K, pan-class I PI3K, Akt and mTOR, respectively, were 
utilized to treat canine cancer cell lines using inhibitors alone or in combination with 
conventional therapeutic drugs. The human acute lymphoblastic leukaemia of T-cell 
origin cell line (Jurkat T cell line) was used as a comparative control.  In another, a stem 
cell culture system was performed to isolate CSCs from canine glioma J3T cell line. 
Subsequently, microarray analysis of transcriptional expression profiles of J3T spheres 
(the putative CSCs) versus J3T parental cells was performed.  
Results: In this study, small molecules ZSTK474 and KP372-1 were found to 
significantly decrease cell viability at lower micromolar and nanomolar ranges, 
respectively.  Rapamycin decreased cell viability at lower micromolar concentrations. 
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However, the efficacy of Wortmannin varied from one cell line to another. Dissection of 
the mechanism of these inhibitors using Western Blot analysis and annexin V staining 
showed that all inhibitors functioned by decreasing phosphorylation of class I PI3K 
pathway members. Notably, the efficacy of Wortmannin for this pathway inhibition is 
confined to certain cell lines. In addition, Wortmannin had shorter drug duration than the 
other three inhibitors. Annexin V staining showed that KP372-1 was a potent inducer of 
apoptosis, with decreasing potency in hierarchy order, Rapamycin, Wortmannin and 
ZSTK474. The data obtained from the combination of pan-class I PI3K inhibitor 
(Wortmannin or ZSTK474) and mTOR inhibitor (Rapamycin) suggested that 
additive/synergistic effects were, in part, due to inactivation of Akt. The class I PI3K 
pathway inhibitors enhanced the efficacy of Doxorubicin in SB cells but not in canine 
REM, 3132 and J3T cells.  
 The CSC colonies of canine glioma J3T cells were successfully isolated and 
expanded in the neurosphere formation assay. By microarray analysis, several class I 
PI3K signaling network-associated genes, particularly IGFBP2 (27-fold), FYN (9.3-
fold), and DDIT4 (8.5-fold), were found to be highly up-regulated in the J3T CSCs. 
However, the genes encoding components, such as Akt1 and eIF4E, of class I 
PI3K/Akt/mTOR axis signaling were either unchanged or down-regulated in the CSCs. 
The majority of the genes encoding translation initiation factors were also down-
regulated in the CSCs.     
 Conclusions:  This study demonstrates that class I PI3K/Akt/mTOR signaling 
pathway is critical for proliferation and survival of cell lines derived from human acute 
lymphoblastic leukemia of T cell origin (Jurkat T cell line) and a variety of canine 
tumours. However, it appears that this pathway is dispensible for maintainence and 
viability of the CSCs isolated from canine gloma J3T cell line. This study suggests that 
the strategy of dual inhibition of class I PI3K and mTOR kinases may have better 
outcomes than the combination inhibitors of this pathway (such as ZSTK474 and 
KP372-1)  with Doxorubicin in canine oncology.  
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GISTs gastrointestinal stromal tumors 
GLUT1 glucose transporter type 1 
GLUT4 glucose transporter type 4 
gp130 glycoprotein 130 
GPCR G protein-coupled receptor 
Grb2 growth factor receptor-bound protein 2 
GRK2 G protein–coupled receptor kinase 2 
GSCs glioma stem cells 
GSK-3α glycogen synthase kinase 3α  
GSK-3β glycogen synthase kinase 3β 
GTP guanosine triphosphate 
HEAT huntingtin, elongation factor 3, a subunit of protein 
phosphatase 2A and TOR1 
HEK human embryonic kidney 
HES hairy and enhancer of split 
HEY hairy/enhancer-of-split-related with YRPW-like Motif 
HIF hypoxia-inducible factor 
HIF-1α hypoxia-inducible factors-1α 
HDM2 murine double minute 2 (MDM2) in human 
HM hydrophobic motif 
HMLEs human mammary epithelial cells 
HNSCC head and neck squamous cell carcinomas 
HRP horseradish peroxidase  
HRs homology regions 
HSCs hematopoietic stem cells 
HSP90 heat shock protein 90 kDa 
hTERT human telomerase reverse transcriptase 
hVps34 human vacuolar protein sorting 34 
IC-100 inhibitory concentration of 100% cell viability 
IFN- γ interferon-γ 
IGF insulin-like growth factor  
IGF-1 insulin-like growth factor-1 
IGF-1R IGF-1 receptor 
IGFBP IGF-binding protein 
IκB inhibitor of the nuclear factor of kappa light polypeptide gene 
enhancer in B-cells (NF-кB) 
IκBα inhibitor of the nuclear factor of kappa light polypeptide gene 
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enhancer in B-cells (NF-кB), alpha 
IKK-α inhibitor of nuclear factor kappa-B kinase, alpha subunit 
IL-2 interleukin-2 
IPA ingenuity pathway analysis 
IRESs internal ribosome entry sites 
IR insulin receptor 
IR-A Insulin receptor, A isoform 
IR-B Insulin receptor, B isoform 
IRS-1 insulin receptor substrate-1 
IRS-2 insulin receptor substrate-2 
iSH2 inter- Src homology 2 
Itk IL2-inducible T-cell kinase 
Jak Janus kinase  
Jak2 Janus kinase 2 
JNK Jun N-terminal kinase 
kg kilogram 
LC8 dynein light chain 8 kDa 
LCA Leber congenital amaurosis 
LC3B isoform B of human microtubule-associated protein 1 light 
chain 3 
Lck lymphocyte-specific protein tyrosine kinase 
Lfa-1 lymphocyte function-associated antigen 1 
LKB1 liver kinase B1 
LOH loss of heterozygosity 
LPC lysophosphatidylcholines 
M molar 
M phase Mitosis phase (cell cycle) 
Mad1 MAX dimerization protein 1 
mA milliampere 
MAGI membrane associated guanylate kinase inverted 
MAP4K3 mitogen-activated protein kinase kinase kinase kinase 3 
MAPK mitogen-activated protein kinase 
MCL mantle cell lymphoma 
Mcl-1 myeloid cell leukemia sequence 1 
MDM2 murine double minute 2 
MEFs mouse embryonic fibroblasts 
Mek mitogen-activated protein kinase 










MK2 MAPK-activated protein kinase-2 
MLCK myosin light chain kinase 




MMPs matrix metalloproteases 
MMP2 matrix metalloprotease 2 
MMP9 matrix metalloprotease 9 
Mnk MAPK-interacting kinase 
MPD myeloproliferative disorder 
MRI magnetic resonance imaging 
mRNA messenger ribonucleic acid 
MRP-1 multidrug resistance protein-1 
mSin1 mammalian stress-activated map kinase-interacting protein 1 
MTD maximum tolerated dose 
mTOR mammalian target of rapamycin 
mTORC1 mammalian target of rapamycin complex 1 
mTORC2 mammalian target of rapamycin complex 2 
Myt1 myelin transcription factor 1 
NCAM  neural cell adhesion molecule 
N-CoR nuclear receptor corepressor 
NEAA non-essential amino acid mix 
NEDD4 neural precursor cell expressed, developmentally down-
regulated 4 
NFAT nuclear factor of activated T cells 
NFAT3 nuclear factor of activated T cells 3 
NF-κB nuclear factor kappa-light-chain-enhancer of activated B cells 
ng nanogram 
NGF nerve growth factor 
NICD Notch intracellular domain 
NK natural killer 
nM nanomolar 
nm nanometer 
NO nitric oxide 
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NOS2 nitric oxide synthase-2 
Notch neurogenic locus notch homologue protein 
NP40 Nonidet-P40 
NSC neural stem cell 
NSCLC non-small cell lung cancer 
NSE neuron-specific enolase 
NSH2 N-terminal Src homology 2 
NT3 neurotrophin 3 
NT4 neurotrophin 4 
NT5 neurotrophin 5 
ODC ornithine decarboxylase 
p- phospho- 
p120 RasGAP RAS p21 protein activator 1 
p21
WAF1 
cyclin-dependent kinase inhibitor 1A 
p27
KIP1
 cyclin-dependent kinase inhibitor 1B 
p38MAPK p38 mitogen-activated protein kinase 
p70S6K or S6K1 70 kDa ribosomal S6 kinase 
PABP1 poly(A) binding protein, cytoplasmic 1 
PAIP-1 poly(A)-binding protein-interacting protein 1 
PAIP-2 poly(A) binding protein interacting protein 2 
PBS phosphate buffered saline 
PBST 1x PBS containing 0.1% Tween-20 
PCR polymerase chain reaction 
PDCD4 programmed cell death 4 
PDE3a phosphodiesterase 3a  
PDGF platelet-derived growth factor 
PDGF-B platelet derived growth factor B 
PDGF-C platelet derived growth factor C 
PDGFR PDGF receptor  
PDGFRα PDGF receptor α 
PDGFR β PDGF receptor β 
PDK1 phosphatidylinositol 3-dependent kinase 1 
PFKFB2 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2 
PFS progression-free survival 
PGC-1 peroxisome proliferator- activated receptor γ coactivator-1  
PH pleckstrin homology 
PI  propidium iodide 
PI3K phosphatidylinositol 3-kinase 
PI4K phosphatidylinositol 4-kinase 
25 
 
PIKK phosphinositide-3-kinase-related kinase 
PIM proviral integration sites associated with murine leukemia 
virus –induced lymphomagenesis 
Pink1 PTEN-induced kinase 1 
PKA cAMP-dependent protein kinase 1  
PKC protein kinase C 
PKCι protein kinase C iota 
PKCδ protein kinase C delta 
PKD protein kinase D 
PKG cGMP-dependent protein kinase 
PKN PKC-related protein kinase 
PLC-γ phospholipase C, gamma type 
PLC-ε phospholipase C,  epsilon type 
PLD phospholipase D 
PLD3 phospholipase D3 
PML promyelocytic leukaemia protein 
pNET pancreatic neuroendocrine tumours 
PP1 protein phosphatase 1 
PP1γ the catalytic subunit of protein phosphatase 1 (PP1), γ 
isoform 
PP2A protein phosphatase 2A 
PP2Ac-β protein phosphatase 2, catalytic subunit, beta isoform 
PP2C-ζ protein phosphatase 2C, zeta isoform 
PPARγ peroxisome proliferator-activated receptor γ 
PRAS40 proline-rich Akt/PKB substrate 40 kDa 
Protor-1 protein observed with Rictor 1 
PS phosphatidylserine 
Ptch1 Patched 1 
PtdIns(4,5)P2 or PIP2 phosphatidylinositol-4,5–biphosphate 
PtdIns(3,4,5)P3 or PIP3 phosphatidylinositol-3,4,5–triphosphate 
PTEN phosphatase and tensin homolog 
PUMA p53 upregulated modulator of apoptosis 
Rac1 Ras-related C3 botulinum toxin substrate 1 
Raf v-raf murine sarcoma/leukemia viral oncogene homolog  
Rag Ras-related small GTP-binding protein 
Raptor regulatory-associated protein of mTOR complex 1 
RCC renal cell carcinomas 
REDD1 regulated in development and DNA damage 1 
pRb retinoblastoma protein 
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Rheb Ras homolog enriched in brain 
Rho ras homolog gene family 
RhoC ras homolog gene family (Rho), member C  
RhoJ ras homolog gene family (Rho), member J 
RhoQ ras homolog gene family (Rho), member Q 
RhoT1 ras homolog gene family (Rho), member T1 
Rictor rapamycin-insensitive companion of mTOR 
RMA Robust Multichip Averaging 
Rnd3 Rho family GTPase 3 
ROSs reactive oxygen species 
RRAS ras-related protein 
RSK 90 kDa ribosomal protein S6 kinase 
RSK1 90 kDa ribosomal protein S6 kinase (RSK), isoform 1 
RTK receptor tyrosine kinase 
RyRs ryanodine receptors 
S phase DNA synthesis phase (cell cycle) 
S6RP S6 ribosomal protein 
SC  stem cell 
SCID mouse severe combined immunodeficiency disease mouse 
SDs standard deviations 
SDF-1 stromal cell-derived factor-1 
SDS-PAGE sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
Ser (S) Serine 
SGK serum- and glucocorticoid-induced protein kinase 
SH2 Src homology 2 
SH3 Src homology 3 
Shh sonic hedgehog 
Shp-2 SH2 domain-containing tyrosine phosphatase 2 
shRNA short hairpin RNA 
siRNA small interfering RNA 
SC stem cell 
SCF stem cell factor 
SDS sodium dodecyl sulphate 
SKAP Src kinase-associated phosphoprotein 
SKAR 46 kDa DNA polymerase delta interaction protein 
SLC1A5 solute carrier family 1 member 5 
SLC3A2 solute carrier family 3 (activators of dibasic and neutral 
amino acid transport), member 2 
SLC7A5 solute carrier family 7 (cationic amino acid transporter, y+ 
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system), member 5 
SLE systemic lupus erythematosus 
SM systemic mastocytosis 
Smo receptor Smoothened receptor 
SNPs single nucleotide polymorphisms 
SOCS suppressor of cytokine signaling 
SP side population 
SREBP sterol regulatory element binding protein 
SRF serum response factor 
SSCP single strand conformation polymorphism 
Stat signal transducers and activators of transcription 
Stat3 signal transducers and activators of transcription 3 
SUCCEED Sarcoma mUlti-Center Clinical Evaluation of the Efficacy of 
riDaforolimus 
TCR T cell antigen receptor 
Tec tyrosine-protein kinase 
TEMED N,N,N’,N’-tetramethylethylenediamine 
TGFβ transforming growth factor beta 
TβRI transforming growth factor beta (TGFβ) receptor type I 
TβRII transforming growth factor beta (TGFβ) receptor type II 
Thr threonine 
TKIs tyrosine kinase inhibitors 
TM turn motif 
TNF tumour necrosis factor 
TNF-α tumour necrosis factor-alpha 
TRADD tumor necrosis factor receptor-associated death domain 
TRAIL tumor necrosis factor (TNF)-related apoptosis inducing 
ligand 
Trip10 thyroid hormone receptor interactor 10 
TSC1 tuberous sclerosis complex 1 
TSC2 tuberous sclerosis complex 2 
Twist-1 twist homolog 1 in Drosophila  
Tyr (Y) tyrosine 
U unit 
ULK1 Unc-51 like kinase 1 
VEGF vascular endothelial growth factor 
VEGFR vascular endothelial growth factor receptor 
VEGFR2 vascular endothelial growth factor receptor 2 
VSM vascular smooth muscle 
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v/v volume to volume 
Wee1Hu Wee1 homolog in S. pombe 
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1.1 Cancer  
 Cancer is a disease, which is characterized by uncontrolled proliferation of a 
subset of cells. In a survey of fifty countries in 2008, about 202-326 cancer cases per 
100,000 people were reported (Bray F et al. 2010; Ferlay J et al. 2010). The etiology of 
cancer is a subset of cells with molecular alterations at genetic level, along with aberrant 
post-translational modifications, as a result of a variety of factors. These factors that 
drive cell transformation encompass chemical and physical carcinogens, hormone 
factors, infections by microorganism (e.g. virus and bacterium) and heredity factors 
(Hisada et al. 1998; IARC-Working-group 2000; Kuper et al. 2000; Konduri and 
Schwarz 2007). Once the normal cells are transformed to the cancer cells, they undergo 
unlimited cell division, uncontrolled growth and escape programmed cell death. When 
the cancerous cells become more malignant, they start to invade surrounding tissue and 
even metastasize to distant organs/tissues via lymphatic and hematological systems. In 
addition, many malignant cancer types produce paraneoplastic syndromes, such as 
cachexia, hypercalcemia and hypoglycemia, in human and canine cancer patients. As 
cancer progresses, it frequently disturbs or destroys normal functions of tissues/organs 
and cause cachexia and death at the terminal stage (Morrison 1979; Finora 2003; 
Withrow and Vail 2007; Pelosof and Gerber 2010).  
1.1.1 The hallmarks of cancer  
 At molecular level, cancer cells are characterized by six crucial traits, which 
make the disease more malignant. These six traits are self-sustenance of growth signals, 
unresponsiveness to growth inhibitory signals, escape of apoptosis, infinite DNA 
replication, angiogenesis, and invasive and metastatic behaviors (Hanahan and Weinberg 
2000). Cancer cells are notorious for not being regulated by exogenous growth factor 
stimulation. Instead, they develop their own systems to constitutively activate growth 
signaling due to the occurrence of molecular alterations of components of one or more 
growth signaling pathway(s). For example, activating mutations in receptor tyrosine 
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kinases (RTKs), the growth factor-binding receptors, have been found to cause 
constitutive activation of growth signaling pathways, in the absence of exogenous 
growth factors (Hirota et al. 1998; Meshinchi and Appelbaum 2009). Moreover, some 
cancer cell types such as human osteosarcoma and glioma have been reported to produce 
growth factors on their own, thus maintaing active growth signaling pathways (Sporn 
and Roberts 1985).  
 Besides self-sustenance of growth signals, cancer cells grow in an uncontrolled 
manner, in part, by acquiring the ability of unresponsiveness to growth inhibitory signals 
such as transforming growth factor β (TGFβ). Colon cancer cells with decreased 
expression of TGFβ receptor are reported to be less sensitive to the stimulation of TGFβ 
signal, thus allowing colon cancer cells to evade growth inhibition regulation 
(Markowitz et al. 1995). It should be mentioned that TGFβ signaling and many other 
growth inhibitory pathways have been found to converge on retinoblastoma protein 
(pRb), which is the first identified tumour suppressor and acts to arrest G1/S phase 
trasition (Hanahan and Weinberg 2000). Decreased or loss of pRb activity, as a result of 
either pRb gene mutation or degradation of pRb protein by DNA viruses such as human 
papillomavirus and simian virus 40, have been observed in a subset of human tumours, 
including retinoblastoma, small cell lung carcinoma and bladder carcinoma (DeCaprio et 
al. 1988; Munger et al. 1989; Horowitz et al. 1990; Classon and Harlow 2002). Loss of 
pRb function is generally condisdered to accelerate tumour transformation (Horowitz et 
al. 1990; Classon and Harlow 2002).  
 The third trait of cancer cells is to acquire the ability of escaping programmed 
cell death. To date, many molecular alterations of oncogenes and tumour suppressor 
genes, which are involved in apoptotic machinery, have been identified. p53, as one of 
the early identified tumour suppressors, is known as a pro-apoptosis factor and 
participates in DNA repair and cell cycle control (Harris 1996). Mutations of p53 gene, 
which frequently occur in a variety of human cancer types, can result in down-regulating 
p53-regulated cellular activities and inducing tumourigenesis through a wide array of 
p53-targeted genes (Lane and Benchimol 1990; Dittmer et al. 1993; Greenblatt et al. 
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1994).  Molecular alterations of the pro-survival factor Akt often result in promoting the 
growth, survival and invasive behavior of cancer cells (Altomare and Testa 2005). 
 Unlike the occurrence of senescence in normal cells, cancer cells are found to 
maintain immortality through several mechanisms. One of the mechanisms to protect 
cancer cells from senescence is to up-regulate telomerase, which acts to add DNA 
sequence repeats TTAGGG onto the telomere regions located at the both ends of 
chromosomes, resulting in cancer cells acquiring the ability of infinite DNA replication. 
In normal cells, the length of telomere is gradually shoterned with each time during 
DNA replication (S phase), which often leads to end-to-end fusion of two chromosomes 
with loss of telomeres and consequently initiating cell apoptosis (Counter et al. 1992; 
Shay et al. 2001).   
 Since 1971, Judah Folkman has discovered angiogenesis, a process of the 
budding of new capillaries from pre-existing blood vessels, as a common phenomenon 
during tumour expansion (Folkman 1971). The critical role of angiogenesis in the supply 
of nutrients and oxygen for tumour development is further supported by a body of 
literature (Kim et al. 1993; Hanahan and Folkman 1996; Arbab 2012; Kubota 2012). To 
date, several pro-angiogenesis factors such as vascular endothelial growth factor 
(VEGF), VEGF receptors (VEGFRs), basic fibroblast growth factor (bFGF) and 
angiopoietins have been identified to be released from cancer cells (Murakami and 
Simons 2008; Takahashi 2011). Moreover, anti-angiogenesis agents targeting VEGF or 
VEGFRs have been either investigated in clinical trials of malignant gliomas or 
approved for clinical use, in combination with chemotherapy, to treat metastatic colon 
cancers (Los et al. 2007; Dietrich et al. 2008).   
 As cancer progresses, a subset of cancer cells invade adjacent tissues, and even, 
metastasize to  distant organs and tissues via blood stream and lymph, leading to 
expanding tumour size and founding new colonies. Cancer cells with invasive and/or 
metastatic phenotypes often utilize two main mechanisms for cancer cell spreading 
(Hanahan and Weinberg 2000). The first mechanism is to alter expression of cell 
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adhesion molecules (CAMs) such as E-cadherin, neural cell adhesion molecule (NCAM) 
and integrins. Down-regulation of E-cadherin, conversion of highly adhesive NCAM to 
loss of adhesive function of NCAM, and up-regulation of certain integrins such as α3β1 
that favors cell migration have been reported to promote invasion and metastasis of 
cancer cells (Kaiser et al. 1996; Christofori and Semb 1999; Gogineni et al. 2011). The 
second mechanism is to up-regulation of extracellular matrix (ECM)-degrading 
proteases such as matrix metalloproteinases (MMPs) (Hanahan and Weinberg 2000). 
Interestingly, despite some MMPs being produced by cancer cells, the majority of these 
proteins are released from stromal cells within and surrounding tumour mass (Egeblad 
and Werb 2002). Proteolysis of ECM by MMPs not only allows cancer cells to invade 
the adjacent tissue but also favors the proliferation and migration of endothelial cells for 
angiogenesis (Stetler-Stevenson 1999). 
 To date, mounting evidence has suggested that accumulation of genetic 
alterations not only causes the onset of cancer but also contributes to cancer 
development (Kinzler and Vogelstein 1996; Bailey and Murnane 2006). In a study of 
heredity colorectal cancer, at least 5 genetic alterations have been considered as the 
lowest threshold of giving rise to a malignant tumour (Kinzler and Vogelstein 1996). 
Later, another study of sporadic (nonhereditary) colorectal cancer has found that each 
carcinoma cell contains around 11,000 events of genetic alterations (Stoler et al. 1999). 
In cancers, there are four types of genetic alterations, including few base pair mutations, 
changes in chromosome numbers, chromosome translocations, and gene amplificaions, 
the latter three belonging to chromosomal instability (Lengauer et al. 1998). Although 
DNA polymerases and two DNA repair systems (mismatch repair and nucleotide-
excision repair) control the rate of mutation accumulation, the majority of mutations are 
frequently caused by a defect in mismatch repair. In contrast to defective mismatch 
repair found in few cancer types, chromosome instability is commonly found in most 
human cancer types (Lengauer et al. 1998; Negrini et al. 2010). Alterations of genes, 
which regulate cell cycle checkpoints and mitotic cell division associated with 
replication and segregation of chromosomes, can result in chromosomal instability 
34 
 
(Lengauer et al. 1998). For example, down-regulation of p53 tumour suppressor gene, 
which serves as a DNA-damage checkpoint gene, is involved in exacerbating 
chromosomal instability at the later stage (but not the early stage) of colorectal cancer 
development (Baker et al. 1990; Kinzler and Vogelstein 1996). Hyperactivation of 
mitotic checkpoint, resulting in extension of mitosis phase, lagging chromosomes and 
subsequent changes in chromosome numbers, have been observed in many human 
cancers (Schvartzman et al. 2010). Telomere dysfunction, as a result of abnormality of 
telomere-related proteins or sudden loss of telomeric repeats (TTAGGC), can promote 
the end-to-end fusion of two chromosomes and generate DNA amplifications and 
translocations (Bailey and Murnane 2006).    
1.1.2 Detection and diagnosis of cancer     
 Most cancers are detected initially through diagnostic imaging tools, such as 
radiography, computed tomography (CT) and magnetic resonance imaging (MRI). 
Routine blood tests including complete blood count (CBC) and biochemical serum 
profile are performed to diagnose hematological malignancy and certain cancer types 
with paraneoplastic syndromes. Pathological examinations of specimens obtained from 
tumour mass and its margin, after surgical resection or biopsy, not only give a definite 
diagnosis of these specimens but also guide clinicians to prescribing a suitable treatment 
for patients with cancer (Sausville and Longo 2001; Withrow and Vail 2007).  
1.1.3 Treatment of cancer   
1.1.3.1 Surgery     
 To cure patients with cancer, conventional therapeutic options are surgery, 
radiation therapy and chemotherapy. Among the three conventional therapies, surgery is 
considered to be the first choice for cancer treatment, in that a bulky tumour mass with 
its margin of normal tissue can be completely removed. Even if complete removal of a 
tumour is not accessible, partial resection of a tumour mass may help to relieve the 
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burden of local organs and tissue in a cancer patient or the pain of spinal cord 
decompression (Sausville and Longo 2001). It has been reported that some patients with 
metastatic tumours, such as osteosarcoma metastasizing to lung, can survive for 5 years 
after surgical resection of these metastasized tumours (Pfannschmidt et al. 2012). For 
certain hormone-responsive tumours such as androgen-responsive prostate and estrogen-
responsive breast cancers, surgical orchiectomy and oophorectomy/adrenalectomy are 
performed to decrease production of androgen and estrogen, respectively (Strong 1963).  
1.1.3.2 Radiation therapy    
 With regard to radiation therapy, X-rays and gamma rays are the forms of 
radiation frequently used for cancer treatment. Whilst X-rays are produced by linear 
accelerators, gamma rays are emitted from radionuclides, such as cobalt-57 and 
manganese-54, which undergo radioactive decay (Sausville and Longo 2001). X-rays 
and gamma rays are able to ionize and excite atoms and molecules in cells, leading to 
production of ions and oxidative free radicals. These products hit the targeted 
chromosomes, which in turn causes chromosomal breaks and disturbance of cell 
division, leading to cellular death. Tumour cells are more sensitive to radiation than 
normal cells, in that the repair kinetics of chromosomal breaks in tumour cells is slower 
than that in normal cells (Sausville and Longo 2001; Kawata et al. 2004). Radiation can 
be used as either primary or adjuvant therapy. Primary radiation therapy is employed for 
the treatment of small malignant solid tumours that are considered to be highly curable 
by radiation. Primary radiation therapy is also performed in tumours located at the sites 
where surgery is difficult to be performed or complete resection of a tumour is 
inaccessible due to anatomic limitation and inadequate skin for wound healing or 
cosmetic surgery (Theon 2000; Sausville and Longo 2001). For dog and cat patients, 
primary radiation therapy is suitable for tumours growing on the head, such as 
carcinomas of the eyelid and nose, and around specific anatomic sites such as spinal 
cord and large vessels. Adjuvant radiation therapy is frequently performed following 
surgical resection of gross lesions, for the purpose of prevention of dissemination and 
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metastasis of tumour cells (Theon 2000). Although radiation can be used to kill tumour 
cells, it also generates toxicities in human patients including fatigue, anorexia, nausea 
and vomiting. Hypoxic or resting cells are more resistant to radiation than their 
normaxic or proliferating counterparts. For instance, neuron cells are found to be highly 
radioresistant whereas bone marrow is radiosensitive (Pizzarello and Witcofski 1972).   
1.1.3.3 Chemotherapy  
 Chemotherapy is often employed to eradicate tumour cells after surgical 
resection of gross lesions or to treat metastatic diseases. There are many commercial 
chemotherapeutic agents avaibable for cancer treatment, which include antimetabolites, 
purines, pyrimidines, vinca alkaloid, alkylating agents and antitumour antibiotics. Based 
on the mechanism, these agents can be classified into drugs that directly target 
deoxyribonucleic acid (DNA), drugs that indirectly affect DNA functions, mitotic 
spindle inhibitors and hormone agents. Drugs that directly target DNA through 
formation of covalent bonds are alkylating agents such as Cyclophosphamide and 
Chlorambucil, and platinum compounds such as Cisplatin and Carboplatin. Some 
antitumour antibiotics, such as Doxorubicin, Bleomycin and Mitomycin C, can bind to 
DNA and cause single strand breaks of DNA (Chabner and Longo 2001). For 
Doxorubicin and its derivatives, their interaction with DNA not only prevents synthesis 
of DNA and RNA but also stops the activity of topoisomerase II (Momparler et al. 1976; 
Burgess et al. 2008). Drugs that indirectly affect DNA functions are antimetabolite 
family such as Methotraxate, 5-Fluorouracil and Cytosine arabinoside (Chabner and 
Longo 2001). Methotrexate inhibits the activity of dihydrofolate reductase that up-
regulates production of folic acid that is required for synthesis of nucleoside thymidine, 
a critical DNA base, through conversion of dihydrofolate into tetrahydrofolate 
(Rajagopalan et al. 2002). 5-Fluorouracil is a pyrimidine analogue and functions as an 
inhibitor of thymidylate synthase that can generate thymidine monophosphate (dTMP) 
which is required for DNA synthesis (Longley et al. 2003). Cytosine arabinoside, an 
analogue of a DNA base cytosine deoxyribose, induces cell death through incorporating 
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itself into DNA and inducing S phase-associated toxicity (Braess et al. 1999). Vinca 
alkaloid and taxane families act as inhibitors of mitotic spindle. For instance, Vincristine 
belongs to a vinca alkaloid family and functions in interaction with α and β tubulins of 
microtubule. The microtubule is a component of cytoskeleton and plays a role in 
chromosomal migration during mitosis phase, maintenance of cell shape during 
interphase and cell motility. The binding of Vincristine to subunits of microtubules 
causes depolymerization of microtubules, resulting in inhibition of DNA mitosis 
(Cooper 2000; Sausville and Longo 2001). The taxane family such as Pacitaxel and 
Docetaxel prevents DNA from completing mitosis by aberrantly stabilizing microtubules 
(Fata et al. 1999; Nagano et al. 2007). Hormone agents such as Glucocorticoids and 
Tamoxifen, have been reported for the treatment of hematopoietic malignancies, breast 
and prostate cancers, respectively (Osborne 1998; Schmidt et al. 2004). Glucocorticoid 
acts as an inducer of apoptosis in tumour cells through direct modulation of apoptotic or 
survival genes and indirect modulation of cellular stress genes (Schmidt et al. 2004). 
Tamoxifen, an antagonist of the estrogen receptor, is efficacious for the treatment of 
breast tumours with overexpression of estrogen receptors (Osborne 1998). Most 
chemotherapeutic agents that are introduced to human oncology can also be used in dogs 
and cats. However, Cisplatin may cause pulmonary toxicity, emesis and other potential 
side effects in cats, whereas its derivative Carboplatin is safe for cats (Knapp et al. 1987; 
Rudd et al. 2000). 5-Fluorouracil has neurotoxic effects on dogs and cats (Harvey et al. 
1977; Dorman et al. 1990; Moore and Frimberger 2000).  
 Although chemotherapeutic agents are cytotoxic to tumour cells, they also cause 
acute toxicities to the human patients. Myelosuppression, nausea, vomiting, alopecia, 
gonadal dysfunction and decreased fertility are adverse effects that are commonly seen 
in cancer patients who receive chemotherapy. Some drugs may cause specific adverse 
effects. For instance, Doxorubicin often induces cardiac toxicity in humans (Licata et al. 
2000). In veterinary oncology, most adverse effects induced by chemotherapeutic agents 
are similar to those observed in human oncology, with the exception of alopecia that is 
rarely a problem in the dogs and cats that have fur. In addition, Cisplatin is not 
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recommended for the dogs with pre-existing renal diesease, or with urinary tract 
tumours, due to the drug-related nephrotoxicities. Like human, Doxorubicin induces 
cardiotoxicity in the dog breeds that are susceptible to cardiac diseases and the dog 
patients with cardiovascular diseases (Moore and Frimberger 2000).   
1.1.3.4 Immunotherapy  
 With the considerable advances in application of genomic and proteomic 
technology to cells over the past decades, more and more information regarding genes 
that are aberrantly expressed or silencing in cancer cells as well as immune response 
against tumour are being unraveled. This inspires scientists to develop new apporoches 
to treat cancer. These new approaches include immunotherapy and molecular/targeted 
therapy. The immunotherapy is to stimulate either nonspecific or specific immune 
responses to antagonize cancer progression. For instance, Bacillus Calmette-Guerin 
(BCG), a vaccine prepared from the attenuated Microbacterium bovis, is currently used 
to treat nonmuscle-invasive bladder cancer, due to BCG-induced attraction and 
activation of immune cells such as neutrophils, macrophages, and natural killer (NK) 
cells and generation of cytokines such as interleukin-2 (IL-2) and interferon-γ (IFN- γ) 
(Patard et al. 1998; Lodillinsky et al. 2010). Other microorganisms and their products, 
such as attenuated virulence of Samonella typhimurium, oncolytic adenovirus, and 
Staphylococcus aureus-related superantigens, have been developed for immunotherapy 
against tumours (Ries and Brandts 2004; Chorobik and Marcinkiewicz 2011; Han et al. 
2011). Delivery of recombinant cytokines such as IL-2 and IFNs into tumour cells to 
trigger both innate and adaptive immune responeses has been tested in metastatic 
melanoma (Schadendorf et al. 2009). In addition, vaccines aimed to kill cancer cells are 
under development and efficacy of some of these vaccines has been assessed in clinical 
trials. These vaccines can be prepared from whole tumour-cell lysates, plasmid DNA 
that carries a targeted gene encoding immunogen, viral vector carrying genes encoding 
tumour-associated antigen or cytokines, or antigen-presenting dendritic cells (DCs) 
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loaded with tumour-associated antigens (Sondak and Sosman 2003; Shaw and Strong 
2006; Larocca and Schlom 2011; Onishi et al. 2011).      
1.1.3.5 Molecular/targeted therapy  
 About molecular/targeted therapy to treat cancer, early studies focused on 
development of gene therapy, which was to replace a mutated gene by delivery of a gene 
of interest into cells through viral or non-viral vector. These targeted genes could encode 
tumour suppressors such as p53, cytokines such as IL-2, or encode enzymes that can 
convert a nontoxic prodrug to cytotoxic agent that can drive cancer cells to death 
(Withrow and Vail 2007). Although clinical trials of gene therapy were initiated since 
1990s, this technique encountered the hurdles of safety issue of gene delivery and 
whether gene could be delivered to targeted cells, instead of miscellaneous tissues and 
organs. These challenges slowed the progress of gene therapy (Blaese et al. 1995; 
Sheridan 2011). Recently, successful cases of gene therapy for Leber congenital 
amaurosis (LCA), adenosine deaminase-deficient severe combined immunodeficiency 
(ADA-SCID), X-linked adrenoleukodystrophy, and Parkinson's disease, have been 
reported (Cartier and Aubourg 2010; Ferrua et al. 2010; LeWitt et al. 2011; Stein et al. 
2011). The technical breakthrough of gene therapy encourages its wide application to 
treatment of a variety of diseases.  
 In addition to gene therapy, other targeted therapies including RNA interference, 
small molecular inhibitor, and monoclonal antibody are currently under development 
and evaluated in preclinical experiments and clinical trials for the treatment of cancer 
and many other diseases (Silva et al. 2008; Kwitkowski et al. 2010; Loi et al. 2011). In 
the field of cancer treatment, these targeted therapies are developed to block specific 
cellular component(s) which are critical for promoting growth, survival and progression 
of cancer. As cancers go through multiple steps of molecular alterations, which leads to 
shaping its own signaling network, many cellular components have been identified to 
participate in cell transformation and cancer progression. For instance, receptor tyrosine 
kinases (RTKs) are popular targets for oncology therapy because they are mainly 
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responsible for transducing signals to regulate cellular growth and survival and 
angiogenesis after RTKs are activated through binding to growth factors (Lemmon and 
Schlessinger 2010). Telomerase is another example of being a therapeutic target for 
cancer treatment due to its important role in prolonging life span of cancer cells through 
maintenance of the length of telomeres at the chromosome ends (Xu et al. 2011). Novel 
therapeutic targets such as aberrant methylation of DNA and histone deacetylation, 
resulting in epigenetic and transcriptional dysregulation in cancer cells, are being 
employed in the preclinical and clinical studies of hematological malignancies (Bishton 
et al. 2007).    
 As accumulating evidence implicated a strong correlation of aberrant activation 
of class I phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of Rapamycin 
(mTOR) signaling pathway with the growth and progression of cancer, this pathway has 
become a popular therapeutic target and most of the functions of this pathway have been 
well-studied. The class I PI3K/Akt/mTOR signaling pathway has been well-established 
for its role in regulation of several cellular processes, including proliferation, survival, 
metabolism, autophagy and motility of cells. Hyperactivity of this pathway has been 
shown to result in tumourigenesis, angiogenesis and malignancy behavior (Bjornsti and 
Houghton 2004; Altomare and Testa 2005; Bertelsen et al. 2006). Currently, many 
therapeutics that target the class I PI3K pathway have been developed and investigated 
in in vitro and in vivo experiments, and clinical trials for cancer treatment. Some class I 
PI3K pathway-targeted drugs such as Temsirolimus and Everolimus have been approved 
by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency 
(EMEA) for the treatment of advanced/relapsed renal cell carcinoma (RCC), due to the 
promising outcomes of administration of the two drugs in clinical settings (Yuan et al. 
2009). Although not all cancer types responded well to the class I PI3K pathway-
targeted monotherapy, strategies for combining inhibitors targeting this pathway with 
surgery/chemotherapy/radiation therapy/targeted therapies toward other signaling 
pathways are investigated in ongoing clinical trials or preclinical studies 
(http://clinicaltrials.gov/ct2/home) (Ciuffreda et al. 2010). 
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 Although a large body of literature addressed the important role of class I 
PI3K/Akt/mTOR pathway in human cancers, there are only few published data from 
canine oncology. Since 2008, the activity and pharmacological inhibition of the class I 
PI3K/Akt/mTOR pathway have been investigated in canine melanomas, mastocytomas 
in vitro and canine osteosarcoma in vitro and in an ongoing clinical trial (Rebuzzi et al. 
2007; Gordon et al. 2008; Kent et al. 2009; Paoloni et al. 2010). Rapamycin that 
targeted mTOR kinase was the only one targeted drug used in these studies. Treatment 
with Rapamycin resulted in reduced signal transduction of mTOR complex 1 
(mTORC1) pathway and proliferation of tumour cells were observed in two out of three 
melanoma cell lines and all tested osteosarcoma cell lines (Gordon et al. 2008; Kent et 
al. 2009; Paoloni et al. 2010). In the study of pharmacokinetic and pharmacodynamics 
of Rapamycin, the doses tested were all well-tolerated in the patients with canine 
osteosarcomas (Paoloni et al. 2010). In the C2 cell line that was derived from canine 
mastocytoma, Rapamycin significantly decreased mTORC1-associated expression of 
vascular endothelial growth factor (VEGF) protein but it failed to inhibit proliferation 
(Rebuzzi et al. 2007).   
1.2 Class I PI3K/Akt/mTORC1 axis pathway 
 The class I PI3K signaling pathway is composed of a series of serine 
(Ser)/threonine (Thr) kinases that can transduce signals through phosphorylation. In the 
canonical phosphorylation process adenosine-5'-triphosphate (ATP) is positioned at the 
catalytic domain in a given protein kinase, and the γ-phosphate group is transferred from 
ATP to serine or threonine residue(s) of a protein substrate, leading to activation or 
inhibition of the substrate (Johnson et al. 1996).  
Class I PI3Ks, which are lipid kinases, are further classified into class IA and IB 
PI3Ks, according to the differences in regulatory subunits and upstream regulators. Class 




1.2.1 Upstream activators of class IA PI3K 
Class IA PI3K consists of a p110α/p110β/p110γ catalytic subunit and a p85 
regulatory subunit whereas Class IB PI3K is composed of a p110γ catalytic subunit and 
a p101 or p87/p84 regulatory subunit (Wymann and Pirola 1998; Kong and Yamori 
2008; Kurig et al. 2009; Vanhaesebroeck et al. 2010). Class IA PI3Ks are predominantly 
activated by RTKs upon receiving growth factors. There are three ways for RTK to 
recruit and activate class IA PI3K. The first way is that the activated RTKs undergo 
autophosphorylation of tyrosine (Tyr, Y) residues and formation of YXXM motif (where 
X represents any amino acid and M is an abbreviation for methionine) at the intracellular 
domains of RTKs. These YXXM motif are soon recognized by cytoplasmic protein 
kinases which contain Src homology-2 (SH2) domain and one of these SH2-containing 
proteins is p85 regulatory subunit of class IA PI3Ks. The interaction between YXXM 
motives of RTK and SH2 domain of p85 allows RTK to recruit class IA PI3K to the 
inner side of plasma membrane. The second way is that RTK phosphorylate Y residues 
on its substrates proteins, such as insulin receptor substrate-1 (IRS-1), insulin receptor 
substrate-2 (IRS-2) and Grb2-associated binding protein 1 (Gab1), which results in 
generating YXXM motives on these substrates and thereby recruiting class IA PI3K. 
Alternatively, RTK recruits class IA PI3K through Ras. RTK-mediated Ras activation 
allows Ras to phosphorylate catalytic p110 subunits of class IA PI3K (Figure 1.01) 
(Rodriguez-Viciana et al. 1996; Kurig et al. 2009; Vanhaesebroeck et al. 2010). In 
addition to RTKs, some cytokine receptors, ligand-binding can trigger tyrosine kinase 
Janus kinase 2 (Jak2), which in turn phosphorylates Y residues on IRS-1/IRS-2/IRS-3, 





Figure 1.01. Class I PI3K/Akt/mTOR signaling pathway. Arrows represent 
active phosphorylation. Bars represent inhibitory phosphorylation. PIP2, 
phosphatidylinositol-4,5–biphosphate; PIP3, phosphatidylinositol-3,4,5–
triphosphate. For the full names of the proteins indicated in this figure, see Lists 
of Abbreviations.   
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1.2.2 Upstream activators of class IB PI3K 
Class IB PI3K is activated by G protein-coupled receptors (GPCRs) after 
chemokine and transmitter stimulation. The activated GPCRs initially bind to βγ 
subunits of guanine nucleotide binding protein (G protein) (Gβγ), which in turn allows 
Gβγ to recruit p101 or p87/p84 regulatory subunits of class IB PI3K and activate class 
IB PI3K (Engelman et al. 2006).  Alternatively, GPCRs can indirectly activate class IB 
PI3K through Ras. After Ras is activated by GPCRs, the Ras can phosphorylate p110γ 
and subsequently activate class IB PI3K (Figure 1.01) (Wymann and Pirola 1998; 
Schlessinger 2000).  
1.2.3 Activation of class I PI3K-dependent Akt/mTOR axis pathway 
 The activated class IA and IB PI3Ks transfer the γ-phosphate group of ATP to 
phosphatidylinositol-4,5–biphosphate (PtdIns(4,5)P2), leading to the conversion of 
PtdIns(4,5)P2 to phosphatidylinositol-3,4,5–triphosphate (PtdIns(3,4,5)P3). The 
PtdIns(3,4,5)P3 can recruit phosphatidylinositol 3-dependent kinase 1 (PDK1) and 
protein kinase B (PKB/Akt,  hereafter referred to as Akt) to the inner side of cell 
membrane. PDK1 has been reported to be constitutively activated in cytosol due to its 
auto-phosphorylation on serine (Ser)241 and its activity can be up-regulated up to ~1000 
fold following PtdIns(4,5)P2 and PtdIns(3,4,5)P3-mediated cytoplasmic membrane 
localization (Alessi et al. 1997; Casamayor et al. 1999). After PDK1 is translocated to 
cell membrane, it can phosphorylate Akt on Ser308, which lead to Akt activation and 
triggering a series of events, including promotion of cell survival, growth and protein 
synthesis, all of which are under the control of Akt (Figure 1.01) (Wymann and Pirola 
1998; Lemmon and Schlessinger 2010; Pearce et al. 2010).  
 Signal transduction by class I PI3K kinase cascades can be inhibited or reversed 
by phosphatase and tensin homolog (PTEN) tumour suppressor catalyzing cleavage  of 
the phosphate group at position 3 on  PtdIns(3,4,5)P3. As a result, PtdIns(3,4,5)P3  is 
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converted back to PtdIns(4,5)P2, thus preventing PDK1 and Akt from being recruited to 
plasma membrane (Figure 1.01) (Maehama and Dixon 1998).  
Once Akt is activated, it can transduce signals to mTORC1 and activate 
mTORC1 pathway. There are two ways for Akt to activate mTORC1. The first way is 
that Akt directly phosphorylates two residues, Ser939 and threonine (Thr) 1462, on 
tuberous sclerosis complex 2 (TSC2) (Manning et al. 2002). The de-phosphorylated 
TSC2 is in complex with tuberous sclerosis complex 1 (TSC1) to form a TSC1–TSC2 
complex heterodimer. The TSC1–TSC2 complex has GTPase-activating protein (GAP) 
activity towards Rheb (for Ras homolog enriched in brain) a member of the Ras 
superfamily of small G proteins. The TSC1-TSC2 complex-mediated GAP activity 
causes a reduction in guanosine triphosphate (GTP)-bound Rheb and an increase in 
guanosine diphosphate (GDP)-bound Rheb. The Akt-dependent phosphorylated TSC2 
suppresses the GAP-activity of the TSC1-TSC2 heterodimer, allowing Rheb to remain 
in the active, GTP-bound state (Manning and Cantley 2003). The active GTP-bound 
Rheb acts as a positive regulator of mTORC1 through direct interaction with the 
catalytic (or kinase) domain in mTOR. In addition to mTOR, GTP-bound Rheb has two 
additional targets, FK506-binding protein 38 (FKBP38) and PLD1, both of which have 
been considered to be possible candidates for mTOR activation. However, further 
investigation into the roles of these two proteins is required (Avruch et al. 2009). 
Alternatively, Akt phosphorylate proline-rich Akt/PKB substrate 40 kDa (PRAS40), 
which impairs PRAS40-mediated inhibition of mTORC1 activity (Figure 1.01) (Sancak 
et al. 2007; Vander Haar et al. 2007). Although an early study suggested that mTORC1 
acted as a direct substrate of Akt through phosphorylation of Ser2448 on mTOR, a 
recent study re-evaluated this phosphorylation site and clarified that 70kDa ribosomal S6 
kinase (p70S6K or S6K1) was the predominant positive regulator (Scott et al. 1998; 
Holz and Blenis 2005).  
mTORC1 is composed of mTOR, regulatory-associated protein of mTOR 
complex 1 (Raptor) which is uniquely present in mTORC1, proline-rich Akt/PKB 
substrate 40 kDa (PRAS40) which acts as an mTORC1 negative regulator, and 
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mammalian lethal with sEC13 protein 8 homolog in S. cerevisiae (mLST8) (Figure 1.01) 
(Sancak et al. 2007; Vander Haar et al. 2007; Ramirez-Valle et al. 2010).  mTORC1 
mediates protein synthesis through its two major downstream targets, eukaryotic 
translation initiation factor 4E (eIF4E)-binding protein 1 (4E-BP1) and p70S6 kinase 
(p70S6K or S6K1). The 4E-BP1 mediates cap-dependent translation, whereas p70S6K 
mediates ribosome biogenesis (Huang and Houghton 2003).  
1.3 mTOR complex 2 (mTORC2) signaling pathway 
In addition to mTORC1, mTOR can be in complex with a group of proteins and 
form mTOR complex 2 (mTORC2). mTORC2 consists of Rapamycin-insensitive 
companion of mTOR (Rictor) which uniquely exists in mTORC2, mammalian stress-
activated map kinase-interacting protein 1 (mSin1) which is essential for Akt 
phosphorylation, protein observed with Rictor-1 (Protor-1)/Protor-2 and mLST8 (Figure 
1.01) (Frias et al. 2006; Yang et al. 2006; Pearce et al. 2007; Zoncu et al. 2011).  
1.3.1 Upstream regulators of mTORC2 siganling pathway 
 There has been little information regarding upstream regulator(s) of mTORC2 
until recent years. To date, phospholipase D (PLD), TSC1-TSC2 complex and ribosome 
have been identified as mTORC2 activators, whereas mTORC2 signaling was restrained 
by glycogen synthase kinase 3β (GSK3β) and p70S6K (Figure 1.02) (Huang et al. 2008; 
Boulbes et al. 2010; Julien et al. 2010; Chen et al. 2011; Zinzalla et al. 2011). A recent 
study of myogenesis mechanism showed that PLD promoted myogenic differentiation 
through activation of both mTORC1 and mTORC2 in response to vasopressin, albeit 
mTORC1 acted as negative regulator of myogenesis whereas mTORC2 signaled to 
PKCα and encouraged myocytic differentiation (Jaafar et al. 2011). An in vitro study of 
normal and cancer cells showed that loss of TSC1-TSC2 complex expression resulted in 
down-regulation of mTORC2 activity. Moreover, the same study showed that the TSC1-
TSC2 complex was only co-immunoprecipitated with components of mTORC2 such as 
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Rictor and mSIN1 whereas Raptor, as the specific feature of mTORC1, was unable to 
bind to TSC1-TSC2 complex. This suggests that the TSC1-TSC2 complex acts as a 
positive regulator of mTORC2 (Huang et al. 2008). In vitro and in vivo experiments of 
yeast and mammalian cells revealed that knockdown of genes encoding 60s or 40s 
ribosome impaired mTORC2 activity but did not affect mTORC2 assembly. Ribosomes 
activate mTORC2 activity through binding Rictor and/or mSIN1 in response to insulin-
stimulated PI3K signalling (Zinzalla et al. 2011). In a recent study, GSK3β was found to 
inhibit mTORC2/Akt signalling through direct phosphorylation of Ser1235 on Rictor in 
response to endoplasmic reticulum (ER) stress (Chen et al. 2011). Recently, 
phosphorylation of Thr1135 on Rictor has also been reported by two research groups. 
However, interpretation of the role of Rictor Thr1135 phosphorylation by these two 
groups is controversial. Boulbes, D. (2010) reported that the phosphorylation status of 
Thr1135 on Rictor did not affect mTORC2-dependent phosphorylation of Ser473 on 
Akt, whereas Julien, L.A. (2010) identified p70S6K as a negative regulator of mTORC2 
through phosphorylation of Thr1135 on Rictor, and dephosphorylation of this residue 
up-regulated mTORC2-mediated phosphorylation of Akt. Although the role of this 
phosphorylation requires further investigation, both research groups suggest that 
phosphorylation of Thr1135 on Rictor is linked to the activation status of class I 




Figure 1.02. An overview of the upstream mTOR signaling factors. Arrows represent active phosphorylation. Bars 
represent inhibitory phosphorylation. For the full names of the proteins indicated in this figure, see Lists of 
Abbreviations.   
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1.3.2 Functions and substrates of mTORC2 
 To date, three kinases, which are Akt, serum and glucocorticoid-inducible kinase 
(SGK) and protein kinase C (PKC), have recently been identified as downstream targets 
of mTORC2 (Figure 1.02) (Sarbassov et al. 2005; Garcia-Martinez and Alessi 2008; 
Ikenoue et al. 2008). Interestingly, these three proteins are members of the AGC family. 
mTORC2 positively regulate Akt through phosphorylation of Akt on Ser473. Evidence 
has shown that simultaneous phosphorylation of both residues can maximally up-
regulate Akt activity (Figure 1.02) (Alessi et al. 1996). Because Akt has a wide array of 
substrates, the detail of these substrates and their functions are described in Section 
1.3.4. mTORC2 phosphorylates turn motif (TM) and hydrophobic motif (HM) in 
conventional PKCs (PKCα, PKCβI, PKCβII, PKCγ), and novel PKCε, thus enabling 
these PKCs to function in a variety of cellular processes such as cell proliferation, 
apoptosis, survival and mobility (Griner and Kazanietz 2007; Ikenoue et al. 2008). 
mTORC2 activates SGK1 through phosphorylating Ser422 (Garcia-Martinez and Alessi 
2008). SGK1 functions in regulation of epithelial ion transport, such as sodium ion, and 
promotion of cell survival (Loffing et al. 2006).  
In a recent study, Potor-1 was found to be essential for mTORC2-dependent 
activation of SGK1, but was not required for regulation of the other two mTORC2 
substrates, Akt and PKCα (Pearce et al. 2011). Both rictor and mSin1 are important for 
mTORC2-regulated phosphorylation of Akt, conventional PKCs (PKCα, PKCβ, PKCγ) 
and novel PKCε, but not other novel PKCs (PKCδ, PKCθ, PKCη) and atypical PKCs 
(PKCζ, PKCλ). mTOR kinase was found to be involved in mTORC2-dependent 
phosphorylation of Akt and PKCα (Ikenoue et al. 2008).   
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1.4 Functional domains and organization of class I PI3K, PDK1, Akt, PTEN 
and mTOR  
1.4.1 Class I PI3K 
1.4.1.1 Catalytic subunit of class IA PI3K 
 Class IA PI3K consists of a p110 catalytic subunit and a p85 regulatory subunit. 
The p110 catalytic subunit has three isoforms p110α, p110β and p110δ, which are 
encoded by PIK3CA, PIK3CB and PIK3CD genes, respectively. As shown in Figure 
1.03, these p110 isoforms of class IA PI3K are characterized by four homology regions 
(HRs) and a Ras-binding domain, all of which are conserved in the class I PI3K catalytic 
subunit, and a p85 regulatory subunit-binding domain at N-terminus. The HR1 at the C-
terminus is conserved across PI3K, PI4-kinase and PI3K-related kinases such as mTOR, 
ataxia telangiectasia mutated (ATM) and DNA-dependent protein kinase (DNA-PK) and 
serves as a domain for Wortmannin (pan-PI3K inhibitor) and catalyzing transfer of the γ 






Figure 1.03. Schematic diagram of p110 catalytic subunits of PI3Ks. Number 1-4 represent the conserved 
homology regions (HR1 to HR4) across all PI3K and related kinases. S represents substrate binding region. The 
arrows indicate the domains that specifically bind to p85, Ras, Wortmannin (Wort) and ATP respectively. The class IB 
PI3K contains a putative pleckstry homology (PH) domain. Class II PI3K contains a C2 domain (reproduced from 
reference (Wymann and Pirola 1998). UniProtKB/Swiss-Prot accession numbers are for p110α catalytic subunit of 
class IA PI3K: P42336, p110γ catalytic subunit of class IB PI3K: P48736, class II PI3Kα: O00443, class III PI3K: 




1.4.1.2 Regulatory subunit of class IA PI3K  
 The p85 regulatory subunit contains five isoforms p85α, p55α, p50α, p85β and 
p55γ. The former three isoforms are encoded by PIK3R1 gene but are expressed in 
different messenger ribonucleic acid (mRNA) and protein variants through alternative 
mRNA splicing. The latter two p85 isoforms are encoded by PIK3R2 and PIK3R3 genes 
respectively. All p85 isoforms consist of, starting from N-terminal, a proline-rich region 
followed by an N-terminal Src homology 2 (NSH2), an inter-SH2 (iSH2) domain and a 
C-terminal SH2 (CSH2) domain (Figure 1.04). The NSH2 and CSH2 domains can 
recognize phosphorylated tyrosine (Y) motif, pYXXM, where X represents any amino 
acid and M is an abbreviation for methionine. The iSH2 domain is the main site for 
interaction with the three p110 isoforms of class IA PI3K. Both p85α and p85β contain 
an additional structure located at N-terminus including a Src homology 3 (SH3) domain, 
a proline-rich region and a breakpoint-cluster-region homology (BH) domain (Wymann 
and Pirola 1998). The proline rich domains serve as ligands for proteins that contain 
SH3 domains, such as Abelson (Abl), lymphocyte-specific protein tyrosine kinase (Lck), 
and p85α and p85β themselves (Kapeller et al. 1994). The BH domain has been reported 
to have GTPase‑activating protein (GAP) activity towards some members of Rho 
GTPase family, such as Ras-related C3 botulinum toxin substrate 1 (Rac1) and Cell 
division control protein 42 homolog (Cdc42), which have a role in cytoskeletal 








Figure 1.04. Schematic diagram of the isoforms of mammalian class IA 
PI3K regulatory subunit. p85α, p55α, and p50α are encoded by PIK3R1 gene, 
followed by translated from different length of splicing mRNA. p85β and p55γ 
are encoded by PIK3R2 and PIK3R3 genes respectively. SH3 represents Src 
homology 3 domain. P1 and P2 represent proline-rich domains. BH represents 
breakpoint-cluster-region (BCR) homology domain. NSH2 represents N-terminal 
SH2 domain. CSH2 represents C-terminal SH2 domains. iSH2 represents inter-
SH2 region (reproduced from reference (Wymann and Pirola 1998)). 
UniProtKB/Swiss-Prot accession numbers are for p85α, p55α and p50α 




1.4.1.3 Class IB PI3K  
 Class IB PI3K is a heterodimer that consists of a p110γ catalytic subunit and a 
p101 or p87/84 regulatory subunit. The p110γ catalytic subunit is encoded by PIK3CG 
gene. As shown in Figure 1.03, the domain structure of p110γ, which is the catalytic 
subunit of class IB PI3K, is similar to those of the catalytic subunits of class IA PI3K 
and contains HR1, HR2, HR3 and HR4 domains and Ras-binding domain. Unlike class 
IA PI3K, p110γ does not have a p85 regulatory subunit-binding domain (Wymann and 
Pirola 1998; Engelman et al. 2006).    
   Both of the p101 and p87/84 regulatory subunits, which are encoded by PIK3R5 
and PIK3R6 genes respectively, contain a p110γ-binding domain and a Gβγ-binding 
domain (Figure 1.05) (Suire et al. 2005; Voigt et al. 2005; Liu et al. 2009). The amino 
acid sequence of p87/84 is 30% identical to that of p101. The p110γ-p101 heterodimer 
has a 4-fold higher binding affinity to Gβγ than p110γ-p87/p84 (Suire et al. 2005). More 
recent study suggests that the activation and recruitment of p110γ-p87/p84 heterodimer 
predominantly relies on the interaction between Ras and p110γ, instead of the weak 
association of Gβγ with p87/p84 (Kurig et al. 2009) 
 
 
Figure 1.05 Schemetic representing of organization of the isoforms of class 
IB PI3K regulatory subunits. The p101 and p87/84 regulatory subunits a p110γ-
binding domain and a Gβγ-binding domain (Suire et al. 2005; Voigt et al. 2005; 
Liu et al. 2009). UniProtKB/Swiss-Prot accession numbers are for p101: 




PDK1, which is encoded by PDPK1 gene, contains a catalytic domain that 
catalyzes transfer of the γ phosphate group from ATP to a protein substrate, and a PH 
domain which allows PtdIns(4,5)P2 and PtdIns(3,4,5)P3 to recognize and recruit to inner 
side of plasma membrane (Figure 1.06) (Alessi et al. 1997). It has been reported to be 
constitutively activated in cytosol due to its auto-phosphorylation on Ser241 and its 
activity can be up-regulated up to ~1000 fold following PtdIns(4,5)P2 and 
PtdIns(3,4,5)P3-mediated cytoplasmic membrane localization (Casamayor et al. 1999).   
 
Figure 1.06. Schematic diagram of PDK1, PTEN and Akt1 kinases. Both of 
PDK1 (A) and Akt1 (B) contain a Catalytic domain that catalyzes transfer of a 
phosphate group from ATP to a protein substrate and a pleckstry homology (PH) 
domain which allows PtdIns(4,5)P2 and PtdIns(3,4,5)P3 to recognize and recruit to 
inner side of plasma membrane. (C) PTEN contains an N-terminal Phosphatase 
domain with a phosphatase motif which can catalyze and release a 3’ phosphate 
group from PtdIns(3,4,5)P3, a C2 domain that allows PTEN association with 
plasma membrane, a tail (T) region that contains CK2 phosphorylation sites and a 
C-terminal PDZ domain that facilitates PTEN association with MAGI proteins 
(Alessi et al. 1997; Simpson and Parsons 2001; Du and Tsichlis 2005). 
UniProtKB/Swiss-Prot accession numbers are for PDK1: O15530, Akt1: P60484 
and PTEN: P31749. 
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1.4.3 Akt kinase family 
          The Akt kinases have three isoforms Akt1, Akt2 and Akt3 that are encoded by 
Akt1, Akt2 and Akt3 genes, respectively. These Akt isoforms shares similar domain 
structure consisting of an N-terminal PH domain for PtdIns(3,4,5)P3 and PtdIns(4,5)P2 
binding, a catalytic domain that can phosphorylate a given substrate protein through 
catalyzing transfer of the γ phosphate group from ATP to substrate proteins, and a C-
terminal extension (Figure 1.06) (Kumar and Madison 2005).   
 To date, two major phosphorylation sites have been identified for Akt activation. 
Whilst PDK1 typically phosphorylates Thr308 on Akt1, Thr309 on Akt2, and Thr305 on 
Akt3, mTORC2 phosphorylates Ser473 on Akt1, Ser474 on Akt2 and Ser472 on Akt3 
(Alessi et al. 1996; Brodbeck et al. 1999; Baer et al. 2005; Sarbassov et al. 2005). 
Evidence has shown that simultaneous phosphorylation of both residues can maximally 
up-regulate Akt activity (Alessi et al. 1996).  
1.4.4 PTEN 
 The PTEN suppressor is encoded by the PTEN gene and is composed of an N-
terminal phosphatase domain for dephosphorylation of PtdIns(3,4,5)P3, a C2 domain that 
allows PTEN to anchor phospholipid membrane, a C-tail region which contains two 
PEST sequences for proteolysis of PTEN substrates and several CK2 phosphorylation 
sites (Ser380, Thr382, Thr383, and Ser385) for promoting PTEN stabilization, and a C-
terminal PDZ motif that interacts with other proteins such as membrane associated 
guanylate kinase inverted (MAGI) proteins (Figure 1.06) (Simpson and Parsons 2001). 
1.4.5 mTOR 
 mTOR belongs to a phosphinositide-3-kinase-related kinase (PIKK) family 
containing catalytic kinase domains for phosphorylation of substrate proteins and large 
molecular weights of ~300-500 kDa. mTOR consists of, starting from N-terminus, two 
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HEAT (for huntingtin elongation factor 3, a subunit of protein phosphatase 2A and 
TOR1) repeat domains that are associated with the interaction between mTOR and other 
proteins, a FAT (for FRAP, ATM and TRRAP) domain which is conserved in the  
phosphinositide-3-kinase-related kinase (PIKK) family, a FKBP12-rapamycin binding 
(FRB) domain which is a unique feature of mTOR explaining the high specificity for 
Rapamycin (an mTOR inhibitor). Immediate downstream of the FRB domain resides the 
PIKK-related kinase domain essential for phosphorylation of downstream targets, then  
the FATC (FAT-C) domain which is homologous to the large N terminal portion of the 
FAT region. Co-existence of FAT and FATC domains implies that their interaction 
contributes to the complete function of the kinase domain (Figure 1.07) (Bosotti et al. 




   
 
Figure 1.07. Schematic diagram of mTOR structural organization. The 
mTOR consists of, staring from N-terminus, two HEAT (for huntingtin, 
elongation factor 3, a subunit of protein phosphatase 2A and TOR1) repeat 
domains, followed by a FAT (for FRAP, ATM and TRRAP) domain, a FRB (for 
FKBP12-rapamycin binding) domain, a kinase domain, and a C-terminal FATC 
(for FAT-C). Rapamycin, a product of the bacterium Streptomyces 
hygroscopicus, is the first indentified compound that specifically targets TOR in 
yeast and mTOR in mammals. The mechanism of Rapamycin inhibition of 
mTOR kinase activity is initially to bind to cytosolic receptor FKBP-12. 
Subsequently, the Rapamycin-FKBP-12 complex targets the FRB domain in 
mTOR (Huang et al. 2003; Chiang and Abraham 2007).  
1.5 Class I PI3K/Akt/mTOR signaling network 
1.5.1 Substrates and functions of class I PI3K 
 Class I PI3K can exert cellular functions after it converts PtdIns(4,5)P2 to 
PtdIns(3,4,5)P3.  Although both PtdIns(4,5)P2 and PtdIns(3,4,5)P3 are able to recognize 
and interact with proteins containing PH domain, PtdIns(3,4,5)P3 only recognizes PH 
domain whereas PtdIns(4,5)P2 has multiple targets in addition to PH domain-containing 
proteins. Currently, there are approximately 250 PH domain-containing proteins in the 
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human genome database but most of their functions remain unresolved (Lemmon 2003). 
Table 1.1 summarizes the functions of the identified proteins which contain PH domain. 
Most cellular effects exerted by class I PI3K is through PDK1/Akt pathway and the 
functions of PDK1 and Akt will be described in Section 1.5.2 and 1.5.3. Besides, class I 
PI3K promotes cell migration through PtdIns(3,4,5)P3-recruited PH-containing proteins 
such as Rac and adenosine diphosphate (ADP)-ribosylating factor 6 (Arf6) (Cantley 
2002; Kamura et al. 2010).  
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Table 1.1 Current identified pleckstrin homology (PH) domain-containing downstream effectors of 
PtdIns(3,4,5)P3     
Protein with pleckstrin 
homology (PH) domain 
Function Reference 
PDK1 PDK1 activates Akt and other member proteins of AGC 
serine/threonine kinase family.  
(Pearce et al. 
2010) 






Rac1 Rac1 stimulates angiogenesis through increasing  expression 
levels of Hypoxia-inducible factors- 1α (HIF-1α) and VEGF, 
and promotes cytoskeletal rearrangement for cell mobility 
(Cantley 2002; 
Xue et al. 
2011) 




Table 1.1 Current identified pleckstrin homology (PH) domain-containing downstream effectors of 
PtdIns(3,4,5)P3 continued 
Protein with pleckstrin homology (PH) 
domain 
Function Reference 
Cytohesin family Cytohesin family is a GDP/GTP exchange factor for Arf and 
functions in promoting Arf-mediated vesicular trafficking 




Poirier et al. 
2005) 
Tyrosine-protein kinase (Tec) family 
members: 
1. Tec  
2. Bruton’s tyrosine kinase (Btk) 
3. IL2-inducible T-cell kinase (Itk)  
4. Bone marrow tyrosine kinase gene 
in chromosome X protein (Bmx) 
Tec family proteins function in development of lymphocytes 
and other hematopoietic cells, such as phospholipase C-γ 
(PLC-γ)-activated calcium mobilization, activation of 
mitogen-activated protein kinase (MAPK) signaling, 






Table 1.1 Current identified pleckstrin homology (PH) domain-containing downstream effectors of 
PtdIns(3,4,5)P3 continued 
Protein with pleckstrin homology 
(PH) domain 
Function Reference 
Dual adaptor for phosphotyrosine 
and 3-phosphoinositides 
(DAPP1) 
The functions of DAPP1 are involved in the development of B 
lymphocytes through regulation of cell growth and survival, 
cytoskeletal rearrangement, PLC-2 γ activation and calcium 
mobilization.   
(Zhang et al. 
2009) 
Grb 2-associated binder 1/2/3 
(Gab1/2/3) 
 
Gab proteins promote activation of PI3K signaling pathway. 
Gab1 functions in termination of PI3K activity but activation of 
Ras/ extracellular signal-regulated kinase (Erk) signaling when 
Gab1 interacts with SH2 domain-containing tyrosine 
phosphatase 2 (Shp-2). By contrast, Gab2 simultaneously 
activates both PI3K and Erk pathways. 
(Mattoon et al. 
2004; 
Sampaio et al. 
2008; Zhang 
et al. 2009) 
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Table 1.1 Current identified pleckstrin homology (PH) domain-containing downstream effectors of 
PtdIns(3,4,5)P3 continued 
Protein with pleckstrin homology 
(PH) domain 
Function Reference 
Centaurin Centaurin inactivates Arf-mediated vesicular trafficking and 
cytoskeletal rearrangement. 




SKAP activates integrin lymphocyte function-associated 





promoting adapter protein 
(ADAP) 
ADAP activates integrin Lfa-1 and promotes cytoskeletal 






Table 1.1 Current identified pleckstrin homology (PH) domain-containing downstream effectors of 
PtdIns(3,4,5)P3 continued 
Protein with pleckstrin homology 
(PH) domain 
Function Reference 
Vav family protein (Vav1/2/3) 
 
Vav family protein is a GDP/GTP exchange factor for Rac. 
Vav can stimulate Rac-mediated cytoskeletal rearrangement 
and cell motility. Vav plays a role in development of T 
lymphocytes through activation of T cell antigen receptor 
(TCR) downstream signaling, including calcium mobilization, 
activation of Erk and nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB) signaling, integrin Lfa-1 
activity, cellular polarization and cytoskeletal rearrangement . 






1.5.2 Substrates and functions of PDK1 
It has been known that the major substrate of PDK1 is Akt. Both PDK1 and Akt 
are members of the AGC serine/threonine kinase family characterized by possession of a 
catalytic kinase domain resembling cAMP-dependent protein kinase 1 (PKA), PKC and 
cGMP-dependent protein kinase (PKG) (Pearce et al. 2010). The functions of Akt will 
be described in Section 1.5.3. In addition to Akt, PDK1 has been reported to 
phosphorylate and activate more than 23 protein kinases belonging to AGC kinase 
family, including p70S6K, 90 kDa ribosomal S6 kinase (RSK), PKC, PKC-related 
protein kinase (PKN) and SGK (Pearce et al. 2010).  
There are two approaches for PDK1 to interact with and activate its downstream 
targets. For Akt that contain a PH domain, alteration of the conformation of Akt occurs 
after it is recruited by PtdIns(4,5)P2 and PtdIns(3,4,5)P3 to the inner side of cell 
membrane. This allows PDK1 to phosphorylate and activate Akt (Calleja et al. 2007). 
The mechanism for PDK1 to phosphorylate and activate the substrates without a PH 
domain, such as p70S6K and SGK, relies on the interaction between the PIF-binding 
pocket in the catalytic domain of PDK1 and the hydrophobic T-loop motif of p70S6K 







Table 1.2 Downstream effectors of PDK1 
PDK1 substrate Substrate and Function Reference 
Akt See Chapter 1, Section 1.5.3 Akt kinase 
 
 
p70S6K or S6K1 
(1) S6RP, eIF4B, eEF2K, Pdcd4: promote protein synthesis  
(2) Rac, CDC42: cytoskeletal rearrangement 
(3) IRS-1: negative feedback loop of insulin/insulin-like growth factor 
signaling 
(4)  mTOR: positive feedback regulation 
(5) 46 kDa DNA polymerase delta interaction protein (SKAR): cell 
growth 






Table 1.2 Downstream effectors of PDK1 continued 
PDK1 substrate Substrate and Function Reference 
RSK (1) Eukaryotic translation initiation factor 4B (eIF4B), eukaryotic elongation 
factor 2 kinase (eEF2K), S6 ribosomal protein (S6RP), TSC2: promote 
protein synthesis 
(2) Nuclear factor of activated T cells 3 (NFAT3), cAMP response element-
binding (CREB): promote transcription  
(3) Cyclin-dependent kinase inhibitor 1B (p27KIP), GSK-3β, MAX 
dimerization protein 1 (Mad1): promote cell cycle progression  
(4) B-cell lymphoma-2 (Bcl-2) antagonist of cell death (Bad), 
CCAAT/enhancer binding protein-β (C/EBPβ), CREB, inhibitor of the 
nuclear factor of kappa light polypeptide gene enhancer in B-cells-
alpha (IκBα): maintain cell survival 





Table 1.2 Downstream effectors of PDK1 continued 
PDK1 substrate Substrate and Function Reference 
PKN Tau: α-actinin cross-linking actin and intermediate filament proteins: 
promote the assembly and stabilization of cytoskeletal proteins 
 
(Kawamata 
et al. 1998) 
PKC 
(1) Adducin 1: cytoskeletal rearrangement (promote cell mobility) 
(2) Glycoprotein 130 (gp130), C/EBPβ, C-reactive protein (CRP), 
epidermal growth factor receptor (EGFR), cluster of differentiation 64 
(CD64), Jun B: tumour progression and metastasis 
(3) G protein–coupled receptor kinase 2 (GRK2): cardiac hypertrophy due 
to down-regulation of β-adrenergic receptor signaling 
(4) GSK3: promote cell cycle progression 
(5) Protein kinase D (PKD): promote Erk signaling, cell survival and cell 
vesicle trafficking  
(6) Phosphodiesterase 3a (PDE3a): increase cAMP level 
(Chen et al. 
2007; Hunter 
et al. 2009; 
Malhotra et 
al. 2010; 
Hafeez et al. 
2011; Mole 





1.5.3 Functions and substrates of Akt 
 Once Akt is activated, it can phosphorylate a wide array of substrates which 
engage activities of normal cell development and tumourigenicity. Previous studies of 
the roles of Akt isoforms in normal cell development suggest that Akt1 preferentially 
functions in promoting growth, proliferation and survival of cells, whereas Akt2 is 
involved in utilizing blood glucose in response to insulin and maintenance of glucose 
homeostasis. Akt3 is involved in stimulation of cell growth (Chen et al. 2001; Cho et al. 
2001; Cho et al. 2001; Easton et al. 2005).  
1.5.3.1 Akt promotes G1/S cell cycle progression  
 To date, Akt has been shown to stimulate G1/S cell cycle progression through 




 (Figure 1.08) 
(Zhou et al. 2001; Liang et al. 2002). Akt phosphorylation of glycogen synthase kinase 
3α (GSK-3α) and GSK-3β prevents ubiquitin-modulated proteolysis of cyclin D1, thus 
maintaining activity of cyclin D1 and promoting G1/S phase transition (Figure 1.08) 
(Cross et al. 1995). Akt has been reported to induce cell cycle progression to S phase 
through phosphorylation and inhibition of several Forkhead box (Fox) transcription 
factors (Figure 1.08). For instance, Akt can inhibit Forkhead box O4 (FoxO4)-induced 
transcription and translation of p27
KIP 
(Medema et al. 2000). Akt also counteracts 
functions of Forkhead box O1a (FoxO1a), Forkhead box O3a (FoxO3a) and FoxO4, 
thereby down-regulating levels of cyclin D1 and cyclin D2 proteins (Figure 1.08) 





Figure 1.08. Akt signaling pathways. Simultaneous PDK1- and mTORC2-
mediated phosphorylation of Akt kinases drives full activition of Akt kinases, 
allowing Akt to phosphorylate its wide array of substrates, resulting in promotion 
of cell proliferation, survival, glucose uptake and prevention of glucose from re-
entering blood stream, and exacerbation of malignant phenotype in tumour cells 
(Whiteman et al. 2002; Altomare and Testa 2005). Arrows represent active 
phosphorylation. Bars represent inhibitory phosphorylation. PIP2, 
phosphatidylinositol-4,5–biphosphate; PIP3, phosphatidylinositol-3,4,5–
triphosphate. For the full names of the proteins indicated in this figure, see Lists 
of Abbreviations.   
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1.5.3.2 Akt promotes G2/M cell cycle progression 
Akt has been reported to promote G2/M cell cycle progression through direct 
phosphorylation of substrates including checkpoint kinase 1 (Chk1), Wee1 homolog in 
S. pombe (Wee1Hu), myelin transcription factor 1 (Myt1), and FoxO transcription 
factors (Figure 1.08) (Okumura et al. 2002; Schmidt et al. 2002; Katayama et al. 2005; 
Puc et al. 2005; Ho et al. 2008). Akt-mediated phosphorylation of Chk1, a DNA damage 
checkpoint kinase, promotes nuclear exportation and ubiquitin-modulated proteolysis of 
ChK1 and facilitates G2/M phase transition (Figure 1.08) (Puc et al. 2005). Akt activates 
cyclin-dependent kinase (Cdc2)-mediated G2/S phase progression through inhibitory 
phosphorylation of Wee1Hu, which is an inhibitor of Cdc2 (Figure 1.08). Akt-mediated 
phosphorylation of Wee1Hu on Ser642 facilitates Wee1Hu binding to 14-3-3θ protein, 
which results in nuclear export of Wee1Hu by 14-3-3θ (Katayama et al. 2005). In a 
starfish model, Akt directly phosphorylates and inactivates Myt1, leading to an increase 
in phosphorylation and activation of Cdc2/cyclinB (Figure 1.08) (Okumura et al. 2002).  
1.5.3.3 Anti-apoptotic activity of Akt  
 A large body of literature has demonstrated Akt to be a critical survival factor. 
Akt has been shown to antagonize apoptotic activity through direct phosphorylation of 
several substrates, including FoxO1a, FoxO3a, FoxO4, Bad, caspase 9, BCL2-associated 
X protein (Bax) and the EL isoform of Bcl-2-like protein 11 (BimEL) (Figure 1.08) 
(Datta et al. 1997; Cardone et al. 1998; Brunet et al. 1999; Tsuruta et al. 2002; Gardai et 
al. 2004; Qi et al. 2006; van der Vos and Coffer 2011). In addition to the arrest of G1/S 
phase transition as mentioned above, FoxO1a, FoxO3a and FoxO4 can induce apoptosis 
through stimulation of pro-apoptotic transcriptional targets, including Bcl-2-like protein 
11 (Bim), p53 upregulated modulator of apoptosis (PUMA), B-cell lymphoma-6 (Bcl-6), 
PTEN-induced kinase 1 (Pink1), Fas ligand (FasL) and tumor necrosis factor (TNF)-
related apoptosis inducing ligand (TRAIL) and tumor necrosis factor receptor-associated 
death domain (TRADD) (Brunet et al. 1999; Modur et al. 2002; Rokudai et al. 2002; 
Tang et al. 2002; Gilley et al. 2003; You et al. 2006; Mei et al. 2009). The Akt-mediated 
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phosphorylation of these FoxO factors promotes nuclear exportation and cytoplasmic 
retention of these substrates, which prevents them from binding to their target genes in 
the nucleus and initiating transcription of pro-apoptosis genes as mentioned above 
(Figure 1.08) (van der Vos and Coffer 2011). Activation of extrinsic apoptotic signals 
such as Fas and TNF induces Bax translocation from the cytoplasm to mitochondria, 
causing the mitochondrial outer membrane to become permeable, allowing the release of 
cytochrome c into the cytosol and subsequent activation of caspase 9, caspase 3 and 
caspase 7. Activation of these caspases directs the cell to apoptosis (Jiang and Wang 
2004). Akt-mediated phosphorylation of Bax prevents movement of Bax into 
mitochondria and inhibits apoptosis (Figure 1.08) (Tsuruta et al. 2002; Gardai et al. 
2004). Bad is usually dephosphorylated in response to apoptotic stimuli. The 
dephosphorylated Bad can then be released from 14-3-3, allowing free Bad to 
translocate to the mitochondria where it can form a heterodimer with two anti-apoptotic 
factors, Bcl-2 and B-cell lymphoma-extra large (Bcl-xL), blocking their functions and 
thereby facilitating Bax/Bcl2-antagonist/killer 1(Bak)-induced apoptosis (Adachi and 
Imai 2002). Akt phosphorylates Bad, thus countering Bad-triggered pro-apoptotic 
activity (Figure 1.08) (Datta et al. 1997; Brunet et al. 1999). Moreover, earlier studies 
found that the activity of pro-apoptotic factor Bim was predominantly regulated by the 
v-raf murine sarcoma/leukemia viral oncogene homolog (Raf)/Erk pathway, which 
functioned in inducing ubiquitination-proteolysis of Bim. In normal cells, Bim is bound 
to microtubule-associated dynein light chain 8 kDa (LC8) to form Bim-LC8 complex. 
After receiving apoptotic stimuli, Bim starts to dissociate from Bim-LC8 complex. The 
free Bim can interact with two anti-apoptotic factors Bcl-2 and B-cell lymphoma-related 
gene (Bcl-X) and counteracts pro-apoptotic activity. However, a more recent study 
shows that phosphorylation of Ser87 in BimEL by Akt facilitates 14-3-3 interaction with 
BimEL, resulting in ubiquitination-proteolysis of BimEL and promotion of cell survival 
(Figure 1.08) (Qi et al. 2006).     
73 
 
1.5.3.4 Pro-survival activity of Akt  
In addition to antagonizing pro-apoptotic activities, Akt can phosphorylate pro-
survival factors for maintaining cell survival, such as inhibitor of nuclear factor kappa-B 
kinase subunit alpha (IKK-α), murine double minute 2 (MDM2), MDM2 in human 
(HDM2) and twist homolog 1 in Drosophila (Twist-1) (Figure 1.08) (Ozes et al. 1999; 
Ma et al. 2009; Vichalkovski et al. 2010; Fenouille et al. 2011). Activation of PI3K/Akt 
signaling allows Akt to phosphorylate IKK-α, which in turn up-regulates the pro-
survival transcription factor NF-κB, thus promoting transcription of anti-apoptotic genes 
(Ozes et al. 1999). Activated Akt phosphorylates MDM2 in murine and HDM2 in 
human, which in turn promotes ubiquitination-mediated proteolysis of p53 tumour 
suppressor and p21
WAF1
, resulting in down-regulation of p53-mediated transcription of 
pro-apoptotic factors such as Bax and PUMA, and of cell cycle arrest protein p21
WAF1
 in 
response to DNA damage (Alarcon-Vargas and Ronai 2002; Ma et al. 2009; Fenouille et 
al. 2011). A recent study also suggests that direct phosphorylation of Twist-1 by Akt 
impairs transcriptional activity of p53 in response to DNA damage and stress stimuli 
(Vichalkovski et al. 2010).  
1.5.3.5 Akt-regulated glucose metabolism 
It is evident that insulin regulates blood glucose homeostasis through activation 
of insulin receptor (IR) and subsequent stimulation of class I PI3K/Akt signaling. Under 
normal conditions, elevated blood glucose stimulates secretion of insulin, which can 
promote adipocytes and skeletal myocytes to take up glucose from the blood stream, 
stimulate glycogen synthesis and inhibit glycogenolysis in the liver and skeletal muscle. 
Insulin also reduces glucose generation (gluconeogenesis) in the liver and blocks 
glucose release, as well as accelerating the conversion of glucose to fatty acid 
(lipogenesis) and suppressing lipolysis (Whiteman et al. 2002). It has been observed that 
the insulin-activated Akt promotes blood glucose uptake into cells through inhibitory 
phosphorylation of a 160 kDa Akt substrate (AS160), a negative regulator of glucose 
transporter type 4 (GLUT4) that functions in carrying glucose into cells (Figure 1.08) 
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(Eguez et al. 2005). Akt can increase glucose uptake into cells by up-regulation of 
glucose transporter type 1 (GLUT1) at the transcription and translation level through 
Akt/mTORC1-activated cap-dependent translation, resulting in an increase in expression 
levels of GLUT1 and hypoxia-inducible factor (HIF). The increased HIF subsequently 
promotes transcription of the gene encoding GLUT1 (Zelzer et al. 1998; Taha et al. 
1999). GSK-3 has been found to down-regulate glycogen synthesis through inhibitory 
phosphorylation of glycogen synthase. GSK-3 is also involved in reducing lipogenesis 
through GSK-3-dependent phosphorylation of sterol regulatory element binding protein 
(SREBP) transcription factor, which in turn promotes ubiquitination-proteolysis of 
SREBP, resulting in down-regulation of SREBP-modulated transcription of target genes 
that promote lipogenesis. Alternatively, GSK-3 phosphorylates and inhibits ATP citrate 
lyase (ACL)-mediated generation of acetyl-CoA, a source of acetyl-CoA for lipogenesis. 
Hence, Akt-mediated phosphorylation and inhibition of GSK-3 allows activation of 
glycogen synthesis and lipogenesis (Figure 1.08) (Potapova et al. 2000; Sundqvist et al. 
2005; Patel et al. 2008). Akt can inhibit gluconeogenesis and lipolysis in the liver 
through phosphorylation and inhibition of peroxisome proliferative activated receptor γ 
coactivator (PGC-1) ((Figure 1.08) (Li et al. 2007). As FoxO1 can up-regulate 
transcription of glucose-6-phosphatase (G6Pase), which acts as an activator of 
gluconeogenesis, Akt can down-regulate gluconeogenesis through inhibition of FoxO1 
activity (Figure 1.08) (Nakae et al. 2001). The third way for Akt to inhibit hepatic 
gluconeogenesis is through direct phosphorylation of 6-phosphofructo-2-
kinase/fructose-2,6-bisphosphatase 2 (PFKFB2) which positively regulates glucose 
uptake into cells and lipogensis (Figure 1.08) (Moon et al. 2011).    
1.5.3.6 Cross-talk of Akt with components of Raf/Erk pathway 
 In addition to the regulation of multiple cellular processes, Akt has been 
demonstrated to cross-talk with Raf/Erk signaling through inhibitory phosphorylation of 
Raf, which in turn may generate cell-specific outcomes (Zimmermann and Moelling 
1999; Guan et al. 2000; Reusch et al. 2001). For example, the Akt-mediated inhibition 
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of Raf results in down-regulation of the Raf/mitogen-activated protein kinase (Mek)/Erk 
pathway and promotes cell cycle progression in HEK293 cells (Zimmermann and 
Moelling 1999). Another study of vascular smooth muscle (VSM) cells showed that 
platelet-derived growth factor (PDGF) is a potent mitogen which can activate Akt, 
which in turn strongly phosphorylates and inhibits Raf activity and blocks the 
downstream Mek/Erk signaling, resulting in proliferation of VSM cells. Conversely, Akt 
only weakly interacted with Raf in response to thrombi, which subsequently activated 
Raf/Mek/Erk signaling, leading to re-differentiation of VSM cells (Reusch et al. 2001).  
1.5.3.7 Dysregulation of Akt signaling drives tumorigenesis 
 Accumulating evidence suggests that Akt regulates cellular processes that 
promote tumourigenicity. For example, Akt promotes vasodilation and angiogenesis 
through phosphorylation of nitric oxide synthase 3 in endothelial cells (eNOS) which 
subsequently activates eNOS-mediated production of nitric oxide (NO) in vascular 
endothelium. The elevated NO can stimulate dilation of blood vessel and angiogenesis 
(Figure 1.08) (Dimmeler et al. 1999). Akt also induces angiogenesis through 
Akt/mTORC1-mediated cap-dependent translation that synthesizes HIF transcription 
factor. The production of HIF up-regulates transcription of target genes associated with 
angiogenesis, such as vesicular endothelial growth factor (VEGF) and endoglin (ENG) 
(Semenza 2003). Akt has been found to promote longevity of cancer cells through 
phosphorylating and activating human telomerase reverse transcriptase (hTERT), which 
prolongs cellular lifespan through maintaining DNA telomere length (Figure 1.08) (Liu 
1999). Akt1 has been described acting as an inhibitor of cellular motility and invasion 
through Akt-dependent phosphorylation of HDM2 and subsequent down-regulation of 
HDM2-modulated ubiquitination-proteolysis of nuclear factor of activated T cells 
(NFAT), which functions in induction of motility and invasion of cancer cells (Figure 
1.08) (Yoeli-Lerner et al. 2005). Previous findings showed that Akt1 also inhibited cell 
motility and migration through down-regulation of Erk-modulated epithelial-
mesenchymal transition (EMT). By contrast, Akt2 was reported to play a role opposite 
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to Akt1 and acted as a positive regulator of EMT in response to growth factor stimuli 
(Irie et al. 2005; Lee et al. 2011).  
1.5.4 Upstream inputs of mTORC1 
1.5.4.1 Growth factors and cytokines regulate mTORC1 
 It has been well established that the predominant upstream regulator of mTORC1 
is the class I PI3K/Akt signaling pathway. Members of the Raf/Erk MAPK pathway 
have also been reported to positively regulate mTORC1 signaling through targeting 
TSC2. ERK and its substrate p90RSK have been found to phosphorylate Ser664 and 
Ser1798 on TSC2, respectively. This in turn inhibits the GAP activity of TSC complex 
towards the Rheb/mTORC1 pathway, resulting in activation of mTORC1 (Figure 1.09) 
(Roux et al. 2004; Ma et al. 2007). Another study showed that p38 MAPK activated 
mTORC1 through its substrate MAPK-activated protein kinase-2 (MK2), which 
phosphorylated Thr1210 on TSC2, which in turn facilitated 14-3-3 binding to TSC2 and 
thereby inhibited TSC2 activity (Figure 1.09) (Li et al. 2003). Recently, IKK-α has been 
demonstrated to act as a transducer of cellular response to tumour necrosis factor-alpha 
(TNF-α) and activate mTORC1 through inhibitory phosphorylation of Ser487 and 







Figure 1.09 Upstream Regulators of mTORC1. The mTORC1 acts as a 
central node to sense the status of growth factors, nutrients (glucose and amino 
acid), stress and energy. Arrows represent activation. Bars represent inhibition. 
PIP2, phosphatidylinositol-4,5–biphosphate; PIP3, phosphatidylinositol-3,4,5–
triphosphate. For the full names of the proteins indicated in this figure, see Lists 
of Abbreviations.   
 
1.5.4.2 Energy regulates mTORC1   
 In addition to mitogen-stimulated PI3K and Raf/Erk signaling, mTORC1 activity 
is tightly controlled in response to the extracellular milieu. mTORC1 activity is down-
regulated when cells sense low levels of energy, as a result of glucose starvation, by 
evaluating the decreased ratio of intracellular ATP:AMP. A high intracellular AMP 
concentration and low ATP concentration promotes interaction between AMP and the γ 
subunit of AMP-dependent protein kinase (AMPK), which facilitates either liver kinase 
B1 (LKB1)- or calcium/calmodulin-dependent protein kinase kinase 2, beta (CaMKKβ-
dependent phosphorylation of Thr172 on the α subunit of AMPK , resulting in AMPK 
activation (Oakhill et al. 2011). Subsequently, the activated AMPK phosphorylates 
TSC2 and promotes TSC2-modulated inhibition of Rheb/mTORC1 signaling (Figure 
1.09) (Inoki et al. 2003).  
 Alternatively, AMPK inactivates mTORC1 through inhibitory phosphorylation 
of Raptor (Gwinn et al. 2008). Moreover, mTORC1 senses blood glucose status through 
an AMPK-independent pathway. Under the conditions of glucose starvation, 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) interacts with Rheb, which 
blocks Rheb-mediated mTORC1 activation. Conversely, an adequate supply of glucose 
prevents GAPDH from binding to Rheb, allowing Rheb to activate mTORC1 (Figure 
1.09) (Lee et al. 2009).  
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 Another study revealed that p53 tumour suppressor played a role in down-
regulation of mTORC1 activity under energy depletion conditions, and that the 
mechanism involved the activities of AMPK and TSC1/TSC2 complexes (Figure 1.09) 
(Feng et al. 2005).    
1.5.4.3 Nutrients regulate mTORC1 
 The mTORC1 activity is sensitive to amino acid status. Under amino acid 
deprivation conditions, mTORC1 does not respond to insulin stimulation, suggesting 
that the availability of amino acids determines the activity of mTORC1 (Hara et al. 
1998). Although the mechanism of amino acid to modulation of mTORC1 signaling 
remains to be determined, some proteins have recently been identified as being involved 
in this amino acid-sensing system. Earlier studies reported the requirement of essential 
amino acids (EAAs) such as leucine, tyrosine, and phenylalanine for mTORC1 
activation (Blommaart et al. 1995; Wang et al. 1998). However, the mechanism for cells 
to absorb EAAs remained unclear until a recent study which utilized HeLa and MCF7 
cancer cell lines to identify a two-step mechanism responsible for EAAs transportation. 
The first step is to utilize a solute carrier family 1 member 5 (SLC1A5) transporter to 
take in L-glutamine (an non-EAA). Following localization of L-glutamine in the cytosol, 
cells utilize a heterodimeric counter-transporter named solute carrier family 7 member 5 
(SLC7A5)/ solute carrier family 3 member 2 (SLC3A2) to pump out L-glutamine and 
take up L-leucine simultaneously (Figure 1.09) (Nicklin et al. 2009). Moreover, 
accumulating evidence suggests that class III PI3K or human vacuolar protein sorting 34 
(hVps34) has a role in activation of mTORC1 signaling in response to both amino acid 
and glucose stimulation (Byfield et al. 2005; Nobukuni et al. 2007; Xu et al. 2011). It 
has been shown that an increase in amino acid levels promotes higher intracellular Ca
2+
 
concentration, which in turn encourages the interaction between calmodulin (CaM) and 
class III PI3K, thereby activating  mTORC1 signaling (Figure 1.09) (Gulati et al. 2008). 
Another study has reported that class III PI3K acts as a positive regulator of PLD, which 
functions in the production of phosphatidic acid. Following amino acid stimulation, class 
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III PI3K-dependent generation of phosphatidic acid can promote the association of 
mTOR with Raptor (Figure 1.09) (Xu et al. 2011).  
 A recent study of human embryonic kidney (HEK) 293 cells showed that Rag 
(Ras-related small GTP-binding protein) acted as a positive regulator of mTORC1 
activity and promoted translocation of mTOR and Raptor from the cytoplasm to the peri-
nuclear region and endomembrane cell compartments, such as ER, in the presence of L-
leucine. Moreover, L-leucine stimulation failed to induce mTORC1 activity after down-
regulation of Rag expression level. Through indirect evidence, the same study 
implicated that Rag functioned in promoting Rheb-activated mTORC1 activity at the 
late endosomal and lysosomal regions (Figure 1.09) (Sancak et al. 2008).  
 Recently, MAP4K3 (mitogen-activated protein kinase (MAPK) kinase kinase 
kinase 4) was proposed as the link between amino acid and mTORC1, based on the 
observed up-regulation of MAP4K3 activity and increased phosphorylation of mTORC1 
downstream targets p70S6K and 4E-BP1 in response to amino acid stimulation. 
However, the role of MAP4K3 in regulation of mTORC1 remains unresolved (Figure 
1.09) (Findlay et al. 2007).  
1.5.4.4 Stress regulates mTORC1 
 It was previously demonstrated that mTORC1 had a role in sensing cellular 
stress. Recent evidence from primary mouse embryo fibroblasts and Drosophila 
suggested that mammalian REDD1 (regulated in development and DNA damage 1) and 
Scylla/Charybdis in Drosophila, the counterpart of RTP801/REDD1 in mammals, 
played a key role in the transduction of energy stress signals to the mTORC1 signaling 
pathway. The expression level of REDD1 was initially increased in the presence of 
stress inputs such as hypoxia, ATP depletion and ionizing radiation. Subsequently, the 
increased REDD1 level impaired mTORC1 activity through targeting TSC2 (Figure 
1.09) (Reiling and Hafen 2004; Sofer et al. 2005). However, more recent findings 
suggest that stress-mediated mTORC1 inhibition through REDD1 is cell-specific. For 
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example, in mouse embryonic fibroblasts, hypoxia abrogates mTORC1 signaling 
through the REDD1/TSC2/Rheb pathway, whereas in primary mouse hepatocytes 
hypoxia down-regulates mTORC1 activity through a mechanism involved in up-
regulation of AMPK and LKB1 activity and Raptor phosphorylation (Figure 1.09) 
(Wolff et al. 2011). An additional study of the impact of mitochondrial dysfunction-
mediated osmotic stress on mTOR localization suggested a correlation of stress inputs 
with redistribution of mTOR at the outer membrane of the mitochondria and suppression 
of mTORC1-mediated cell growth (Desai et al. 2002).     
1.5.5 Functions and substrates of mTORC1  
1.5.5.1 mTORC1 promotes 4EBP1-regulated cap-dependent translation 
mTORC1 inhibits the activity of 4E-BP1 via phosphorylation of  four sites, 
Thr37, Thr46, Thr70 and Ser65, in a hierarchical manner (Mothe-Satney et al. 2000). 
The phosphorylated 4E-BP1 subsequently releases eIF4E, allowing Ser209 on eIF4E to 
be phosphorylated by MAPK-interacting kinase (Mnk) which is positively regulated by 
Erk and p38 MAPK. Subsequently, the free and/or phosphorylated eIF4E enters an 
eIF4F complex which is composed of eIF4A, eIF4E and eIF4G (Figure 1.10). The 
assembly of the eIF4F complex activates translation of mRNA with 5’ terminal cap 
consisting of m7GpppN (where m7G represents methyl group on the 7
th
 position of 
guanine nucleotide, ppp represents three phosphate groups and N represents any 
nucleotide at 5’ end of mRNA) (Raught and Gingras 1999).  
In vitro studies of a variety of tumour types suggest that Mnk-mediated 
phosphorylation of eIF4E correlates with proliferation and malignancy of cancer cells, 
whereas the development of normal cells does not seem to be related to eIF4E activity 
(Ueda et al. 2004; Wang et al. 2007; Bianchini et al. 2008). The 5’capped mRNAs are 
further divided into two groups, according to the length of 5’ terminal untranslated 
region (5’UTR). The first group of capped mRNA is characterized by possession of a 
short 5’UTR, such as 5' terminal oligopolypyrimidine (5’TOP) which encodes ribosomal 
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proteins, and is usually translated efficiently. Conversely, the second group contains 
long and secondary structured 5’UTR which is unwound by the eIF4F complex. In 
normal cells, these capped mRNAs with highly structured 5’UTR are poorly translated, 
resulting in low expression levels of these proteins (Koromilas et al. 1992; Meyuhas and 
Hornstein 2000 ; Mamane et al. 2004). These long 5’UTR capped mRNA  usually 
encode  proteins involved in promoting cell cycle progression such as cyclin D1, c-Myc, 
ornithine decarboxylase (ODC) and p27
kip1
; cell survival such as Bcl-2 and PIM-1; 
angiogenesis such as VEGF and basic fibroblast growth factor (bFGF-2); and tumour 
invasion such as matrix metalloprotease 9 (MMP9) (De Benedetti and Graff 2004; 
Mamane et al. 2004). Increasing evidence suggests that eIF4E plays a central role in 
controlling the translational rate of these long 5’UTR mRNA (De Benedetti et al. 1991; 
Koromilas et al. 1992). Up-regulation of eIF4E activity, resulting from either 
overexpression of eIF4E or deregulation of eIF4E upstream signalling, has been reported 
to increase translation of these long 5’UTR mRNAs and contribute to cell 





Figure 1.10. Downstream effectors of mTORC1. Activation of mTORC1 results 
in initiation of protein synthesis and inhibition of autophagy. Notably, translation of 
capped mRNAs is concurrently regulated by both mTORC1 and Erk/Mnk 
pathways. Arrows represent activation. Bars represent inhibition. PIP2, 
phosphatidylinositol-4,5–biphosphate; PIP3, phosphatidylinositol-3,4,5–
triphosphate. For the full names of the proteins indicated in this figure, see Lists of 
Abbreviations.   
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1.5.5.2 mTORC1 promotes p70S6K-regulated translation of 5’TOP mRNA  
 Meanwhile, the mTORC1-dependent phosphorylation of four serine/threonine 
residues including Thr229, Thr389, Ser404, and Ser411 on p70S6K drives activation of 
p70S6K and subsequently stimulates p70S6K-dependent phosphorylation of Ser235, 
Ser236, Ser240, and Ser244 on its substrate S6RP, resulting in activation of S6RP and 
triggering translation of 5’TOP mRNA (Figure 1.10) (Ferrari et al. 1991; Han et al. 
1995). The 5’TOP mRNAs encode nearly all ribosomal proteins and elongation factors, 
and also the e, f, and h subunits of translation initiation factor 3 (eIF3), which implies 
that the mTOR-activated 5’TOP mRNA translation plays a critical role in controlling 
rate of translation process (Jefferies et al. 1997; Fumagalli and Thomas 2000; Meyuhas 
and Hornstein 2000 ; Iadevaia et al. 2008).  
1.5.5.3 Other functions of mTORC1/p70S6K signaling  
 In addition to S6RP, activated p70S6K has been found to accelerate mRNA 
translation machinery through direct phosphorylation of other protein substrates such as 
eukaryotic eEF2K, eIF4B, and programmed cell death 4 (PDCD4) (Figure 1.10) (Wang 
et al. 2001; Raught et al. 2004; Dorrello et al. 2006). For example, p70S6K stimulates 
eukaryotic elongation factor 2 (eEF2)-mediated elongation during translation process 
through inhibitory phosphorylation of eEF2 kinase, which acts as a negative regulator of 
eEF2 (Wang et al. 2001). The p70S6K can enhance helicase activity of eIF4A, which is 
a member of eIF4F complex, through positive regulation of eIF4B and negative 
regulation of PDCD4 (Raught et al. 2004; Dorrello et al. 2006). Additionally, recent 
findings showed that active p70S6K was recruited by SKAR onto newly synthesized 
mRNAs and functioned in splicing these pre-mRNAs, thereby accelerating mRNA 
translation machinery following mTORC1-mediated activation of p70S6K (Ma et al. 
2008).  
 Although active mTORC1/p70S6K signaling enhances mRNA translation 
efficiency, in vitro and in vivo studies of adipocytes and muscle cells have shown that 
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activation of p70S6K induces inhibitory phosphorylation of Ser636/639/1101 on IRS-1, 
which impairs insulin-stimulated class I PI3K activity (Figure 1.10). The purpose of the 
p70S6K-induced negative feedback loop is to maintain glucose homeostasis. Recently, 
this negative feedback has been found to be linked to insulin resistance and diabetes 
mellitus (Tremblay et al. 2007; Veilleux et al. 2010). Moreover, this negative feedback 
loop was associated with resistant mechanism of cancer therapy that targets class I PI3K 
signaling (Carracedo et al. 2008; Chen et al. 2010).   
1.5.5.4 mTORC1 negatively regulates autophagy 
 Recently, evidence suggests that mTORC1 plays a role in negatively regulating 
autophagy through phosphorylation of Unc-51 like kinase 1 (ULK1)/ULK2 and 
autophagy-related 13 (Atg13) (Figure 1.10) (Yan et al. 1999). Autophagy involves the 
formation of a double-membraned autophagosome to enwrap proteins, organelles and 
even pathogens, followed by fusion of the autophagosome and a lysosome, allowing 
hydrolases in the lysosome to digest the contents. Under nutrient deprivation or energy 
stress conditions, cells may undergo autophagy in order to efficiently utilize limited 
energy sources and maintain cell survival (He and Klionsky 2009). In mammalian cells, 
insufficient nutrient supplies or the presence of energy stress down-regulates mTORC1-
dependent phosphorylation of ULK1/2 and Atg13, which in turn promotes ULK1/2 
auto-phosphorylation and induces ULK1/2 to phosphorylate Atg13 and FIP200 (focal 
adhesion kinase (FAK) family interacting protein of 200 kDa), resulting in formation of 
an ULK1/2-Atg13-FIP200 complex-regulated autophagosome (Yan et al. 1999).   
1.6 Dysregulation of class I PI3K/Akt/mTOR axis pathway in tumours  
1.6.1 Molecular alterations of components of class I PI3K/Akt/mTOR 
signaling 
 Over the past two decades, a large body of literature has shown that over 
expression of the class I PI3K/Akt/mTOR pathway is tightly correlated with 
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tumourigenesis. The constitutive activation of PI3K kinase cascades can be instigated by 
molecular alterations in any component of the class I PI3K/Akt/mTOR axis pathway and 
its upstream signals. With regard to class I PI3K, amplification (or multiple gene copies) 
and somatic mutations of PIK3CA which encodes the p110α catalytic subunit (Samuels 
et al. 2004; Pedrero et al. 2005), amplification of PIK3CB encoding the p110β catalytic 
subunit (Liu et al. 2008), over-expression of PIK3CD mRNA without amplification of 
PIK3CD which encodes the p110δ catalytic subunit (Knobbe and Reifenberger 2003), 
and somatic mutations of PIK3R1 encoding the p85α regulatory subunit (Philp et al. 
2001) have been reported. Loss or attenuation of PTEN function was mostly attributed 
to loss of heterozygosity (LOH), somatic mutations of PTEN or both (Chiariello et al. 
1998; Sakai et al. 1998; Byun et al. 2003; Knobbe and Reifenberger 2003). Methylation 
of PTEN promoter resulting in loss of PTEN expression has been described in human 
cervical cancer (Cheung et al. 2004). PTEN activity can be suppressed through post-
translational modification. A study of T cell leukemia showed that either up-regulation 
of casein kinase 2 (CK2) activity or elevation of reactive oxygen species (ROSs) levels 
promoted phosphorylation of serine/threonine residues at C-terminus on PTEN, resulting 
in attenuation of PTEN activity (Silva et al. 2008). Although PDK1 was not considered 
to be oncogenic, amplification of PDPK1 which resulted in over expression of PDK1 
mRNA and protein was found to enhance effects of aberrant expression of PDK1 
upstream signaling (Maurer et al. 2009).  
 Alterations of three Akt isoforms, including amplification of Akt1, somatic 
(activating) mutations of Akt1, amplification of Akt2, overexpression of Akt2 without 
evidence of Akt2 amplification, amplification of Akt3, overexpression of Akt3 mRNA 
and protein but lack evidence of Akt3 amplification, and somatic (activating) mutations 
of Akt3, have been reported in a wide range of tumour types (Bellacosa et al. 1995; 
Nakatani et al. 1999; Knobbe and Reifenberger 2003; Carpten et al. 2007; Davies et al. 
2008; Kim et al. 2008; Kirkegaard et al. 2010). Recently, deletion of either Akt1 or Akt2 
has been detected in 4.8% and 21% of breast carcinomas respectively by utilizing 
fluorescence in situ hybridization (FISH). However, further study of the effect of Akt 
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gene deletion was not carried out (Kirkegaard et al. 2010). It was previously 
demonstrated that overexpression of Akt2 was responsible for tumourigenicity and 
invasion behavior by comparison of tumour-initiation capability of human pancreatic 
cancer PANC1 cells exhibiting high levels of Akt2 expression with PANC1 cells 
transfected with antisense Akt2 RNA in a nude mouse model (Cheng et al. 1996). In 
contrast to Akt2, expression of wild-type Akt1 was unable to induce cell transformation. 
However, NIH3T3 fibroblasts transfected with Myr-Akt1 construct for constitutive 
activation of Akt1 kinase were found to induce tumourigenesis in nude mice (Sun et al. 
2001). To date, there are controversial studies on the role of Akt3 in cancer 
development. In cell lines derived from estrogen-negative breast cancers or androgen-
insensitive prostate carcinomas, overexpression of Akt3 tightly correlated with increased 
Akt3 kinase activity and was associated with tumour aggressiveness, whereas expression 
of Akt3 inversely correlated with malignant phenotype of gliomas (Kirkegaard et al. 
2010; Mure et al. 2010).  
 Somatic mutations or LOH in either TSC1 or TSC2 tumour suppressor were 
reported to cause inactivation of TSC1-TSC2 complex and frequently gave rise to 
benign tumours such as lymphangioleiomyomatosis and hamartomas. Sporadically, 
these benign tumours developed to malignant phenotypes such as renal cell carcinomas. 
Accumulating evidence suggests that loss of TSC1/TSC2 function not only caused high 
levels of mTORC1 signaling but also released TSC1/TSC2-mediated inhibition of 
Wnt/β-catenin signaling and transforming growth factor beta (TGFβ)-dependent growth 
inhibition (Niida et al. 2001; Mak and Yeung 2004; Rendtorff et al. 2005).  
 So far, only one recent study has described a point (activating) mutation in the 
kinase domain of yeast TOR2, the mammalian homologue mTOR. However, it has been 
found that mutant mTOR introduced into NIH/3T3 fibroblasts did not transform cells 
(Ohne et al. 2008). Molecular alterations of mTORC1 downstream effectors including 
amplification and subsequent overexpression of RPS6KB1 encoding S6K1, or EIF4E 
encoding eIF4E, have been detected in breast cancers and head and neck squamous cell 
carcinomas (Sorrells et al. 1999; Heinonen et al. 2008). Interestingly, although 4EBP1 
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functions in blockade of eIF4E-mediated cap-dependent translation, two recent studies 
of breast cancers suggests that amplification or overexpression of 4EBP1 is associated 
with malignant behavior and a poor prognosis (Braunstein et al. 2007; Karlsson et al. 
2010). In experiments with breast cancer cell lines and a chick embryo model, 
concomitant overexpression of 4EBP1 and eIF4G under hypoxic conditions was shown 
to promote tumour survival and angiogenesis through up-regulation of translation of 
mRNAs containing internal ribosome entry sites (IRESs), but not through promoting 
cap-dependent translation machinery (Braunstein et al. 2007).  
1.6.2 Molecular alterations of upstream inputs of class I PI3K 
 Recently, many studies have shown that constitutive activation of class I PI3K 
kinase cascades can be as a result of alterations of its upstream inputs, such as RTKs, 
tyrosine kinases and Ras. So far, activating mutations in several RTKs, such as KIT, 
FMS-like tyrosine kinase 3 (Flt3), EGFR and fibroblast growth factor receptor (FGFR), 
have been identified in a variety of cancers. For instance, a high frequency of D816V 
mutation in kinase domain and V560G mutation in juxtamembrane domain in c-kit, 
which encodes KIT protein, was reported in human systemic mastocytosis (SM) and 
gastrointestinal stromal tumors (GISTs) respectively. These point mutations were found 
to enable constitutive activation of KIT via phosphorylation of tyrosine residues despite 
the absence of stem cell factor (SCF) ligand (Furitsu et al. 1993; Hirota et al. 1998). 
Similarly, activating mutations, encompassing tandem duplications, deletions, 
transitions, and insertions, in the juxtamembrane domain of c-kit have been identified in 
canine mast cell tumours (London et al. 1999; Ma et al. 1999). In acute myeloid 
leukemia (AML), either internal tandem duplication or activation loop mutation in FLT3 
has been found to induce constitutive activation of FLT3-mediated MAPK, STAT and 
class I PI3K pathways (reviewed in (Meshinchi and Appelbaum 2009)). High frequency 
of amplification of EGFR variant III (EGFRvIII), which is characterized by a deletion 
from exon 2 to exon 7 and subsequent fusion of exon 1 and exon 8 with creation of a 
glycine codon between the two exons in the extracellular domain of EGFR, has been 
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reported to cause overexpression and constitutive activation of this mutant EGFR in 
glioblastoma multiforme (GBM) (Humphrey et al. 1988; Sugawa et al. 1990). Other 
mutant EGFRs resulting in ligand-independent activation of this RTK include EGFRvI 
which consists of an N-terminal truncation in the extracellular domain, double mutant 
EGFRvIII/∆12-13 which contains a deletion from exon 2 to7 and exon 12 to 13 in the 
extracellular domain, EGFR.TDM/18–25 and EGFR.TDM/18–26  which contain 
intracellular tandem duplication of exon 18 to 25 and exon 18 to 26 respectively (Wong 
et al. 1992; Callaghan et al. 1993; Ciesielski and Fenstermaker 2000). Translocation of 
the chromosome containing the FGFR1 gene, leading to fusion of FGFR1 with other 
genes, was commonly found in 8p12 stem cell myeloproliferative disorder (MPD), 
characterized by myeloid hyperplasia, eosinophilia and lymphoblastic lymphoma. So 
far, FGFR1 has been reported to be translocated and fused with FIM, FOP, CEP110, 
BCR, or HERV gene, resulting in constitutive activation of FGFR1 signaling in MPD 
(Popovici et al. 1998; Popovici et al. 1999; Guasch et al. 2000; Fioretos et al. 2001; 
Guasch et al. 2003). Aberrant expression of fusion tyrosine protein BCR (breakpoint 
cluster region)-ABL (Abelson) as a result of reciprocal translocation of chromosomes 9 
and 22, and generation of a chimeric BCR-ABL gene on chromosome 22, has been found 
in more than 90% of patients with chronic myelogenous leukemia (CML) and a minority 
group of patients with either acute lymphoblastic leukemia (ALL) or AML. The 
cytoplasmic BCR-ABL fusion protein is a constitutively activated tyrosine kinase that 
induced cell transformation through triggering Jak-Stat, class I PI3K/Akt, and Ras 
pathways and blocked apoptosis (Reviewed in (Skorski et al. 1997; Kurzrock et al. 
2003)). Point (activating) mutations of three isoforms of oncogenic Ras,  comprising H-
Ras, K-Ras, and N-Ras genes, have  been reported in a wide range of human cancers and 
canine lung tumours (http://www.sanger.ac.uk/genetics/CGP/cosmic/) (Richter et al. 
2005; Castellano and Downward 2011; Fernandez-Medarde and Santos 2011; Forbes et 
al. 2011). For instance, previous studies have shown point mutations of K-ras in 95% of 
human pancreatic carcinomas (Almoguera et al. 1988). K-ras mutations were also 
detected in 16.4% of human and 25% of canine non-small cell lung cancer (NSCLC) 
specimens (Kraegel et al. 1992; Graziano et al. 1999). It has been suggested that N-ras 
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mutations are more related to early onset of primary cutaneous melanoma than 
metastasis of melanoma, and the frequency of N-ras mutations in primary melanoma is 
28% (Omholt et al. 2002). Mutations of the H-ras gene have been observed in 9 out of 
30 (30%) human transitional cell carcinoma specimens. Moreover, comparison of these 
30 bladder cancer specimens with the adjacent normal tissue detected a high incidence 
(77%) of overexpression of one or more Ras genes (Boulalas et al. 2009). Although the 
predominant downstream signaling of Ras is often referred to as the Raf/Mek/Erk 
pathway, constant signal transduction of mutant Ras has been demonstrated to be, in 
part, via interaction with the p110α and/or p110β subunits of class I PI3K (Moodie et al. 
1993; Warne et al. 1993; Lim and Counter 2005; Gupta et al. 2007; Jia et al. 2008).    
1.6.3 Molecular alterations of mTORC2 
 So far, little information regarding mTORC2 dysfunction is available. However, 
one study of glioma has reported that mTORC2 activity, and its regulation of invasive 
behavior, were increased as a result of the up-regulation of Rictor mRNA and protein 
(Masri et al. 2007). 
1.7 Targeting the class I PI3K/Akt/mTOR pathways for cancer therapy 
1.7.1 mTOR inhibitors 
  The class I PI3K/Akt/mTOR signaling pathway regulates many functions 
including cellular growth, proliferation, angiogenesis, metabolism and motility, all of 
which are critical for normal cell development and tumourigensis. Drugs that 
specifically target this pathway have been developed to treat cancer and have entered 
clinical trials. Among these class I PI3K/Akt/mTOR inhibitors, Rapamycin (also known 
as Sirolimus), which is a product of the bacterium Streptomyces hygroscopicus, is the 
first indentified compound that specifically targets TOR in yeast and mTOR in 
mammals. Rapamycin acts as a cytostatic to accumulate cells at G0/G1 phase (Huang et 
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al. 2003). The mechanism by which Rapamycin blocks mTOR signaling involves two 
steps; Rapamycin interacts with FKBP-12, a cytosolic receptor, resulting in a  
Rapamycin-FKBP12 complex which then binds to an FRB domain in the mTOR protein, 
abolishing its downstream activities (Figure 1.06) (Huang and Houghton 2003). 
However, Rapamycin is no longer used to treat human patients with cancer due to its 
potent immunosuppression and poor pharmacological properties, such as water 
insolubility and instability (Huang et al. 2003). Nevertheless, it has recently been 
demonstrated to safely treat canine patients with osteosarcoma and a clinical trial in 
canine oncology is currently ongoing (Paoloni et al. 2010). In human cancer studies, 
three novel Rapamycin analogues or Rapalogues, Temsirolimus (also known as CCI-
779), Everolimus (also known as RAD001) and Ridaforolimus (also known as AP23573 
or MK-8669), are being investigated in clinical trials which are either ongoing or 
recently completed. These three mTOR inhibitors, which exhibit different 
pharmacokinetic properties, have similar mechanisms towards the blockade of mTOR 
activity, with the advantage of improved aqueous solubility relative to their parent 
compound Rapamycin (Yuan et al. 2009). For instance, Temsirolimus displays 
improved aqueous solubility for intravenous use and no observable immunosuppression, 
whereas Everolimus is orally bioavailable and displays immunosuppressive activity 
(Alexandre et al. 1999; Boulay et al. 2004). Ridaforolimus can be administered orally or 
intravenously and is an immunosuppressant (Mita et al. 2008).  
 With regard to the clinical trials of these Rapalogues, the most promising results 
with Temsirolimus and Everolimus have been observed in patients with advanced or 
relapsed RCC, and both inhibitors have been approved by U.S. Food and Drug 
Administration (FDA) for the treatment of advanced renal cell carcinoma (RCC) (Hudes 
et al. 2007; Wang 2010). Although some adverse reactions (e.g. skin symptoms) and 
abnormalities of the blood and serum profile (e.g. hyperglycemia, anemia) were 
commonly seen in patients treated with Temsirolimus in phase III clinical trials, severe 
reactions such as interstitial pneumonia rarely occurred. The median  survival time in 
metastatic RCC patients receiving Temsirolimus alone  (10.9 months) was longer than 
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those receiving interferon alone (7.3 months) or in combination with Temsirolimus (8.4 
months) (Hudes et al. 2007; Kwitkowski et al. 2010). In a phase III trial of Everolimus 
in patients with metastatic RCC after failure of treatment with vascular endothelial 
growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs), the median  
progression-free survival in Everolimus and placebo groups were ~5 months and 1.9 
months respectively. The overall survival in the Everolimus group was 1.9-fold longer 
than that of the placebo group (Motzer et al. 2010). The most common adverse effects 
related to Everolimus were stomatitis and a rash, less than 5% of patients developed 
severe infections or symptoms (Motzer et al. 2008; Motzer et al. 2010). In 2011, 
Everolimus  was approved by the FDA for the treatment of advanced pancreatic 
neuroendocrine tumours (pNET), based on the promising results obtained from a phase 
III trial of Everolimus in patients with advanced pNET after failure of radiation therapy 
(Saif 2011; Yao et al. 2011). This trial showed that the median progression-free survival 
was 11 months in the Everolimus group, which was approximately 6 months longer than 
in the placebo group. In addition, 34% of patients treated with Everolimus were 
progression-free at 18 months or longer, whereas only 9% of patients treated with 
placebo achieved the same result (Yao et al. 2011). Although Ridaforolimus is not yet 
approved for the treatment of any cancer type, the most promising results with this 
inhibitor have been obtained in soft tissue and bone sarcomas (Mita et al. 2008). 
Currently, intravenous and oral formulations of Ridaforolimus are being investigated in 
a phase III trial in patients with sarcomas and the scheme is entitled “Sarcoma mUlti-
Center Clinical Evaluation of the Efficacy of riDaforolimus” (SUCCEED). 
Ridaforolimus was reported to be well-tolerated in patients with a variety of cancers and 
the most common side effects, such as mucositis,  mouth sores, fatigue and 
myelosuppression, were mild and generally reversible (Mita et al. 2008; Rizzieri et al. 
2008; Hartford et al. 2009).  
 Despite the efficacy of these mTOR inhibitors in treating advanced RCC, pNET 
and certain sarcomas, other tumour types showed lower responses (Yuan et al. 2009). 
For instance, the results obtained from a phase II trial in mantle cell lymphoma (MCL) 
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were once considered promising; this trial showed that 35 patients with 
relapsed/refractory MCL whose disease had progressed on chemotherapy or the 
monoclonal antibody therapy Rituximab had a 38% overall response rate with a median 
disease progression-free in all patients of 6~7 months (Witzig et al. 2005). In a phase III 
trial for the treatment of advanced MCL, the median progression-free survival (PFS) in 
the patients receving either one of two regimes of Temsirolimus monotherapy, 175/75- 
milligram (mg) and 175/25-mg, was 4.8 and 3.4 months respectively, whereas the 
median PFS in the patients receiving investigator’s choice treatment was 1.9 months. 
The Temsirolimus (175/75-mg) group had longer median overall survival (12.8 months) 
and a higher objective response rate (22%) compared with the investigator’s choice (9.7 
months and 2%) (Hess et al. 2009). However, due to the utilization of high doses of 
Temsirolimus in this study, severe adverse events were observed, such as 
haematological abnormalities in the majority of patients, grade 3 or 4 thrombocytopenia 
in 50-60% of patients and death in 5 of the patients. The limited efficacy but high risk of 
severe drug-related side effects limits the use of Temsirolimus as a single agent in 
advanced MCL (Hess et al. 2009).  
 Recently, novel chemical compounds which specifically target both mTORC1 
and mTORC2 have been developed. PP242 was designed to inhibit both mTOR 
complexes by targeting an ATP binding site in the catalytic domain of mTOR kinase. It 
has been demonstrated that the efficacy of PP242 in inhibiting mTORC1-mediated 
downstream targets is much better than Rapamycin, as evidenced by more potent 
inhibition of 4EBP1 phosphorylation and cap-dependent translation compared to 
Rapamycin. PP242 also inhibited cellular proliferation more potently than Rapamycin. 
However, the inhibitory effect of PP242 on Akt substrates (through mTORC2/Akt 
inhibition) was modest. Moreover, PP242 developed autophagic resistance mechanism 
which counteracted drug efficacy more significantly than Rapamycin (Feldman et al. 
2009). An  in vivo study of acute leukemia initiated by overexpression of BCR-ABL 
tyrosine kinase showed that the efficacy of PP242 in leukemia treatment was greater 
than that of Rapamycin, and PP242 was less toxic to normal lymphocytes compared to 
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Rapamycin (Janes et al. 2010). AZD8055 is another novel ATP-competitive inhibitor 
targeting both mTOR complexes, and is orally bioavailable. The effects of AZD8055 on 
inhibition of both mTORC1 and mTORC2, and induction of autophagy resistance 
mechanism to counteract drug efficacy, were similar to PP242 both in vitro and in vivo. 
In a mouse model of tumour xenografts, no drug-related cytotoxicity was observed in 
the AZD8055 treatment group. AZD8055 is currently being investigated in a phase I 
clinical trial in patients with glioblastoma multiforme (GBM), advanced hepatocellular 
carcinoma, and other advanced solid tumours (Chresta et al. 2010).   
1.7.2 Class I PI3K inhibitors 
 With regard to inhibitors targeting class I PI3K, early studies showed that 
LY294002, a quercetin compound, had a higher specificity of inhibition for all isoforms 
of class I PI3K and CK2 than other protein kinases, and effectively inhibited tumour 
growth in a mouse model (Sanchez-Margalet et al. 1994; Davies et al. 2000; Hu et al. 
2000). Another early identified pan-class I PI3K inhibitor is Wortmannin, which is a 
product of the fungus Penicillium wortmannii (Powis et al. 1994). Unlike LY294002 
which inhibits class I PI3K in an ATP-competitive manner, Wortmannin irreversibly 
inhibits PI3K activity by binding covalently to Lys802, which is a residue in the 
catalytic domain of  p110α and responsible for transfering a phosphate group from ATP 
to substrate proteins (Wymann et al. 1996). Wortmannin was reported to have anti-
tumour activity against tumour xenografts in a mouse model (Schultz et al. 1995). 
However, due to the dermatological toxicity of LY294002, the liver and hematological 
toxicity of Wortmannin, and the poor solubility and other phamacological disadvantages 
of both drugs, the usage of LY294002 and Wortmannin is confined to laboratory studies 
(Schultz et al. 1995; Hu et al. 2000). To overcome the poor pharmacological properties 
and significant side effects of Wortmannin, a novel Wortmannin analogue, PX-866, was 
synthesized with improved pharmacological properties compared with Wortmannin, 
such as longer drug duration, higher stability and less cytotoxicity (Ihle et al. 2004). 
Currently, PX-866 has entered phase I clinical trials for drug toxicity in healthy 
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volunteers and cancer patients, the results of which are pending (clinical trials identifiers 
(IDs): NCT00726583 and NCT01408316; http://clinicaltrials.gov/ct2/search). In 
addition to PX-866, another novel pan-class I PI3K inhibitor that reversibily abolishes 
PI3K activity in an ATP-competitive manner is ZSTK474, an s-triazine derivative 
compound. An in vivo study has shown that ZSTK474 had anti-tumour effects in a 
tumour xenograft mouse model, and no severe organ toxicity was observed (Yaguchi et 
al. 2006). Currently, a stage I trial of the phamarcological safety of ZSTK474 in human 
patients is ongoing, and the results are pending (clinical trial ID: NCT01280487; 
http://clinicaltrials.gov/ct2/search). The third newly synthesized pan-class I PI3K 
inhibitor is GDC-0941 which shares similar inhibition profile for all classes of PI3Ks 
with ZSTK474 (Kong et al. 2010). GDC-0941, a thieno[3,2-d]pyrimidines derivative, is 
orally bioavailable and has entered phase I clinical trials to evaluate drug safety in 
cancer patients (clinical trial IDs: NCT00999128 and NCT01474668; 
http://clinicaltrials.gov/ct2/search).  
 There are also newly developed inhibitors that specifically target either one or 
two isoforms of class I PI3K. For example, TGX-221, a LY294002 analogue, was 
developed to selectively inhibit class I PI3Kβ-induced adhesion of integrin α(IIb)β(3) 
and thereby prevent platelets aggregation and thrombus formation (Jackson et al. 2005). 
AS-605240, a selective class I PI3Kγ inhibitor, was reported to suppress PI3Kγ-induced 
inflammation in mose model of systemic lupus erythematosus (SLE) (Barber et al. 
2005). TG100-115 was designed to specifically target class I PI3Kγ and δ, thereby 
eliminating PI3Kγ- and δ-induced inflammation and edema (Doukas et al. 2006).  
1.7.3 Dual Class I PI3K and mTOR inhibitors 
 Recently, inhibitors targeting class I PI3K, mTORC1 and mTORC2, such as 
PI103 and NVP-BEZ235, have been developed and entered clinical trials. For example, 
NVP-BEZ235 is an orally bioavailable inhibitor which targets ATP binding sites in the 
catalytic domains of these enzymes. NVP-BEZ235 has displayed effective inhibition of 
cell proliferation and induction of apoptosis in vitro (Maira et al. 2008; Baumann et al. 
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2009). This dual class I PI3K/mTOR kinase inhibitor was also found to be well tolerated 
in vivo, and exhibited potent anti-tumour activity against human tumour xenografts in a 
mouse model (Maira et al. 2008). Despite the high efficacy of NVP-BEZ235 in inducing 
apoptosis, this compound was found to significantly induce autophagic resistance. It has 
therefore been suggested that it be used in combination with the autophagy inhibitor 
chloroquine (CQ) (Xu et al. 2011). NVP-BEZ235 is currently being investigated in 
phase I/II clinical trials in patients with advanced solid malignancies (ID: 
NCT00620594), advanced RCC (ID: NCT01453595), or advanced endometrial 
carcinoma (ID: NCT01290406) (http://clinicaltrials.gov/ct2/search) (Maira et al. 2008).   
1.7.4 Akt inhibitors   
 To date, several novel inhibitors which selectively target all isoforms of Akt 
kinases have entered phase I clinical trials in cancer patients. GSK690693, an ATP-
competitive pan-Akt inhibitor, was shown to suppress proliferation and induce apoptosis 
of 50% of cell lines derived from hematological malignancy whereas normal T 
lymphocytes were not affected by this inhibitor (Levy et al. 2009). GSK690693 showed 
significant anti-tumour activity against xenograft tumours in a mouse model. However it 
also caused drug-associated acute hyperglycemia due to inhibition of Akt-mediated 
glucose uptake (Rhodes et al. 2008). So far, an ATP-competitive inhibitor designed to 
specifically target Akt kinase has not been identified due to the high similarity in ATP-
binding pockets between Akt and some of AGC kinase family (a protein kinase group is 
named after cAMP-dependent protein kinase 1 (PKA), cGMP-dependent protein kinase 
(PKG) and protein kinase C (PKC)) (Cheng et al. 2005; Rhodes et al. 2008). Akt 
inhibitor VIII is an allosteric Akt inhibitor that does not compete with ATP for binding 
to the catalytic (kinase) domain of Akt. Instead, Akt inhibitor VIII binds Trp80 residue 
located in PH domain of cytosolic Akt kinase, resulting in maintenance of Akt in a 
closed and inactive conformation, preventing Akt membrane recruitment by 
PtdIns(3,4,5)P3 and hindering PDK1-mediated phosphorylation of Thr308. In addition, 
the association of inhibitor VIII with PH domain of Akt results in incorrect positioning 
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of the c-terminal hydrophobic motif of Akt, where residue Ser473 is located. As a result, 
Akt inhibitor VIII impairs mTORC2-modulated phosphorylation of Ser473 on Akt. 
However, the allosteric inhibitor VIII-mediated anti-tumour activity is PH domain-
dependent. Moreover, due to slight differences in the closed conformation between Akt3 
and the other two Akt isoforms (Akt 1 and Akt2), Akt3 is insensitive to this inhibitor 
(Calleja et al. 2009). A modified Akt inhibitor VIII, MK206, has been investigated in 
monotherapy or combination therapy against tumour activity in vitro and in vivo; the 
results showed that MK-2206 had a high efficacy in tumours harboring mutiations of 
class I PI3K/Akt pathway, but had moderate or no efficacy in tumours with mutations of 
other pathways (Hirai et al. 2010; Meng et al. 2010; Liu et al. 2011). MK-2206 has been 
reported to synergize with receptor tyrosine kinase inhibitors, chemotherapeutic 
inhibitors or a MEK inhibitor when used to treat a variety of tumours in vitro and in vivo 
(Hirai et al. 2010; Meng et al. 2010). To date, preclinical studies and phase I clinical 
trials have reported MK-2206 as being well-tolerated in patients and animal models 
(Lindsley 2010). Perifosine is a novel oral alkylphospholipid and its structure resembles 
lysophosphatidylcholines (LPC), a component of lipid bilayer cell membrane. The 
mechanism by which Perifosine inhibits Akt kinase is twofold; by directly binding the 
PH domain of Akt, and by utilizing its long hydrocarbon chain to anchor the 
phospholipid membrane and accumulate lipid rafts composed of phospholipid bilayer 
and protein receptors. As a result, the association of Akt with Perifosine prevents Akt 
from being recruited by PtdIns(3,4,5)P3. Currently, Perifosine is under investigation in 
phase II clinical trials which are confined to patients affected by chondrosarcoma, 
alveolar soft tissue sarcoma or Waldenström’s macroglobulinemia (WM) (Gills and 
Dennis 2009). Of the 37 patients with relapsed/refractory WM, 13 showed partial or 
minimal responses (35%), 20 showed stable disease (54%), and the median progression-
free survival was approximately one year (Ghobrial et al. 2010). The most frequent 
adverse effects were gastrointestinal symptoms (Argiris et al. 2006; Ghobrial et al. 
2010). However, Perifosine was observed to be well-tolerated in patients with WM 
(Ghobrial et al. 2010). Most phase II trials of Perifosine monotherapy in patients with 
other types of tumour have been suspended due to the disappointing results of phase I or 
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II trials (Argiris et al. 2006; Gills and Dennis 2009). A previous in vivo study suggested 
that the efficacy of Perifosine for cancer treatment is correlated with the degree of Akt 
inactivation present (Hennessy et al. 2007). However, lack of data on biomarkers such 
as Akt phosphorylation in specimens from patients in these trials limited the 
interpretation of the results in this respect. In preclinical studies, Perifosine was shown 
to inhibit Akt kinase activity and down-regulate Thr308 and Ser473 phosphorylation 
without affecting the activity of PDK1, mTORC2 and PI3K (Kondapaka et al. 2003; 
Papa et al. 2008). In addition to Akt inhibition, Perifosine has been reported to induce 
apoptosis or cell cycle arrest through modulation of other pathways, such as up-
regulation of p21
WAF1 
expression, down-regulation of Erk phosphorylation, stimulation 
of p38 and Jun N-terminal kinase (Jnk), etc (Patel et al. 2002; Kondapaka et al. 2003; 
Papa et al. 2008). Triciribine or API-2 (Akt/PKB signaling inhibitor-2), a purine 
analogue compound, was identified to function in inhibition of DNA synthesis and was 
used as a chemotherapeutic agent in phase I and II clinical trials for treatment of a 
variety of cancers (Cobb et al. 1983; Mittelman et al. 1983; Wotring et al. 1990; 
Hoffman et al. 1996). However, due to the requirement for high doses to achieve 
significant efficacy, leading to the presence of the drug-related side effects, Triciribine is 
currently no longer used as cytotoxic agent in the clinic setting (Cheng et al. 2005). 
Since 2004, Triciribine has been identified as a highly specific Akt inhibitor that has 
potent efficacy in tumours harbouring over-expression of Akt signaling in vitro and in 
vivo. No side effects were observed in a mouse model when used at 1 mg/ kilogram (kg) 
per day (Yang et al. 2004). The mechanism by which Triciribine inhibits Akt activity is 
by binding the PH domain of Akt, thereby preventing Akt being recruited by 
PtdIns(3,4,5)P3 to inner side of the cytoplasm and subsequently activated by PDK1 
(Berndt et al. 2010). Currently, a phase I trial of Triciribine in patients with metastatic 
cancer has been completed but the results have not been published yet (clinical trial IDs: 
NCT00363454; http://clinicaltrials.gov/ct2/search).  
 A novel synthetic compound named KP372-1 was originally identified as an 
inhibitor that selectively targeted Akt (Mandal et al. 2005; Mandal et al. 2006). Soon 
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after, this inhibitor was found to have two additional targets, PDK1 and Flt3 (Zeng et al. 
2006). To date, the mechanism by which KP372-1 inhibits Akt activity remains 
unresolved. In vitro studies have shown that KP372-1 can effectively inhibit the 
proliferation of tumour cells without affecting the growth of normal cells, and the anti-
tumour activity of KP372-1 was found to preferentially induce apoptosis (Koul et al. 
2006; Zeng et al. 2006). So far, no in vivo data regarding KP372-1 has been published 
yet. 
1.7.5 Class I PI3K pathway inhibitors in combination with 
chemotherapeutic agents  
 Accumulating evidence implies that constitutive activation of the class I PI3K 
pathway contributes to chemoresistance in cancer due to up-regulation of PI3K-
mediated survival, cell cycle progression and protein synthesis (Brognard et al. 2001; 
Clark et al. 2002; Hu et al. 2002; Lee et al. 2004). For instance, Doxorubicin, a 
chemotherapeutic agent, was reported to stimulate Akt survival factor in breast cancer 
cell lines for up to 24 hours (Clark et al. 2002). Another study of NSCLC cell lines 
showed that the pan-class I PI3K inhibitor LY294002 enhanced the efficacy of 
chemotherapy in cells expressing high Akt activity, but this inhibitor did not potentiate 
chemotherapy-mediated anti-tumour activity in cells with low Akt activity. Furthermore, 
after introducing constitutively active Akt into the cells exhibiting low Akt activity, the 
efficacy of chemotherapy was attenuated (Brognard et al. 2001). In some prostate cancer 
cell lines increased expression levels of multidrug resistance protein-1 (MRP-1) and 
breast cancer resistance protein (BCRP), which function in pumping out 
chemotherapeutic agents, were  correlated with overexpression of class I PI3K activity 
(Lee et al. 2004; Sherbakova et al. 2008). Based on the findings mentioned above, in 
vitro and in vivo experiments of chemotherapy in combination with class I PI3K 
pathway inhibitors such as LY294002, Akt inhibitor I, Everolimus and NVP-BEZ235 
were conducted, and most of the results showed that inhibition of the PI3K pathway did 
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sensitize tumour cells to chemotherapy (Brognard et al. 2001; Clark et al. 2002; Hu et 
al. 2002; Lee et al. 2004; Wang et al. 2009; Manara et al. 2010; O'Reilly et al. 2011).  
1.8 Cancer stem cell (CSC) theory 
1.8.1 CSC theory 
 Traditionally, Cancer Disease is thought of as cells with accumulation of 
mutations and each cell within a tumour has an equal opportunity to acquire the abilities 
of unlimited replication in an uncontrolled manner, escape apoptosis and malignant 
behaviours such as angiogenesis, invasion and metastasis, resulting in the enlargement 
of tumour mass and tumour progression. To date, most cancer therapies used in clinics 
are based on this concept. Although most benign tumours and low grade cancers can be 
cured, high grades cancers such as advanced renal cell carcinomas often respond to these 
therapies during a short period of time but relapse later (Withrow and Vail 2007). Over 
the past three decades, growing evidence has suggested that a single cancer is 
heterogeneous and contains subpopulations of cells with various biological properties, 
such as cellular morphology, karyotype, antigen expression, gene expression, response 
to chemotherapy and radiation therapy, etc (Heppner 1984). For example, multiple 
subpopulations of cells with diverse metastatic proclivity were isolated from single 
murine tumours (Fidler and Kripke 1977; Miller et al. 1983). More recently, a study of 
human breast tumours demonstrated that a single tumour contained heterogeneous 
subpopulations, in light of changes in DNA copy number. Among these subpopulations, 
few clones were identified to be associated with tumour expansion whereas most 
subpopulations of cells with variable pseudodiploid chromosome(s) were irrelavant to 
metastasis (Navin et al. 2011). Due to heterogeneity being common in single tumours, it 
is proposed that the origin of tumour heterogeneity might be analogous to that of organs 
and tissue, in which cells are heterogenous but arranged in a hierarchical structure. It has 
been well-established that a normal organ/tissue is derived from a small number of stem 
cells (SCs). Therefore, it is proposed that a bulk of tumour mass might be derived from 
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few tumour-initiating cells that inherit or acquire SC properties, including self-renewal, 
differentiation potential, and resistance to chemotherapy and radiotherapy (Reya et al. 
2001).  
 Since the novel Cancer Stem Cell (CSC) theory is based on activities of SCs, the 
understanding of SC biology is necessary. The SCs can self renew through symmetric 
division to two SCs, thus maintaining SC pool and life span of SCs. To construct a 
whole organ or tissue, the SCs can undergo asymmetric division to simultaneously 
produce one SC and one differentiated progeny cells. Alternatively, SCs undergo 
committed symmetric division to produce to two differentiated progeny cells (Tang 
2012). Based on differentiation potential, SCs are classified into totipotent, pluripotent, 
multipotent, oligopotent, and unipotent SCs. The differentiation potential of SC is 
correlated with cellular differentiation degree. The more primative a SC is, the more 
potent differentiation potential it has. In embryo, the cells at the zygote and the morula 
stages are totipotent. These totipotent SCs are able to differentiate to all embryonic and 
adult cells, thus constructing an entire animal body. As the morula cells undergo cell 
division, the embryo develops to form blastocyst. In blastocyst, the cells located at the 
inner cell mass are pluripotent and have the capability of producing cells of three germ 
layers, endoderm, mesoderm, and ectoderm. After the embryonic cells are partitioned 
into the three germ layers, most of these cells such as adult SCs become multipotent and 
have the capability of differentiation into cells of multiple but closely related lineages 
(Wagers and Weissman 2004; Tsonis 2007). However, there are few exceptions of 
certain adult SCs which can differentiate to cells crossing different germ layers. For 
instance, mesenchymal SCs of mesodermal origin, which give rise to not only 
mesenchymal cell lineages incuding osteocytes chondrocytes and adipocytes but also 
several cell lineages of three germ layers (Jiang et al. 2002; Wagers and Weissman 
2004). The multipotent SCs can further differentiate into more committed progenitors 
with oligopotency. These oligopotent progenitors, such as common lymphoid progenitor 
(CLP) and common myeloid progenitor (CMP) residing in bone marrow, have the 
capacity of producing few cell types. For instance, CLP can futher differentiate into 
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committed progenitors of B and T lymphocytes and natural killer cells. The unipotent 
progenitors are the descents of oligopotent progenitors and have the limited ability of 
differentiation potency, which is producing terminally differentiated cells. For instance, 
a B cell progenitor can differentiate into a B lymphocyte (Bryder et al. 2006). 
 Beyond the self-renewal and differentiation potential, SCs have been reported to 
be more resistant to chemotherapy and radiotherapy, due to the following reasons. In the 
first place, chemotherapeutic agents and radiation are used to damage DNA synthesis 
and preferrentially target dividing cells (Sausville and Longo 2001). However, SCs are 
slow-cycling and frequently at quiescent state (Cotsarelis et al. 1989). Secondly, a subset 
of SCs express several ATP-binding cassette (ABC) transporters that acts to extrude a 
variety of chemical compounds such as Hoechst dye 33342 and chemotherapeutic agents 
from cells, which is the leading cause of multi-drug resistance in SCs (Bunting 2002). 
Thirdly, SCs have been found to contain lower concentrations of ROSs than their non-
SC counterparts. The lower ROS levels are correlated with higher free radical scavenge 
levels, resulting in cells being less sensitive to ionizing radiation-induced DNA damage 
(Diehn et al. 2009).  
 The CSC theory states that Cancer is derived from SCs with accumulation of 
molecular alterations such as genetic mutations and epigenetic changes. In other words, 
Cancer is a Stem Cell disorder. Like normal SCs, it is hypothesized that CSCs are able 
to self-renew and differentiate in an uncontrolled manner, which results in producing 
heterogeneous cancerous cells and thereby building a whole but abnormal organ/tissue. 
In contrast to CSCs, their more mature progeny cells which lose the ability to self renew 
and have restricted differentiation potential are less likely to produce cancer (Figure 
1.11) (Polyak and Hahn 2006). Since SCs are chemoresistant and radioresistant due to 
slowly cycling, containing multi-drug resistance mechanism and lower ROS levels, it is 
presumed that CSCs inherit these properties, which may account for cancer recurrence 
after chemotherapy and radiation therapy (Sausville and Longo 2001; Bunting 2002; 
Diehn et al. 2009). In addition, accumulating evidence suggests that CSCs acquire 
radioresistance through molecular alterations, such as mutation of p53 which is a DNA 
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damage checkpoint gene (Gorgoulis et al. 2005). For instance, the putative CSCs 
derived from human glioma xenograft and patients’ specimens were found to be more 
resistant to ionizing radiation than their non-CSC counterparts, in that the CSCs acquired 
radition-induced DNA damage response mechanism that accelerated DNA repair 
whereas those non-CSCs that lacked this mechanism were radiosensitive (Bao et al. 
2006).   
 
Figure 1.11 The model of cancer stem cell (CSC) theory. A small population 
of tumour cells with stem cell-like properties that can undergo both symmetrical 
and asymmetrical division, resulting in tumour cell heterogeneity. CSC, cancer 
stem cell; P, lineage committed progenitors; D1, incompletely differentiated 
tumour cells; D2, fully differentiated tumour cells.     
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1.8.2 CSC niche 
 In human and mouse, SCs have been found to reside in a specific 
microenvironment, termed SC niche, where serves as a reservoir of SCs by regulating 
self-renewal, proliferation and differentiation of SCs (Gould 2007; Borovski et al. 2011; 
Nagasawa et al. 2011). SC niche consists of various stromal cells such as fibroblasts and 
inflammatory cells, vascular-associated cells, soluble molecules, and extracellular matrix 
(Borovski et al. 2011). For example, adult neural SCs (NSCs) and progenitors reside in 
perivascular regions in the the hippocampus and the olfactory bulb, where neurogenesis 
takes place (Gould 2007). An in vitro study showed that co-culture of murine NSCs and 
murine endothelial cells promoted expansion of NSC colony. The phenomenon of self-
renewal and colony expansion was contributed by endothelial cells that released 
endothelial factors and subsequently activated Notch/Hes1 signaling pathway in NSCs 
(Shen et al. 2004). Hematopoietic SCs (HSCs) are found to reside in the endosteal niche 
composed of bone-lining osteoblasts and the vascular niche composed of endothelial 
cells, reticular cells and nestin cells. It is suggested that these stromal and vascular cells 
may contribute to maintenance of undifferentiated state and the homing of HSCs 
(Nagasawa et al. 2011).   
 Like SC niche, recent studies suggest that CSC niche is presumed to exist and 
may execute several functions, including maintenance of CSC pool, up-regulation of 
CSC phenotype and contribution to metastasis (Borovski et al. 2011).  For instance, the 
maintainence of the pool and self-renewal of CSCs derived from glioblastoma 
multiforme (GBM), which is characterized by necrotic foci surrounded by anaplatic 
astrocytic cells and vascular endothelial proliferation, has been suggested to be partly 
contributed by nitric oxide (NO) that is produced by intratumoural endothelial cells 
(Charles et al. 2010; Westphal and Lamszus 2011). It has been demonstrated that 
elevated production of NO activate Notch signaling cascades through NO/cGMP/PKC 
pathway in glioma cells and down-regulation of NO activity decrease Notch signaling 
(Charles et al. 2010). Moreover, an in vitro study of primary GBM specimens cultured 
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in three-dimensional explant system suggested that tumour endothelial cells were 
associated with promoting self-renewal and proliferation of CSCs by up-regulating 
Notch signaling (Hovinga et al. 2010). Although studies have shown that anti-
angiogenesis therapy sensitizes glioma CSC to chemotherapy in vivo and amplifies 
cytotoxic effects of chemotherapy and prolongs survival time in phase II clinical trial of 
recurrent GBM (Folkins et al. 2007; Buie and Valgus 2008), a more recent study of 
mouse model of GBM and pancreatic neuroendocrine carcinoma has warned of risk to 
increase invasive and metastatic phenotypes in tumours after anti-angiogenesis therapy 
and suggested that hypoxia may be a key factor for tumour cells to escape anti-
angiogenesis therapy (Paez-Ribes et al. 2009). In addition to vascular niche, it is 
proposed that CSCs may reside in the periphery of necrotic foci where hypoxic in GBM, 
based on the observation of preferential expression of HIF2α and other hypoxia response 
genes in CSCs derived from surgical gliomblastoma specimens and human tumour 
xenografts compared to non-CSC counterparts and physiological neural progenitors (Li 
et al. 2009; Borovski et al. 2011).    
 Recently, evidence has shown that microenvironement plays a key role in 
reprogramming differentiated tumour cells to CSCs and affecting cancer cell plasticity 
(Borovski et al. 2011). A study of colon cancer demonstrated that myofibroblasts secret 
hepatocyte growth factor and other unknown factors to maintain active Wnt signling in 
the neighbor CSCs and other differentiated tumour cells, thus maintaining CSC pool and 
driving differentiated tumour cells to express CSC phenotype (Vermeulen et al. 2010). 
Intratumoural hypoxia, as a microenrivonment factor, has been reported to not only 
encourage differentiated tumour cells to gain CSC phenotype but also enhance plasticity 
in cancer cell migration through induction of epithelial-mesenchymal transition 
(Heddleston et al. 2009; Taddei et al. 2013).   
 Increasing evidence suggests that foreign niches may express certain factors, 
which attract cancer cells to metastasize from the primary tumour site and to form new 
colonies. Some chemokines and their receptors have been found to be involved in cancer 
cell metastasis (Mishra et al. 2011). For instance, stromal cell-derived factor-1 (SDF-1), 
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a chemokine secreted by bone-lining osteoblasts and endothelial cells in bone marrow 
and by epithelial cells in organs, can be one of many mechasnisms for prostate cancer 
metastasis to bone, due to SDF1 attracting and transducing signal to its receptor CXCR4 
which is expressed on the surface of prostate cancer cells (Nagasawa et al. 1998; 
Ponomaryov et al. 2000; Taichman et al. 2002).    
1.8.3 Isolation of CSCs by sphere formation assay 
 Over the past fifteen years, putative CSCs have been identified within human 
leukaemia and solid tumours, and many cancer cell lines. Experimental methods, 
including sphere formation assay, colony formation assay, side population (SP) analysis, 
CSC maker, and xenograft assay, have been used to identify those tumour-initiating cells 
(Singh et al. 2003; Kondo et al. 2004; Collins et al. 2005; Fang et al. 2005; Seigel et al. 
2005; Ho et al. 2007; Li et al. 2007).  
1.8.3.1  Sphere formation assay  
The sphere formation assay has been established to isolate and grow neural stem 
cells. This assay uses a non-adherent and serum-deprived culture system specifically 
developed to maintain SCs in an undifferentiated state. Additional constituents and 
growth factors such as epidermal growth factor (EGF) and basic fibroblast growth factor 
(bFGF) which are required for the expansion and self-renewal of neural SCs are added 
to the serum-deprived culture medium. The neural SCs proliferated under such culture 
condition look like spheres or a cluster of cells. Therefore, the neural SCs are also 
termed neural spheres. These neural spheres were demonstrated to be capable of self-
renewal by being passaged to produce multiple new spheres after the old spheres were 
dissociated to single cells. These neural spheres were shown to express nestin which is a 
marker for neural SCs, but not the differentiated neural cell markers, including neuron-
specific enolase (NSE), neurofilament (168 kD) and glial fibrillary acidic protein 
(GFAP). After the sphere cells were transferred to cell plates coated with an adhesion 
substrate poly-L-ornithine, these spheres were demonstrated as being multipotent and 
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differentiating into mature cell types including neurons, astrocytes, and oligodendrocytes 
(Reynolds and Weiss 1992). To date, the sphere formation assay have been employed to 
isolate putative CSCs from many solid tumours, such as neurospheres isolated from 
brain tumours, sarcospheres from bone sarcomas and mammospheres from breast cancer 
(Singh et al. 2003; Gibbs et al. 2005; Grimshaw et al. 2008). Like neural spheres 
derived from mouse central nervous system, spheres derived from solid cancer were 
demonstrated as being capable of self-renewal and possessing differentiation potential. 
For instance, a clinical study showed that mammospheres derived from most (20/27) 
pleural effusion specimens of patients with metastatic human breast cancer could be 
passaged serially by using sphere formation assay. After these mammosphere were 
transferred to adherent plates, the sphere cells were differentiated to more mature cell 
types such as luminal epithelial, basal and myoepithelial cells. The mammospheres were 
demonstrated as being more potent to produce tumours than their differentiated progeny 
cells in severe combined immunodeficiency disease (SCID) mouse model (Grimshaw et 
al. 2008).  
The published recipes for growing CSCs from brain, bone and breast cancers 
were quite similar. The basic serum-free medium utilized for isolating CSCs was N2 
medium with addition of EGF. The N2 medium is composed of a 1:1 mixture of Ham's 
F12 medium and the Dulbecco’s modified Eagle's medium (DMEM) supplemented with 
insulin, transferrin, progesterone, putrescine, and selenium (as Na2SeO3) (Bottenstein 
and Sato 1979; Reynolds and Weiss 1992; Singh et al. 2003; Gibbs et al. 2005; Chen et 
al. 2008; Grimshaw et al. 2008). EGF was demonstrated to be critical for expanding 
neural stem cell (NSC) population whereas medium plates coated with adhesive 
substrates such as poly-L-ornithine hindered proliferation of NSCs (Reynolds and Weiss 
1992). Recently, a commercial available supplement B27/NS21 (for 21 different 
ingredients) has been widely used in serum-free culture system for growing breast and 
brain CSCs. The B27/NS21 contains not only all of the supplements in N2 medium and 
but also other ingredients to support neural cell growth (Chen et al. 2008). Other 
ingredients such as bFGF, sodium bicarbonate (as NaHCO3), Hepes buffer were 
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documented in recipes of neurosphere and sarcosphere whereas hydrocortisone was 
added in mammosphere recipe (Singh et al. 2003; Gibbs et al. 2005; Grimshaw et al. 
2008). 
1.8.3.2  Colony formation assay  
 The in vitro colony formation assay, which is defined as semi-solid culture 
medium, has been employed to isolate hematopoietic and neural SCs (Ploemacher et al. 
1989; Louis et al. 2008). This assay keeps all the advantages of the sphere formation 
assay, including maintainence of SCs in undifferentiated state, propagation of SCs and 
revelation of self-renewal capacity of SCs. Additional advantage of the colony formation 
assay is that it is capable of quantifying the actual frequency of SCs, in that SCs can stay 
in this culture system long enough (~ 21 days) to expand colony size. In contrast, the the 
maximal length of time for SCs to proliferate in sphere formation assay is 5-7 days, due 
to the development of central necrosis in spheres and disseminated cell debris after the 
spheres grow larger. Since the colony formation assay gives SCs adequate time to 
expand colony size, SCs are easily distinguished from their progeny cells such as 
progenitors and mature cells, based on self-renewal and proliferation capacities 
(Marshall et al. 2007; Louis et al. 2008).          
1.8.3.3 Side population (SP) analysis   
It is known that some tumour cells can survive after cancer therapy and 
contribute to the recurrence of tumours and metastatic diseases. One possible 
mechanism is that these tumour cells possess some drug-resistant mechanisms that can 
exclude drug from cells. The best characterized drug-resistance mechanism is that 
imparted by the superfamily of cell membrane-bound ABC transporters which are 
classified into seven subfamilies that are designated A to G. The subfamily B (ABCB), 
C (ABCC), and G (ABCG) of the ABC transporter superfamily confer a multidrug 
resistant mechanism to tumour cells (Vasiliou et al. 2009; Lebedeva et al. 2011). 
Interestingly, two ABC transporters, ABCB1 (also called MDR1) and ABCC1 (also 
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called BCRP), are commonly expressed by SCs and progenitors derived from bone 
marrow and skeletal muscle (Zhou et al. 2001; Bunting 2002). Since the ABCB, ABCC 
and ABCG subfamilies of ABC transpoters function in efflux of certain cytotoxic drugs 
and fluorescent dyes, the SP discrimination assay is employed to distinguish SCs or 
progenitors from their differentiated progeny cells which do not express ABC 
transpoters. The SP analysis identifies SCs and progenitors by comparison of fluorescent 
substrate (flow cytometry) profile of cells in the presence of ABCB1 and ABCC1 
inhibitors with that of cells in the absence of these inhibitors. The SP cells are present in 
the fluorescent substrate profile when cells are treated with the inhibitors whereas no SP 
cells are found in the absence of the inhibitors. For instance, Hoechst33342 dye, as a 
substrate of both ABCB1 and ABCC1 transporters, was rarely accumulated in murine 
hematopoietic stem cells, due to efflux of this dye by both transporters. With addition of 
ABCB1 and ABCC1 inhibitors, these primitive cells could not pump out Hoest 33342 
dye and restore the staining of these precursors, resulting in the presence of SP tail in 
Horchst33342 dye profile (Goodell et al. 1996). 
To date, SP cells have been identified in many tissues and organs, including bone 
marrow (where SP cells comprise 0.1% of total bone marrow cells), skeletal muscle 
(2.3%), kidney (0.03~0.1%), umbilical cord blood (~0.4%), liver (~2% of non-
parenchymal cells), mammary gland (~0.4%), lung (0.03~0.07%) and forebrain (3.6%) 
(Goodell et al. 1996; Storms et al. 2000; Asakura et al. 2002; Kim and Morshead 2003; 
Shimano et al. 2003; Summer et al. 2003; Clayton et al. 2004; Iwatani et al. 2004). 
Cumulative evidence suggests that SP cells are multipotent and have plasticity. For 
instance, a report showed that SP cells derived from murine skeletal muscle were able to 
differentiate into hematopoietic lineage cells after these SP cells were transplanted to 
bone marrow of mouse recipient (Jackson et al. 1999). SP cells derived from mouse 
bone marrow were able to differentiate to cardiomyocytes and endothelial cells and 
subsequently reconstitute functional cardiac tissue in a mouse model of myocardial 
infarction following transplantation (Jackson et al. 2001).  
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Despite the enrichment of cells with SC characteristics in the SP of some tissues, 
there are some conflicting data that do not support that SP cells represent SCs. Firstly, 
the data obtained from human and murine embryonic stem (ES) cells and epidermis 
suggested that SP cells might either be distinct from SCs or represent only a subgroup of 
SC pool. It was reported that human and mouse epidermal SP cells display phenotypes 
which were different from those of epidermal SCs (Terunuma et al. 2003; Triel et al. 
2004). Moreover, whether SP phenomenon can serve as a SC marker continues to be 
questioned because ABCB1 transporter is normally expressed on the surface of certain 
differentiated epithelial and endothelial cells in tissue or organs, including small 
intestine, liver, kidney, placenta, endothelial cells in the blood-brain and blood-testes 
barriers (Cordon-Cardo et al. 1989; Kamimoto et al. 1989; Hsing et al. 1992; Okamura 
et al. 1993; Lankas et al. 1998; Choo et al. 2000). It was supposed that these cells might 
utilize ABCB1 transporter to pump out toxins and drugs, serving as a cell protection 
mechanism (Fromm 2000).  
Recently, SP discrimination assay has been applied to CSC biology, in that 
tumours resistant to conventional therapy may be attributed to these CSCs displaying SP 
phenotype (Hirschmann-Jax et al. 2004; Chua et al. 2008). For instance, SP cells were 
identified in most neuroblastoma specimens (65%) from patient. These SP cells were 
capable of generating SP and non-SP cell populations ex vivo, excluded the 
chemotherapeutic drug Mitoxantrone and expressed higher levels of mRNAs encoding 
ABCA3 and ABCG2 transporters, as compared with non-SP cells (Hirschmann-Jax et 
al. 2004). Another example is that human astrocytoma SP cells expressed SC markers 
including nestin and musashi-1 and outcompeted for reconstitution of new tumours and 
aggressiveness. Interestingly, SP fraction was increased in response to chemotherapeutic 
agent Temozolomide, suggesting that the SP represents cells resistant to, and thus 
potentially selected by, conventional chemotherapy (Chua et al. 2008). In addition to 
brain cancers, SP cells were identified from a variety of tumour types, incluing breast, 
gastrointestinal, liver, lung, prostate, ovarian and thyroid cancers, representing 0.02-
2.2% fraction of a whole tumour. These SP tumour cells were demonstrated to be more 
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competitive for recapitulation of new tumours in vivo as compared with their non-SP 
counterparts (Patrawala et al. 2005; Chiba et al. 2006; Haraguchi et al. 2006; Ho et al. 
2007; Mitsutake et al. 2007; Bleau et al. 2009). For instance, 1000 – 10,000 SP cells 
identified from glioma and breast cancer recapitulated new tumours whereas 50,000-
250,000 non-SP cells were required for tumour formation. It should be noted that not 
every tumour contain SP cells. In this study, SP cells were identified in ~30% of 
tumours (Patrawala et al. 2005).    
1.8.3.4 CSC marker  
Currently, many markers, such as nestin, CD34 and CD133, are used for 
identification of SCs and progenitors (Reynolds and Weiss 1992; Simmons et al. 1992; 
Lee et al. 2005). For example, CD133 is a marker used to identify SCs and progenitors 
derived from many organs and tissue, including bone marrow, brain, liver, muscle, 
prostate, kidney and cord blood (Mizrak et al. 2008). A study showed that CD133+ cells 
isolated from murine brain were able to form neurospheres and differentiated into 
multiple neural cells including astrocytes, oligodendrocytes and neurons, demonstrating 
self-renewal and multipotency of CD133+ murine neural cells (Lee et al. 2005). These 
markers for labeling normal primative cells are also used to identifiy putative tumour-
initiating cells. Characterization of the phenotypes of a certain tumour-initiating cell is 
usually performed after the isolation of the spheres from SC culture and/or SP analysis. 
For instance, neurospheres derived from specimens of human brain cancers were 
demonstrated to express nestin and CD133 whereas their progeny cells expressed 
differentiated cell markers such as GFAP but lost expression of nestin and CD133 
(Singh et al. 2003). Alternatively, tumour-initiating cells can be detected and isolated by 
directly staining with antibodies for markers which are known to identify normal stem 
cells. CD133+ hepatocarcinoma cells have been identified and considered to be tumour-
initiating cells based on the previous demonstration of expression of this marker on 
normal liver stem cells. In the hepatocarcinoma stem cell study, the cell lines were not 
screened in advance by stem cell culture and SP analysis. Instead, they were staining 
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with CD133 surface marker and compared the ability of reconstitution of tumour types 
of CD133+ cells compared with CD133- cells in vitro and in vivo (Ma et al. 2007).  In 
addition to CD133 and nestin, other makers for labeling tumour-initiating cells from 
various tumours have been identified. For examples, CSCs of AML are defined as co-
expression of CD34+CD38-Thy-1 (Blair et al. 1997; Blair et al. 1998; Blair and 
Sutherland 2000; Jordan et al. 2000). The CSCs of human head and neck squamous cell 
carcinomas (HNSCC) carcinoma have phenotype of CD29+CD44+CD133+ (Harper et 
al. 2007).  
1.8.3.5  Xenograft assay  
 In vivo xenograft assay is the gold standard assay to validate the CSCs identified 
by any of the four in vitro methods as described above (sphere formation assay, colony 
formation assay, SP analysis and labeling of SC marker). In order to prove whether 
CSCs possess SC properties, the xenograft assay is employed by initially fractionation of 
tumour cells into CSC and non-CSC populations. Subsequently, the two cell populations 
are serially diluted to various cell densities. After that, the two cell populations are 
injected into immunodeficient mice to evaluate tumour initiation potential. It is 
hypothesized that the CSC population with self-renewal, proliferation and differention 
properties are more capable of producing xenograft tumours which resemble the parent 
tumour than the non-CSC population. In addition, it is supposed that the xenograft 
tumours contain the CSC fraction which can then go on to form secondary xenografts 
successfully and the non-CSC fraction is expected to lose this tumourigeneicity (O'Brien 
et al. 2010). Increasing evidence supports the CSCs isolated by in vitro experimental 
methods are able to produce xenograft tumours in animal models. For instance, as few as 
(5000) single cells dissociated from the mammaospheres derived from pleural effusion 
specimens of human breast tumours were found to produce xenograft tumours in SCID 
mice. In contrast, and supporting the CSC hypothesis, the same number of the pleural 
effusion tumour cells did not produce tumours in SCID mice (Grimshaw et al. 2008).   
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1.8.4 Signaling pathways that regulate SCs and CSCs  
1.8.4.1 Notch-Shh-TGFβ-Wnt-FGF signaling network 
 To date, several signaling pathways, including neurogenic locus notch 
homologue protein (Notch), sonic hedgehog (Shh), Wnt and class I PI3K pathways, have 
been reported to be relevant to regulation of normal SCs and CSCs. Stemness property 
of normal stem cells was regulated by a balance of Notch-Shh-TGFβ-Wnt-fibroblast 
growth factor (FGF) signaling network (Katoh 2007).  
 In neural SC biology, Notch signaling pathway plays a key role in keeping SCs 
at quiescent state and maintaining SC pool through inhibition of differentiation and 
proliferation of SCs. This pathway is activated following the Notch receptors (Notch1, 
Notch2, Notch3, and Notch4) binding to their ligands, including Delta-like protein 1 
(DLL1), DLL2, DLL3, Jagged 1 and Jagged 2. The binding of ligand to Notch receptors 
results in the release of the signal-transducing Notch intracellular domain (NICD) from 
Notch receptor, allowing NICD to enter nucleus and subsequently interact with RBP-
Jkappa family, thereby activating expression of genes encoding transcription factors 
Hairy and Enhancer of Split (HES) and Hairy/Enhancer-of-split-related with YRPW-like 
Motif (HEY). The HES and HEY family transcription factors acted as negative 
regulators of differentiation (Iso et al. 2003; Westphal and Lamszus 2011). However, 
emerging evidence suggested that Notch signaling might have a role in induction of 
neuronal differentiation (Furukawa et al. 2000; Morrison et al. 2000). For instance, 
multipotent neural crest stem cells were observed to undergo committed glial 
differentiation in response to DLL1 stimulation (Morrison et al. 2000).  
 Activation of Shh signaling is required for SCs to maintain self-renewal. Recent 
evidence suggested that active Shh signaling contributed to the growth of CSCs and 
tumour metastasis and invasion through regulation of EMT (Lee et al. 2008; Tang et al. 
2012). The binding of Shh ligand to its receptor, Patched 1 (Ptch1), relieved inhibition of 
intrinsic Ptch1-mediated inhibition of Smoothened (Smo) receptor on cell surface. This 
114 
 
resulted in the dissociation of Gli family transcription factors from an inhibitory protein 
complex, allowing Gli to enter the nucleus to activate transcription of its target genes 
such as Gli1 and Ptch1 (Huse and Holland 2010; Stanton and Peng 2010).  
 TGF-β/bone morphogenetic protein (BMP) played a role in proliferation and 
differentiation during embryogenesis and was reported to induce EMT in cancer. The 
binding of TGF-β ligand to its receptor resulted in phosphorylation of SMAD family 
transcriptors. This promoted migration of SMAD to nucleaus, thus activation of 
expression of its target genes (Javelaud et al. 2011).    
 Wnt signaling has been reported to function in embryogenesis, tumourigenesis 
and tissue regeneration (Katoh 2007). Wnt signaling can be directed to canonical Wnt 
pathway to dictate cell fate or be directed to noncanonical Wnt pathway for cytoskeletal 
rearrangement and cell polarity. Canonical Wnt pathway is initiated by Wnt ligand-
binding to its frizzled family receptors and LRP5/LRP6 coreceptor, which leads to the 
dissociation of its substrate β‑catenin from an inhibitory cytosolic complex composed of 
adenomatous polyposis coli (APC), Axin and GSK3β. This allows β‑catenin to migrate 
to nucleus and activate expression of its target genes such as MYC, CCND1 (encoding 
cyclin D1), FGF20 (Katoh 2007; Huse and Holland 2010).  
 The binding of FGF to its receptor FGFR, a subfamily of RTK, triggered 
activation of FGFR-mediated downstream pathways, including PLC-γ/PKC, class I 
PI3K/Akt, Ras/Raf, STAT and RSK2 pathways. As a result, FGF signaling modulated 
physiological cell functions such as proliferation, differentiation, mobility, survival and 





1.8.4.2 The role of class I PI3K/Akt/mTOR pathway in regulation of SCs and 
CSCs  
 More recently, many reports have addressed that class I PI3K/Akt/mTOR 
pathway is involved in regulation of viability, proliferation, and multidrug resistance 
mechanism of CSCs (Bleau et al. 2009; Dubrovska et al. 2009; Martelli et al. 2010). A 
study of prostate cancer showed that spheres expressed higher phosphorylation levels of 
class I PI3K downstream components than adherent cells. Down-regulation of either 
PTEN or FoxO3a expression by short hairpin RNA (shRNA) increased in sphere 
production and up-regulated tumourigenic capability (Dubrovska et al. 2009). Akt, 
instead of mTOR, was found to up-regulate ABCG2 transporter activity, resulting in an 
increase in SP fractions in mouse and human gliomas (Bleau et al. 2009). Knockdown of 
PTEN in hematopoietic SCs resulted in leukemia-initating cell transformation. This 
disorder was mainly attributed to mTOR dysregulation, as evidenced by Rapamyin 
restoring functions of PTEN-deficient hematopoietic SCs (Yilmaz et al. 2006). Down-
regulation or loss of PTEN expression resulting in production of tumour cells with stem 
cell-like properties has been observed in many cancer types, including brain, breast, 
liver, lung and prostate cancer and leukemia (Yilmaz et al. 2006; Zhang et al. 2006; 
Zhou et al. 2007; Yang et al. 2008; Bleau et al. 2009; Dubrovska et al. 2009; Korsten et 
al. 2009; Rountree et al. 2009).   
 1.8.5 Therapy targeting CSCs 
 As CSCs are assumed to be responsible for tumour relapse, development of 
strategies to effectively eliminate CSCs is required. These strategies include targeting 
CSC biomarkers, targeting CSC signaling pathways, sensitizing CSCs to therapy and  
targeting specific CSC metabolism (Baccelli and Trumpp 2012). Strategy to target CSC 
biomarkers, such as anti-CD44 antibody and anti-CD123 antibody, has been reported to 
effectively inhibit relapse of xenograft of human acute myeloid leukemia (AML) in 
mouse model (Jin et al. 2006; Jin et al. 2009). However, due to CD44 and CD123 
markers being expressed not only on CSCs but also on normal SCs, it is speculated that 
116 
 
these antibodies may affect normal SCs and have adverse reactions on patients (Taussig 
et al. 2005; Orian-Rousseau 2010).  
 Based on the theory that CSCs may rely heavily on certain signaling pathways to 
maintain stemness and self-renewal as compared with their normal counterparts, strategy 
to target these pathways is under investigation (Weinstein 2002; Baccelli and Trumpp 
2012). For instance, previous studies of brain tumours showed that suppresion of Notch 
pathway by γ-secretase inhibitors remarkably reduced or complete depleted the CSC 
fraction in in vitro experiments and significantly inhibited the growth of tumour 
xenografts of brain CSCs in mouse model (Fan et al. 2006; Fan et al. 2010). Promoting 
CSCs to undergo differentiation is an alternative way to reduce the CSC fraction. For 
instance, activation of bone morphogenetic protein (BMP)/Smad pathway by BMP4 
promoted differentiation, decreased proliferation but not affected viability, of CSCs 
derived from human GBM. Furthermore, intracranial delivery of BMP4 effectively 
inhibited the growth of GBM xenografts in mouse model (Piccirillo et al. 2006).  
  Strategy to sensitize CSCs to radiotherapy/chemotherapy is currentlty being 
assessed in preclinical studies. For instance, inhibition of Notch signaling by γ-secretase 
inhibitor-I has been observed to augment radiosensitivity of radioresistant CSCs isolated 
from glioblastomas. Moreover, pretreatment of unsorted glioblastoma cells with Notch 
inhibitor and radiation remarkably reduce tumor incidence in mouse model, as compared 
with single treatment groups and control cells (Lin et al. 2010). Recently, promyelocytic 
leukaemia protein (PML) tumour suppressor has been found to be crucial for 
maintaining stemness of HSCs and leukaemia SCs (LSCs. In vitro and in vivo results 
revealed that pretreament of LSCs with arsenic trioxide (As2O3), resulting in decreasing 
expression of PML and initiates differentiation of LSCs, sensitized LSCs to 
chemotherapy and delayed tumour incidence (Ito et al. 2008). 
 Strategy to target specific CSC metabolism such as nitric oxide synthase-2 
(NOS2) in glioma SCs and glycine decarboxylase in CSCs derived from non-small cell 
lung cancer, is being investiageted in preclinical studies (Eyler et al. 2011; Zhang et al. 
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2012). For instance, evidence has shown that nitric oxide (NO), produced by 
intratumoural endothelial cells through endogenous NOS3 enzyme, maintains stemness 
of CSCs derived from malignant glioma (Charles et al. 2010; Eyler et al. 2011; 
Westphal and Lamszus 2011). In addition, higher expression levels of NOS2 enzyme, 
which acts to produce NO, has been detected in glioma CSCs than their differentiated 
progeny cells. Furthermore, inhibition of NOS2 activity did arrest the growth and 
proliferation of glioma CSCs in vitro and reduced the tumourigenecity in vivo (Eyler et 
al. 2011).  
1.8.6 Controversy of cancer stem cell theory 
 Although many studies support CSC theory based on the evidence showing SC-
like tumour cells being more tumourigenic than their differentiated progeny cells 
(Bonnet and Dick 1997; Al-Hajj et al. 2003; Singh et al. 2003; Grimshaw et al. 2008), 
the findings of two recent studies challenge this CSC concept (Kelly et al. 2007; Yoo 
and Hatfield 2008). One study showed that as few as 10-100 randomly chosen tumour 
cells from murine lymphoma or leukaemia developed tumour in histocompatible mice 
whereas no tumour incidence was detected mice injected with control group (normal 
spleen cells) (Kelly et al. 2007). The other study showed that as few as 1-10 unsorted 
single cells from murine lung cancer or breast cancer form colonies in vitro. 
Subsequetly, 2 x 10
5
 cells from each tumour colony were injected to histocompatible 
mice, which led to tumour formation (Yoo and Hatfield 2008). The results of these two 
studies suggest that tumourigenecity (the capability of generating tumours) may not 
necessarily be confined to a rare population of CSCs.  
 Increasing evidence suggests that CSCs are composed of heterogenous 
subgroups, instead of one single clone. Besides, it is suggested that CSC model is 
dynamic and tumour undergoes evolution during disease progression (Mullighan et al. 
2008; Anderson et al. 2011; Notta et al. 2011). Recently, two studies of human 
leukaemia have discovered that genetic diversity exists in CSCs. Furthermore, it has 
been observed that a predominant CSC clone in an initial diagnostic tumour may remain 
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predominant clone or replaced by minor CSC subclone in recurrent tumour(s) after 
cancer therapy and tumour xenografts after serial transplantations in immunodeficient 
mouse model. Both studies have suggested that genetic diversity within CSC subclones 
allows tumour cells to develop drug resistantance mechanism, survive and adapt 
stringent milieu, and metastasize to distant sites (Anderson et al. 2011; Notta et al. 
2011). Another example to support diverse heterogeneity within CSCs is the markers 
expressed by CSCs derived from human breast cancers. Previously, two studies 
employed different approaches to isolate CSCs from human breast cancer and gain two 














 phenotype represented 11-35% of total tumour cell population 
(Al-Hajj et al. 2003). In the other study, 3-10% of CSCs expressing ALDH1 were 
detected in total tumour cells. Moreover, only 0.1-1.2 % of breast cancer cells exhibiting 






, suggesting that most 
cells of the two CSC groups did not overlap. The results of in vivo experiment showed 
that CSCs expressing ALDH1 alone or both phenotypes were tumourigenic whereas 






 did not initiate 
tumour (Ginestier et al. 2007). Although breast tumour cells expressing ALDH1 were 











 were demonstrated to produce mammosphere in sphere 
formation assay and express EMT phenotype (Grimshaw et al. 2008; Mani et al. 2008).  
 The third issue about the controversy of CSC theory is that some extrinsic factors 
such as microenvironment and intrinsic factors genetic instability may have considerable 
impact on increasing the fraction of CSCs, leading to directing radiosensitive tumour 
cells to evolving to radioresistant cells, and enhacing invasive and metastatic phenotypes 
(Baccelli and Trumpp 2012). Indeed, it has been demonstrated that differentiated tumour 
cells can aquire CSC phenotypes through reprogramming process (Baccelli and Trumpp 
2012). Induction of EMT, by either TGFβ1 treatment or ectopic expression of Snail or 
Twist transcription factors, allowed immortalized human mammary epithelial cells 
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) of mammary SCs and CSCs. In the 
same study, expression of EMT-associated genes, such as up-regulation of genes 
encoding vimentin, Snail, Slug, Twist and N-cadherin and down-regulation of E-
cadherin, was detected in SCs isolated from normal human and mouse mammary tissues 
as well as CSCs isolated from human breast carcinomas (Mani et al. 2008). In addition, 
intratumoural microenvironment may release factors which can maintain or increase 
self-renewal and stemness of tumour cells. For instance, hepatocyte growth factor 
released by intratumoural myofibroblasts has been found to maintain active Wnt 
signaling in the neighbor CSCs and other differentiated tumour of colon cancer, thus 
maintaining CSC pool and driving differentiated tumour cells to express CSC phenotype 
(Vermeulen et al. 2010).  
 Taken together, as tumour relapse and metastasis remain to be the major problem 
to solve, it is suggested that tumour evolution during disease progression, existence of 
genetically diverse subclones in CSCs, genetic instability in tumour cells, and 
micronenvironment factors should be considered, in addition to CSC concept, for future 




1.9 Research hypothesis  
 It is evident that class I PI3K regulates a wide range of cellular processes, 
including cell cycle progression, survival, protein synthesis, motility, metabolism and 
autophagy, via its two major downstream effectors Akt and mTOR (Huang and 
Houghton 2003; Manning and Cantley 2007; Engelman 2009). In recent decades, 
overexpression of class I PI3K/Akt/mTOR pathway as a result of alterations of the 
components of this pathway has been implicated in tumourigenesis in various cancer 
types in human, mouse and canine species. More recently, emerging evidence suggests 
overexpression of class I PI3K pathway may positively maintain CSC viability and 
confer multidrug reasistance of CSCs (Bleau et al. 2009; Dubrovska et al. 2009). In 
preclinical studies, inhibition of class I PI3K/Akt/mTOR axis signaling by utilizing 
small molecular inhibitors or small interfering RNA (siRNA) has been demonstrated to 
significantly reduce cell viability in vitro or tumour regression in vivo (Bjornsti and 
Houghton 2004; Altomare and Testa 2005; Bertelsen et al. 2006). In addition, some of 
this pathway inhibitors, such as Temsirolimus (CCI-779) and Everolimus (RAD001), 
have been approved by FDA and the European Medicines Agency for the treatment of 
advanced renal cell carcinoma and advanced pancreatic neuroendocrine tumours (Yuan 
et al. 2009; Saif 2011; Yao et al. 2011).   
 Therefore, the hypothesis underlying this research is that canine tumourigenesis 
is class I PI3K/Akt/mTOR axis pathway-dependent. Blockade of this pathway by 
utilizing selective small molecule inhibitors can prevent proliferation and survival of 





1.10 Research aims 
 Investigation into the role of the class I PI3K/Akt/mTOR pathway in canine 
tumourigenecity in vitro 
 Evaluation of the efficacy of class I PI3K pathway inhibitors against cell 
viability in canine tumours in vitro 
 Investigation into the mechanism of class I PI3K pathway inhibitors 
 Evaluation of the efficacy of the combined therapy of two class I PI3K pathway 
inhibitors for canine tumours in vitro  
 Evaluation of the efficacy of the PI3K pathway inhibitors in combination with 
chemotherapy for the treatment of canine tumours in vitro   
 Investigation into the activity of the class I PI3K/Akt/mTOR pathway in the 

















2.1 Cell lines  
2.1.1 Cell lines and growth medium 
Jurkat T (human acute lymphoblastic leukemia of T cell orgin, 3132 (canine 
lymphoma of B-cell origin), REM134 (canine mammary carcinoma), SB (canine 
hemangiosarcoma), J3T (canine glioma) and C2 (canine mast cell tumour) cells, were 
used in this study (Table 2.1). The Jurkat T, 3132, REM134 and J3T cells were grown in 
RPMI1640 (11835, Gibco, Invitrogen, Paisley, UK), RPMI 1640 (11835, Gibco, 
Invitrogen, Paisley, UK), DMEM (41965, Gibco, Invitrogen, Paisley, UK) and DMEM 
(41966, Gibco, Invitrogen, Paisley, UK) media respectively, all of which contained 10% 
v/v (volume to volume) fetal bovine serum (FBS), 100 unit (U)/milliliter (ml) penicillin 
and 100 μg/ml streptomycin. The C2 cell line was grown in Minimum Essential Medium 
Eagle (M5650, Sigma-Aldrich, Ayrshire, UK) medium containing 5% FBS, 1% non-
essential amino acid mix (NEAA) (Sigma-Aldrich, St Louis, MO, USA), 1% 
GlutaMAX-1 (Invitrogen, Paisley, UK), 50 microgram (μg)/ml gentamicin. The SB cell 
line was grown in EBM-2 (CC-3135, Lonza, Basel, Switzerland) supplemented with 2% 
FBS and EGM-2 SingleQuots (CC-4176, Lonza, Basel, Switzerland) kit containing 
0.04% hydrocortisone, 0.4% hFGF, 0.1% VEGF, 0.1% R3-IGF-1, 0.1% ascorbic acid, 




Table 2.1. Cell lines used in this study 
Cell line Origin Source Culture medium 
Jurkat T acute lymphoblastic 
leukemia of T cell orgin 
(Schneider et al. 
1977) 
RPMI1640 






REM134 canine mammary 
carcinoma 
(Else et al. 1982) DMEM 
J3T  canine glioma (Berens et al. 1999; 




(Akhtar et al. 2004) EBM-2/EGM-2  










2.1.2 Cells from liquid nitrogen  
 Eppendorfs containing cryopreserved cells were taken out of liquid nitrogen and 
stored in dry ice until ready for cell culture. The growth medium and sterilized 1 x 
phosphate buffered saline (PBS) were warmed in water bath to 37 
o
C. The eppendorfs 
were quickly thawed in water bath. 70% ethanol was sprayed on the eppendorfs and the 
bottles of growth media and PBS for disinfection before they were placed in a Class 2 
Biological Safety Cabinet. After that, the defrosted cells were transferred from the 
eppendorffs to a 15 ml tube. 9 ml of PBS was pipetted into the 15 ml tube and mixed 
with the cells. Subsequently, the 15 ml tube was spun in a centrifuge at 1500 rpm for 5 
mins at room temperature. The supernatant was discarded. The cell pellet was 
resuspended in 7 ml of growth medium, followed by transferred to a T25 flask and 
cultured at 37 
o
C in a humidified atmosphere with 5% CO2.    
2.1.3 Passaging cells 
 Growth media and 0.25% Trypsin-EDTA (1x) containing phenol red (Cat. No. 
25200, Gibco) were stored at 4 
o
C. Sterilized PBS was stored at room temperature. 
Before cells were passaged, all the reagents, including growth media, Trypsin-EDTA 
and sterilized PBS, were warmed in water bath to 37 
o
C. 70% ethanol was sprayed on 
the surface of all the reagents and equipments for disinfection before they were placed in 
a Class 2 Biological Safety Cabinet. 
2.1.3.1 Passaging cells- Adherent cells 
 When adherent cells, such as REM134, J3T, and SB cells, were grown at 80-95% 
confluency in a flask, cells were passaged. Growth medium was taken off by pipetting 
and cells were washed twice with PBS. Subsequently, various volumes (T25 flask– 1 ml, 
T75 flask- 2 ml, T150 flask- 4 ml) of 0.25% Trypsin-EDTA were added to the flask, 
ensuring that the Trypsin-EDTA covered the monolayer of cells. Then, the flask was 
incubated at 37 
o
C with 5% CO2 for 3-5 mins until cells were detached. An equal 
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volume of FBS-containing growth medium was mixed with 0.25% Trypsin-EDTA in the 
flask, in order to terminate trypsinization. Cell suspension was transferred to a 50 ml 
tube and spun in a centrifuge at 1500 rpm for 5 mins at room temperature. The 
supernatant was discarded and cell pellet was resuspended in 10 ml of growth medium. 
For splitting cells at the ratio of 1:10, 1 ml out of the 10 ml cell suspension was 
transferred from the 50 ml tube to a new flask which contained the appropriate volumes 
of fresh growth medium (T25 flask- 6 ml, T75 flask- 12 ml, T150 flask- 27 ml). Then, 
the flask was incubated at 37 
o
C in a humidified atmosphere with 5% CO2.     
2.1.3.2 Passaging cells- Non-adherent cells  
 When non-adherent (suspension) cells, including Jurkat T and 3132 cells, were 
grown to 80% confluency, the whole cell suspension was transferred from the flask to a 
50 ml tube and spun at 1500 rpm for 5 mins at room temperature. The supernatant was 
discarded and cell pellet was resuspended in 10 ml of growth medium. For splitting cells 
at the ratio of 1:10, 1 ml out of the 10 ml cell suspension was transferred from the 50 ml 
tube to a new flask containing the appropriate volumes of fresh growth medium (T25 
flask- 6 ml, T75 flask- 12 ml, T150 flask- 27 ml). Then, the flask was incubated at 37 
o
C 
in a humidified atmosphere with 5% CO2.     
2.1.3.3 Passaging cells- C2 cell line  
 60% of C2 cells were adherent whereas 40% of C2 cells were non-adherent. As 
for cell passage, the whole cell suspension was transferred the cell suspension from the 
flask to a 50 ml tube. Then, the flask was washed twice with PBS. Various volumes 
(T25 flask– 1 ml, T75 flask- 2 ml, T150 flask- 4 ml) of 0.25% Trypsin-EDTA were 
added to the flask. Then, the flask was incubated at 37 
o
C with 5% CO2 for 3-5 mins 
until cells were detached. An equal volume of FBS-containing growth medium was 
mixed with 0.25% Trypsin-EDTA in the flask, in order to terminate trypsinization. The 
whole cell suspension was transferred from the flask to the 50 ml tube which contained 
non-adherent C2 cells, followed by spun in a centrifuge at 1500 rpm for 5 mins at room 
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temperature. The supernatant was discarded and cell pellet was resuspended in 10 ml of 
growth medium. For splitting cells at the ratio of 1:10, 1 ml out of the 10 ml cell 
suspension was transferred from the 50 ml tube to a new flask containing the 
approapriate volumes of fresh growth medium (T25 flask- 6 ml, T75 flask- 12 ml, T150 
flask- 27 ml). Then, the flask was incubated at 37 
o
C in a humidified atmosphere with 
5% CO2.     
2.1.4 Counting cells 
 Cells were counted by using Neubauer improved haemacytometer (bright-lined, 
with spring clips). For adherent cells and the C2 cell line, cells were counted following 
the termination of trypsinization (see Chapter 2, Section 2.1.3.1 and 2.1.3.3).   
 A cover slip was placed on top of both counting chambers of the 
haemacytometer. 15 µl of 0.4% Trypan Blue (Sigma-Aldrich) was mixed with 15 µl of 
cell suspension. 10 µl of the mixture was pipetted into each counting chamber. Cells 
were counted in the central 25 squares, which contained 0.1 µl of the mixture, in each 
counting chamber. Then, the following formula of cell count was used: 





 After cells were counted, cells were spun at 1500 rpm for 5 mins at room 
temperature. The supernatant was discarded and the cell pellet was resuspended in 
growth medium at the density of 6 x 10
6
 cells/ml. 0.5 ml of cell suspension which 
contained 3 x 10
6
 cells was stored in 0.5 ml of freezing medium composed of 10% 
dimethyl sulfoxide (DMSO) and 90% FBS in an 1.5 ml vial. The vial containing cells 





cryopreservation container and stored at -70
o
C for 1-2 days. Then, the vial was stored in 
liquid nitrogen.   
2.2 Sphere cell culture 
All work of Section 2.2 Sphere cell culture courtersy of Dr. Lisa Pang  
2.2.1 Growing J3T sphere and growth medium 
 Before cells were passaged, all the reagents, including N2 growth media, 0.25% 
Trypsin-EDTA and sterilized PBS, were warmed in water bath to 37 
o
C. 70% ethanol 
was sprayed on the surface of all the reagents and equipments for disinfection before 
they were placed in a Class 2 Biological Safety Cabinet. 
 The pellet of canine J3T cells was resuspended in 2 ml of sterilized PBS 
following trypsinization was terminated and cells were spun in a centrifuge (see Chapter 
2, Section 2.1.3.1). Then, the cell counting method was performed (see Chapter 2, 
Section 2.1.4). Cells were spun in a centrifuge at 1500 rpm for 5 mins at room 
temperature. The supernatant was discarded and the cell pellet was resuspended in 
serum-free N2 medium with 0.8% methylcellulose at the density of 3 x 10
5
 cells/ml. For 
this, a 1:1 mixture of 1.6% methylcellulose (Sigma-Aldrich) and 2X DMEM/F12 
medium  (Sigma-Aldrich) supplemented with 20 nM progesterone (Sigma-Aldrich), 100 
µM putrescine dihydrochloride (Sigma-Aldrich), 30 nM sodium selenite (Sigma-
Aldrich), 25 µg/ml human apo-Transferrin (Sigma-Aldrich), 20 µg/ml insulin from 
bovine pancreas (Sigma-Aldrich), 2.4 mg/ml sodium bicarbonate (Sigma-Aldrich), 10 
nanogram (ng)/ml human EGF (PeproTech, Rocky Hill, USA) and 10 ng/ml human 
bFGF (PeproTech, Rocky Hill, USA).  
2 ml of cell suspension which contained 60,000 cells was pipetted into each well 
in six-well Ultra Low Attachment plates (Corning) and incubated at 37 
o
C in a 
humidified atmosphere with 5% CO2. Sphere cells were fed with 10 µl of 10 ng/ml 
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human EGF and 10 ng/ml human bFGF in each well every 3 days. After culture for 1-2 
weeks, colonies were counted under light microscope.  
2.2.2 Passaging spheres 
 2 ml of PBS was added to each well and mixed with the growth medium, in order 
to reduce the viscosity of N2 grwoth medium. The cell suspension was collected and 
transferred to a 15 ml tube. Another 2 ml of PBS was added to the tube and the tube was 
spun at 1000 rpm for 5 mins at room temperature. Supernatant was discarded and the 
cell pellet was resuspended in 0.5 ml of 0.05% Trypsin-EDTA, followed by incubated at 
37 
o
C for 10 mins or until spheres were dissociated into sigle cells. 0.5 ml of FBS-
containing medium was added to the tube for termination of trypsinization. After that, 
sphere cells were counted (see Chapter 2, Section 2.1.4). Cells were spun in a centrifuge 
at 1000 rpm for 5 mins at room temperature. Supernatant was discarded and the cell 
pellet was resuspended in serum-free N2 medium with 0.8% methylcellulose at the 
density of 3 x 10
5
 cells/ml. 2 ml of cell suspension which contained 60,000 cells was 
pipetted into each well in six-well Ultra Low Attachment plates and incubated at 37 
o
C 
in a humidified atmosphere with 5% CO2. 
2.3 Drug compounds and pathway inhibitors 
ZSTK474 (pan-PI3K inhibitor, Z-1066, LC Laboratories, USA) and Wortmannin 
(pan-PI3K inhibitor, 1232, Tocris bioscience, USA), and KP372-1 (Akt inhibitor, B-
0102, Echelon, USA), all of which were supplied in powder forms, were made up to 40 
millimolar (mM) stock solutions in DMSO and stored in 15 μl aliquots at -70 
o
C. 
Rapamycin (mTOR inhibitor, R0395, Sigma-Aldrich, USA), which was supplied in 
powder form, was made up to 20 mM stock solution in DMSO and stored in 10 μl 
aliquots at -70 
o
C. All the stock solutions of the inhibitors, including ZSTK474, 
Wortmannin, KP372-1 and Rapamycin were diluted freshly in cell medium before use. 
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Doxorubicin at 2 mg/ml concentration was purchased from Pharmacia, Pfizer Service 
Company (Zaventem, Belgium) and was soluble in water.   
2.4 Cell viability assay 
 Cells were seeded at a density of 3 x 10
3 
cells per well in 96-well plates 
overnight at 37
o
C with 5% CO2, followed by incubated with various doses of either 
single agent or in combination with other drugs, or DMSO vehicle for a period of time. 
All experiments were performed in at least three replicates. After the drug treatment, the 
number of viable cells was determined by using CellTiter-Glo® Luminescent Cell 
Viability Assay (Promega, Madison, WI, USA) according to the manufacturer’s 
instructions. This commercial kit quantified cell viability by measuring the amount of 
ATP released from viable cells. The more viable cells were present, the more ATP 
released and the higher the value of luminescence detected.  
2.5 Analysis of apoptosis and cell death 
Cells were plated at a density of 3 x 10
4
 cells per ml and incubated overnight at 
37
o
C with 5% CO2. After that, cells were exposed to 20 micromolar (µM) ZSTK474 for 
2 days, 400 nanomolar (nM) KP372-1 for 1 day, 20 µM Rapamycin for 2 days or vehicle 
control and then were collected for apoptosis analysis by using FITC Annexin V 
Apoptosis Detection Kit I (556547, BD Pharmingen™, San Diego, CA, USA). In brief, 
harvested cells were washed with cold PBS and re-suspended in 100 µl of 1x Binding 
Buffer, followed by stained with FITC Annexin V antibody and propidium iodide (PI) 
for 15 min in the dark at room temperature, according to the manufacturer’s instructions. 
Cells were analyzed by flow cytometry using FACS Calibur Flow Cytometer and 
CellQuest software (BD Biosciences, San Jose, California). 
2.6 Western blotting 
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2.6.1 Cell lysis 
Cells were seeded at a density of 20,000 cells per ml overnight at 37 
o
C with 5% 
CO2, and then incubated with various doses of either single agents or combinations of 
other drugs, or DMSO vehicle for a period of time. After the drug treatment, the cells 
were prepared for cell lysis. For adherent cell lines, medium was discarded and cells 
were rinsed with 1 ml cold PBS. Then, the cold PBS was taken off and 1 ml fresh cold 
PBS was added to cells. After that, cells were harvested by using cell scrapers and 
transferred to an 1.5 ml eppendorf, which was placed on ice. For suspension cell lines, 
cells were spun down in Centrifuge for 5 mins at the rotational speed of 1500 rpm at 25
 
o
C. Then, medium was discarded. Cells were resuspened in 1 ml cold PBS and 
transferred to 1.5 ml eppendorf, which was placed on ice.  
Cells in cold PBS in 1.5 ml eppendorfs were centrifuged for 5 mins at the speed 
of 5000 rpm at 4 
o
C and the supernatant was removed. After that, cell pellets could be 
either lyzed by using Nonidet-P40 (NP40) lysis buffer, or snap frozen in dry ice for 5 




   
The 1% NP40 lysis buffer contained 1% IGEPAL CA-630 (Sigma-Aldrich, St. 
Louis, MO), 150 millimolar (mM) KCl, 25 mM Hepes (pH 7.4), 5 mM dithiothrietol 
(DTT), and 50 mM NaF. This lysis buffer was stored in 450 μl aliquots at -20 
o
C. In 
addition, 10 x Complete Mini Protease Inhibitor Cocktail Tablet (Roche, Mannheim, 
Germany) was dissolved in 500 μl distilled water, dispensed into aliquots (50 µl) and 
stored at -20 
o
C. To lyse cells, one volume of 10 x Complete Mini Protease Inhibitor 
Cocktail Tablet and nine volumes of 1% NP40 lysis buffer were thawed and mixed well. 
Then, twice the pellet volume of 1% NP40 buffer which contained 1 x Complete Mini 
Protease Inhibitor Cocktail Tablet was added to the cell pellet. The cell pellet was mixed 
thoroughly by pipetting in the lysis buffer and the pipetting process should be performed 
on ice. Then, cell pellet in lysis buffer was incubated on ice for 15 mins and centrifuged 
at 14000 rpm for 15 mins at 4 
o
C. After that, the supernatant was aspirated and 
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transferred to 1 ml eppendorff, followed by snap frozen in dry ice. All frozen 
supernatant samples were stored at -70 
o
C.    
2.6.2 Protein quantification 
The protein extracts were quantified by using Quick Start Bradford Protein 
Assay (Biorad Laboratories, CA, USA) according to the manufacturer’s instruction. In 
the first place, samples were prepared as 1/20 and 1/40 dilutions. For 1/40 dilution, 19.5 
µl distilled water was mixed with 0.5 µl sample by pipetting. For 1/20 dilution, 19 µl 
distilled water was mixed with 1 µl sample by pipetting. Volumes prepared were 
sufficient for two replicates.  
Secondly, 2 mg/ml bovine serum albumin (BSA) standards and serial dilutions 
were prepared as shown in Table 2.2, according to the manufacturer’s instruction. 
Volumes prepared were sufficient for three replicates.    
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Table 2.2. BSA standards and serial dilutions 








1 20 2 mg/ml stock 0 2000 
2 30 2 mg/ml stock 10 1500 
3 20 2 mg/ml stock 20 1000 
4 20 Tube 2 20 750 
5 20 Tube 3 20 500 
6 20 Tube 5 20 250 
7 20 Tube 6 20 125 
8 0 none 20 0 
Table 2.2 was reproduced from Quick Start™ Bradford Protein Assay Instruction 
Manual (Biorad Laboratories, CA, USA).  
 5 µl of diluted samples and standards were dispensed to a clear 96-well plate. 
Then, 250 µl of Quick Start™ Bradford Dye Reagent (BioRad) was mixed with samples 
and BSA standards. The 96-well plate was read on a plate reader by measuring the 
absorbance at 595 nanometer (nm). Protein concentration of each tested sample was 
determined from a standard curve, which was produced from plotting the mean 
absorbances for BSA standards.       
2.6.3 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) 
2.6.3.1 Making resolving gels 
 Gel cassettes and glass plates were assembled for gel casting. After that, 6%, 
10% and 15% resolving gels (10 ml) were prepared using the following recipes shown in 
135 
 
Table 2.3. As for the reagents for making resolving gels, 30% (w/v) acrylamide/bis-
acrylamide (National Diagnostics, UK) was stored in a dark area at room temperature. 
1.5M Tris-HCl (pH 8.8) and 10% (w/v) sodium dodecyl sulphate (SDS) (Sigma-Aldrich) 
were stored at room temperature. 10% (w/v) ammonium persulfate (APS) (Sigma-
Aldrich) was stored at 4 
o
C. N,N,N’,N’-tetramethylethylenediamine (TEMED) (Sigma-
Aldrich) was protected from light and stored at 4 
o
C. 
 It should be noted that both of 10% APS and TEMED were added to the 
resolving gel solution right before the gel solution was poured between the assembled 
glass plates, because both reagents could cause gel polymerization. Then, isopropanol 
was overlaid on the gel solution which was poured between the assembled glass plates, 
in order to prevent air bubbles existing in the gel. The gel solution was allowed to 
polymerize for 30-45 mins. After that, isopropanol was discarded and stacking gel 
solution was prepared.       
Table 2.3. Recipes for making 10 ml resolving gels.  
 6% (ml) 10% (ml) 15% (ml) 
Distilled water 5.3 4 2.35 
30% (w/v) acrylamide/bis-
acrylamide   
2.0 3.3 4.95 
1.5M Tris-HCl pH 8.8 2.5 2.5 2.5 
10% (w/v) SDS 0.1 0.1 0.1 
10% (w/v) APS  0.1 0.1 0.1 
TEMED 0.008 0.004 0.004 
 The resolving gels were used to separate a variety of molecular weight proteins. 
Lower molecular weight proteins required higher percentage resolving gels, which 
contained smaller pore sizes, for resolution.       
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2.6.3.2 Stacking gels 
 5% stacking gel was prepared using the following recipe (Table 2.4). 10% APS 
and TEMED, which acted to initiate gel polymerization, were added to staking gel 
solution right before the gel solution was poured and overlaid on the resolving gel in the 
assembled glass plates. Then, a comb was placed between the assembled glass plates, for 
the purpose of creating wells for loading samples. The stacking gel solution was allowed 
to polymerize for 30 mins.  After polymerization of the stacking gel was completed, the 
whole SDS gel set which was composed of staking and resolving gels was ready for 
electrophoresis. Alternatively, the whole SDS gel set with comb could be wrapped in 
cling film and stored at 4 
o
C for 1-2 days.  
   Table 2.4. Recipes for making a 5 ml stacking gel.  
 5% (ml) 
Distilled water 3.4 
30% (w/v) acrylamide/bis-
acrylamide   
0.83 
1 M Tris-HCl pH 6.8 0.63 
10% (w/v) SDS 0.05 
10% (w/v) APS  0.05 
TEMED 0.005 
 
2.6.3.3 Sample and Running buffer prepared for electrophoresis  
 16 ml of 4 x Sample Buffer which contained 4 ml of 20% SDS, 4 ml of 1 M Tris-
HCl (pH 6.8), 5 ml of 80% glycerol, 2 ml of 0.1 M ethylenediaminetetraacetic acid 
(EDTA), and 1 ml of 1% bromophenol blue. At each use, 800 µl of 4 x Sample Buffer 
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was mixed with 200 µl of fresh 1M DTT. Protein samples were thawed on ice. Then, 1 
volume of 50 µg protein sample was mixed thoroughly with 1 volume of 4 x Sample 
Buffer that contained DTT. Pre-stained molecular weight markers and all of the samples 
with Sample Buffer were heated to 100 
o
C for 2-3 mins. In this study, two types of pre-
stained molecular weight markers were used; the pre-stained, broad range SDS-PAGE 
standards (Cat No. 161-0318, BioRad) and the Amersham full-range rainbow molecular 
weight marker (Cat No. RPN800E, GE Healthcare). After all of the samples were 
denatured by heating, the samples and molecular markers were ready for being loaded 
into the wells of SDS gel.  
 1000 ml of 1 x Running Buffer (pH 8.3) was prepared by mixing 100 ml of 10 x 
Running Buffer with 900 ml of distilled water. To make 1000 ml of 10 x Running Buffer 
(pH 8.3), 30.3 gram (g) Tris-HCl, 144 g Glycine, and 10 g SDS were dissolved in 
distilled water and made up to 1000 ml with distilled water.   
 The whole gel set with glass plates and electrophoresis apparatus were assembled 
and placed in the electrophoresis tank. The comb was removed from the stacking gel. 
Both of the assembled electrophoresis apparatus and the wells of the stacking gel were 
filled up with 1 x Running Buffer. Each sample and 5 µl of pre-stained molecular weight 
marker were loaded in each well of the stacking gel. The electrophoresis tank was filled 
up with the rest of 1 x Running Buffer. Samples were run by electrophoresis at 150 Volt 
for 90 mins, or until the dye molecule (the migration front) migrated to the bottom of the 
gel.      
2.6.4 Blotting/Transfer  
 1000 ml of 1 x Transfer Buffer, which contained 100 ml of 10 x Transfer Buffer, 
700 ml of distilled water and 200 ml of methanol, was prepared.  To make 1000 ml of 10 
x Transfer Buffer, 30.3 g Tris-HCl and 144 g Glycine were dissolved in distilled water 
and made up to 1000 ml with distilled water.  
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 The items, including SDS gels, fliter papers, fiber pads and Hybond ECL 
nitrocellulose membranes (Cat No. RPN203D, GE Healthcare), were pre-soaked in 1 x 
Transfer Buffer, followed by assembled as a blotting sandwich. The gel faced the 
negative electrode (black) side and the Hybond ECL nitrocellulose membrane faced the 
positive electrode (clear) side of the cassettes. A plastic 10 ml tube was rolled over the 
nitrocellulose membrane to remove bubbles between the membrane and gel. The placing 
order of each item in the blotting sandwich was shown in Table 2.5. Because proteins 
were denatured and wrapped in negative charges by SDS, these proteins were migrated 
from the gel facing negative electrode side to the nitrocellulose membrane facing the 
positive electrode side during transferring.      
 Table 2.5. The placing order of each item in the blotting sandwich. 
Negative electrode side 
Black cassette 
1 fiber pad 
2-3 sheets of filter papers 
SDS gel 
1 Hybond ECL nitrocellulose membrane 
2-3 sheets of filter papers 
1 fiber pad 
Clear cassette 
Positive electrode side 
  
 After the blotting sandwich was assembled, the cassettes were closed and placed 
into the transblot module. Then, the transblot module, along with an ice pack and 
magnetic flea, were placed in a tank, which was on a magnetic stirrer. The tank was 
filled up with 1 x Transfer Buffer and samples were transferred at 100 Volt for 1 hr, or 
overnight at 20 milliampere (mA).  
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2.6.5 Visulization of proteins in nitrocellulose membranes  
 After transferring, the nitrocellulose membrane was washed with 1 x phosphate 
buffered saline (PBS) containing 0.1% Tween-20 (PBST) 3 times (5 mins each time) on 
an orbital shaker. Then, the nitrocellulose membrane was rinsed in Ponceau-S solution 
for 5-10 mins on an orbital shaker. The Ponceau-S solution was used to stain proteins 
and check whether the proteins were transferred on the nitrocellulose membrane. The 
Ponceau-S was made of 0.1% (w/v) Ponceau S and 5% (v/v) acetic acid in distilled 
water.  The nitrocellulose membrane was destained completely by repeated washing in 
PBST on an orbital shaker.  
 2.6.6 Blocking the membrane and incubation with primary antibody  
After several washes in PBST, the nitrocellulose membrane was blocked with 
5% (w/v) skimmed milk in PBST for at least 1 hr at room temperature on an orbital 
shaker, in order to prevent non-specific binding of the primary and secondary antibodies. 
After that, the nitrocellulose membrane was incubated with primary antibody diluted in 
5% (w/v) skimmed milk in PBST at 4 
o
C, overnight (Table 2.6.). The primary antibodies 
were diluted at various concentrations, according to manufacturer’s recommendation. 
All antibodies have previously been validated for canine proteins (Paoloni et al. 2010). 
140 
 
Table 2.6. Primary antibodies used for western blotting analysis 
Protein Name Manufacturer Catalog No. Dilution used Molecular 
weight 
Raised in Clonality 
PTEN Abcam ab23694 1:1000 47 rabbit polyclonal 
phospho (p)-Akt 
(Ser473) 
Cell Signaling 4060 1:1000 60 rabbit monoclonal 
mTOR Cell Signaling 2972 1:1000 289 rabbit polyclonal 
p-mTOR (Ser2448) Cell Signaling 2971 1:1000 289 rabbit polyclonal 
p-S6RP 
(Ser235/236) 
Cell Signaling 2211 1:1000 32 rabbit polyclonal 
p-4E-BP1 (Thr37/46) Cell Signaling 9454 1:1000 15-20 rabbit polyclonal 
p-4E-BP1 (Thr70) Cell Signaling 9455 1:1000 15-20 rabbit polyclonal 
eIF4E Cell Signaling 9742 1:1000 25 rabbit polyclonal 
p-eIF4E (Ser209) Abcam ab76256 1:1000 25 rabbit monoclonal 
β-actin Abcam ab6276 1:5000 45 mouse monoclonal 
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2.6.7 Incubation with secondary antibody 
 After the completion of incubation with primary antibody, the nitrocellulose 
membrane was washed with PBST three times (5 mins each time) on an orbital shaker. 
Subsequently, the membrane was incubated with either swine anti-rabbit horseradish 
peroxidase (HRP) conjugated secondary antibody or rabbit anti-mouse HRP conjugated 
secondary antibody, both of which were purchased from DAKO (Glostrup, Denmark). 
Both types of secondary antibody were diluted 1:2000 in 5% (w/v) skimmed milk in 
PBST. The membrane was incubated with secondary antibody for 1 hr on an orbital 
shaker at room temperature. After that, the membrane was washed in membrane was 
washed with PBST three times (10 mins each time) on an orbital shaker and prepared for 
chemiluminescent detection.  
2.6.8 Chemiluminescent detection 
 To detect the presence of a targeted protein band, one volume of a luminol 
solution which contained luminol (a chemiluminescent substrate for HRP) was mixed 
with one volume of an enhanced luminol solution. The luminol solution (100 ml) was 
made up of 1 ml of 250 mM luminol stock, 0.44 ml of 90 mM p-Coumaric acid stock, 
6.67 ml of 1.5 M Tris-HCl (pH 8.8), and 91.89 ml of distilled water. The enhanced 
luminol solution (100 ml) contained 64 μl of 30% hydrogen peroxide, 6.67 ml of 1.5 M 
Tris-HCl (pH 8.8) and 93 ml of distilled water. Both solutions were protected from light 
and stored at 4 
o
C.  
 The membrane was covered by the mixing solution composed of the luminol 
solution and the enhanced luminol solution for 1-2 mins at room temperature. Then, 
excess solution was drained off. The membrane was transferred to a rectangular glass 
plate and wrapped in cling film (Saran
TM
 Premiun Wrap). The presence of air bubbles 
between the cling film and the membrane should be avoided. The wrapped membrane 
and glass plate were placed in an X-ray film cassette. In a dark room, a sheet of 
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radiographic film (Hyperfilm ECL, Cat No. 45-001-506, GE Healthcare Amersham) was 
placed on top of the wrapped membrane and the film cassette was closed for 10 secs to 
20 mins, depending on signal intensity. The radiographic film was sent to an automated 
x-ray film developer for film development.  
2.6.9 Stripping  
 To reuse a blot (nitrocellulose membrane) for detecting and probing other 
targeted proteins, stripping buffer was used to remove the previous set(s) of protein 
probes, including primary and secondary antibodies, from the blot. After the film 
development, the blot (nitrocellulose membrane) was washed with PBST twice (5 mins 
each time) on an orbital shaker. The blot was rinsed with Restore™ Western Blot 
Stripping Buffer (Cat No. 21059, Thermo Fisher Scientific Inc-Pierce, USA) for 10-45 
mins, depending on the signal intensity of the previous set(s) of protein probes, on an 
orbital shaker at room temperature. It was recommended that the antibody probed side of 
the blot faced the stripping buffer, allowing the stripping buffer to work efficiently. 
After stripping, the stripping buffer was recycled and stored in the dark at room 
temperature. The blot was washed with PBST 3 times (10 mins each time) on an orbital 
shaker. To check whether the stripping buffer was compeletly washed away and the 
proteins remained bound the blot/membrane, Ponceau-S solution was used to stain 
proteins and the staining method was described in Chapter 2, Section 2.6.3.5. If the 
proteins on the blot were not stained with Ponceau-S solution, the blot should be washed 
with PBST until the presence of protein bands with using Ponceau-S staining.  
After the blot (membrane) was destained from Ponceau-S completely by 
repeated washing in PBST on an orbital shaker, the blot was ready for blocking and 
being reprobed with other primary antibodies by repeating the steps described in Chapter 
2, Section 2.6.6 to Section 2.6.9.  




2.7 Analysis of drug combination effect 
The inhibitory effect of two drug combination on cell viability was defined to be 
additive, synergistic and antagonistic by using Bliss additivism model. The methods of 
Bliss analysis was adopted from Buck E et al (2006) (Buck et al. 2006). Hypothetical 
curve was generated by using the equation Ebliss= EA + EB – (EA x EB). While EA 
represented the percentage of decreased cell viability by drug A, EB represented the 
percentage of decreased cell viability by drug B. Therefore, if the cell decreased viability 
(%) of the combination of the two drugs experimentally was greater than Ebliss, the effect 
of the combination was considered to be synergistic. On the contrary, if the percentage 
of decreased viability obtained by an experiment was less than Ebliss, the effect of the 
combination would be considered to be antagonistic. In the present study, the Bliss 
additivity curves were generated by the combination of various doses of drug A and a 
constant dose of drug B.     
2.8 Statistical Analysis 
For analysis of the effects of drugs alone, the values obtained from cell viability 
assay, as shown in the figures in Chapter 3, were compared with the vehicle control on 
the same culture plates, then expressed as percentages of mean values with standard 
deviations (SDs) of at least three replicates using Microsoft Excel 2010 software 
(Microsoft Corporation, USA).   
To analyze the drug combination effects on the inhibition of cell viability, the 
Anderson-Darling Normality Test was performed on all datasets, in which each dataset 
contained all values of two drug treatment groups. If the p-value was greater less than 
0.05, this indicated that a given dataset fitted the assumption of normal distribution, with 
95% confidence, for a t-test. Subsequently, the Two-Sample t-Test with assuming equal 
variances was performed on the dataset that followed the normal distribution. If the p-
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value of the Two-Sample t-Test was less than 0.05, the null hypothesis which stated that 
the effects of two drug treatment groups were equal was rejected. In other words, the 
dataset with a p-value less than 0.05 stated that the effects of two drug treatment groups 
were siginificantly different. If the p-value of the Two Sample t-Test was equal or 
greater than 0.05, this meant that the effects of the two treatment groups were equal.  
  For a dataset which did not fit normal distribution (p-value ≤0.05), the Mann–
Whitney Test was performed on this dataset to determine whether the effects of the two 
drug treatment groups that were compared in this dataset were significantly different. If 
the p-value of the Mann–Whitney Test was less than 0.05, the null hypothesis which 
declared the effects of the two drug treatment groups were the same was rejected. In 
other words, the effects of the two drug treatment groups that were compared in this 
dataset were significantly different when p-value <0.05. On the contrary, a dataset with a 
p-value ≥ 0.05, it was declared that both drug treatment groups had the same effects on 
cell viability inhibition. The Anderson-Darling Normality Test, the Two-Sample t-Test, 
and the Mann–Whitney Test were performed by using Minitab software (Minitab Inc., 
State College, PA, USA).  
2.9 Microarray 
 All work of Section 2.9 Microarray coutersy of Dr. Lisa Pang.  
2.9.1 RNA isolation 
 Total RNA from four samples of J3T parental cells and four samples of J3T 
spheres was purified using the RNA-Bee kit (Qiagen) according to the manufacturer’s 
instructions. Briefly, specimens at a density of 5 x 10
6
 cells were homogenized with 1 ml 
RNA-Bee reagent. Subsequently, phase separation step was performed with addition of 
0.2 ml Choloroform (Sigma-Aldrich), followed by placement on ice for 5 mins and, 
then, centrifuged at 12,000 g (relative centrifugal force (rcf)) for 15 minutes (mins) at 4 
o
C. As a result, RNA was separated from cellular components and remained in 
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transparent aqueous phase. The third step, RNA precipitation, was carried out by 
transferral of aqueous phase to another tube, followed by addition of 0.5 ml Isopropanol 
(Sigma-Aldrich), which led to formation of white pellet composed of RNA fragments. 
Then, the RNA precipitate was washed once with 1 ml 75% ethanol, followed by 
centrifuged at 7,500 g for 5 mins at 4-25 
o
C, air-dried RNA pellet, and resuspended the 
pellet in ~50 µl of sterile distilled water. The purity of RNA yields was measured by 
spectrophtometer NanoDrop 6100 (NanoDrop Technologies, DE). The absorbance (A) 
was measured at 260 nanometer (nm) and 280 nm. The ratio of A260/A280 should be 
within the range between 1.6 and 1.9.  
2.9.2 Microarray data analysis 
 Purified RNA products (1-15 µg of each RNA sample) were sent to ARK-
Genomics (the Roslin Institute, University of Edinburgh, UK) for RNA amplification by 
using MessageAmp aRNA (antisense RNA) kit (Ambion #1750), according to the 
protocol described on the ARK-Genomics website (http://www.ark-
genomics.org/protocols/RNAamplification.php). Subsequently, amplified RNA samples 
were used to generate Biotin-labeled cRNA templates, which were hybridized to 
GeneChip Canine 2.0 Genome Arrays (Affymetrix, Santa Clara, CA, USA). Then, the 
array was washed and scanned with using GeneChip® Operating Software (GCOS) 
software, according to the protocols described on Affymentrix website 
(http://media.affymetrix.com/support/downloads/manuals/expression_analysis_technical
_manual.pdf). The microarray data were analyzed by using Partek Genomic Suite 
software (Agilent), normalized by using Robust Multichip Averaging (RMA) algorithm. 
The statistic analysis was performed by using ANOVA with P value set to 0.005 to 
determine the significant fold changes between the gene profile of progeny cells and that 
of sphere cells.   
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2.9.3 Ingenuity Pathway Analysis (IPA) 
 The microarray data which had gene identifiers with their corresponding fold 
changes were uploaded to the Ingenuity Pathways Analysis (IPA) database website 
(http://ingenuity.com/) for mapping each gene identifier to its corresponding gene 
objective. Graphics of the networks and signaling pathways, which showed genetic 
expression fold changes, were generated for each data set. In these network graphics, 
green colour indicated down-regulation (≥1.5 fold change) of a gene expression whereas 










CHAPTER 3: Dissection of the PI3K/Akt/mTOR pathway 





 The central role of class I PI3K/Akt/mTOR signaling pathway in the regulation 
of cell growth, survival, protein synthesis, metabolism and autophagy in normal and 
cancer cells has made it a promising therapeutic target (Huang and Houghton 2003; 
Manning and Cantley 2007; Engelman 2009). Using small-molecular inhibitors, the 
feasibility of the class I PI3K/Akt/mTOR signaling pathway was explored as a 
therapeutic target in canine oncology either by using pathway inhibitors alone, in 
combination or combined with conventional chemotherapeutic drugs. The inhibitors 
used in this study were Wortmannin (pan-class I PI3Ks inhibitor), ZSTK474 (pan-class I 
PI3K inhibitor), KP372-1 (Akt inhibitor) and Rapamycin (mTOR inhibitor). The results 
showed that ZSTK474, KP372-1 and Rapamycin significantly down-regulated cell 
viability at micromolar, nanomolar and micromolar ranges, respectively whereas the 
effects of Wortmannin were cell line-dependent. Dissection of the mechanism of these 
inhibitors using western blot analysis and annexin V staining showed that all inhibitors 
acted to decrease phosphorylation of class I PI3K pathway members. Annexin V 
staining demonstrated that KP372-1 and Rapamycin induced apoptosis at nanomolar and 
micromolar ranges respectively whereas the induction of apoptosis by ZSTK474 and 
Wortmannin were cell-line dependent. Simultaneous inhibition of class I PI3K and 
mTOR by either Wortmannin or ZSTK474 in combination with Rapamycin additively or 
synergistically reduced cell viability, with the exception of canine J3T and REM cell 
lines treated with Wortmannin and Rapamycin. The effects of the four inhibitors 
combined with the chemotherapeutic agent Doxorubicin were cell line-dependent. 
Rapamycin-induced autophagy was cell-line dependent. In conclusion, this study shows 
that the class I PI3K/Akt/mTOR signaling pathway supports the survival and viability of 





 The class I PI3K/Akt/mTOR signaling pathway comprises a series of 
serine/threonine kinase cascades that regulate a variety of cellular processes, including 
cell cycle progression, cellular survival and migration, protein synthesis, motility, 
metabolism and autophagy. Recent evidence supports the hypothesis that the 
dysregulation of class I PI3K/Akt/mTOR signaling promotes tumourigenesis and 
angiogenesis in various cancer types (Altomare and Testa 2005; Chiang and Abraham 
2007; Engelman 2009). 
 The class I PI3K/Akt/mTOR pathway is frequently activated by two types of cell 
surface receptors, which are RTKs and GPCRs after binding to their ligands such as 
growth factors, hormones and chemokines (Dorsam and Gutkind 2007; Lemmon and 
Schlessinger 2010). The class I PI3Ks can be further categorized into class IA PI3K and 
class IB PI3K, according to their upstream regulators and regulatory subunits. The RTKs 
stimulate class IA PI3Ks by direct interaction with p85 regulatory subunit and indirect 
interaction with p110α/p110β/p110δ catalytic subunit of class IA PI3K via Ras. The 
GPCRs stimulate class IB PI3K through interaction with p110γ catalytic subunit via Ras 
and with p101 or p87/p84 regulatory subunit of class IB PI3K (Wymann and Pirola 
1998; Suire et al. 2005). After class I PI3Ks are activated, their catalytic subunits can 
transfer the γ-phosphate group of ATP to PtdIns(4,5)P2, leading to the conversion of 
PtdIns(4,5)P2 to PtdIns(3,4,5)P3. Subsequently, the PtdIns(3,4,5)P3 can recruit PDK1 
and Akt to the inner side of cell membrane, which facilitates PDK1 to phosphorylate and 
activate Akt. In contrast, Akt activity can be counteracted by PTEN through conversion 
of PtdIns(3,4,5)P3 back to PtdIns(4,5)P2 (see Chapter 1, Figure 1.01) (Faivre et al. 
2006). 
Activated Akt can transduce signals to mTORC1 which is composed of mTOR, 
Raptor, PRAS40 and mLST8 (Sancak et al. 2007; Vander Haar et al. 2007; Ramirez-
Valle et al. 2010). Akt activates mTORC1 through two routes. The first route is that Akt 
inhibits TSC1–TSC2 complex by direct phosphorylation of TSC2. This decreases 
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TSC1–TSC2 complex-regulated GAP activity towards Rheb and in turn maintains high 
levels of active GTP-bound Rheb. The GTP-bound Rheb acts as a positive regulator of 
mTORC1 (Manning et al. 2002; Manning and Cantley 2003). Alternatively, Akt 
phosphorylates PRAS40 and impairs PRAS40-mediated mTORC1 inhibition (see 
Chapter 1, Figure 1.01) (Sancak et al. 2007; Vander Haar et al. 2007).  
 The class I PI3K effects on cellular functions through its two major downstream 
effectors Akt and mTOR. The activated Akt can perform multiple functions by direct 
phosphorylation of its downstream effectors. These functions of the Akt are activation of 
protein synthesis through mTORC1, promotion of G1/S cell cycle progression through 




 and GSK3, promotion of G2/M cell cycle 
progression through Chk1, against apoptosis through FoxO transcription factors and 
Bad, promotion of survival through IKK-α and MDM2, encouragement of glucose 
uptake into cell through AS160, up-regulation of glycogen synthesis through GSK-3, 
and inhibition of gluconegesis through FoxO1 (see Chapter 1, Figure 1.08) (Cross et al. 
1995; Datta et al. 1997; Brunet et al. 1999; Ozes et al. 1999; Nakae et al. 2001; Zhou et 
al. 2001; Liang et al. 2002; Huang and Houghton 2003; Eguez et al. 2005; Puc et al. 
2005; Patel et al. 2008; Fenouille et al. 2011; van der Vos and Coffer 2011).   
mTORC1 plays an important role in regulation of protein synthesis via its two 
well-characterized downstream effectors, p70S6K and 4E-BP1. mTORC1 activates 
p70S6K through direct phosphorylation of p70S6K on Thr229, Thr389, Ser404, and 
Ser411. This enables p70S6K to activate S6RP through phosphorylation of S6RP on 
Ser235, Ser236, Ser240, and Ser244, which results in triggering S6RP-modulated 
translation of TOP mRNAs that frequently encode ribosomal proteins and elongation 
factors (see Chapter 1, Figure 1.01) (Ferrari et al. 1991; Terada et al. 1994; Han et al. 
1995; Jefferies et al. 1997; Iadevaia et al. 2008). mTORC1 phosphorylates 4E-BP1 on 
Thr37, Thr46, Thr70 and Ser65 in a hierarchical manner, which causes the dissociation 
of eIF4E from 4E-BP1 and allows Mnk1/2 to phosphorylate eIF4E on Ser209. 
Subsequently, the free and/or phosphorylated eIF4E enters an eIF4E complex which is 
composed of eIF4A, eIF4E and eIF4G. The assembly of the eIF4F complex activates 
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translation of mRNA with 5’ terminal cap (see Chapter 1, Figure 1.01) (Raught and 
Gingras 1999; Mothe-Satney et al. 2000). The 4E-BP1/eIF4E-modulated cap-dependent 
translation can synthesize proteins that promote cell growth (e.g. cyclin D1 and c-Myc) 
and neovascularization (e.g. VEGF, bFGF) and tumour-associated malignancies (e.g. 
matrix metalloprotease 9) (De Benedetti and Graff 2004; Mamane et al. 2004).  
mTORC1 is not only the signaling downstream of RTKs and GPCRs in response 
to their ligands such as growth factors and chemokines but also acts as a sensor of 
nutrient and energy status and stress stimulus. Low levels of energy, nutrient 
deprivation, stress stimuli or decreased the availability of growth factors down-regulates 
mTORC1 activity, resulting in down-regulation of protein synthesis but up-regulation of 
autophagy (see Chapter 1, Figure 1.09) (Jung et al. 2010). Autophagy is a cellular 
process for cells to efficiently utilize limited energy sources and maintain cell survival 
(He and Klionsky 2009). mTORC1 acts as negative regulator of autophagy through 
phosphorylation of ULK1/2 and Atg13 (see Chapter 1, Figure 1.10) (Yan et al. 1999).  
In addition to mTORC1, mTOR can be in complex with Rictor, mSin1, Protor-
1/2 and mLST8 to form mTORC2 (Frias et al. 2006; Yang et al. 2006; Pearce et al. 
2007; Zoncu et al. 2011). In contrast to mTORC1 that acts as Akt substrate, mTORC2 
acts as upstream activator of Akt. mTORC2 activates Akt by direct phosphorylation of 
Akt on Ser473 (see Chapter 1, Figure 1.01)  (Huang and Houghton 2003).  
Over the past two decades, a large body of literature has shown that 
overexpression of the class I PI3K/Akt/mTOR pathway is tightly correlated with 
tumourigenesis. The constitutive activation of PI3K kinase cascades can be instigated by 
molecular alterations in components of the class I PI3K/Akt/mTOR axis pathway and its 
upstream signals. So far, molecular alterations or post-translational modifications in 
RTKs such as KIT and EGFR, Ras, class I PI3K, PTEN, Akt, TSC1-TSC2 complex, 
p70S6K, 4E-BP1, eIF4E and Rictor (an mTORC2 component) have been identified in 
human cancers (Wong et al. 1992; Sakai et al. 1998; Sorrells et al. 1999; Niida et al. 
2001; Bellacosa et al. 2005; Akin 2006; Masri et al. 2007; Heinonen et al. 2008; Silva et 
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al. 2008; Karlsson et al. 2010; Castellano and Downward 2011). Alterations of RTKs 
such as KIT and EGFR, Ras and PTEN have been identified in canine tumours (Levine 
et al. 2002; Richter et al. 2005; Gleixner et al. 2007; Gama et al. 2009).  
 In human oncology, many small molecular inhibitors that target one or two 
components of the class I PI3K/Akt/mTOR pathway are available for preclinical studies 
and clinical trials for cancer therapy. So far, Temsirolimus and Everolimus, both of 
which are Rapamycin analogs and target mTOR kinase, have been approved by FDA for 
monotherapy in patients with either advanced renal cell carcinomas (Temsirolimus and 
Everolimus) or progressive neuroendocrine tumors of pancreatic origin (Everolimus) 
(http://www.cancer.gov/)(Kwitkowski et al. 2010; Saif 2011). In veterinary oncology, a 
phase I trial study of Rapamycin monotherapy in patients with canine osteosarcoma 
showed that the drug doses tested in this study were well-tolerated in patients (Paoloni et 
al. 2010).    
 The aim of this study was to investigate the role of class I PI3K/Akt/mTOR 
pathway in tumourigenicity of canine cancers in vitro. Four small molecular inhibitors 
targeting class I PI3K, Akt, or mTOR was used to treat five cell lines derived from 
different canine cancers to evaluate the drug efficacy in cell viability inhibition and to 
investigate the mechanism of these inhibitors. To investigate effects of the combination 
therapy on these canine lines, cells were treated with either the combination of two 
inhibitors or the combination of the inhibitors with Doxorubicin.  
3.3 Results 
3.3.1 Class I PI3K signaling is activated in canine cancer cells 
To determine the PI3K kinase activity in the five canine tumour cell lines (C2, 
J3T, REM134, SB and 3132), Western blot analysis (see Chapter 2, Section 2.6) was 
employed to examine active (phosphorylated) forms of several components of PI3K 
pathway, including phosphorylated Akt, mTOR, S6RP, 4E-BP1 and eIF4E.  In addition 
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to these canine cells, the human Jurkat T leukemic cell line was used as control as the 
cell line has constitutive activation of PI3K signaling through PTEN loss (Shan et al. 
2000). As shown in Figure 3.01, all canine cell lines with either PTEN expression (3132, 
SB, J3T and C2 cells) or PTEN loss (REM134 cells) expressed detectable levels of 
active forms of these proteins, indicating active PI3K signaling in these canine cells. It 
was observed that all cell lines expressed three 4EBP1 isoforms, including a 
hyperphosphorylated isoform (γ), a middle form (β), and an unphosphorylated isoform 
(α). The hyperphosphorylated isoform (γ) is phosphorylated with mTORC1 with high 
affinity and does not bind to eIF4E whereas the unphosphorylated isoform (α) strongly 
binds eIF4E. The middle form (β) is phosphorylated by mTORC1 and interacts with 
eIF4E with low affinity (Lin et al. 1995; Beretta et al. 1996; Gingras et al. 1996; 
Gingras et al. 1998).   
Because accumulating evidence suggests cross-talk between PI3K and 
Ras/Raf/Erk MAPK pathways occurred frequently, the activity of the Erk-MAPK 
pathway was investigated in these canine cells (Aksamitiene et al. 2010; Andreu-Perez 
et al. 2010; Shao and Aplin 2010). The Western blot results showed that the canine cells 
expressed detectable levels of active (phosphorylated) forms of ERK1/2, indicating 




Figure 3.01. Western blot analysis of components of the class I PI3K and 
ERK pathways in human and canine cancer cells. Whole cell lysates 
comprising 50 μg total protein were subjected to Western blotting analysis (see 
Chapter 2, Section 2.6) with β-actin as a loading control. Three 4EBP1 
isoforms, including a hyperphosphorylated isoform (γ), a middle form (β), and 
an unphosphorylated isoform (α), were observed (Gingras et al. 1998).   
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3.3.2 Effects of the inhibitors targeting class I PI3K/Akt/mTORC1 axis 
pathway 
3.3.2.1 Effects of inhibitors on cell viability 
To investigate the potential central role of PI3K signaling in cells, specific 
chemical inhibitors were used to block pathway components. Inhibitors used were 
Wortmannin (pan-class I PI3K inhibitor), ZSTK474 (pan-class I PI3K inhibitor), 
KP372-1 (Akt inhibitor) and Rapamycin (mTORC1 inhibitor). Subsequently, cell 
viability of drug-treated cells was compared with those of vehicle-treated cells by using 
a standard cell viability assay (see Chpater 2, Section 2.3 and Section 2.4). As shown in 
Figure 3.02A, the responses of these cell lines to Wortmannin were variable. At the 
highest dose (40 μM), canine C2 cells as well as human Jurkat T control cells were the 
most sensitive to Wortmannin, which reduced cell viability by >80%. 3132 and SB cells 
were relatively sensitive to Wortmannin with inhibition of ~50% cell viability. J3T and 
REM134 cells showed relative resistance to Wortmannin with less than 20% inhibition 
of cell viability. It was previously reported that Wortmannin selectively inhibited class I 
and class II PI3K (except PI3KC2α) at a similar potency. In addition, Wortmannin also 
targeted PI3KC2α and other serine/threonine kinases that contain catalytic domains 
resembling PI3Ks, such as mTOR, ATM, DNA-PK and phosphatidylinositol 4-kinase 
(PI4K). But the doses used for inhibition of these PI3K-related kinases were at least 10-
fold higher than those for class I PI3K inhibition (Nakanishi et al. 1995; Domin et al. 
1997; Banin et al. 1998; Misawa et al. 1998; Izzard et al. 1999). Compared with 
Wortmannin, the novel pan-class I PI3K inhibitor was more specific to class I PI3K and 
was reported to have weak or no inhibitory effect on other Wortmannin targets (Kong 
and Yamori 2007; Kong et al. 2009; Kong et al. 2010). In this study, ZSTK474 at 10 
μM effectively down-regulated ≥74% cell viability in all lines and fully inhibited the 
viability of SB (96%) and Jurkat T cells (100%). ZSTK474 at concentrations between 10 
µM and 40 µM resulted in a slower decline in J3T, C2 and 3132 cells and no further 
inhibition in REM134 and SB cells (Figure 3.02B).  
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KP372-1, an Akt inhibitor, efficiently inhibited all cell lines causing 100% loss 
of cell viability after incubation with this compound at concentrations of ≥ 250 nM for 2 
days, compared with the other three inhibitors, which required a longer period of time (3 
days) and much higher doses (micromolar concentrations) to reach effective inhibition 
(Figure 3.02). Notably, REM134 cells were most sensitive to KP372-1 with full 
inhibition of cell viability at concentrations ≥ 62.5 nM. 
 With regard to Rapamycin, it was observed that the doses within a nanomolar 
range had limited inhibitory effects on the viability of these canine cells. Jurkat T cells 
were observed to be most sensitive to Rapamycin, with an IC-50 (concentration for 50% 
inhibition of viability of ~ 1nM). By contrast, all canine cancer cell lines were relatively 
resistant to Rapmycin with IC50 values for 3132, C2, SB, REM134 and J3T cells of 1 
µM, 1-10 µM, 10 µM, 10-20 µM and > 20 µM, respectively. Canine J3T and REM134 
cells were most resistant to Rapamycin. The doses for Rapamycin to reach full inhibition 





Figure 3.02. Sensitivity of canine and human cancer cells to inhibitors 
targeting class I PI3K/Akt/mTOR pathway. Cells were treated with a range of 
doses of the pan-class I PI3K inhibitors Wortmannin for 3 days (A), ZSTK474 for 3 
days (A), Akt inhibitor KP372-1 for 2 days (B), or mTOR inhibitor Rapamycin for 3 
days (C) (see Chpater 2, Section 2.3). After drug treatment, the number of viable 
cells was determined by using CellTiter-Glo® Luminescent Cell Viability Assay (see 
Chapter 2, Section 2.4). Results are expressed as mean (±standard deviations 
(SD)) counts of quadruplicate wells, relative to vehicle (DMSO)-treated controls on 




3.3.2.2 Effects of the inhibitors on PI3K signaling by Western Blotting    
 To study the inhibitory effects of Wortmannin, ZSTK474, KP372-1 and 
Rapamycin on the PI3K/Akt/mTOR axis signaling in cells, Western blot analysis (see 
Chapter 2, Section 2.6) was performed to evaluate expression levels of active 
(phosphorylated) forms of class I PI3K downstream effectors, including Akt, S6RP, 4E-
BP1 and eIF4E. Previous studies demonstrated that 10-100 nM Wortmannin, 0.5-2 µM 
ZSTK474, and 10 nM Rapamycin could reduce the phosphorylation levels of 
components of the class I PI3K/Akt/mTOR axis pathway in a variety of cancer cell lines 
(Yaguchi et al. 2006; El-Salem et al. 2007; Howes et al. 2007). As for KP372-1, the 
doses of inhibitory concentration of 100% cell viability (IC-100) and lower than IC-100 
were used to treat cancer cells, which were cultured in serum-containing medium, for 8-
16 hours (Zeng et al. 2006). Therefore, in this study, 1 µM Wortmannin and ZSTK474, 
100 nM Rapamycin and the concentration of IC-100 of KP372-1, were used to 
investigate the inhibitory of effect on the class I PI3K/Akt/mTOR axis pathway in all 
cell lines.  
 As shown in Figure 3.03A, Wortmannin down-regulated phosphorylation levels 
of Akt in most cell lines but not in REM134 or J3T cells, indicating this inhibitor 
abrogated PI3K activity only in Jurkat T, 3132, SB and C2 cells. Compared with 
Wortmannin, ZSTK474 showed more potent effects on PI3-Kinase inhibition, based on 
down-regulated phosphorylation of Akt and even mTORC1 substrates S6RP and 4EBP1. 
Both PI3K inhibitors were observed to slightly up-regulate eIF4E phosphorylation in 
Jurkat T cells (Figure 3.03A and 3.03B).   
KP372-1, at 400 nM, down-regulated phosphorylation levels of S6RP and 4E-
BP1 in all cell lines. Moreover, it profoundly inhibited phosphorylation of Akt and 
eIF4E in J3T and REM134 cells. However, in Jurkat T cells, the phosphorylation of 
eIF4E was significantly up-regulated (Figure 3.03C).  
Rapamycin inhibited mTORC1 signaling in all cell lines, based on decreased 
hyperphosphorylation levels of 4EBP1 isoform (γ) and/or phosphorylation of S6RP 
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(Figure 3.03A). As for the effects of Rapamycin on three 4EBP1 isoforms, this inhibitor 
was observed to decrease the levels of hyperphosphorylated γ isoform, which was 
phosphorylated with mTORC1 with high affinity and did not bind eIF4E. However, 
Rapamycin did not decrease the levels of middle β isoform and unphosphorylated α 
isoform. The middle β isoform of 4EBP1 was phosphorylated by mTORC1 and 
interacted with eIF4E with low affinity. The unphosphorylated α isoform of 4EBP1 
stronly bound eIF4E (Lin et al. 1995; Beretta et al. 1996; Gingras et al. 1996; Gingras et 
al. 1998).  
Instead of down-regulation of eIF4E phosphorylation, Rapmaycin up-regulated 
eIF4E activity in Jurkat T and SB cells (Figure 3.03A).  
To investigate whether the effects of Rapamycin on S6RP, 4EBP1 and eIF4E 
phosphorylation were transient or long-term, prolonged exposure of cells to this 
inhibitor was performed at two different time points, 48 and 72 hours. As shown in 
Figure 3.04, the effects of Rapamycin on mTORC1 signaling at 48 and 72 hours were 









Figure 3.03 Effects of the inhibitors on class I PI3K/Akt/mTOR axis signaling in 
canine and human cancer cells. Cells were seeded at a density of 20,000 cells/ml 
and incubated overnight, followed by treatment with 1µM Wortmannin, 100 nM 
Rapamycin (A), 1 µM or 10 µM ZSTK474 (B), or 400 nM KP372-1 (C) for 5 hours 
(see Chapter 2, Section 2.3). Whole cell lysates, comprising 50 µg total protein, 
were subjected to Western blot with the indicated antibodies (see Chapter 2, 
Section 2.6). β-actin was used as a loading control. The arrows indicated the 
targeted protein bands recognized by primary antibodies. Three 4EBP1 isoforms, 
including a hyperphosphorylated isoform (γ), a middle form (β), and an 





Figure 3.04 Rapamycin increases eIF4E phosphorylation in Jurkat T and SB cells. Cells were seeded at a density of 
20,000 cells/ml and incubated overnight, followed by treatment with 1 µM Wortmannin, 100 nM Rapamycin or vehicle 
control for 48 hours (A) and 72 hours (B) (see Chapter 2, Section 2.3). Whole cell lysates (comprising 50 µg total protein) 
were subjected to Western blot with the indicated antibodies (see Chapter 2, Section 2.6). β-actin was used as a loading 
control. Three 4EBP1 isoforms, including a hyperphosphorylated isoform (γ), a middle form (β), and an unphosphorylated 
isoform (α), were observed (Gingras et al. 1998). 
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3.3.2.3 Time course study of drug efficacy by Western blotting technique   
To dissect the dynamics of inhibition further, a time-course study was performed 
utilizing the C2 cell line. As shown in Figure 3.05A, both pan-PI3K inhibitors ZSTK474 
and Wortmannin blocked PI3K activity, as evidenced by significant reduction in 
phosphorylation levels of Akt and its downstream substrates S6RP and γ hyper-
phosphorylated form of 4E-BP1. However, compared with Wortmannin, ZSTK474 
showed greater potency and longer efficacy in down-regulating PI3K kinase signaling, 
based on the results showing that inhibition of phosphorylation of downstream elements 
of PI3K by ZSTK474 lasted for 50 hours whereas Wortmannin lasted for 12 hrs (Figure 
3.05A).  
For the time course study of KP372-1 in C2 cells, three doses higher than 
inhibitory concentration of 100% cell viability (IC-100), including 150, 200 and 400 
nM, were tested. On one hand, the highest dose (400 nM) decreased the phosphorylation 
levels of PI3K/Akt substrates S6RP and 4EBP1 at the earlier time point of 4 hours but 
inhibited profoundly the phosphorylation of all PI3K substrates, including Akt, S6RP, 
4E-BP1 and eIF4E, at later time points of 8 and 12 hours (Figure 3.05B). On the other 
hand, KP372-1 at concentrations between 150 nM and 200 nM showed no inhibitory 
effects on PI3K activity at early time points (4 and 8 hours) but gradually down-
regulated all of its downstream components at later time points (12, 21 and 24 hours). 
Results for treatment with 200 nM and 400 nM KP372-1 at later time points (21 and 24 
hours) were unavailable, due to these cell lysates with little amount of or no protein 
(Figure 3.05B). It was assumed that these cell lysates with scarce amount of protein 
were related to the late apoptosis (or secondary necrosis) of the majority of C2 cells, 
which cause leakage of proteins to cell medium (Figure 3.06C) (Krysko et al. 2008).   
As shown in Figure 3.04 and 3.05A, indicators of inhibition of mTORC1 
signaling by Rapamycin, such as down-regulation of S6RP and γ form of 4E-BP1 
phosphorylation, were evident for 72 hours. This is consistent with previous findings 





Figure 3.05. Effects of the inhibitors on class I PI3K/Akt/mTOR axis 
signaling in canine C2 cells. Cells were treated with vehicle control DMSO (C), 
pan-class I PI3K inhibitor Wortmannin (W) at 1 µM and ZSTK474 (Z) at 1 µM, 
mTOR inhibitor Rapamycin (R) at 100 nM (A), and Akt inhibitor KP372-1 at 0, 
150, 200 and 400 nM (B) for the indicated period of time. Whole cell lysates 
(comprising 50 µg total protein) were subjected to Western blot with the indicated 
antibodies (see Chapter 2, Section 2.6). β-actin was used as a loading control. 
N/A indicates data unavailable due to induction of apoptosis in all cells. Three 
4EBP1 isoforms, including a hyperphosphorylated isoform (γ), a middle form (β), 
and an unphosphorylated isoform (α), were observed (Gingras et al. 1998). 
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3.3.2.4 Effects of PI3K/Akt/mTOR inhibitors on apoptosis induction 
To determine whether the four PI3K pathway inhibitors Wortmannin, ZSTK474, 
KP372-1 and Rapamycin induce apoptosis, cells were stained with annexin V (a cell 
apoptosis marker) and propidium iodide (PI) (taken up by dead and necrotic cells), 
followed by flow cytometry (see Chapter 2, Section 2.5). 
3.3.2.4.1 Utilization of C2 cells to titrate drug dosage  
Using C2 cells to titrate these four PI3K pathway inhibitors, KP372-1 was 
observed to induce apoptosis of the majority of cells, increasing cell loss by 71% and 
76% at 200 nM and 400 nM, respectively (Figure 3.06). The other three inhibitors 
Wortmannin, ZSTK474, and Rapamycin induced significant apoptosis at concentrations 
greater than 10 µM. At 10 µM, Wortmannin, ZSTK474, and Rapamycin increased 
apoptosis by 39%, 19% and 20% respectively, as compared with the controls. Notably, 
the apoptosis rates were measured after cells were exposed to KP372-1 for 1 day 
whereas the exposure period for the other drugs was 2 days, suggesting KP372-1 as the 





Figure 3.06. Effects of the class I PI3K pathway inhibitors on apoptosis of 
canine C2 cells. The C2 cells were treated with the indicated concentrations of 
Wortmannin, ZSTK474, and Rapamycin for 2 days, and of K P372-1 for 1 day. 
Induction of apoptosis was determined by measuring/quantifying annexin V/PI 
staining using flow cytometry (see Chapter 2, Section 2.5).  Live, early apoptotic 
and late apoptotic cells were located, respectively, in the lower left, lower right 
and upper right quadrants of a bivariate dotplot.      
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3.3.2.4.2 Effects of the class I PI3K/Akt/mTOR inhibitors on apoptosis of all 
cancer cell lines  
All cell lines were treated with Wortmannin, ZSTK474 and Rapamycin at 20 µM 
for 2 days and with KP372-1 at 400 nM for 1 day. The data obtained from two 
individual experiments showed that Wortmannin significantly increased apoptosis of 




 experiments respectively, C2 by 55% and 
28%, and 3132 by 27% and 17% as compared with controls. However, Wortmannin did 
not have any obvious efficacy on the other cell lines (Figure 3.07A and 3.07B).  





 experiment respectively, C2 by 24% and 23%, and SB by 19% and 20%, as 
compared with the controls. By contrast, ZSTK474 showed no efficacy towards the 
other cell lines (Figure 3.07A and 3.07B).   





experiments respectively, 3132 by 76% and 82%, SB by 44% and 35%, REM134 by 
93% and 93%, J3T by 89% and 96% and C2 by 84% and 89% (Figure 3.07A and 
3.07B).  
 With regard to Rapamycin, the data obtained from the 1
st
 experiment showed that 
20 µM Rapamycin significantly increased apoptosis of all cell lines by 26%-62%, except 
REM134 and J3T cells (Figure 3.07A). In the 2
nd
 experiment, Rapamycin at the same 
concentration showed better efficacy in apoptosis induction with an increase in apoptotic 
fraction by 80%-95% in most cell lines (including Jurkat T, 3132, SB and C2 cells) and 
by 43% in REM134 cells. In contrast, no apoptosis was observed in Rapamycin-treated 
J3T cells (Figure 3.07B). Due to the inconsistent results from REM134 cells, the 3
rd
 
experiment was performed on this cell line and the data showed that Rapamycin at the 
concentration of 20 µM increased apoptosis by 31%, as compared with the control 
(Figure 3.07C). Taken together, it was observed that Rapamycin had no effect on 
inducing apoptosis of REM cells in the 1
st
 experiment whereas this inhibitor increased 




 experiment, by 43% and 31 %, 
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respectively. It was assumed a decrease in the effectiveness of Rapamycin in the 1
st
 
experiment on REM cells, presumably due to something going wrong during storage of 











Figure 3.07. Effects of the class I PI3K pathway inhibitors on induction of apoptosis. Cells were treated with 
20 µM Wortmannin for 2 dyas, 20 µM ZSTK474 for 2 days, 400 nM KP372-1 for 1 day, 20 µM Rapamycin for 2 days, 
or vehicle control. Induction of apoptosis was determined by annexin V/PI staining and analysis by flow cytometry 
(see Chapter 2, Section 2.5). Percentages of live, early apoptotic and late apoptotic cells were indicated in lower left, 
lower right and upper right quadrants, respectively, of bivariant dotplots. (A) and (B) represented two independent 
experiments (C) The 3rd experiment for REM134 cells incubated with/without Rapamycin.  
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3.3.2.4.3 Responses of REM, J3T and C2 cells to short exposure to KP372-
1    
As KP372-1 down-regulated phosphorylation of PI3K substrates in REM134 and 
J3T cells after 5 hour incubation (Figure 3.03C), annexin V/propidium iodide staining 
(see Chapter 2, Section 2.5) was performed to determine the relationship between PI3K 
pathway inhibition and the level of apoptosis. As shown in Figure 3.08, KP372-1 
increased apoptosis of REM134 cells by 84%, followed by - in decreasing order of drug 
potency - J3T (65%) and C2 (31%).  
 
Figure 3.08. Significant increased apoptosis in REM134 and J3T cells after 
treatment of KP372-1 for 5 hrs. Cells were treated with 400 nM KP372-1 or 
vehicle control for 5 hours. Induction of apoptosis was determined by annexin 
V/PI staining and flow cytometry analysis (see Chapter 2, Section 2.5). 
Percentages of live, early apoptotic and late apoptotic cells were located at 
lower left, lower right and upper right quadrants, respectively.   
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3.3.3 Effects of Rapamycin combined with either Wortmannin or ZSTK474 
To investigate the effects of simultaneous inhibition of both PI3K and mTOR 
signaling, cells were treated with Rapamycin combined with either Wortmannin or 
ZSTK474. The inhibitory effect of drug combination on cell viability was evaluated by 
using the Bliss additivism model (the methods used being described in Chapter 2, 
Section 2.4 and Section 2.7) (Buck et al. 2006). Briefly, if the cell viability rates 
generated by Bliss additivism model analysis are greater than, overlap, or are less than 
rates obtained from experimental results, a drug combination is interpreted as having 
synergistic, additive, or antagonistic effects, respectively. 
3.3.3.1 Rapamycin combined with Wortmannin showed variable inhibitory 
effects on cell viability 
 As shown in Figure 3.09 and Appendix 1, the Bliss analyses showed that 
simultaneous treatment with Wortmannin and Rapamycin inhibited the viability of 
Jurkat T, 3132 and J3T cells in an additive manner. Over the range of concentrations 
tested in this study, the drug combination increased efficacy in Jurkat T cells by 17-25% 
(p<0.05), 3132 by 7-18% (p<0.05), J3T cells by 6-8% (p<0.05), as compared with either 
Rapamycin or Wortmannin alone, depending on which single agent achieved maximal 
inhibition of cell viability.  
Wortmannin synergized with Rapamycin and in SB and C2 cells, increasing drug 
efficacy by 7-41% (p<0.05) and 23-41% (p<0.05), respectively.  









Figure 3.09. Cell viability in response to combined Rapamycin/Wortmannin 
treatment. Cells were treated with the indicated doses of Wortmannin, 
Rapamycin, and the combination of the former two inhibitors or vehicle control for 
3 days. After drug treatment, the number of viable cells was determined by using 
CellTiter-Glo® Luminescent Cell Viability Assay (see Chapter 2, Section 2.4). 
Viability of the drug-treated cells was compared with the vehicle (DMSO)-treated 
cells on the same culture plates. Results were expressed as mean (±SD) counts 
of quadruplicate wells. Theoretical values for the combined inhibitory effects of 
the two drugs were obtained using the Bliss additivism model as described in 
Chapter 2, section 2.7. Statistical analysis to determine whether there is 
significant difference between two treatment groups was described in Chapter 2, 
Section 2.8 (p-value < 0.05 indicates significant difference). Bliss, Bliss 
theoretical value; Exp, Experiment value; R, Rapamycin; W, Wortmannin.    
3.3.3.2 Rapamycin combined with ZSTK474 inhibited cell viability in an 
additive manner  
 As shown in Figure 3.10B and Appendix 2, the Bliss analyses showed that 
ZSTK474 combined with Rapamycin had an additive effect on most cell lines. However, 
statistical analyses indicated that the additive effects on REM134 were Insignificant. 
Over the range of concentrations tested in this study, the drug combination increased 
efficay in Jurkat T cells by 8-22% (p<0.05), 3132 by 16-23% (p<0.05), SB by 7-18% 
(p<0.05), REM134 cells by 9% (p<0.05), and C2 cells by 13-29% (p<0.05), as 
compared with either Rapamycin or ZSTK474 alone, depending on which single agent 
achieved maximal inhibition of cell viability.  
ZSTK474 synergized with Rapamycin in J3T cells, increasing efficacy by 23-




Figure 3.10. Rapamycin combined with ZSTK474 inhibited cell viability in 
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an additive or synergistic manner. Cells were treated with the indicated doses 
of Wortmannin, Rapamycin, and the combination of the former two inhibitors or 
vehicle control for 3 days. After drug treatment, the number of viable cells was 
determined by using CellTiter-Glo® Luminescent Cell Viability Assay (as 
described in Chapter 2, Section 2.4). Results were expressed as mean (±SD) 
counts of quadruplicate wells. Viability of the drug-treated cells was compared 
with the vehicle (DMSO)-treated cells on the same culture plates. Theoretical 
values for the combined inhibitory effects of the two drugs were obtained using 
the Bliss additivism model as described in Chapter 2, section 2.7. Statistical 
analysis to determine whether there is significant difference between two 
treatment groups was described in Chapter 2, Section 2.8 (p-value < 0.05 
indicates significant difference). Bliss, Bliss theoretical value; Exp, Experiment 
value; R, Rapamycin; Z, ZSTK474.    
3.3.3.3 Western blotting analysis on effects of Rapamycin combined with 
Wortmannin on the class I PI3K/Akt/mTOR signaling pathway 
Western blot analysis was performed to dissect further the effects of combining 
Wortmannin with Rapamycin. As shown in Figure 3.11A, Western blot analysis 
revealed that the drug combination profoundly or fully inhibited 4E-BP1 
phosphorylation in 3132, SB and J3T cells, but not in REM134 cells, at the time point of 
5 hours. Prolonged exposure (for 9 hours) to the drug combination was observed to 
profoundly inhibit 4E-BP1 phosphorylation in all cell lines (Figure 3.11B). However, it 
appeared that there was no profound inhibition of S6RP phosphorylation, based on the 
same levels observed in the Rapamycin treatment group and the drug combination group 
in 3132, REM134 and J3T cells (Figure 3.11A).  
It was observed that full suppression of 4E-BP1 phosphorylation did not 
contribute to down-regulation of eIF4E phosphorylation. In all cell lines except Jurkat T 
and SB cells, the phosphorylation levels were not altered by drug treatment. In Jurkat T 
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cells, eIF4E phosphorylation was up-regulated in response to Rapamycin alone, but this 
phenomenon was not observed in cells treated concomitantly with Rapamycin and 
Wortmannin. In SB cells, eIF4E phosphorylation was up-regulated in response to 
Rapamycin alone, Wortmannin alone and the combination of the both drugs. Besides, 
Akt phosphorylation was slightly up-regulated in SB cells treated with Rapamycin alone 





Figure 3.11. Western blot analysis on inhibitory effects of Rapamycin 
combined with Wortmannin on class I PI3K/Akt/mTOR axis pathway. Cells 
were seeded at a density of 20,000 cells/ml and incubated overnight, followed 
by treated with the indicated concentrations of Rapamycin, Wortmannin, or the 
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combination of Rapamycin and Wortmannin for 5 hours (A) or 9 hours (B). 
Whole cell lysates (comprising 50 μg total protein) were subjected to Western 
blotting analysis (described in Chpater 2, Section 2.6) with β-actin as a loading 
control. Three 4EBP1 isoforms, including a hyperphosphorylated isoform (γ), a 
middle form (β), and an unphosphorylated isoform (α), were observed (Gingras 
et al. 1998).  
3.3.3.4 Western blotting analysis on effects of Rapamycin combined with 
ZSTK474 on the PI3K/Akt/mTOR signaling pathway 
The effect of treatment with a combination of Rapamycin and the pan-class I 
PI3K inhibitor ZSTK474 was also evaluated using Western Blot analysis. The effect of 
this drug combination was similar to that seen with combined Rapamycin/Wortmannin 
treatment. As shown in Figure 3.12, the drug combination profoundly inhibited 4E-BP1 
phosphorylation only. Again, the full inhibition of 4E-BP1 phosphorylation did not 
further down-regulate eIF4E phosphorylation. For 3132, SB, REM134 and J3T cells 
treated with both drugs, inhibition of S6RP phosphorylation equivalent to that produced 
by Rapamycin alone. For Jurkat T cells, whilst Rapamycin alone up-regulated eIF4E 
phosphorylation, this was not observed in response to combined Rapamycin/ZSTK474. 
Akt phosphorylation levels in Jurkat T cells were decreased by Rapamycin after 





Figure 3.12. Western blot analysis on inhibitory effects of Rapamycin 
combined with ZSTK474 on class I PI3K/Akt/mTOR axis pathway. Cells were 
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seeded at a density of 20,000 cells/ml and incubated overnight, followed by 
treated for 18 hours with 5 µM* ZSTK474, 100 nM Rapamycin, or a combination 
of both inhibitors. Whole cell lysates (comprising 50 μg total protein) were 
subjected to Western blotting analysis (as described in Chapter 2, Section 2.6) 
with β-actin as a loading control. *(10 µM ZSTK474 for REM134 cells). Three 
4EBP1 isoforms, including a hyperphosphorylated isoform (γ), a middle form (β), 
and an unphosphorylated isoform (α), were observed (Gingras et al. 1998). 
3.3.4 Effects of the combination of the class I PI3K inhibitors and 
Doxorubicin on cell viability 
To investigate whether the PI3K/Akt/mTOR signaling affects the sensitivity to 
conventional chemotherapy, the effects of combined treatment with PI3K pathway 
inhibitors and Doxorubicin were evaluated for SB, REM134, 3132 and C2 cells and 
analyzed using Bliss additivism model (as described in Chapter 2, Section 2.7).  
As shown in Figure 3.13A and Appendix 3, the Bliss analysis predicted that the 
combination of Doxorubicin and PI3K pathway inhibitors decreased the viability of SB 
cells in an additive or synergistic manner. Wortmannin, ZSTK474 and Rapamycin 
combined with Doxorubicin showed additive effects, which increased drug efficacy by 
5-16% (p<0.05), 4-13% (p<0.05) and 5-23% (p<0.05), respectively, as compared with a 
single agent, depending on which single agent achieved maximal inhibition of cell 
viability.  
The Bliss analysis predicted that KP372-1 combined with Doxorubicin had a 
synergistic effect on SB cells (Figure 3.13A). However, the statistical analyses only 
confirmed the synergism in one dataset, which was obtained from 80 nMKP372-1 group 
versus 80 nM KP372-1 combined with 2.5 nM Doxorubicin group. In this dataset, the 
combination of KP372-1 and 2.5 nM Doxorubicin increased drug efficacy by 13% 
(p<0.05), as compared with KP372-1 alone (Figure 3.13A and Appendix 3).   
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With regard to REM cells, the Bliss analysis showed that Wortmannin, ZSTK474 
and KP372-1 antagonized the inhibitory activity of Doxorubicin towards REM134 cells. 
Only Rapamycin combined with Doxorubicin produce a complementary effect (additive) 
with an increase in efficacy of 13% (p<0.05), as compared with Rapamycin alone 
(Figure 3.13B and Appendix 3).  
For 3132 and C2 cells, Wortmannin, ZSTK474, and Rapamycin combined with 







Figure 3.13. Effects of the combination of the PI3K/Akt/mTOR pathway 
inhibitors and Doxorubicin on cell viability. Canine SB (A), REM134 (B), 3132 
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(C), and C2 (D) cells were treated with the indicated does of the PI3K/Akt/mTOR 
pathway inhibitors, Doxorubicin, a combination of these drugs, or vehicle control for 
3 days (except KP372-1 for 2 days). After drug treatment, the number of viable 
cells was determined by using CellTiter-Glo® Luminescent Cell Viability Assay (as 
described in Chapter 2, Section 2.4). Results were expressed as mean (±SD) 
counts of quadruplicate wells. Viability of the drug-treated cells was compared with 
the vehicle (DMSO)-treated cells on the same culture plates. Theoretical values for 
the combined inhibitory effects of the two drugs were obtained using the Bliss 
additivism model as described in Chapter 2, section 2.7. Statistical analysis to 
determine whether there is significant difference between two treatment groups 
was described in Chapter 2, Section 2.8 (p-value < 0.05 indicates significant 
difference). Bliss, Bliss theoretical value; D, Doxorubicin; Exp, Experiment value; R, 
Rapamycin; W, Wortmannin; Z, ZSTK474.  
3.3.5 Effects of the class I PI3K pathway inhibitors on autophagy induction 
Accumulating evidence suggests that mTORC1 signaling is a negative regulator 
of autophagy that may protect tumour cells from apoptosis under poor conditions such as 
stress and nutrient deprivation. Cells were treated with low doses of PI3K pathway 
inhibitors, followed by Western blot analysis on expression amounts of isoform B of 
human microtubule-associated protein 1 light chain 3 (LC3B) (Aoki et al. 2008). During 
autophagy, LC3B is converted from cytosolic LC3B-I to autophagosome membrane-
bound LC3B-II, allowing LC3B-II to serve as an indicator of autophagy induction.  
As shown in Figure 3.14A, REM134, J3T and C2 cells exposed to Rapamycin 
for 18 hours expressed similar levels of LC3B-II to their controls whereas Jurkat T, 3132 
and SB cells did not express LC3B-II in response to Rapamycin. Prolonged treatment 
(48-72 hours) of Rapamycin was performed on SB, REM134, J3T and 3132 cells 
(Figure 3.14B and 3.14C). It was observed that a slight increase in LC3B-II level was 
observed in SB cells following 72 hour post-drug treatment. Drug-treated REM134 cells 
188 
 
expressed higher levels of LC3B-II through 48-72 hours as compared with the controls. 
The data obtained from J3T cells were paradoxical. Whilest J3T cells exposed to 
Rapamycin for 48 hours expressed higher LC3B-II levels, 72 hour post-drug treatment 
of J3T cells was observed to have less amount of LC3B-II as compared with the control 
(Figure 3.14B and 3.14C). For 3132 cells, expression of LC3B-II was not observed in 
the Rapamycin-treated cells, except the cells with 5 µM Rapamycin treatment for 3 
hours (Figure 3.14D).    
With regard to ZSTK474 treatment, increased levels of LC3B-II expression were 
observed in ZSTK474-treated SB and C2 cells, as compared with the controls. When 
combined ZSTK474 and Rapamycin, induction of autophagy was only observed in SB 








Figure 3.14. Evaluation of the effects of Rapamycin and ZSTK474 on 
autophagy induction. (A) Cells were treated for 18 hours with 5 µM ZSTK474 
(10 µM ZSTK474 for REM134 cells), 100 nM Rapamycin, a combination of both 
inhibitors or vehicle control. (B) Cells were treated with 200 nM Rapamycin for 
48 hours. (C) Canine 3132 cells were treated with Rapamycin at the indicated 
concentrations for 3, 24, or 48 hours. Whole cell lysates (comprising 50 µg total 
protein) were subjected to Western blot (described in Chapter 2, Section 2.6) 





3.4.1 Active class I PI3K/Akt/mTOR signaling in canine cancer cells 
Accumulating evidence has demonstrated the critical role of class I 
PI3K/Akt/mTOR signaling in tumourigenicity in a wide array of human cancer types 
through a series of preclinical studies of either stimulation or shut-down of this pathway 
(Altomare and Testa 2005; Chiang and Abraham 2007; Engelman 2009). Moreover, 
some inhibitors that specifically target this pathway have been approved for the 
treatment of renal and pancreatic cancers in clinic (Kwitkowski et al. 2010; Saif 2011). 
So far, only few reports concerning the role of this pathway in canine oncology have 
been published (Yuan et al. 2009; Kwitkowski et al. 2010; Wang 2010). In the present 
study, five cell lines derived from a variety of canine tumours were selected for 
investigation into the impact of this pathway on canine tumourigeneity. Canine REM134 
and human Jurkat T cells were demonstrated to constitutively express this signaling, as 
evidenced by loss of PTEN and expression of phosphorylated Akt. Evidence of active 
class I PI3K/Akt/mTOR axis signaling was also demonstrated for the other tested canine 
cell lines, with detectable levels of phosphorylated forms of PI3K downstream effectors, 
including Akt, mTOR, S6RP, 4EBP1 and eIF4E.  
Although Akt was activated in all lines, 3132 cells were found to express much 
lower levels of phosphorylated Akt than the other cell lines. Previous studies of mouse 
embryonic fibroblasts (MEFs) suggested a positive correlation of knockdown of TSC1 
or TSC2 gene expression with decreased phosphorylation of Akt on Ser473 (Zhang et al. 
2003; Harrington et al. 2004; Shah et al. 2004). More recently, it has been reported that 
the TSC1-TSC2 complex interacts with mTORC2 to positively regulate mTORC2-
mediated Akt phosphorylation, whereas the complex acts as a negative regulator of 
mTORC1 signaling (Huang et al. 2008). As the Western blot profile (Figure 3.01) shows 
that 3132 cells exhibit active mTORC1 signaling and minimal Akt phosphorylation, it is 
possible that molecular alterations of the TSC1-TSC2 complex occur in 3132 cells. 
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Indeed, LOH and somatic mutations in TSC1 or TSC2 are described in many types of 
cancer (Niida et al. 2001). Using polymerase chain reaction (PCR) - single strand 
conformation polymorphism (SSCP) analysis of DNA or complementary DNA (cDNA) 
of TSC1 and TSC2 genes in canine 3132 cells or Western blot analysis of expression 
status of TSC1-TSC2 complex can help to clarify whether dysfunction of TSC1-TSC2 
complex contributes to low levels of Akt phosphorylation in this cell line (Hayashi 1991; 
Henske et al. 1996). An alternative explanation for the low levels of Akt 
phosphorylation in 3132 cells would be due to low expression level of total Akt kinase. 
Further investigation of expression levels of total Akt by using Western blotting may 
provide a clearer understanding of Akt activity in 3132 cells.  
Levels of Akt phosphorylation for canine J3T, SB and C2 cells were comparable 
to those of PTEN-null REM134 and and Jurkat T cells. High levels of phosphorylated 
Akt might presumably result from any molecular alterations of Akt upstream regulators, 
such as RTKs, Ras, and class I PI3Ks. Indeed, a recent study of cell lines derived from a 
variety of human cancer types has revealed that activating mutations of Ras alone or 
coupled with mutations of PIK3CA leads to PTEN-positive cells exhibiting high levels 
of phosphorylated Akt (Ihle et al. 2009). In addition, hyperactivity of mTORC2 as a 
result of over-expression of the Rictor subunit can contribute to up-regulation of Akt 
phosphorylation in some glioma cell lines (Masri et al. 2007). Further investigation of 
somatic mutations (including deletion, insertion and single nucleotide substitution) of 
the genes encoding upstream regulators of Akt in all cell lines could be carried out by 
using PCR amplification and DNA sequencing analysis, followed by using computer 
softwares such as mutation detection algorithms and single nucleotide polymorphisms 
(SNPs) detector to analyze and identify genetic mutations (Ding et al. 2008). In addition, 
dysregulation of genes encoding RTKs, such as KIT, VEGFR and EGFR, and class I 
PI3Ks such as p110α and p110β catalytic subunits, is well-documented in cancers, and 
analysis of copy number gains of these genes using quantitative PCR may help to clarify 
the mechanism for constitutive activation of Akt (Humphrey et al. 1988; Knobbe and 
Reifenberger 2003; Liu et al. 2008). Semi-quantitative RT-PCR evaluating mRNA 
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expression levels of oncogenic RTK, class I PI3K and PDK1 might identify 
overexpression of oncoproteins resulting from elevated mRNA levels in the absence of 
gene amplification. As phosphorylation of multiple serine/threonine residues at C-
terminus of PTEN may result in down-regulation of activity, Western blot analysis to 
determine the phosphorylation status at these sites (Ser380; Thr382/383) could be 
performed (Vazquez et al. 2001; Birle et al. 2002; Dal Col et al. 2008; Silva et al. 2008).  
As active class I PI3K/Akt/mTOR signaling was detected in all tested cell lines, 
the class I PI3K pathway was subsequently inhibited at different levels by using the 
small molecules inhibitors Wortmannin, ZSTK474, KP372-1 and Rapamycin. The 
former two inhibitors specifically target all p110 isoforms of class IA and IB PI3Ks, 
whereas KP372-1 and Rapamycin specifically inhibit Akt and mTOR, respectively 
(Nakanishi et al. 1995; Huang et al. 2003; Mandal et al. 2005; Kong and Yamori 2007).  
3.4.2 pan-class I PI3K inhibitors 
3.4.2.1 Wortmannin and ZSTK474 
The current results show that ZSTK474, KP372-1 and Rapamycin significantly 
down-regulate cell viability whereas cells show variable responses to Wortmannin. 
Wortmannin and ZSTK474 are both pan-class I PI3K inhibitors, but additional factors 
may account for the contrasting effects of the two drugs on cell viability. Wortmannin 
acts as a non-ATP competitive inhibitor towards class I PI3K through the irreversible 
interaction between Lys802 residue of p110α and the furan ring (at C-20) of 
Wortmannin, thus preventing p110α from transferring the γ-phosphate group from ATP 
to PtdIns(4,5)P2 (Wymann et al. 1996). By contrast, ZSTK474 competes with ATP for 
the ATP-binding pocket in the p110 catalytic subunit of class I PI3K, resulting in arrest 
of PtdIns (3,4,5)P3 generation (Kong and Yamori 2007). Although Wortmannin acts as 
an irreversible pan-class I PI3K inhibitor, this drug is reported to  have poor stability in 
cell medium, with a half life of 8-13 mins (Holleran et al. 2003). Moreover, the efficacy 
towards class I PI3K signaling, as measured by inhibition of Akt phosphorylation, only 
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lasts for ~18 hours (Howes et al. 2007). Consistent with previous findings, Wortmannin 
in this study displays shorter duration (~12 hours) of suppression of Akt phosphorylation 
than ZSTK474. Moreover, it has been demonstrated that ZSTK474 is a more potent 
inhibitor of class I PI3K/Akt/mTOR axis signaling than Wortmannin, as evidenced by 
decreased phosphorylation levels of not only Akt but also S6RP and 4EBP1 in 
ZSTK474-treated cells. Hence, it appears that viability of all cell lines tested in this 
study, is at least in part, class I PI3K-dependent. 
The hypothesis of class I PI3K-driven cell viability in all lines is further 
supported by previous findings. Wortmannin is reported to target p110α, p110β, p110γ 
and p110δ catalytic subunits of class I PI3K with an inhibitory concentration for 50% 
kinase activity (IC-50) of 4 nM, 1 nM, 4 nM and 9 nM, respectively (Kong and Yamori 
2008). Moreover, this inhibitor showed ≥ 100 fold selective inhibition for class I PI3Kα 
over other classes of PI3K such as class II PI3K-C2β and class III PI3K (yeast Vps34) 
(Nakanishi et al. 1995; Stein 2001). Several serine/threonine kinases that contain 
catalytic domains resembling PI3Ks such as PI4Ks, mTOR, ATM and DNA-PK as well 
as non-PI3K-related kinase such as myosin light chain kinase (MLCK) have been shown 
to have 20-50 fold IC50 values of Wortmannin as compared with p110α (Stein 2001).  
In contrast to Wortmannin, evidence suggests that ZSTK474 is a more specific 
inhibitor of class I PI3K. ZSTK474 inhibits four p110 isoforms of class I PI3K with IC-
50 values ranging from 5-49 nM (Kong and Yamori 2007). It has been demonstrated to 
have ~11, ~24, and ~27 fold specific inhibition for class I PI3Kα (IC-50 value of 16 nM) 
over class II PI3K-C2β, mTOR and DNA-PK, respectively. Moreover, ZSTK474 
showed weak or no inhibitory effects on activities of class II PI3K-C2α, class III PI3K, 
and PI4K. In addition, ZSTK474 did not down-regulate phosphorylation of ERK and 
activities of several components of MAPK pathway (Yaguchi et al. 2006; Kong and 
Yamori 2007; Kong et al. 2009; Kong et al. 2010). Thus, the more restricted activity of 
ZSTK474 as compared with Wortmannin suggests that the viability of all lines is, in 
part, driven by active class I PI3K.   
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3.4.2.2 Inhibitory activity of ZSTK474 is not mediated through induction of 
apoptosis 
Although both pan-class I PI3K inhibitors show similar flow cytometry profiles 
for annexin V/PI staining, with no significant increase in apoptosis for most canine lines, 
both Wortmannin and ZSTK474 induce apoptosis of Jurkat T and C2 cells, with the 
former showing the more potent effect. However, ZSTK474 effectively down-regulates 
the viability of most lines and fully inhibits the proliferation of Jurkat T and SB cells. 
This suggests that ZSTK474 does not inhibit cell viability entirely through induction of 
apoptosis. A recent study of human cancer cell lines showed that ZSTK474 induces cell 
cycle arrest through inhibition of phosphorylation or expression of Akt and/or mTORC1 
substrates, such as phospho (p)-GSK3β, p-mTOR, p-p70S6K and cyclin D1. However, 
ability to induce apoptosis is cell line dependent and ZSTK474 is considered, in general, 
a weak inducer of apoptosis (Yaguchi et al. 2006). As Western blot analysis 
demonstrated that ZSTK474 inhibits class I PI3K/Akt/mTOR axis signaling, the current 
findings suggest that class I PI3K is critical to the viability of cancer cell lines but 
implicates the mechanism of ZSTK474 to be largely through inhibition of 
Akt/mTORC1-mediated protein synthesis and cell growth rather than apoptosis 
induction.   
3.4.2.3 Wortmannin inhibits cell viability through effects on class I 
PI3K/Akt/mTOR signaling and induction of apoptosis  
In this study, Wortmannin fully inhibited cell viability in Jurkat T and C2 cells 
and had moderately inhibitory effects on 3132 and SB cells, whereas no inhibition of 
REM134 and J3T cells was observed. Further dissection of the mechanism using 
Western blot revealed that Wortmannin significantly decreased Akt phosphorylation in 
Jurkat T, 3132, SB and C2 cells, and also decreased phosphorylation of mTOR 
substrates in Jurkat T and C2 cells. This suggests a positive correlation between 
activation of the class I PI3K/Akt/mTOR axis and cell viability.   
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Wortmannin significantly induced apoptosis of Jurkat T and C2 cells but had no 
pro-apoptotic effects on the other lines (see Figure 3.07A and B). It is suggested that cell 
inhibitory effect of Wortmannin to occur through not only inhibition of class I 
PI3K/Akt/mTOR axis signaling but also apoptosis induction. However, since specific 
inhibition by ZSTK474 of class I PI3K weakly promotes apoptosis (see Figure 3.07A 
and B), the possibility that Wortmannin decreases cell survival through targeting 
additional protein kinases cannot be ruled out.  
3.4.2.4 ZSTK474 does not fully inhibit cell viability in most lines. 
 Canine 3132, J3T, REM134 and C2 cells are sensitive to the specific PI3K 
inhibitor ZSTK474, as demonstrated by cell viability assays showing ≥74% inhibition of 
proliferation at the concentration of 10 µM. However, ZSTK474 fails to fully inhibit cell 
viability in most of the tested canine cell lines, suggesting the existence of another 
mechanism for cell survival. The active Erk signaling detected in these canine cells may 
play a role in resistance to PI3K pathway inhibition because the functions of class I 
PI3K/Akt/mTOR pathway and Erk pathway are partially overlapped. Erk has been 
reported to regulate cellular responses, including proliferation, survival, cap-dependent 
translation (through its downstream Mnk/eIF4E pathway), nuclear response to stress, 
transcription, and immediate-early response (Roux and Blenis 2004). In addition, both 
class I PI3K/Akt/mTOR and Raf/Mek/Erk pathways are downstream of RTKs and Ras 
(Lemmon and Schlessinger 2010; Castellano and Downward 2011). 
3.4.2.5 Maximum tolerated dose (MTD) for Wortmannin and ZSTK474 
 In addition to challenges posed by its pharmacological properties (instability, 
poor solubility), studies in vivo of both murine tumours and human tumour xenografts in 
murine hosts indicated that Wortmannin produced severe hepatic and hematological 
toxicities. Whilst this has prevented Wortmannin from being taken forward into clinical 
trials, the compound remains widely used in vitro for signaling studies (Schultz et al. 
1995; Ihle et al. 2004).  
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 Recently, new derivatives of Wortmannin, such as PX-866, have been developed 
to overcome these pharmacological drawbacks. PX-866 has been applied to in vitro and 
in vivo experiments; as yet, there is no data published from clinical trials (Howes et al. 
2007; Koul et al. 2010). A pharmacokinetic study of PX-866 reports its maximum 
tolerated dose (MTD) in the mouse model is 19.5 mg/kg, much greater than Wortamnnin 
(3 mg/kg) (Ihle et al. 2004).  
 As ZSTK474 is a novel and orally administered drug, available data regarding 
MTD for ZSTK474 is currently confined to in vivo experiments (Anzai et al. 2011). 
Weight loss was the only side effect that was observed in the mouse models of human 
tumour xenografts or artheritis when administered orally at doses up to 800 mg/kg, 
suggesting that ZSTK474 was well-tolerated in the mouse species (Yaguchi et al. 2006; 
Toyama et al. 2010). 
3.4.3 KP372-1 
3.4.3.1 KP372-1 is a potent inducer of apoptosis 
 In this study, KP372-1 was observed to produce the most potent inhibition of cell 
viability, indicating the critical role for Akt in the tested cell lines. Western blot analysis 
demonstrated that, compared with ZSTK474 and Rapmycin, high doses of or prolonged 
exposures to KP372-1 are required to inhibit Akt/mTORC1 signaling. However, KP372-
1 showed remarkable efficacy for inducing apoptosis. A previous study of KP372-1 on 
AML cells / cell lines / xenografts suggests that this drug predominantly acts through 
inhibition of the PDK1/Akt-mediated anti-apoptotic mechanism, but has no effect on 
cell cycle progression (Zeng et al. 2006). In agreement with this study, our data suggests 
that KP372-1 is a potent inducer of apoptosis through down-regulation of Akt-mediated 
survival signaling but has less effect on inhibition of Akt/mTORC1-mediated activities 
such as protein synthesis and cell cycle progression. In addition, as REM134 cells are 
highly sensitive to KP372-1 but relatively resistant to Rapamycin, it is suggested that 
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Akt-mediated anti-apoptosis activity (rather than mTORC1 activity) is critical for the 
viability of REM134 cells.  
3.4.3.2 Decreased phosphorylation of Akt and eIF4E is presumably due to 
apoptotic effect    
 In the time course study of C2 cells (see Figure 3.05), KP372-1 at 400 nM 
initially down-regulated phosphorylation of mTORC1 substrates S6RP and 4E-BP1, and 
then gradually down-regulated phosphorylation of Akt and eIF4E. Finally, no protein 
was available from the KP372-1-treated cells. Besides, Annexin V/PI staining showed 
that 400 nM KP372-1 induced late apoptosis in most C2 cells after 24 hours of 
incubation (Figure 3.07A and 3.07B). Taken together, the experiments indicate that the 
phenomena of decreased phosphorylation and loss of protein may be correlated with 
apoptosis and/or the drug action of KP372-1. In addition to Akt, KP372-1 has been 
reported to target PDK1 and Flt3, a RTK (Zeng et al. 2006). Thus it could be inferred 
that the profound inhibition by KP372-1 of Akt and eIF4E phosphorylation in the 
present study is mediated by these two additional targets. However, whilst PDK1 
inhibition may account for the reduced Akt phosphorylation, it is more difficult to 
explain the observed decrease in eIF4E phosphorylation. First, accumulating evidence 
has shown that Erk and p38 mitogen-activated protein kinase (p38MAPK)/Mnk-
mediated phosphorylation of eIF4E on Ser209 is critical for tumourigenicity but not 
essential for normal cell development. Down-regulation of Mnk-mediated eIF4E 
phosphorylation can be achieved through simultaneous inhibition of both Erk and 
p38MAPK (Ueda et al. 2004; Bianchini et al. 2008). In the present study, the 
combination of Rapamycin and pan-class I PI3K, including Wortmannin and ZSTK474 
(see Figure 3.12 and 3.13), shows that full inhibition of 4E-BP1 phosphorylation fails to 
down-regulate eIF4E activity in all cell lines, in agreement with previous findings that 
both mTORC1 and MAPK pathways concurrently regulate eIF4E activity (Raught and 
Gingras 1999). Second, in a study of human throid cancer cells in vitro, KP372-1 
produced no inhibitory effect on MAPK phosphorylation (Mandal et al. 2005). Although 
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KP372-1 simultaneously inhibits Akt, PDK1 and Flt3 in AML cells in vitro, no 
inhibition of ERK and PDK1 phosphorylation has been observed, suggesting that 
KP372-1 does not abrogate Flt3-mediated class I PI3K and Erk MAPK pathways but can 
down-regulate the Flt3-mediated Jak/STAT pathway (Zeng et al. 2006). Moreover, Flt3 
is commonly expressed on precursor cells of myeloid and lymphoid lineages in bone 
marrow and less commonly on the hematopoietic system-associated organs, including 
liver, spleen, thymus and placenta. Expression of mutant Flt3 has been observed in 
seveal cancer types, all of which are confined to hematologic malignancies including B-
cell or T-cell acute lymphoblastic leukemia and B-cell acute myeloid leukemia, 
myelodysplasia, chronic myeloid leukemia and chronic lymphocyctic leukemia 
(Meshinchi and Appelbaum 2009). Jurakt T and C2 cells, derived from human acute 
myeloblastic leukemia and canine mastocytoma respectively, have been reported as 
having low or lost expression of Flt3 (Lyman and Jacobsen 1998; Inomata et al. 2006). 
Canine REM134, J3T and SB cells, derived from canine mammary gland tumour, 
glioma, and hemangiosarcoma respectively, are considered to be unlikely to express 
Flt3, based on the cell origins of the three tumours derived from epithelial/mesenchymal, 
neural, and endothelial cells, respectively, instead of bone marrow cells (Moulton 1990). 
Only 3132 cells derived from B cell lymphoma is required for further investigation 
(Drexler 1996). Collectively, Western Blot analysis has shown that Erk signaling is 
active in all canine cell lines in the present study. KP372-1 has been reported to have no 
effects on inhibition of Erk and MAPK phosphorylation. Therefore, it is unlikely that 
KP372-1 inhibits Erk and p38MAPK/Mnk-mediated eIF4E phosphorylation (Zeng et al. 
2006).  
 It has been documented that cells undergoing apoptosis, at the molecular level, 
are characterized by exposure of phosphatidylserine (PS) on the cell surface, 
mitochondrial changes and the release of cytochrome c from the inner membrane of 
mitochondria to cytosol, activation of caspase signaling cascades that result in DNA 
fragmentation, degradation of nuclear material and cytoskeletal proteins (Elmore 2007). 
During apoptosis, cells display morphological changes, including blebbing of 
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cytoplasmic membrane, chromatin condensation, nuclear degradation, disintegration of 
the cells into apoptotic bodies (Elmore 2007; Krysko et al. 2008). In a host body, 
apoptotic bodies are normally engulfed by phagocytes (Krysko et al. 2008). When cells 
are grown in medium in the absence of phagocytes, apoptotic cells proceed to secondary 
necrosis that are characterized by lack of cell membrane integrity and changes in cell 
membrane permeability, thereby allowing PI to intercalate with fragmented DNA and 
leakage of proteins in the cell medium (Kelly et al. 2003; Krysko et al. 2008). In the 
current study, the most possible explanation for the occurrence of protein loss in the 
KP372-1 treated C2 cell group may be attributed to the leakage of proteins from cytosol 
to cell medium during secondary necrosis, based on the observation of the majority (73-
88%) of C2 cells being positive for both PI and Annexin V staining (Figure 3.05, 3.07A 
and 3.07B). The secondary necrosis-related leakage of proteins may also provide an 
explanation for the decreased levels of all the proteins, including Akt, S6RP, 4E-BP1 
and eIF4E, in C2 cells. An alternative explanation for the down-regulation of these four 
phosphorylated proteins by KP372-1 may be attributed to the cleavage (or degradation) 
of Akt1 and Raf1 kinases by caspases. Over the past decade, a wide array of proteins has 
been identified as caspase substrates. Caspases can promote apoptosis through cleavage 
of their protein substrates (Earnshaw et al. 1999). An in vitro study showed that caspases 
inhibited class I PI3K/Akt and Raf/Erk pathways through cleavage of Raf-1 and Akt1. In 
the same study, Ras was identified as an additional target of caspases and cleavage of 
Ras by caspases shut down Ras activity (Widmann et al. 1998).  
 Taken together, the most likely scenario for the drug action of KP372-1 on C2 
cells is that KP372-1 inhibits the levels of phosphorylated S6RP, 4E-BP1, and Akt. 
Meanwhile, KP372-1 promotes apoptosis, followed by activates caspase signaling 
cascades, cleaves Akt-1 and Raf-1 proteins in C2 cells, inhibits both class I PI3K/Akt 
and Raf/Erk signaling cascades, and thereby decreased phosphorylation levels of Akt 
and eIF4E. With apoptosis proceeding to secondary necrosis, there are changes in the 
permeability of C2 cell membrane, which results in leakage of proteins to cell medium 
and allowing propidium iodide to enter cells and intercalate with fragmented DNA.          
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 Like C2 cells, KP372-1 decreased levels of phosphorylated Akt, S6RP, 4E-BP1 
and eIF4E in REM134 and J3T cells. Besides, REM134 cells, as an adherent cell line, 
were observed to float in the medium following high dose of KP372-1 treatment for 5 
hours and subsequently far less amount of protein was available as compared with the 
control. By contrast, the phenomena observed in REM cells did not happen to J3T cells 
(Figure 3.03C). It was observed that 92% of REM134 cells, 65% of J3T cells, and 31% 
of C2 cells were apoptotic after 5 hour incubation with KP372-1 (Figure 3.08). A 
majority of adherent cells, including REM134, J3T and SB cells, detached from the 
monolayer to float in the medium following 24 hour incubation with KP372-1. Taken 
together, it is speculated that the scenario of the drug action of KP372-1 on C2 cells may 
occur in REM134 and J3T cells as well.     
3.4.3.3 KP372-1 induces apoptosis through inhibition of PDK1/Akt, 
independent of Flt3 inhibition 
 Previous studies of AML cell lines / xenografts / patients showed that KP372-1 
inhibited mutant Flt3-mediated over-expression of PIM (stands for proviral integration 
sites associated with murine leukemia virus–induced lymphomagenesis) kinase through 
Janus kinase (Jak)/ signal transducers and activators of transcription (Stat) signaling 
(Zeng et al. 2006). PIM kinase functions to promote cell survival and growth through 
PIM substrates - some of these substrates, such as Bad, 4E-BP1 and p70S6K, are also 
regulated by Akt (Fox et al. 2003; Yan et al. 2003; Aho et al. 2004; Chen et al. 2005; 
Nawijn et al. 2011). KP372-1 is reported to have little impact on normal Flt3-mediated 
PIM activity. Moreover, the remarkable effect of KP372-1 on apoptosis induction has 
“not” been shown to correlate with normal or mutant Flt3 expression (Zeng et al. 2006). 
This suggests that induction of apoptosis by KP372-1 occurs predominantly through 
inhibition of PDK1/Akt-mediated pro-survival and anti-apoptotic activities. In 
agreement with previous findings (Zeng et al. 2006), it seems that there is no correlation 
between sensitivity to apoptosis and level of Flt3 expression among all the cell lines 
tested in the current study.  
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3.4.3.4 Comparison of the effects of KP372-1 on Akt/mTORC1 inhibition in 
previous studies with those in the current study 
 In the present study, KP372-1 down-regulates Akt/mTORC1 signaling in C2 
cells after either short exposure to drug concentrations of ≥ IC-100 or prolonged 
exposure to lower doses. However, previous reports showed that lower doses (such as 
IC-50) of KP372-1 could suppress Akt/mTOR signaling in tumour cells cultured under 
different conditions. For example, in serum-free medium, short exposure (4-6 hours) to 
IC-50 concentrations of KP372-1 significantly decreased phosphorylation of Akt 
(Ser473) and S6RP in cells derived from human thyoid cancer and glioblastoma 
(Mandal et al. 2005; Koul et al. 2006). In a study of HNSCC, phosphorylation of Akt 
(Ser473) and S6RP was down-regulated in cells concomitantly incubated with IC-50 
concentrations of KP372-1 and EGF for 30 mins, as compared with cells incubated with 
EGF only (Mandal et al. 2006). In the study of AML by Zeng et al (2006), the 
concentrations of IC-100 and lower than IC-100 of KP372-1 were utilized to treat cells, 
which were culture in serum-containing medium, for 8 to 16 hours. Notably, chronic 
exposure (16 hours) to IC-100 concentration of KP372-1 abrogated phosphorylation of 
Akt (Thr308 and Ser473) but had no inhibitory effect on Erk signaling in AML cells. 
Moreover, it was observed that phosphorylation of Akt on Ser473 was more sensitive to 
KP372-1 than Thr308, in that lower doses of KP372-1 could inhibit phosphorylation on 
Ser473 but not on Thr308 (Zeng et al. 2006). Taken together, an explanation for the 
requirement for longer drug exposure and higher concentration to inhibit Akt/mTORC1 
signaling in the cells tested in the current study could possibly be due to cells cultured in 
serum-containing medium, which allows serum that may contain unidentified growth 
factors to constantly activate class I PI3K pathway in these cells.  
 It has been shown that levels of phosphorylated Akt (Ser473) were decreased to 
varying degrees in KP372-1-treated human HNSCC, thyroid and AML cells (Mandal et 
al. 2005; Mandal et al. 2006; Zeng et al. 2006). In contrast to previous findings, KP372-
1 did not abrogate phosphorylation of Akt on Ser473 in human Jurkat T, canine 3132 
and SB cells. This disparity in the blockade of Akt phosphorylation could be a 
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consequence of different drug treatment protocols. For example, HNSCC and thyroid 
cancer cells were treated with this inhibitor under serum-free condition whereas AML 
cells which were grown in serum-containing medium had been exposed to KP372-1 for 
16 hours before harvested for Western blotting analysis (Mandal et al. 2005; Mandal et 
al. 2006; Zeng et al. 2006). In the current study, since Akt phosphorylation in C2 cells 
was abrogated after chronic exposure to KP372-1, it is speculated that Jurkat T, 3132 
and SB cells might follow the same track as C2 cells. Moreover, the failure of KP372-1 
to inhibit Akt phosphorylation in these cell lines suggests that PDK1 may not be the first 
priority target of KP373-1. However, to elucidate this issue whether PDK1 activity or 
Akt phosphorylation can be inhibited in Jurkat T, 3132 and SB cells, prolonged exposure 
to KP372-1, along with Western blotting analysis of phosphorylation of Akt on both 
Thr308 and Thr473, may provide a better understanding of the drug mechanism.       
The exact mechanism by which KP372-1 inhibits Akt kinase activity remains 
unresolved.  Other Akt inhibitors have been developed, such as AKTide-2T (which 
competes with substrate binding in the kinase (catalytic) domain), TCN/API-2 (which 
interacts with PH domain), and Akti-1,2 (an allosteric, non-competitive inhibitor which 
alters the overall shape of Akt kinase) (Cheng et al. 2005). So far, a competitive ATP 
inhibitor which specifically targets Akt has not been yet developed because Akt shares 
similar three dimensional structure of ATP-binding pocket with PKA and PKC 
(Lindsley et al. 2007).  
3.4.3.5 Pharmacokinetic properties of KP372-1 
KP372-1 is a recently-synthesized inhibitor and, at the time of writing, only data 
from in vitro experiments have been published. An in vitro study demonstrated dose-
dependent induction of apoptosis for AML cells by KP372-1, whilst normal 
hematopoietic progenitors were unaffected/spared. The same study shows lesser 
inhibitory effects on clonogenic growth of normal bone marrow cells, as compared with 
that of AML cells (Zeng et al. 2006). In line with this, much less cytotoxic effects of 
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KP372-1 on normal human astrocytes and fibroblasts than those on glioblastoma cell 
lines has been reported in another study of human glioblastomas (Koul et al. 2006).  
3.4.4 Rapamycin  
3.4.4.1 Rapamycin triggers eIF4E survival pathways in certain cell lines 
In this study, all canine cell lines exhibited relative resistance to Rapamycin, as 
indicated by less than 50% inhibition of viability at the dose (~600 nM) recommended 
for clinical treatment (Kwitkowski et al. 2010). Further, Rapamycin at the doses lower 
than 10 µM showed only cytostatic effects on cell viability in these canine cells whereas 
remarkable reduction in cell viability was observed at doses of 10-40 µM, in agreement 
with previous findings that micromolar ranges of CCI-779 or Rapamycin could achieve 
full inhibition of cell proliferation (Shor et al. 2008). Accumulating evidence suggests 
that Rapamycin at lower doses (nanomolar range) requires initial interaction with the 
cytoplasmic receptor FKBP12, which in turn allows Rapamycin to bind mTORC1, 
leading to inhibition of mTORC1 pathway but also generation of drug resistance issue 
(Shor et al. 2008; Chen et al. 2010). At least three mechanisms have been reported as 
giving rise to Rapamycin resistance, and all of them are linked to mTORC1 inhibition. 
The first is through inhibition of mTORC1/p70S6K, which in turn releases the feedback 
loop of p70S6K/IRS-1/PI3K/Ras and stimulates Ras/Erk MAPK and PI3K/Akt 
pathways (Harrington et al. 2004; Wang et al. 2007; Carracedo et al. 2008). For the 
second, inhibition of mTORC1 stimulates expression of insulin growth factor (IGF-1) 
and IRS-2, followed by activation of IGF-1/IGF-1 RTK/IRS-2/PI3K with consequent 
stimulation of the class I PI3K/Akt pathway (Tamburini et al. 2008). The third route is 
through mTORC1 inhibition, which triggers the c-SRC/RTK pathway and causes 
activation of Ras/Erk MAPK pathway (Chaturvedi et al. 2009). By contrast, Rapamycin 
at higher doses (micromolar range) directly binds mTOR, which in turn inhibits 
mTORC2, mTORC1 and global translation process, leading to dramatic decline in cell 
viability (Shor et al. 2008). A more recent study confirmed that high concentrations of 
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Rapamycin inhibited both mTORC1 and mTORC2 and had better efficacy in eradiaction 
of tumour cells than low concentrations of Rapamycin. Rapamycin (at high 
concentrations)-mediated mTORC2 inhibition causes a reduction in phosphorylation 
levels of Akt and Erk (Chen et al. 2010).  
 In agreement with previous findings (Shor et al. 2008), the current Western blot 
results show that a low dose (100 nM) of Rapamycin inhibits mTORC1 signaling in all 
lines, as evidenced by decreased phosphorylation of either S6RP or 4E-BP1. However, it 
also stimulates phosphorylation of eIF4E in Jurkat T cells. As eIF4E phosphorylation is 
under the control of Erk and/or p38 MAPK pathways following mTORC1-mediated 
dissociation from 4E-BP1, these results suggest that Rapamycin at the low dose 
stimulates the Erk or p38MAPK/Mnk/eIF4E pathway in Jurkat T cells, possibly through 
one of the three Rapamycin-resistance mechanisms described above (Waskiewicz et al. 
1997; Raught and Gingras 1999; Sun et al. 2005; Bianchini et al. 2008). Indeed, a 
previous study of PIM inhibitor demonstrated that inhibition of p70S6K activity in 
Jurkat T cells triggered p70S6K/IRS-1 feedback loop and activated Ras/Erk signaling 
(Lin et al. 2010). In this study, not only Rapamycin but also KP372-1 significantly 
increased phosphorylation of eIF4E in the tested cell lines. Interestingly, the Rapamycin-
induced phosphorylation of eIF4E in Jurkat T cells was suppressed when cells were 
treated with combinations of Rapamycin with either ZSTK474 or Wortmannin. In fact, it 
was observed that Rapamycin up-regulated eIF4E phosphorylation in 3132 and SB cells 
and the effects lasted for 48-72 hours. eIF4E phosphorylation in SB cells was up-
regulated by Rapamycin alone, Wortmannin alone and the combination of both 
inhibitors. As previous study reported that Rapamycin-induced eIF4E phosphorylation 
could be reversed by the combination of Rapamycin and PI3K inhibitor but, sometimes, 
PI3K inhibitor alone still increased eIF4E phosphorylation. Therefore, it is suggested 
that tumour cells may escape the drug treatment through additional mechanisms other 
than p70S6K/IRS-1/PI3K/Ras feedback loop (Wang et al. 2007). Consistent with 
previous findings, the data suggest that the resistance of Jurkat T, SB and 3132 cells to 
these PI3K pathway inhibitors is through more than one mechanism.  
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3.4.4.2 The possible mechanism for high doses of Rapamycin to induce 
apoptosis  
Rapamycin at higher doses (micromolar range) was demonstrated to directly 
binds to mTOR, which in turn inactivated mTORC2 activity and inhibited mTORC1-
independent protein synthesis mechanism, leading to a dramatic decline in cell viability 
(Shor et al. 2008). Besides, inhibition of mTORC2 by a high dose (1 µM) of Rapamycin 
was shown to increase apoptotic cell numbers and down-regulate Akt and Erk 
phosphorylation, as compared with the controls (Chen et al. 2010). In this study, 
Rapamycin at 20 µM significantly increased apoptosis for most of the tested cell lines, 
confirming that reduction of cell viability was in part through apoptosis.   
To date, mTOR kinase is the only target of Rapamycin (Huang et al. 2003). It is 
speculated that Rapamycin-mediated apoptosis and inhibition of mTORC1-independent 
protein synthesis may be attributed to Rapamycin-mediated mTORC2 inhibition. 
mTORC2 has recently been identified as an activator of not only Akt survival kinase but 
also SGK, a pro-survival factor, and PKC which is involved in a variety of cellular 
physiological functions and tumourigenesis (Sarbassov et al. 2005; Garcia-Martinez and 
Alessi 2008; Ikenoue et al. 2008; Gonelli et al. 2009). More recently, mTORC2 has 
been found to play a role in regulation of Erk signalling through Rictor, a component of 
mTORC2. Previous studies showed that the role of Rictor in regulation of Erk pathway 
is cell-specific. In human MCF-7 (breast cancer) and DU145 (prostate cancer) cell lines, 
high concentrations of Rapamycin or silencing of Rictor mRNA inhibited Erk 
phosphorylation (Chen et al. 2010). By contrast, in glioma cell lines and glioma primary 
cells, silencing of Rictor mRNA induced Erk phosphorylation and showed no effect on 
inhibition of cell viability although Akt activity was impaired (Das et al. 2011). Taken 
together, it appears that the role of Rictor in activation or inhibition of Erk is cell line-
dependent. Rictor regulates not only Erk but also Akt and some PKCs (Ikenoue et al. 
2008; Chen et al. 2010; Das et al. 2011). Protor-1 regulates SGK (Pearce et al. 2011). 
The mechanism of high doses of Rapamycin-mediated apoptosis may rely on inhibition 
of mTORC2-dependent Akt, all conventional PKCs, novel PKCε and SGK survival 
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pathways. After mTORC2 inhibiton, Erk survival pathway may be inactivated and drive 
cells apoptosis, or may be stimulated and resistant to Rapamycin treatment.        
3.4.5 Rapamycin combined with Wortmannin 
In this study, the combination of Wortmannin and Rapmycin inhibited most cell 
lines in an additive or synergistic manner, except REM134. By utilizing Western blot 
analysis to further dissect the mechanism, it was observed that all cell lines presented 
similar Western blot profiles except the phosphorylation levels of Akt in the drug 
combination-treated cells (Figure 3.11). The combination of Wortmannin with 
Rapamycin significantly down-regulated Akt phosphorylation in most cell lines, 
including Jurkat T, 3132, SB and C2 cells, whereas this combination had no effects on 
REM134 and J3T cells (Figure 3.11). Therefore, it is suggested that the failure of the 
drug combination to down-regulate Akt phosphorylation in REM134 cells, leading to 
constitutive activation of Akt survival signaling, may provide an explanation for the 
antagonostic effects on this cell line. In line with this explanation, in J3T cells, there was 
not much difference in viability inhibition between Rapamycin alone and the drug 
combination groups (see Figure 3.09), suggesting a correlation between the degree of 
decreased levels of Akt phosphorylation and inhibitory efficacy of Wortmannin 
combined with Rapamycin.  
However, the Western blot results cannot distinquish the difference between 
additive and synergistic effects of the drug combination. The discrepancy may be 
explained by multiple targets of Wortmannin. As mentioned above, Wortmannin has 20-
50 fold selective inhibition of p110α catalytic subunit over PI4K and other PI3K-related 
kinases (Stein 2001). It is suggested that the synergistic effects may be the result of the 
effects on other targets of Wortmannin in addition to class I PI3K.  
 Although the drug combination profoundly inhibited 4E-BP1 phosphorylation, as 
compared with single drug-treated cells, this did not contribute to down-regulation of 
eIF4E activity across all cell lines (Figure 3.11). This is in agreement with previous 
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findings that eIF4E phosphorylation is concurrently regulated by mTORC1/4E-BP1 and 
Erk and p38MAPK/Mnk signaling pathways (Raught and Gingras 1999; Wang et al. 
2007; Bianchini et al. 2008). Grzmil M et al (2011) reported that simultaneous inhibition 
of Mnk and mTOR kinases synergistically decreased growth of human glioblastoma 
cells in vitro (Grzmil et al. 2011). The same group described unpublished observations 
whereby concomitant inhibition of Mnk and mTOR kinases promoted the association of 
4E-BP1 with eIF4E, suggesting that the Erk and p38 MAPK/Mnk and mTOR pathways 
co-regulated eIF4E phosphorylation and the cap-dependent translation. Since all the 
tested canine lines demonstrate active Erk signaling, it seems likely that constant eIF4E 
phosphorylation is sustained by active Erk. Although active Erk is not expressed in 
Jurkat T cells, it cannot be ruled out that Jurkat T cells might express active p38MAPK, 
which is another upstream activator of Mnk/eIF4E pathway (Ueda et al. 2004; Bianchini 
et al. 2008). To elucidate whether mTOR and Mnk concurrently regulate eIF4E activity 
in these cell lines, investigation of inhibitors specifically targeting the Erk and/or 
p38MAPK/Mnk pathway may give better understanding of eIF4E regulation.   
3.4.6 Rapamycin combined with ZSTK474 
 It is suggested that the mechanism for the additive or synergistic effects of 
ZSTK474 and Rapamycin on cells occurs through simultaneous inhibition of Akt 
activity and mTORC1 activity. Like Wortmannin combined with Rapamycin, the 
combination of ZSTK474 and Rapamycin has no effects on eIF4E phosphorylation, 
consistent with previous reports that eIF4E phosphorylation was concurrently regulated 
by mTOR and Mnk pathways (Raught and Gingras 1999; Wang et al. 2007; Bianchini et 
al. 2008). Interestingly, it was observed that the combination of ZSTK474 and 
Rapamycin did not profoundly inhibit phosphorylation of S6RP in tested canine cell 
lines other than C2 cells. S6RP was reported to have three upstream activators - 
PDK1/p70S6K, mTORC1/p70S6K and Ras/Erk/RSK pathways. It is suggested that 
Ras/Erk/RSK is most likely to contribute to the maintenance of S6RP phosphorylation 
after blockade of both PI3K and mTORC1 signaling in these four canine cell lines 
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(Burnett et al. 1998; Pullen et al. 1998; Roux et al. 2007). As simultaneous inhibition of 
class I PI3K and mTOR by the drug combination can result in down-regulation of 
PDK1- and mTOR-mediated phosphorylation of PDK1, it is possible that the active Erk 
signaling which is detected in these canine cell lines supports S6RP activity. This would 
also explain the limited effects of Rapamycin on S6RP phosphorylation in some cell 
lines such as 3132.  
 Recently, simultaneous inhibition of class I PI3K/Akt and Raf/Mek/Erk signaling 
pathways has been proposed as a novel anti-cancer strategy, as mutant Ras may trigger 
both signaling pathways to maintain survival and proliferation of tumour cells. 
Moreover, cross-talk between class I PI3K and Mek pathways is the major resistance 
mechanism which attenuates efficacy of single agent targeting either PI3K or Mek 
signaling (Castellano and Downward 2011). Indeed, accumulating evidence from in 
vitro and in vivo studies has demonstrated that concomitant treatment with class I PI3K 
and Mek pathway inhibitors exerts additive effects on growth inhibition of tumour cells 
(Bianchini et al. 2008; Engelman et al. 2008). As the data presented here have revealed 
activation of both class I PI3K and Erk pathways in the tested canine cells, future 
strategies to effectively eliminate cell viability in canine tumours may utilize inhibitors 
co-targeting both pathways.   
Although cells displayed variable responses to the combination of Wortmannin 
and Rapamycin, Wortmannin demonstrated synergism with Rapamycin in C2 and SB 
cells; by constrast, for J3T cells, ZSTK474 and Rapamycin acted synergistically. This 
suggests that the sensitivity to a given drug combination may vary from one cell line to 
another, presumably due to each cell line possessing its unique cellular context for 
survival and proliferation. Moreover, the results also implicate that each cancer patient 
may suit different combination of the PI3K pathway inhibitors to antagonize cancer 
progression.  
In this study, it is observed that chronic exposure (18 hours) to Rapamycin 
down-regulates Akt phosphorylation in Jurkat T cells (Figure 3.12). The same effect of 
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Rapamycin on reducing Akt phosphorylation in Jurkat T cells and certain cell lines after 
exposure for 24 hours has been described in previous studies (Sarbassov et al. 2006; Dal 
Col et al. 2008). The present study shows that chronic exposure to Rapamycin down-
regulates both mTORC1 signaling and Akt phosphorylation in Jurkat T cells, which may 
underlie the high sensitivity of Jurkat T cells to Rapamycin (Figure 3.02D).   
3.4.7 Drug combination strategy – class I PI3K pathway inhibitors and 
Doxorubicin 
In the current study (see Figure 3.13), cells showed variable responses to the 
combination of class I PI3K pathway inhibitors and Doxorubicin, a cytotoxic agent that 
intercalates DNA at synthesis (S) phase, interfering with DNA synthesis, and which also 
directly inhibits topoisomerase II activity (Momparler et al. 1976; Burgess et al. 2008). 
Interestingly, SB cells were the least sensitive to KP372-1 treatment but the combination 
of KP372-1 with Doxorubicin acted synergistically on this cell line whereas for 
REM134 cells, which were highly sensitive to KP372-1, the drug combination resulted 
in antagonism (Figure 3.02C and 3.13). One possible explanation for such results could 
be an unknown mechanism at the level of DNA synthesis (S phase) may antagonize 
KP372-1-mediated apoptosis in SB cells. 
In the three cell lines REM134, 3132 and C2, the combination of Doxorubicin 
with the class I PI3K pathway inhibitors was antagonistic. Although accumulating 
evidence supports that inhibition of PI3K signaling pathway (with resultant cell cycle 
arrest and apoptosis induction), may enhance effects of Doxorubicin and other 
chemotherapeutic drugs, a small number of studies have reported that cells respond 
poorly to this drug combination. This may occur because sequential exposure to the 
PI3K inhibitors prior to (earlier than) Doxorubicin, leading to more cells resting in G0-
G1 phase, thereby preventing Doxorubicin from binding to proliferative cancer cells 
(Opel et al. 2008; McDonald et al. 2010; Bender et al. 2011). As the canine cells were 
treated with Doxorubicin and the PI3K pathway inhibitors simultaneously, it is possible 
that Wortmannin, ZSTK474 and Rapamycin lead to accumulation of cells in G0-G1 
211 
 
phase, abrogating the efficacy of Doxorubicin. Previous data demonstrated that the 
mechanism of ZSTK474 to down-regulate cell viability was predominantly through 
inhibition of cell growth (Yaguchi et al. 2006). In line with the findings by Yaguchi et al 
(2006), the current data showed that 20 µM ZSTK474 significantly inhibited viability in 
all cell lines with a reduction in viability ≥79%. However, this inhibitor at 20 µM 
produced apoptosis with an increase in apoptotic fraction by ≤ 35% in Jurkat T, SB and 
C2 cells, and even had almost no apoptotic effects on 3132, REM134 and J3T cells 
(Figure 3.02B, 3.07A and 3.07B). Wortmannin and Rapamycin have been well-
established for their ability to arrest cell cycling (De Nadai et al. 1998; Dal Col et al. 
2008). Therefore, previous data, along with the current findings, may provide an 
explanation for the antagonistic effects of Doxorubicin in combination with the three 
class I PI3K pathway inhibitors Wortmannin, ZSTK474 and Rapamycin. To improve the 
efficacy of Doxorubicin combined with PI3K pathway inhibitors, cells could be 
pretreated with Doxorubicin for 24 hours, and then concomitantly treated with 
Doxorubicin and the PI3K pathway inhibitors for a further ≥ 48 hours. This approach 
might prevent cells from accumulating at G0/G1 phase and allow Doxorubicin to 
interact with more cells at S phase (McDonald et al. 2010).  
In contrast to Wortmannin, ZSTK474 and Rapamycin, the mechanism for 
KP372-1 to reduce cell viability is preferentially through apoptosis induction (Zeng et 
al. 2006). This may explain the synergistic effects of the KP372-1 / Doxorubicin 
combination observed for SB cells. However, only data of the combination of KP372-1 
and Doxorubicin are available from SB and REM134 cells. This is not enough to 
validate the theory that KP372-1 has less interference with Doxorubicin than the other 
three PI3K pathway inhibitors. To avoid the issue that class I PI3K pathway inhibitor-
induced G0/G1 cell cycle arrest may conteract the efficacy of Doxorubicin, the approach 
of investigation into the effects of Doxorubicin in combination with these inhibitors on 
cancer cells should be performed by treating cells with Doxorubicin 24 hours prior to 
these inhibitors, instead of comcomitant treatment of two drugs for cells. Other factors 
that may influence the efficacy of the PI3K pathway inhibitors combined with 
Doxorubicin include genetic background and cellular context in a given cell line, 
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activation of the PI3K/Akt survival mechanism in response to Doxorubicin treatment, 
and other pharmacological properties such as potential interations between the lipid-
soluble inhibitor and water-soluble Doxorubicin (Wang et al. 2009; Wallin et al. 2010). 
One solution to eliminate the interaction between lipid- and water-soluble drugs is to 
treat cells with both drugs which are water-soluble. For example, Temsirolimus is a 
water-soluble Rapamycin derivative (Kwitkowski et al. 2010).  
Taken together, the true reasons that cause variable responses to the drug 
combination remain to be learned and one of the reasons could be cell-type-dependent. 
Nonetheless, few additive/synergistic effects of the drug combination cases still 
encourage the potential of integrating the PI3K pathway inhibitors into conventional 
chemotherapy protocol in canine oncology.  
3.4.8 Autophagy 
 Under nutrient deprivation or stress condition, cells undergo either apoptosis or 
autophagy. Autophagy is a process that degrades proteins and organelles and then 
recycling macromolecules in order to maintain cell survival (Shintani and Klionsky 
2004). The current data (see Figure 3.14B and 3.14C) show that prolonged exposure to 
Rapamycin for 48-72 hours, leads to increasd levels of LC3B-II, which is an indicator of 
autophagy induction, in canine SB, REM134 and J3T cell lines. This suggests that these 
drugs may potentiate the autophagy process to resist anti-cancer therapy. Recently, 
PP242, a novel inhibitor specifically targeting mTORC1 and mTORC2, has been 
reported to delay tumour onset and inhibit cancer cell growth more efficiently than 
Rapamycin. However, PP242 also showed greater potency to induce autophagy than 
Rapamycin (Janes et al. 2010). NVP-BEZ235, a newly developed inhibitor specifically 
targeting class I PI3K, mTORC1 and mTORC2 and currently enters clinical trials, is 
reported to induce autophagic resistance despite this inhibitor displaying promising 
activity against tumour in vitro (http://clinicaltrials.gov/ct2/search) (Baumann et al. 
2009). One strategy currently under investigation is combined treatment with NVP-
BEZ235 and the autophagic inhibitor Chloroquine; this approach is reported to enhance 
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the effect of NVP-BEZ235 on apoptotic induction (Chiarini et al. 2010; Fan et al. 2010; 
Xu et al. 2011). However, not all inhibitors targeting the class I PI3K/Akt/mTOR 
pathway can cooperate with autophagic inhibitors. For example, inhibition of autophagy 
process does not enhance the efficacy of Rapamycin towards glioma cells due to 
activation by Rapamcin of the Akt survival pathway (Fan et al. 2010).  
 One confounding issue in the current study is that induction of autophagy was 
observed in control cells as well as drug-treated cells. Vehicle-treated (control) J3T and 
REM134 cells expressed similar levels of LC3B-II to drug-treated groups after short 
exposure to ZSTK474 and/or Rapamycin (Figure 3.14A). Moreover, in the time course 
study over 72 hours, a higher level of LC3B-II expression was seen in vehicle-treated 
J3T cells as compared with Rapamycin-treated cells (Figure 3.14C). One possibility is 
that J3T and REM134 cells are more sensitive to stress stimuli in the environment, based 
on the consistent presence of LC3B-II expression in both lines after short-term or long-
term cell culture. Standard tissue culture manipulations, including removal of cells from 
incubators when adding drugs, or scraping cells from plates, are likely to result in a 
degree of cellular stress. Another source of stress stimuli might come from fast 
proliferation rates of cells, which resulted in over-confluence of cells in culture plates 
and followed by nutrient deprevation and autophagy induction. This may provide an 
explanation for presence of autophagy induction in J3T cells following long hour cell 
culture. Thus, it appears vital that external stress stimuli should be minimized 
throughout the course of experiments investigating the autophagy process. There are 
some ways to reduce external stimuli to cells. The first way is to use a flask with 80-
90% confluence of cells, instead of a flask with over-confluence of cells. Secondly, cells 
prefer to be cultured in the incubator at at 37 
o
C in a humidified atmosphere with 5% 
CO2, rather than stay in the hood at room temperature. Therefore, to avoid leaving cells 
outside the incubator for a long period of time, the time for for adding drug(s) or vehicle 
control reagent, such as DMSO, to each experimental or control group should be 
shortened. Thirdly, because scraping cells from each flask cannot be completed in a 
short period of time, it is recommended to handle few samples (flasks) at the same time, 
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in order to avoid leaving cells on a lab bench too long causing cellular stress. The 
solutions provided here may reduce the possibility of autophagy induction in vehicle 
control, avoidthe misunderstanding of the drug effects on autophagic resistance, and 
assure the credibility of data interpretation. Besides, future work should include a 
positive control cell line such as human neuroblastoma SH-SY5Y cell line, when 
investigating the effect of Rapamycin on induction of autophagy (Pan et al. 2009).    
 With regard to 3132 cells, the data suggest that Rapamycin and ZSTK474 do not 
promote autophagy in 3132 cells (Figure 3.14D), as indicated by a lack of LC3B-II 
expression in drug-treated cells. Similar effects are also observed in Jurkat T cells, 
suggesting that this cell line does not undergo autophagic resistance to either 
Rapamycin/ZSTK474 alone or the combination of both drugs. This may provide an 
explanation for high sensitivity of Jurkat T cells to ZSTK474 and Rapamycin. Taken 
together, the current study suggests that Rapamycin- and ZSTK474-induced autophagy 
is cell type-specific.  
 An alternative explanation for increased LC3B-II expression, an indicator of 
autophagy induction, in vehicle control cells would be the quality of the antibody used 
for Western blot analysis. Thus it will be important to validate the Western blot analysis 
of LC3B-II expression in canine cell lines using other approaches. To further investigate 
the role of autophagy, transmission electron microscopy analysis for presence of 
autophagic vacuoles could be performed (Chiarini et al. 2010). Other techniques could 
include acridine orange staining or autofluorescent monodansylcadaverine staining (to 
detect autophagosomes or autophagic vacuoles), and analysis of expression of the 
autophagy marker Beclin using Western blot (Takeuchi et al. 2005; Chiarini et al. 2010). 
However, as genetic sequence of canine Beclin has not been published yet, to check 
sequence homology of Beclin gene between human and canine species is necessary 
before performing western blotting analysis of Beclin expression in canine cells.          
 It appears that  the canine cancer cell lines, with the exception of 3132 cells, may 
develop autophagic resistance in response to Rapamycin or ZSTK474. Although 
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previous studies have offered a solution to overcome autophagic resistance to some 
novel class I PI3K pathway inhibitors by concomitant treatment with the autophagy 
inhibitor Chloroquine, this may not prove effective with Rapamycin, due to Rapamycin-
mediated up-regulation of Akt survival pathway in certain cell lines (Fan et al. 2010). 
Conversely, Chloroquine may enhance the efficacy of ZSTK474 which promotes down-
regulation of Akt activity. However, this theory should be validated by the data obtained 











Chapter 4: Expression profiling of class I PI3K signaling 







 Growing evidence has demonstrated the existence of cancer stem cells (CSCs) 
within a variety of primary tumours and tumour cell lines and the critical role of CSCs in 
recapitulating a new tumour similar to its parent tumour. Moreover, many studies have 
shown the correlation of class I PI3K/Akt/mTOR signaling with the viability and 
maintenance of CSCs. In this study, we have successfully isolated putative CSCs from 
canine glioma J3T cells by neurosphere formation assay and identified several highly 
up-regulated genes, particularly IGFBP2 (27-fold), FYN (9.3-fold), and DDIT4 (8.5-
fold), in the CSCs by cDNA microarray analysis. In the J3T CSCs, the genes encoding 
components of class I PI3K/Akt/mTOR axis pathway either remain unchanged or down-
regulated. The majority of the genes encoding components of mTORC1/eIF4E pathway-
modulated translation-initiation machinery are down-regulated. Ingenuity Pathways 
Analysis of the entire differentially expressed genes between the J3T CSCs and their 
parental cells indicate that the cell cycle, genetic disorder and protein synthesis vary the 
greatest between the two cell groups. In conclusion, the cDNA microarray data suggest 
that the stem cell biology of J3T CSCs are independent of class I PI3K/Akt/mTOR axis 
pathway.    
4.2 Introduction   
 Gliomas are the most frequent primary brain tumours in human adults as well as 
certain dog breeds including Boxers and Boston Terriers (Stoica et al. 2011). High-grade 
gliomas, especially the most malignant GBM, display highly aggressive behavior and 
locally infiltrative nature, which often leads to incomplete surgical excision and tumour 
relapse. Current therapeutic regime by using the combination of 
surgery/radiotherapy/chemotherapy prolongs medium survival time of 12-15 months in 
human patients with glioblastoma multiforme (GBM) (Stupp et al. 2005; Wen and 
Kesari 2008). Dogs with astrocytic gliomas were reported to have maximal survival time 
of ~8 months after receiving chemotherapy alone or combined with radiotherapy and 
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surgery (Stoica et al. 2011). Therefore, it is suggested that poor prognosis continue to 
exist in the majority of human and dogs with high-grade malignant gliomas, which 
highlights the urgent need to develop new strategies for effectively controlling this 
disease.  
 There is growing evidence to support CSC theory based on the fact of tumour 
heterogeneity, a single tumour containing multiple tumour subpopulations that display 
diverse biological properties (Heppner 1984). The CSC theory states that a bulk of 
tumour mass is derived from few tumour cells that possess Stem Cell (SC) properties, 
including self-renewal, pluripotent/multipotent differentiation potential, unlimited 
replication and resistance to radiotherapy and chemotherapy. Like normal SCs that can 
build a whole organized organ/tissue, CSCs which are considered as transformed SCs 
are capable of self-renewing, differentiating and replicating in an uncontrolled manner, 
thus ultimately constructing an aberrant organ/tissue. As SCs express ABC transporters 
to exclude chemical compounds and are frequently at quiescent state, which contributes 
to SCs being resistance to chemotherapeutic agents and radiation, it is hypothesized that 
SCs may confer these resistant mechanisms to CSCs, which may account for the 
unresponsiveness of some tumours to chemotherapy/radiotherapy or relapse of tumours 
after chemotherapy/radiotherapy (Reya et al. 2001; Sausville and Longo 2001; Bunting 
2002; Diehn et al. 2009).   
  To date, increasing evidence shows that class I PI3K/Akt/mTOR signaling 
pathway is associated with CSC biology and tumourigenesis. Studies showed that 
insertion of a myristolayted (constitutively active) Akt1 or inactivation of PTEN in 
hematopoietic stem cells (HSCs), which resulted in HSCs with hyperactive class I 
PI3K/Akt/mTOR signaling, induced transient cycling and proliferation of HSCs, but 
subsequently decreased HSC pool. Besides, hyperactivation of this pathway induced 
transformation of HSCs and initiated leukemia and other hematological malignancies 
(Zhang et al. 2006; Kharas et al. 2010). Reports of CSCs derived from human prostate, 
brain and breast cancers and preneoplastic mouse liver demonstrated that active class I 
PI3K/Akt/mTOR signaling contributed to survival and proliferation of CSCs and up-
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regualtion of the activity of ABCG2, a multi-drug resistant ABC transporter (Zhou et al. 
2007; Bleau et al. 2009; Dubrovska et al. 2009; Rountree et al. 2009).  
 In this study, the CSCs derived from canine glioma J3T cells were isolated and 
capable of proliferation in sphere formation assay. Subsequently, cDNA microarray 
analysis of J3T spheres versus their parental cells revealed differential expression of 
genes encoding several signaling pathways such as class I PI3K and Raf. Notably, 
several transcripts encoding components of class I PI3K/Akt/mTOR core signaling were 
down-regulated.  
4.3 Results 
4.3.1 Canine J3T cells form neurosphere colonies 
 Serum-free N2 medium supplemented with growth factors (EGF and bFGF), 
which favors the expansion of stem cell colony, has been established for the 
identification of neurospheres from mouse brain tissue and human brain tumours 
(Reynolds and Weiss 1992; Singh et al. 2003). In this study, J3T cells derived from 
canine glioma were observed to proliferate and form floated neurosphere-like clusters in 
a clonogenic manner. The materials and methods to grow J3T spheres were described in 
Chapter 2, Section 2.2.  Like neurospheres derived from mouse brain tissue, the spheres 





Figure 4.01. J3T cells formed nonadherent spheres under neural SC 
culture condition. Photomicrographs of cultured J3T cells were taken on Day 5 
after plating in N2 medium with EGF and bFGF (the materials and methods 
described in Chapter 2, Section 2.2). The magnification of photomicrographs A 
and B of neurosphere-like cells was 10X and 40X, respectively. The photos 




4.3.2 Expression profiles of class I PI3K signaling network of J3T sphere 
cells  
 To identify genes that are differentially expressed in cells grown in sphere 
formation culture system compared with their parental cells grown in adherent 
monolayer culture, microarray analysis of gene expression profile of the two cell types 
derived from J3T cells by using Genechip Canine 2.0 Genome Arrays was performed 
and compared (the materials and methods being decribed in Chapter 2, Section 2.9). The 
fold change (or ratio) of each gene was obtained by comparison of the average value of 
the gene from J3T spheres with that from J3T parental cells. Analysis of the expression 
profiles of the genes encoding components of class I PI3K/Akt/mTOR axis pathway, its 
downstream p70S6K pathway and its main upstream regulators that are IR and IGF-1 
pathways identified 73 genes being up-regulated and 59 genes being down-regulated 
(Table 4.01 and Table 4.02). Among the 73 up-regulated genes, IGFBP2 was the most 
up-regulated gene with a fold change of 27-fold. Besides, there were the other 11 genes 
which up-regulated ≥ 3-fold, including FYN, DDIT4, PPP1R3C, NTRK2, FOS, 
PDGFRB, CBL, IGF2R, CTNNB1, PLD3 and NTRK3 (Table 4.01). With regard to the 
59 down-regulated genes, YWHAG was the most down-regulated gene with a fold 
change of 3-fold (Table 4.02).  
 It was observed that the key components of class I PI3K/Akt/mTOR axis 
pathway, including PIK3CD (encoding p110δ catalytic subunit of class I PI3K), PIK3R5 
(p101 regulatory subunit of class I PI3K), AKT1 and EIF4E transcripts, were down-
regulated (Table 4.02). Twenty-two transcripts encoding proteins involved in regulation 
of translation initiation were down-regulated, which included several subunits or 
isoforms of eukaryotic translation initiation factor (eIF)-1 (eIF1), X chromosome-linked 
eIF1A, eIF2, eIF2A, eIF2B, eIF2C, eIF3, eIF4A, and the protein product of PABPC1 
gene (Table 4.02). On the contrary, five transcripts which were associated with 
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translation initiation were found to be up-regulated, including EIF1, EIF2C1, EIF2C3, 
PAIP1 and PAIP2 (Table 4.01).  
 In order to investigate the relationship of these genes categorized into class I 
PI3K pathway and its associated network, Ingenuity Pathways Analysis (IPA)  was used 
to generate graphics of class I PI3K signaling network with showing differentially up-
regulated and down-regulated genes (the method described in Chpater 2, Section 2.9.3). 
As shown in Figure 4.02, an overview of graphics of IR, IGF-1, class I PI3K/Akt, 
PTEN, mTOR, and regulation of eIF4 and p70S6K signaling pathways suggested that 
both class I PI3K/Akt/mTOR core signaling and eIF4E-mediated cap-dependent 
translation were down-regulated in J3T spheres. Additional information obtained from 
these graphics suggested that IR and most of its adaptor proteins including Cbl, Gab1, 
IRS-1, Jak1/2, and Shc were up-regulated (Figure 4.02A). IGFBPs were up-regulated 
but IGF-1 receptors (IGF-1Rs) were down-regulated (Figure 4.02B). With regard to 
those IR and IGF-1Rs-regulated downstream pathways in addition to class I PI3K 
signaling, Raf1/Mek1/Erk and Jak2/signal transducers and activators of transcription 3 
(Stat3) pathways were up-regulated (Figure 4.02 A and B).  
 To further investigate the differences between the J3T spheres and their parental 
cells, IPA was employed to identify which canonical pathways and biological functions 
are relevant to these differentially expressed genes. As shown in Figure 4.03, the most 
relevant canonical pathways containing differentially expressed genes between the J3T 
spheres and their parental cells were ranked by statistical significance. It could be clearly 
seen that the majority of the top 17 canonical pathways were involved in regulation of 
protein synthesis and cell cycle progression. The regulation of p70S6K and eIF4E 
pathway, IGF-1R and PTEN pathways were ranked at top 8, 13 and 17, respectively 
(Figure 4.03). The most relevant (top 10) biological functions and diseases enriched with 
these differentially expressed genes between the J3T spheres and the J3T parental cells 
were related to cell cycle, genetic disorder, protein synthesis, cell death, cancer, post-
transcriptional modification, DNA synthesis and repair, and post-translational 
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modification (Figure 4.04). The majority of these functions and diseases are involved in 
the tumourigenesis and cancer development.   
Table 4.01. Ranking of the up-regulated genes encoding member proteins 
of class I PI3K pathway in J3T spheres, as compared with J3T parental 
cells. ANOVA was performed to determine significant differences (p< 0.005). 
The table courtesy of Dr. Lisa Pang. 







IGFBP2 Insulin-like growth factor-binding protein 2 3.41E-13 27.128 3485 
FYN FYN oncogene related to FGR, SRC, YES 1.48E-13 9.334 2534 
DDIT4 DNA-damage-inducible transcript 4 2.99E-07 8.506 54541 
PPP1R3C Protein phosphatase 1, regulatory subunit 3C 2.82E-05 7.969 5507 
NTRK2 Neurotrophic tyrosine kinase, receptor, type 2 6.71E-13 7.805 4915 
FOS G0/G1 switch regulatory protein 7 1.39E-09 7.450 2353 
PDGFRB Platelet-derived growth factor receptor, beta 
polypeptide 
1.14E-07 7.251 5159 
CBL Cas-Br-M murine ecotropic retroviral 
transforming sequence (c-CBL) 
2.08E-12 5.566 867 
IGF2R Insulin-like growth factor 2 receptor 3.62E-07 4.862 3482 
CTNNB1 Catenin (cadherin-associated protein), beta 1, 
88kDa 
2.72E-15 4.145 1499 
PLD3 Phospholipase D family, member 3 3.89E-07 3.925 23646 
NTRK3 Neurotrophic tyrosine kinase, receptor, type 3 5.79E-08 3.138 4916 
IGFBP7 Insulin-like growth factor-binding protein 7 9.15E-14 2.991 3490 
IGFBP4 Insulin-like growth factor-binding protein 4 3.11E-11 2.852 3487 
GAB1 GRB2-associated binding protein 1 5.07E-05 2.444 2549 
JAK2 Janus kinase 2 1.02E-05 2.405 3717 
PDGFRA Platelet-derived growth factor receptor, alpha 
polypeptide 
5.84E-04 2.371 5156 
ACCN1 Amiloride-sensitive cation channel neuronal 1  3.83E-05 2.253 40 
RHOQ Ras homolog gene family, member Q 5.58E-08 2.132 23433 
FOXO1 Forkhead box O1 9.61E-07 2.116 2308 
SOCS5 Suppressor of cytokine signaling 5 1.71E-06 2.045 9655 
CDKN1A Cyclin-dependent kinase inhibitor 1A 7.86E-07 2.040 1026 
STX4 Syntaxin 4 5.28E-09 1.974 6810 
RASA1 RAS p21 protein activator 1 1.65E-08 1.921 5921 
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Table 4.01. Ranking of the up-regulated genes encoding member proteins 
of class I PI3K pathway in J3T spheres, as compared with J3T parental 
cells. ANOVA was performed to determine significant differences (p< 0.005). 
The table courtesy of Dr. Lisa Pang. Continued 







FGFR1 Fibroblast growth factor receptor 1 2.33E-05 1.920 2260 
BCL2 B-cell CLL/lymphoma 2 1.60E-04 1.918 596 
FNBP1 Formin binding protein 1 9.19E-06 1.874 23048 
RND3 Rho family GTPase 3 3.92E-05 1.863 390 
PRKCD Protein kinase C, delta 3.24E-07 1.835 5580 
IGFBP6 Insulin-like growth factor-binding protein 6 6.03E-06 1.807 3489 
CCND1 Cyclin D1 3.92E-06 1.799 595 
RRAS Related RAS viral (r-ras) oncogene homolog 1.76E-07 1.770 6237 
PAIP2 Poly(A) binding protein interacting protein 2 5.59E-06 1.764 51247 
KDR Kinase insert domain receptor (a type III 
receptor tyrosine kinase) 
1.14E-05 1.764 3791 
EIF2C1 Eukaryotic translation initiation factor 2C, 1 8.66E-07 1.763 26523 
NEDD4 Neural precursor cell expressed, 
developmentally down-regulated 4 
5.43E-06 1.750 4734 
PRKAR1A Protein kinase, cAMP-dependent, regulatory, 
type I, alpha (tissue specific extinguisher 1) 
1.22E-08 1.749 5573 
INSR Insulin receptor 3.83E-04 1.747 3643 
PDGFC Platelet derived growth factor C 9.35E-06 1.743 56034 
MCL1 Myeloid cell leukemia sequence 1 (BCL2-
related) 
2.34E-07 1.734 4170 
SOCS2 Soc-2 suppressor of clear homolog (C. 
elegans) 
5.88E-04 1.705 8835 
TRIP10 Thyroid hormone receptor interactor 10 8.66E-06 1.703 9322 
DDR1 Discoidin domain receptor tyrosine kinase 1 1.16E-05 1.673 780 
RAF1 v-Raf-1 murine leukemia viral oncogene 
homolog 1 
6.66E-07 1.659 5894 
PIK3C3 Phosphoinositide-3-kinase, class 3 4.93E-07 1.619 5289 
STAT3 Signal transducer and activator of transcription 
3 (acute-phase response factor) 
6.43E-06 1.603 6774 
ACLY ATP citrate lyase 1.38E-06 1.592 47 
ITGA5  
Integrin, alpha 5 (fibronectin receptor, alpha 
polypeptide) 
5.75E-04 1.573 3678 
CNKSR3 Connector enhancer of kinase suppressor of 
ras 3 
3.06E-04 1.555 154043 
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Table 4.01. Ranking of the up-regulated genes encoding member proteins 
of class I PI3K pathway in J3T spheres, as compared with J3T parental 
cells. ANOVA was performed to determine significant differences (p< 0.005). 
The table courtesy of Dr. Lisa Pang. Continued 







RHOT1 Ras homolog gene family, member T1 3.60E-08 1.540 55288 
BCL2L1 BCL2-like 1 1.10E-06 1.536 598 
RHOC Ras homolog gene family, member C 1.56E-05 1.477 389 
INPPL1 Inositol polyphosphate phosphatase-like 1 8.18E-06 1.473 3636 
RAC1 Ras-related C3 botulinum toxin substrate 1 
(rho family, small GTP binding protein Rac1) 
7.03E-07 1.465 5879 
MAPK1 Mitogen-activated protein kinase 1 7.06E-05 1.461 5594 
EIF1 Eukaryotic translation initiation factor 1 6.27E-06 1.442 10209 
EIF2C3 Eukaryotic translation initiation factor 2C, 3 4.30E-04 1.438 192669 
GHR Growth hormone receptor 2.29E-04 1.426 2690 
JUN Jun proto-oncogene 2.85E-04 1.395 3725 
GSK3B Glycogen synthase kinase 3 beta 8.44E-04 1.381 2932 
CSNK2A2 Casein kinase 2, alpha prime polypeptide 5.52E-05 1.357 1459 
PAIP1 Poly(A) binding protein interacting protein 1 2.77E-07 1.345 10605 
ITGB1 Integrin, beta 1 ibronectin receptor, beta 
polypeptide, antigen CD29 includes MDF2, 
MSK12 
2.84E-05 1.334 3688 
STK11 Serine/threonine kinase 11 9.84E-05 1.320 6794 
SOCS6 Suppressor of cytokine signaling 6 3.61E-04 1.319 9306 
MAP2K1 Mitogen-activated protein kinase kinase 1 8.29E-06 1.308 5604 
RHOA Ras homolog gene family, member A 6.05E-08 1.300 387 
IRS1 Insulin receptor substrate 1 1.20E-03 1.292 3667 
PRKD3 Protein kinase D3 3.67E-04 1.265 23683 
PPP2CB Protein phosphatase 2, catalytic subunit, beta 
isozyme 
3.25E-06 1.235 5516 
FKBP1A FK506 binding protein 1A, 12kDa 4.43E-04 1.172 2280 
CYR61 Cysteine-rich, angiogenic inducer, 61 1.07E-03 1.171 3491 
SHC1 SHC (Src homology 2 domain containing) 
transforming protein 1 
4.94E-04 1.098 6464 
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Table 4.02. Ranking of the down-regulated genes encoding member 
proteins of class I PI3K pathway in J3T spheres, as compared with J3T 
parental cells. ANOVA was performed to determine significant differences (p< 
0.005). The table courtesy of Dr. Lisa Pang. 











YWHAG Tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, gamma 
polypeptide 
2.63E-09 -3.020 7532 
EIF2B2 Eukaryotic translation initiation factor 2B, 
subunit 2 beta, 39kDa 
7.01E-07 -2.551 8892 
PTPN11 Protein tyrosine phosphatase, non-receptor 
type 11 
3.63E-08 -2.548 5781 
PPP1R14B Protein phosphatase 1, regulatory (inhibitor) 
subunit 14B 
1.48E-08 -2.333 26472 
EIF2S1 Eukaryotic translation initiation factor 2, 
subunit 1 alpha, 35kDa 
4.15E-07 -2.288 1965 
EIF3B Eukaryotic translation initiation factor 3, 
subunit B 
1.65E-11 -2.253 8662 
PIK3CD Phosphoinositide-3-kinase, catalytic, delta 
polypeptide 
7.52E-04 -2.243 5293 
PTK2 PTK2 protein tyrosine kinase 2 1.78E-09 -2.200 5747 
FGFR2 Fibroblast growth factor receptor 2 2.29E-09 -2.200 2263 
EIF2B1 Eukaryotic translation initiation factor 2B, 
subunit 1 alpha, 26kDa 
3.05E-07 -2.190 1967 
KRAS v-Ki-ras2 Kirsten rat sarcoma viral oncogene 
homolog 
4.57E-06 -2.151 3845 
THEM4 Thioesterase superfamily member 4 1.19E-07 -2.129 117145 
FLT1 Fms-related tyrosine kinase 1 (vascular 
endothelial growth factor/vascular 
permeability factor receptor) 
1.81E-05 -2.106 2321 
EIF3J Eukaryotic translation initiation factor 3, 
subunit J 
1.21E-12 -2.040 8669 
EIF2B3 Eukaryotic translation initiation factor 2B, 
subunit 3 gamma, 58kDa 
2.03E-08 -1.926 8891 
EIF4A1 Eukaryotic translation initiation factor 4A1 6.48E-11 -1.871 1973 
STXBP4 Syntaxin binding protein 4 3.11E-04 -1.855 252983 
PRKCI Protein kinase C, iota 7.03E-06 -1.822 5584 
PRKAR2A Protein kinase, cAMP-dependent, regulatory, 
type II, alpha 
2.47E-07 -1.790 5576 
AKT1 v-Akt murine thymoma viral oncogene 
homolog 1 
1.39E-04 -1.760 207 
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Table 4.02. Ranking of the down-regulated genes encoding member 
proteins of class I PI3K pathway in J3T spheres, as compared with J3T 
parental cells. ANOVA was performed to determine significant differences (p< 
0.005). The table courtesy of Dr. Lisa Pang. Continued 











EIF1AX Eukaryotic translation initiation factor 1A, X-
linked 
2.59E-10 -1.714 1964 
EIF3D Eukaryotic translation initiation factor 3, 
subunit D 
9.24E-06 -1.696 8664 
EIF3E Eukaryotic translation initiation factor 3, 
subunit E 
8.95E-06 -1.672 3646 
EIF4E Eukaryotic translation initiation factor 4E 1.86E-07 -1.654 1977 
RPS6KA2 Ribosomal protein S6 kinase, 90kDa, 
polypeptide 2 
4.19E-06 -1.589 6196 
PPP2R3B Protein phosphatase 2, regulatory subunit 
B'', beta 
4.57E-05 -1.583 28227 
PPP1R7 Protein phosphatase 1, regulatory (inhibitor) 
subunit 7 
1.13E-05 -1.575 5510 
EIF3A Eukaryotic translation initiation factor 3, 
subunit A 
1.54E-07 -1.572 8661 
RHOJ Ras homolog gene family, member J 3.75E-05 -1.559 57381 
IGF1R Insulin-like growth factor 1 receptor 9.62E-08 -1.554 3480 
EIF3I Eukaryotic translation initiation factor 3, 
subunit I 
1.95E-05 -1.515 8668 
TGFBR2 Transforming growth factor, beta receptor II 
(70/80kDa) 
2.45E-05 -1.495 7048 
EIF2B4 Eukaryotic translation initiation factor 2B, 
subunit 4 delta, 67kDa 
5.39E-09 -1.459 8890 
MRAS Muscle RAS oncogene homolog 1.14E-04 -1.459 22808 
PPM1J Protein phosphatase, Mg2+/Mn2+ 
dependent, 1J 
4.75E-05 -1.418 333926 
PRKAB2 Protein kinase, AMP-activated, beta 2 non-
catalytic subunit 
1.18E-03 -1.413 5565 
RRAS2 Related RAS viral (r-ras) oncogene homolog 
2 
9.18E-07 -1.403 22800 
EIF2A Eukaryotic translation initiation factor 2A, 
65kDa 
1.52E-06 -1.402 83939 
PPP1R12A Protein phosphatase 1, regulatory (inhibitor) 
subunit 12A 
7.18E-06 -1.398 4659 
HSP90B1 Heat shock protein 90kDa beta (Grp94), 
member 1 
4.67E-08 -1.393 7184 
EIF2S2 Eukaryotic translation initiation factor 2, 
subunit 2 beta, 38kDa 
5.66E-09 -1.365 8894 
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EIF2S3 Eukaryotic translation initiation factor 2, 
subunit 3 gamma, 52kDa 
1.01E-04 -1.363 1968 
CHUK Conserved helix-loop-helix ubiquitous 
kinase 
2.07E-04 -1.349 1147 
EIF3H Eukaryotic translation initiation factor 3, 
subunit H 
2.64E-04 -1.347 8667 
PPP1R10 Protein phosphatase 1, regulatory 
(inhibitor) subunit 10 
1.17E-03 -1.337 5514 
MAPK14 Mitogen-activated protein kinase 14 1.07E-05 -1.335 1432 
RPS6KA1 Ribosomal protein S6 kinase, 90kDa, 
polypeptide 1 
5.12E-06 -1.333 6195 
BMPR1B Bone morphogenetic protein receptor, type 
IB 
7.50E-05 -1.320 658 
PIK3R5 Phosphoinositide-3-kinase, regulatory 
subunit 5 
7.45E-05 -1.289 23533 
NRAS Neuroblastoma RAS viral (v-ras) oncogene 
homolog 
3.10E-06 -1.288 4893 
PPP1CC Protein phosphatase 1, catalytic subunit, 
gamma isozyme 
1.78E-06 -1.266 5501 
YWHAQ Tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, theta 
polypeptide 
3.85E-07 -1.255 10971 
EIF4A3 Eukaryotic translation initiation factor 4A3 1.85E-04 -1.255 9775 
YWHAQ Tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, theta 
polypeptide 
3.85E-07 -1.255 10971 
PABPC1 Poly(A) binding protein, cytoplasmic 1 6.47E-04 -1.228 26986 
CSNK2A1 Casein kinase 2, alpha 1 polypeptide 1.88E-05 -1.226 1457 
YWHAB Tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, beta 
polypeptide 
2.84E-04 -1.223 7529 
SRF Serum response factor (c-fos serum 
response element-binding transcription 
factor) 
2.82E-05 -1.219 6722 
EIF3G Eukaryotic translation initiation factor 3, 
subunit G 
3.47E-05 -1.215 8666 










Figure 4.02. Graphic representations of the networks of class I PI3K and its 
major downstream targets. IPA was performed to analyze microarray data sets 
of sphere versus parental J3T cells and the graphics of  insulin receptor (IR) 
pathway (A), insulin-like growth factor-1 (IGF-1) pathway (B). Gene expression 
variation by at least 1-fold was depicted by either green (down-regulated) or red 
(up-regulated) colour. The darker the colour (green/red) was, the greater the 
value of fold-change was. represents enzyme,  represents group or 
complex,  represents growth factor,  represents ion channel,  represents 
kinase,  represents ligand-dependent nuclear receptor,  represents 
phosphatase,  represents transcription regulator,  represents translation 
regulator,  represents transmembrane receptor,  represents transporter,  




Figure 4.03. Top 17 canonical pathways relevant to the differentially expressed genes between the J3T 
spheres and their parental cell line, ranked by significance. IPA of the entire differentially expressed genes 
between the J3T spheres and their parental cells determined the degree of the relevance of each pathway to these 
differentially expressed genes and defined the confidence of the relevance. Yellow dot represented a ratio of the 
number of the differentially expressed genes pertaining to each pathway divided by the total number of genes in 
each pathway. Blue bar indicated the p-value of statistical significance. A high ratio represented high relevance of a 
given pathway to the differentially expressed genes in this pathway. A low p-value represented high confidence of 







Figure 4.04. Top 10 biological functions and diseases relevant to the 
differentially expressed genes between the J3T spheres and their 
parental cell line, ranked by significance. IPA of the entire differentially 
expressed genes between the J3T spheres and their parental cells determined 
the degree of the association of a given function/disease with these 
differentially expressed genes. Blue bar indicated the p-value of statistical 
significance. A low p-value represented that a given function/disease was more 
significantly related to the microarray data, not because of random chance. The 




 To date, increasing evidence is in favor of CSC theory, implicating CSCs as a 
promising therapeutic target for the treatment of cancer. This study demonstrates that 
canine glioma J3T cells contain CSCs by using neurosphere culture system. 
Furthermore, cDNA microarray analysis shows that many genes are differentially 
expressed between J3T spheres and their parental cells. Some of these genes that have 
previously been described as activators of class I PI3K/Akt/mTORC1 axis pathway are 
CBL, CSNK2A1, CSNK2A2, DDR1, FGFR1, FGFR2, FLT1, FYN, GAB1, GHR, 
GRB2, HSP90B1, IGF1R, INSR, IRS1, JAK2, KDR, KRAS, MRAS, NRAS, NTRK2, 
NTRK3, PDGFC, PDGFRA, PDGFRB, PIK3C3, PTK2, PTPN11, RRAS2, and SHC1 
(see Table 4.03) (Marshall 1995; VanderKuur et al. 1995; Jain et al. 1997; Leonard and 
O'Shea 1998; Wymann and Pirola 1998; Hunter et al. 1999; Kimmelman et al. 2000; 
Rodrigues et al. 2000; Sato et al. 2000; Herrington and Carter-Su 2001; Ravichandran 
2001; Wu et al. 2001; Rong et al. 2002; Cully et al. 2006; Nobukuni et al. 2007; 
Radhakrishnan et al. 2008; Calzolari and Malatesta 2010; Guan 2010; Hanif et al. 2010; 
Lemmon and Schlessinger 2010; Saito et al. 2010; Castellano and Downward 2011). 
Among these activators, CBL, FYN, NTRK2, NTRK3 and PDGFRB are significantly 
up-regulated by ≥ 3-fold in the spheres as compared with their parental cells. Expression 
of FYN, NTRK2 and NTRK3 in human glioma cells and expression of PDGFR in 
endothelial cells in gliomas have been documented (Wang et al. 1998; Furnari et al. 
2007; Yadav and Denning 2011). CBL, FYN, and NTRK2 have been reported to play a 
role in glioma progression. FYN up-regulates invasion and migration of glioma (Ohira et 
al. 2006). CBL promotes tumor invasion (Lee and Tsygankov 2010). Truncated NTRK2, 
instead of full-length NTRK2, regulates cytoskeletal arrangement and alteration of 
cellular morphology in glioma through its substrate RhoA (Ohira et al. 2006). However, 
not all of these activators of class I PI3K/Akt/mTOR pathway are up-regulated in the 
sphere cells. CSNK2A1, FGFR2, FLT1, GRB2, HSP90B1, IGF1R, KRAS, MRAS, 
NRAS, PTK2, PTPN11, and RRAS2 are found to be down-regulated by less than 3-fold 
in J3T spheres.  
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 Some of these differentially expressed genes that have previously been described 
as inhibitors of class I PI3K/Akt/mTORC1 axis pathway are DDIT4, IGFBP2, IGFBP4, 
IGFBP6, IGFBP7, INPPL1, PLD3, PRKAR1A, PRKAR2A, PRKAB2, RASA1, 
SOCS2, SOCS5, STK11,  THEM4 (Vogel et al. 1988; Damen et al. 1996; Oh et al. 
1996; Rajaram et al. 1997; Filippa et al. 1999; Seki et al. 2002; Howe 2004; Knobbe et 
al. 2004; Reiling and Hafen 2004; Woodcock and Hughes 2004; Kario et al. 2005; Sofer 
et al. 2005; Hardie et al. 2006; Rico-Bautista et al. 2006; Zhang et al. 2009; Oakhill et 
al. 2011). Among these inhibitors, IGFBP2, DDIT4, and PLD3 are significantly up-
regulated by ≥ 3-fold in the spheres as compared with their parental cells (see Table 
4.03). So far, no report regarding the role of DDIT4 and PLD3 in glioma development 
has been published. Increased expression of IGFBP2 is commonly found in human as 
well as canine high-grade gliomas and is associated with poor prognosis (Becher et al. 
2008; Lin et al. 2009; Stoica et al. 2011). Although the function of IGFBP2 protein in 
normal cells is to counteract IGF signaling, this protein has been reported to stimulate 
Akt activity in gliomas in response to platelet derived growth factor B (PDGF-B) 
stimulation (Rajaram et al. 1997; Dunlap et al. 2007). Previous data suggested that 
IGFBP2 was involved in promoting invasion and motility, and up-regulating DNA 
repair mechanism in high-grade gliomas (Wang et al. 2003; Wang et al. 2006; Becher et 
al. 2008). IGFBP2 was demonstrated to induce proliferation, maintain survival and drug 
resistance of glioma CSCs, in part through Akt signaling (Hsieh et al. 2010). Of these 
class I PI3K pathway inhibitors, three genes, which are PRKAR2A, PRKAB2, and 
THEM4 are found to be down-regulated in the J3T spheres.   
In addition to CBL, DDIT4, FYN, IGFBP2, NTRK2, NTRK3, PDGFRB, and 
PLD3 genes which have previously been identified as regulators of class I 
PI3K/Akt/mTOR pathway and been detected to express much higher mRNA levels (> 3-
fold) in the J3T spheres than their parental cells (Jain et al. 1997; Rajaram et al. 1997; 
Hunter et al. 1999; Huang and Reichardt 2003; Reiling and Hafen 2004; Sofer et al. 
2005; Zhang et al. 2009; Calzolari and Malatesta 2010; Saito et al. 2010), there are some 
genes, including CTNNB1, FOS, IGF2R, PPP1R3C, and YWHAG, which are 
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significantly up-regulated or down-regulated (> 3-fold ) in the J3T spheres. CTNNB1 
encodes β-catenin, which serves as an important component of Wnt core signaling. 
Wnt/β-catenin signaling was reported to exert dual effects on stem cells. On one hand, 
this pathway acted to maintain self-renewal and pluripotent properties of ES cells and 
somatic SCs. On the other hand, Wnt//β-catenin signaling triggered differentiation and 
regulated lineage commitment of ESCs (Miki et al. 2011). β-catenin was reported to 
promote proliferation, induce chemoresistance and radioresistance, and up-regulate 
invasiveness and EMT in glioma (Nager et al. 2012; Shi et al. 2012). In addition, Wnt/β-
catenin pathway played a key role in maintenance of glioma stem cell pool (Nager et al. 
2012). FOS encodes c-Fos which is a subunit of activator protein-1 (AP-1) transcription 
factor (Hess et al. 2004). The levels of c-Fos are increased with tumour grading of 
gliomas (Yu et al. 1999). c-Fos was found to positively regulate proliferation of glioma 
cells (Koul et al. 2007). IGF2R encoding IGFII/mannose-6-phosphate receptor which 
acts to attenuate IGF-II signaling (Furstenberger and Senn 2002). Loss of IGF2R 
expression, as a result of chromosomal translocation, was detected in clinical specimens 
and cells lines of human GBM (Mulholland et al. 2006). PPP1R3C encodes the 
regulatory subunit 3C of protein phosphatase 1 (PP1), which and functions in promoting 
glycogen synthesis, in all kinds of cells, particularly in liver and muscle cells (Cohen 
2002). So far, no report regarding the role of PPP1R3C in gliomas has been published 
yet. YWHAG encodes 14-3-3γ, which belongs to 14-3-3 
phosphoserine/phosphothreonine-binding protein family and participate in a variety of 
cellular functions through binding to its protein partners (Wilker and Yaffe 2004). 
Previous findings showed that 14-3-3 family proteins generally promoted survival and 
proliferation of glioma cells (Cao et al. 2010).  
 In this study, the expression levels of four components, including p101 and 
p110δ subunits of class I PI3Ks, Akt1, and eIF4E, are decreased in the spheres. 
However, it should be borne in mind that cDNA microarray analysis shows the variation 
in mRNA levels but cannot show signal transduction status, such as the phosphorylation 
status of class I PI3K pathway. Besides, class I PI3Ks are composed of four p110 
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catalytic subunit isoforms (p110α, β, γ and δ) at least three regulatory subunits such as 
p85, p101 and p87/84 (Wymann and Pirola 1998; Suire et al. 2005; Voigt et al. 2005). 
There are three Akt isoforms, including Akt1, Akt2 and Akt3 (Altomare and Testa 
2005). Although J3T spheres contain lower levels of transcripts encoding p110δ, p101 
and Akt1, there might be a possibility that class I PI3K/Akt/mTOR signaling is activated 
in J3T spheres through phosphoarylation/activation of p110α, p110β, p110γ, p85 and 
p87/84 subunits of class PI3K, Akt2 and Akt3 and a wide array of class I PI3K and Akt 
substrates, such as Rac1, mTOR, GSK3 and FoxO1 (Cantley 2002). Due to this potential 
disvantage of cDNA microarray, techniques, such as Western Blotting and Reverse-
Phase Protein Array, can be employed for comparison of phosphorylation status of class 
I PI3K/Akt/mTOR signaling proteins in the J3T spheres with that in the J3T parental 
cells (Zhou et al. 2007). Hence, it cannot be ruled out the possibility that class I 
PI3K/Akt/mTOR is activated through phosphorylation of the components whose 
expression levels are not decreased.  
 In J3T spheres, 22 transcripts encoding proteins involved in regulation of 
translation initiation are down-regulated (Table 4.02). Of these translation initiation 
factors, EIF2S1 and EIF3B have been reported to participate in glioma progression by 
up-regulating cell cycle progression (by EIF2S1 and EIF3B) and survival (by EIF3B) of 
high-grade glioma cells (Kambara et al. 2005; Liang et al. 2012). 5 transcripts, including 
EIF1, EIF2C1, EIF2C3, PAIP1 and PAIP2, are up-regulated. EIF1 and PAIP1 express 
proteins which enhance translation initiation whereas EIF2C1, EIF2C3 and PAIP2 act to 
inhibit mRNA translation (Khaleghpour et al. 2001; Doi et al. 2003; Preiss and Hentze 
2003; Meister et al. 2004). There is no published data about the 5 up-regulated genes. 
Moreover, the mRNA levels of EIF4E, which encodes the key component of mTOR 
pathway and trigger cap-dependent mRNA translation, is found being down-regulated 
(Huang and Houghton 2003). Taken together, it is suggested that translation initiation 
mechanism and cap-dependent mRNA translation are down-regulated in the J3T 
spheres.   
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 In this study, several class I PI3K/Akt/mTOR pathway-related transcripts which 
are differentially expressed in J3T spheres have previously been identified to be up-
regulated in human glioma stem cells (GSCs) as well. The class I PI3K pathway-
associated transcripts, including anti-apoptotic factors BCL2 and BCL2L1, IGFBP2, 
integrin receptor ITGB1, and PRKCD encoding protein kinase C δ (PKCδ), are 
increased in both canine J3T spheres and human GSCs (Liu et al. 2006; Gunther et al. 
2008; Hsieh et al. 2010; Lamszus and Gunther 2010; Lathia et al. 2010). IGFBP2 was 
demonstrated to induce proliferation, maintain survival and drug resistance of glioma 
CSCs, in part through Akt signaling (Hsieh et al. 2010). ITGB1 was reported to up-
regulate self-renewal, proliferation and tumourigenic capabilities of GSCs (Lathia et al. 
2010). PRKCD was found to up-regulate self-renewal capability of glioma upon 
radiotherapy, suggesting that PRKCD might play a role in radioresistant mechanism 
(Kim et al. 2011). In addition, some transcripts, including AKT1, BMPR1B, CTNNB1, 
GSK3B, JAK2,  PPP2CB, PIK3CD, PIK3R5, RAC1, STAT3, and TGFBR2, which are 
identified to be expressed differentially between the spheres and parental cells have 
previously been found to be involved in regulation of many processes of human GSCs 
(see Table 4.03) (Lee et al. 2008; Korur et al. 2009; Howard et al. 2010; Hsieh et al. 
2010; Lamszus and Gunther 2010; Lathia et al. 2010; Liu et al. 2010; Kim et al. 2011; 
Yoon et al. 2011; Nager et al. 2012; Sai et al. 2012). Previous studies showed that class 
I PI3K, Jak2/Stat3, TGFβ and Wnt/β-catenin pathways and Rac1 up-regulated stem cell 
properties including self-renewal, multipotency and proliferation, and malignant 
behaviours, including survival, invasion, migration, immune suppression, 
chemoresistance and radioresistance (Lamszus and Gunther 2010; Liu et al. 2010; Yoon 
et al. 2011; Miyazono et al. 2012; Nager et al. 2012; Sai et al. 2012). Conversely, BMP 
signaling and protein phosphatase 2A (PP2A) acted to induce differentiation and/or 
inhibit survival of GSCs (Lee et al. 2008; Lu et al. 2010). There is conflicting data 
regarding the role of GSK-3β in GSCs. There is conflicting data regarding the role of 
GSK-3β in glioblastoma stem cells. On one hand, active EGFR/Akt signaling-mediated 
inhibitory phosphorylation of GSK-3β was found to promote proliferation of 
neurosphere cells (Howard et al. 2010). On the other hand, down-regulation of GSK3B 
240 
 
expression or GSK-3β activity reduced GBM stem cell pool and induced differentiation 
and apoptosis (Korur et al. 2009). The present study displays increased CTNNB1 (β-
catenin), JAK2, STAT3, PPP2CB (catalytic subunit-beta isoform of PP2A), and RAC1 
transcripts, but decreased BMPR1B (type I BMP receptor), TGFBR2 (TGFβ receptor 
type II), PIK3CD, PIK3R5 and AKT1 transcripts. This suggests that Wnt/β-catenin and 
Jak2/Stat3 pathways, PP2A, GSK3B and Rac1 activity are up-regulated whereas BMP, 
TGFβ and class I PI3K pathways are down-regulated in the J3T spheres.         
 Among these differentially expressed genes between the J3T spheres and 
parental cells, many of them were previously identified to regulate glioma development, 
including cell cycle progression, survival, invasion, migration, adhesion, 
chemoresistance, radioresistance, angiogenesis and CSC-associated properties. The 
genes which have previously been identified to promote cell cycle progression of glioma 
cells are BCL2, CTNNB1, EIF2S1, EIF3B, EIF4E, FGFR1, FOS, GSK3B, HSP90B1, 
IGF1R, IGFBP10, INSR, JAK2, PTK2, MAP2K1, MAPK1, PRKCI, STAT3, YWHAB, 
YWHAG and YWHAQ (Glick et al. 1989; Yamada et al. 1998; Natarajan et al. 2003; 
Kambara et al. 2005; Pelloski et al. 2006; Koul et al. 2007; Sciaccaluga et al. 2007; 
Messaoudi et al. 2008; Dubois et al. 2009; Hargrave 2009; Miyashita et al. 2009; Cao et 
al. 2010; Goodwin et al. 2010; Hagerstrand et al. 2010; Liu et al. 2010; Rouschop et al. 
; Desai et al. 2012; Kouri et al. 2012; Liang et al. 2012; Nager et al. 2012). In addition, 
since PKA negatively regulates cellular proliferation in gliomas, PRKAR1A and 
PRKAR2A, both of which are inhibitors of PKA, are suggested to up-regulate 
proliferation of tumour cells (Chen et al. 1998). The role of FGFR2 in up-regulating 
cellular proliferation of gliomas was cell line-specific (Yamada et al. 1999; Auguste et 
al. 2001). The cDNA microarray data show that BCL2, CTNNB1, FGFR1, FOS, INSR, 
JAK2, GSK3B, MAP2K1, PRKAR1A, MAPK1, and IGFBP10 STAT3 transcripts are 
increased. In contrast, EIF2S1, EIF3B IGF1R, FGFR2, PTK2, HSP90B1, EIF4E, 
PRKCI, PRKAR2A, YWHAB, YWHAG, and YWHAQ are down-regulated in the J3T 
spheres. Previous studies showed that INPPL1, MAPK14, RAF1, RND3, STK11, and 
TGFBR2 inhibited cell cycle progression (Taylor et al. 2000; Fanton et al. 2001; Wick 
et al. 2006; Poch et al. 2007; Yao et al. 2008; Godlewski et al. 2010). The J3T spheres 
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are found to contain higher mRNA levels of INPPL1, RAF1 and RND3 but lower 
mRNA levels of STK11, TGFBR2 and MAPK14 than the J3T parental cells. Taken 
together, it is suggested that up-regulation of the genes encoding positive regulators of 
cell cycle progression such as CTNNB1 and down-regulation of the genes encoding 
inhibitors of cell cycle transition such as EIF2S1 may be involved in up-regulating the 
growth and proliferation of the J3T spheres. On the contrary, down-regulation of 
activators such as INPPL1 of cell cycle transition and up-regulation of cell cycle 
inhibitors such as STK11 are implicated to down-regulate expansion ability of the 
tumour spheres.  
 The genes which have previously been identified to promote survival of glioma 
cells are BCL2, BCL2L1, CSNK2A1, CSNK2A2, EIF3B, MAP2K1, MAPK1, MCL1, 
and PPP1CC GSK3B, HSP90B1, IGFBP2, PRKAB2, PRKCI, PTK2, STK11, STAT3, 
YWHAB, YWHAG, YWHAQ (see Table 4.03) (Natarajan et al. 2003; Pelloski et al. 
2006; Weiler et al. 2006; Becher et al. 2008; Messaoudi et al. 2008; Hargrave 2009; 
Harhaji-Trajkovic et al. 2009; Miyashita et al. 2009; Cao et al. 2010; Godlewski et al. 
2010; Liu et al. 2010; Olsen et al. 2010; Sheng et al. 2010; Desai et al. 2011; Kelsall et 
al. 2011; Kouri et al. 2012; Liang et al. 2012). In addition, since PKA induce apoptosis 
in gliomas, PRKAR1A and PRKAR2A, both of which are inhibitors of PKA, are 
suggested to promote survival of tumour cells (Chen et al. 1998; Howe 2004). The 
BCL2, BCL2L1, CSNK2A2, MAP2K1, MAPK1, MCL1, GSK3B, IGFBP2 and STAT3 
transcripts are increased in the J3T spheres, as compared with their parental cells. 
Conversely, CSNK2A1, EIF3B, PPP1CC, HSP90B1, PRKAB2, PRKCI, PTK2, STK11, 
YWHAB, YWHAG, and YWHAQ transcripts are decreased in the J3T spheres. 
MAPK14, PRKCD and RND3 were previously reported to induce apoptosis in glioma 
cells. The J3T spheres are detected to contain higher mRNA levels of PRKCD and 
RND3 but lower mRNA levels of MAPK14, as compared with the J3T parental cells. 
Taken together, it is suggested that up-regulation of the genes encoding anti-apoptotic 
factors such as BCL2 and down-regulation of pro-apoptotic factor MAPK2 may 
contribute to promote survival of the J3T sphere cells. By contrast, down-regulation of 
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anti-apoptotic factors such as EIF3B and up-regulation of pro-apoptotic factors such as 
RND3 may induce apoptosis of the J3T spheres.  
 The genes which have previously been identified to enhance invasion of glioma 
cells are ACLY, BCL2L1, CBL, CHUK, DDR1, FYN, HSP90B1, IGFBP2, JAK2, 
PIK3CD, PRKCI, PTK2, RAC1, CTNNB1, MAPK1, MAPK14, RAF1, PRKCD, 
IGFBP10, RHOC and TGFBR2 (Natarajan et al. 2003; Wang et al. 2003; Salhia et al. 
2005; Nakada et al. 2006; Ram et al. 2006; Weiler et al. 2006; Wick et al. 2006; 
Demuth et al. 2007; Messaoudi et al. 2008; Sasayama et al. 2009; Young et al. 2009; 
Baldwin et al. 2010; Beckner et al. 2010; Lee and Tsygankov 2010; Sarkar and Yong 
2010; Das et al. 2011; Senft et al. 2011; Yadav and Denning 2011; Luk et al. 2012; 
Nager et al. 2012; Shi et al. 2012; Zhang et al. 2012). In this study, up-regulation of 
ACLY, BCL2L1, CBL, DDR1, FYN, IGFBP2, JAK2, PRKCI, RAC1, CTNNB1, 
MAPK1, RAF1, PRKCD, IGFBP10, and RHOC genes in the J3T spheres when 
compared to their parental cells suggests that these highly expressed genes may increase 
invasive behavior for the J3T spheres. On the contrary, down-regulation of the genes of 
CHUK, HSP90B1, PIK3CD, PTK2, MAPK14, and TGFBR2 in the J3T spheres 
suggests that regulation of the invasive phenotype for the J3T spheres is irrelevant to 
these genes.  
The genes which have previously been identified to promote migration or 
metastasis of glioma cells are ACLY, CHUK, CTNNB1, FYN, HSP90B1, IGFBP2, 
IGFBP10, INPPL1, ITGA5, JAK2, PIK3CD, PRKAB2, PTK2, RAC1, STK11, 
MAPK14, MAPK1, SRF and TGFBR2 (Damen et al. 1996; Natarajan et al. 2003; Salhia 
et al. 2005; Hardie et al. 2006; Song and Moon 2006; Wang et al. 2006; Wick et al. 
2006; Demuth et al. 2007; Messaoudi et al. 2008; Beckner et al. 2010; Goodwin et al. 
2010; Tabatabai et al. 2010; Oakhill et al. 2011; Senft et al. 2011; Yadav and Denning 
2011; Ziv-Av et al. 2011; Luk et al. 2012; Nager et al. 2012; Shi et al. 2012; Zhang et 
al. 2012). Among these genes, ACLY, CTNNB1, FYN, IGFBP2, IGFBP10, INPPL1, 
ITGA5, JAK2, RAC1, STK11 and MAPK1 are up-regulated in the J3T spheres when 
compared to their parental cells, whereas CHUK, HSP90B1, PIK3CD, PRKAB2, PTK2, 
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MAPK14, SRF and TGFBR2 are down-regulated in the sphere cells. Besides, two 
genes, RHOA and PRKCD, which have previously been identified to attenuate 
migration of glioma cells are found to be up-regulated in the J3T spheres (Cachero et al. 
1998; Ziv-Av et al. 2011). Taken together, it is suggested that up-regulation of the 
genes, such as ACLY and CTNNB1, which are involved in inducing migration may play 
a role to up-regulate the migration behavior for the J3T spheres. Conversely, it is 
suggested that either down-regulation of the genes (e.g. CHUK and HSP90B1) involved 
in promoting migration, or up-regulation of the genes (e.g.RHOA and PRKCD) 
associated with blockade of migration may weaken the migration/metastasis capability 
of the J3T spheres.  
 In addition to the genes which are related to invasion, migration, and metastasis, 
certain genes are involved in cytoskeletal arrangement and alteration of cell 
morphology. Expression of truncated NTRK2, instead of full-length NTRK2, was 
reported to regulate RhoA-modulated cell morphology and cytoskeletal rearrangement in 
rat C6 glioma cell line in response to brain-derived neurotrophic factor (BDNF) (Ohira 
et al. 2006). RND3, which encoded RhoE, was thought of as tumour suppressor in 
glioblastoma by not only impairment of cytoskeletal arrangement, but also inhibition of 
survival and growth (Poch et al. 2007). 
 The genes which have previously been identified to promote angiogenesis or 
vascular formation within gliomas are FGFR1, FGFR2, FLT1, HSP90B1, STAT3 and 
ITGA5 (Auguste et al. 2001; Xiang et al. 2001; Liu et al. 2010; Tabatabai et al. 2010). 
In this study, the transcriptional levels of FGFR1, STAT3 and ITGA5 are increased in 
the J3T spheres whereas those of FGFR2, FLT1 and HSP90B1 are decreased. Besides, 
the genes which have previously been identified to inhibit angiogenesis of glioma cells 
are IGFBP4 and MAPK14 (Moreno et al. 2006; Yoshino et al. 2006). The J3T spheres 
express higher levels of IGFBP4 transcript but lower levels of MAPK14 transcript than 
the J3T parental cells. Collectively, it is suggested that up-regulation of these genes (e.g. 
FGFR1) which positively regulate angiogenesis in the J3T spheres or down-regulation of 
MAPK14 which functions in blockade of angiogenesis may contribute to blood vessel 
244 
 
formation and sufficient oxygen for glioma development. Conversely, it is suggested 
that down-regulation of the genes (e.g. FGFR2) which positively regulate angiogenesis 
or up-regulation of IGFBP4 which acts to inhibit angiogenesis may serve as tumour 
suppressors which antagonize glioma progression.    
 In this study, the class I PI3K signaling network graphics which are generated by 
using IPA suggests up-regulation of IR signaling in the J3T spheres, based on increased 
transcriptional levels of the genes encoding IR and many of its adaptors and decreased 
transcription of the gene encoding IGF-1R. IR is mainly activated by insulin and plays a 
critical role in regulation of carbohydrate metabolism. IGF-1R is mainly activated by 
IGF-1 and IGF-2 and this receptor is involved in regulation of cell growth. Under certain 
circumstance, IR can be activated by IGF-2 and IGF-1R can be activated by insulin 
when IR isoform A dimerizes with IGF-1R (Pollak 2012). Despite no report concerning 
the roles of IR and IGF-1R in glioma stem cells, accumulating evidence suggests that 
both receptors regulate neurogenesis by controlling self-renewal and differentiation of 
NSCs. IGF-1 has been found to promote cycling (proliferation) of NSCs, followed by 
initiate differentiation of NSC into more mature neural cells. Insulin has been speculated 
to maintain survival of NSC by regulating nutrient metabolism in NSC (Rafalski and 
Brunet 2011). Taken together, increased transcription of INSR (encoding IR) and 
decreased transcription of IGF1R (encoding IGF-1R) in the J3T spheres indicate that IR 
expression, instead of IGF-1R, may play a role in regulation of CSC biology of the J3T 
cells, presumably through regulation of nutrient metabolism in the spheres.    
 The IPA-generated signaling network graphics suggest that the J3T spheres 
contain hypo-activities of class I PI3K/Akt/mTOR pathway and eIF4E-modulated cap-
dependent translation but hyper-activities of Raf1/Mek1/Erk and Jak2/Stat3 pathways. 
Besides, it appears that PTEN activity is enhanced in the spheres, as evidenced by 
decreased CK2 transcript, a PTEN negative regulator, and increased MAGI transcripts 
(Simpson and Parsons 2001; Hanif et al. 2010). However, previous manuscripts often 
addressed the important role of class I PI3K/Akt pathway, particularly Akt activity, in 
NSC and GSC biology (Eyler et al. 2008; Bleau et al. 2009; Rafalski and Brunet 2011). 
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For example, an in vitro study showed that increased Akt activity in neural progenitors 
isolated from adult murine brain, by introducing overexpressed Akt to these progenitors, 
enhanced proliferation but attenuated differentiation capabilities of these neural 
progenitors (Peltier et al. 2007). Similar results obtained from another research group 
showed that murine neurospheres with PTEN loss increased proliferation of NSCs but 
did not affect the differentiation capability of NSCs. Furthermore, these PTEN-null 
NSCs produced enlarged but aberrant brain in mouse model, due to up-regulating the 
growth, proliferation and survival of NSCs (Groszer et al. 2001). Generally, 
accumulating evidence suggests that up-regulation of Akt signaling in neural 
SCs/progenitors from either adult or postnatal mouse brains up-regulates self-renewal, 
proliferation and survival of these neural primitive cells but does not necessarily 
attenuate differentiation capability of these cells (Groszer et al. 2001; Peltier et al. 
2007). In addition, some Akt substrates, mTORC1 and FoxO transcription factors, were 
found to regulate cellular processes of NSCs. These Akt substrates were modulated not 
only by active Akt in response to insulin/insulin-like growth factor (IGF) stimulation but 
also by other upstream inputs such as Notch and CD95 stimuli. Whilst mTORC1 was 
found to play a role in neurogenesis through up-regulation of translation, survival and 
differentiation, FoxO transcription factors, such as FoxO3, were more likely to maintain 
NSCs at primitive state and preserved SC properties such as self-renewal and 
multipotency, prevented quiescent NSCs from entry to cell cycling, inhibited 
differentiation, and protected cells from oxidative resistance (Rafalski and Brunet 2011). 
As to the role of class I PI3K/Akt/mTOR pathway in GSC biology, evidence showed the 
important roles of both Akt and mTOR in regulation of cellular processes of GSCs 
(Eyler et al. 2008; Bleau et al. 2009; Jhanwar-Uniyal et al. 2011). A study showed that 
Akt increased the fraction of stem cell phenotype in both human and mouse gliomas via 
mTOR-independent downstream signaling (Bleau et al. 2009). Another study showed 
that CD133+ cells (enriched for putative CSCs) which were isolated from human 
glioblastomas were more sensitive to Akt inhibition than their non-CSC counterparts 
(CD133- tumour cells), as evidenced by remarkable decline in cell viability and 
attenuation of migration and invasion capabilities in CD133+ glioblastoma cells in vitro. 
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Moreover, mouse model transplanted with CD133+ human glioblastoma cells in which 
Akt activity was inhibited was observed to have prolonged survival time (Eyler et al. 
2008). It was suggested that mTOR, particularly mTORC1, might exert dual effects on 
human GSC biology. On one hand, down-regulation of mTORC1 signaling by 
Rapamycin was observed to reduce neurosphere colonies which were derived from 
human GBM cells, suggesting the involvement of mTORC1 in positively regulating 
self-renewal. On the other hand, mTOR or MAPK inactivation was found to induce 
nestin (a SC marker) expression in the human GBM cells, indicating that these pathways 
might participate in reversion of differentiation process and maintenance of GSC 
multipotency (Jhanwar-Uniyal et al. 2011). Taken together, previous data obtained from 
NSCs and GSCs in human or mouse showed that Akt activity was involved in up-
regulating proliferation, self-renewal and survival of NSC and GSCs, and increased GSC 
malignant behaviors, including multidrug-resistant mechanism (ABCG2 activity), 
invasion and migration (Groszer et al. 2001; Peltier et al. 2007; Eyler et al. 2008; Bleau 
et al. 2009). In contrast to previous findings, it appears that the class I PI3K/Akt/mTOR 
pathway is dispensable for cellular activities of canine GSCs (the J3T spheres).    
 It is observed that transcription of the genes encoding Raf1, Mek1, and Erk2 are 
slightly up-regulated by 1.3~1.7 fold in the J3T spheres when compared to their parental 
cells. Previous reports described that Mek/Erk MAPK pathway was involved in 
regulation of several processes of NSCs, including self-renewal, multipotency, 
differentiation and survival (Rueda et al. 2002; Hao et al. 2004; Imamura et al. 2008; 
Ohtsuka et al. 2009; Wang et al. 2009; Phoenix and Temple 2010; Gan et al. 2011). Erk 
MAPK pathway was found to up-regulate survival of murine and rat NSC following 
stimulation of apolipoprotein E or a mood stabilizer Valproate (Hao et al. 2004; Gan et 
al. 2011). The Erk pathway-modulated NSC survival was, in part, through up-regulation 
of survival genes such as BCL2 (Hao et al. 2004). However, previous studies about 
elucidating the role of this pathway in self-renewal, multipotency, and differentiation of 
NSCs, were controversial. Many studies addressed that Raf/Mek/Erk MAPK pathway 
contributed to neurogenesis, through inducing proliferation and subsequent 
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differentiation of NSCs, upon stimulation of neurotrophins such as nerve growth factor 
(NGF) and neurotrophin 3 (NT3), Valproate, and BMP4 (Huang and Reichardt 2003; 
Hao et al. 2004; Moon et al. 2009). Moreover, down-regulation of Erk signaling by 
endocannabinoids was found to suppress differentiation of neural primitive cells (Rueda 
et al. 2002). However, some studies showed the opposite effects of Erk pathway, 
particularly Erk2 activity, on NSC/neural progenitors (Imamura et al. 2008; Samuels et 
al. 2008; Wang et al. 2009; Phoenix and Temple 2010). For instance, a study in mouse 
model showed that Erk2-null NSCs attenuated cell proliferation. Moreover, Erk2-null 
neural progenitors resulted in not only cell cycle arrest but also disruption of self-
renewal, multipotency and induction of apoptosis (Imamura et al. 2008). Similar effects 
on NSCs with Erk2 loss were observed by another research group (Samuels et al. 2008). 
U0126-modulated Erk1/2 inhibition was observed to inhibit proliferation and initiate 
differentiation of NSCs (Wang et al. 2009). Inhibition of Spred1, acting as negative 
regulator of Erk pathway, was observed to up-regulate self-renewal and proliferation of 
NSCs through the release of Erk MAPK pathway (Phoenix and Temple 2010). With 
regard to the role of Raf/Mek/Erk pathway in GSCs, previous data showed that this 
pathway, particularly Erk1/2 pathway, reduced the expression levels of nestin and 
induced differentiation of GSCs. It was suggested that Erk1/2 pathway was responsible 
for down-regulation of pluripotency and up-regulation of differentiation in human GSCs 
(Karsy et al. 2010; Jhanwar-Uniyal et al. 2011). Collectively, it appears that the role of 
Raf1/Mek1/Erk2 in canine GSCs is in contrast to previous findings which revealed that 
this pathway promoted differentiation of human GSCs. It is suggested that the 
Raf1/Mek1/Erk2 pathway may be involved in maintenance of undifferentiated state and 
viability of canine GSCs (the J3T spheres).  
 Previous manuscripts showed that Jak/Stat pathway was essential for maintaining 
self-renewal in murine ESCs, but was dispensable for maintaining monkey ESCs at 
undifferentiated state (Matsuda et al. 1999; Burdon et al. 2002; Sumi et al. 2004). For 
NSCs, this pathway was essential for cell fate determination, preferentially directing 
NSCs to astroglial differentiation rather than neuronal differentiation (Bonni et al. 1997; 
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Rajan and McKay 1998; Gu et al. 2005). In contrast to the effects of Jak2/Stat3 pathway 
on NSCs, accumulating evidence showed that this pathway exerted opposite effects on 
GSCs. For instance, a previous report showed that loss of Stat3 expression prevented 
propagation and reduced expression of NSC markers, suggesting that this pathway was 
critical for sustaining self-renewal and multipotency of GSCs (Sherry et al. 2009). Other 
effects, including maintenance of GSC survival and suppression of immune response, on 
GSCs were documented (Liu et al. 2010; Sai et al. 2012). Collectively, the current 
findings which reveal up-regulation of Jak2/Stat3 pathway in the J3T spheres are 
consistent with previous findings on human GSCs. This suggests that the effects, 
including maintenance of self-renewal, multipotency and survival, and 
immunosuppression, of the Jak2/Stat3 pathway on canine GSCs may be similar to those 
on human GSCs (Sherry et al. 2009; Sai et al. 2012).     
 The current data show that the translation machinery in the J3T spheres is down-
regulated, as evidenced by decreased mRNA levels of many genes encoding translation 
initiation factors and translation initiation enhancers such as eIF4E and poly(A) binding 
protein, cytoplasmic 1 (PABP1), and increased mRNA levels of genes encoding 
translation initiation suppressors such as eIF2C, isoform1 and poly(A) binding protein 
interacting protein 2 (PAIP-2) (Khaleghpour et al. 2001; Doi et al. 2003; Mamane et al. 
2004). One possible explanation for the down-regulated translation machinery in the J3T 
spheres is that these canine GSCs tested in the current study may be at the 
resting/quiescent state. This explanation is based on the reason that normal SCs and 
CSCs can be either at quiescent state which may account for drug and radiation resistant 
mechanism, or at cycling state for expanding stem cell pool (Roth and Fodde 2011). 
Besides, the J3T neurosphere colonies in serum-free culture propagated slower and more 
difficult than their parental cells in serum-containing culture (Reynolds and Weiss 
1992). 
 In the current study, the results of IPA canonical pathway analysis indicate that 
the pathways involved in regulation of cell cycle and protein synthesis are the most 
significantly relevant to the entire differentially expressed genes between the J3T sphere 
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and their parental cells. IGF-1R, PTEN, and the regulation of p70S6K and eIF4E 
pathways, which are known for regulation of protein synthesis or cell growth, are found 
to be highly relevant to the genetic expression variation between the two cell groups. On 
the contrary, the Erk MAPK and Jak/Stat pathways are less relevant to these altered gene 
expression, as compared with IGF-1R, PTEN, and eIF4E pathways. In line with this, the 
results of IPA functional analysis address that the genetic expression patterns of cell 
cycle and protein synthesis are greatly altered between the two cell groups. Taken 
together, this highlights that cell cycle and protein synthesis are the most altered cellular 
functions in the J3T spheres.    
  In conclusion, the putative stem cells have been shown to be successfully 
isolated from canine glioma J3T cells by Sphere Formation Assay. Further, by using 
cDNA microarray analysis, the genes which are differentially expressed between the J3T 
spheres and their parental cells have been successfully identified. IPA of these 
differentially expressed genes further classified these genes into each canonical pathway. 
Of the genes belonging to members of class I PI3K signaling network, several genes 
including IGFBP2, FYN, NTRK2, NTRK3, FOS, PDGFRB, CBL, IGF2R, CTNNB1, 
PLD3 and YWHAG are significantly up-regulated or down-regulated in the J3T spheres 
and have previously been related to gliomagenesis and glioma progression in 
human/mouse/rat species. Some genes, including DDIT4, PLD3 and PPP1R3C, which 
are highly up-regulated in the J3T spheres are, at the first time, found to be related to 
glioma development. Future work will validate the current microarray data and 
subsequently investigate the roles of the genes whose expression levels are significantly 
different between the two cell groups. In order to validate microarray data, techniques 
such as Western blotting can be employed to investigate if significant differences in 
mRNA expression correlate with changes in protein production. Additionally, Northern 
blot analysis can be used to confirm that singinficant fold changes identified in 
microarray data sets correlate with measurable changes in mRNA expression in the cell 
lines (Al Moustafa et al. 2002; Chuaqui et al. 2002). With regard to the investigation of 
the roles of the genes with highly differential expression ratios, there are some 
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approaches for such investigation. One of these approaches is to alter the expression 
levels of these genes in the spheres by transfection of siRNA (to down-regulate the 
expression of a specific gene), or delivery of a constitutively activated gene of interest 
into the sphere cells (for gene overexpression). Subsequently, functional assays such as 
cell viability and apoptotic assays, are performed on both of the spheres with genetic 
modifications by siRNA or genetic overexpression, and the control spheres. Thus, the 
results of these functional assays may provide some clues regarding the effects exerted 
by the genes of interest on the J3T spheres.  
 IPA of the current microarray data indicate that the expression patterns of 
canonical pathways involved in the regulation of cell cycle and protein synthesis are 
remarkably altered in the J3T spheres. Since the majority of the transcripts encoding 
eukaryotic initiation factors that initiate mRNA translation are decreased and the 
transcripts that encoding the factors against translation initiation are increased, it is 
conceivable that down-regulation of translation initiation causes fewer mRNAs being 
placed on the ribosomes and being subsequently translated to polypeptides (Preiss and 
Hentze 2003). As a result, the protein synthesis is down-regulated in the J3T spheres. 
From the current microarray data, it is suggested that the J3T sphere cells display 
reduced activities of class I PI3K/Akt/mTOR and IGF-1R pathways and increased 
activities of Raf/Mek/Erk and Jak/Stat pathways, when compared to their parental cells. 
However, the cDNA microarray data fail to distinguish whether these pathways are in 
the active or inactive state. Further investigation of the activities, such as 
phosphorylation status, of these pathways by Western Blot and Reverse-Phase Protein 




Chapter 5: General discussion 
 This study demonstrates that class I PI3K/Akt pathway plays an important role in 
the maintenance of viability and survival of the cell lines derived from a variety of 
canine tumours, as evidenced by the effective inhibition of the survival and viability of 
these canine cells by the inhibitors specifically targeting components of this pathway. 
However, while these class I PI3K/Akt/mTOR pathway inhibitors show cytotoxic or 
cytostatic effects on these cancer cells, these inhibitors are found to induce hyper-
phosphorylation of eIF4E. Slight hyper-phosphorylation of Akt is occasionally observed 
in canine REM and J3T cells in the presence of Rapamycin. This suggests that these 
inhibitors potentially trigger Erk and/or p38MAPK survival pathways which are 
activators of eIF4E and release p70S6K/IRS1/PI3K/Akt feedback loop (Wang et al. 
2007; Bianchini et al. 2008). To overcome the resistance induced by these class I 
PI3K/Akt/mTOR pathway inhibitors and simultaneously avoid the issue of maximum 
tolerated dose, future study can investigate the effects of the combination of inhibitors 
which target both class I PI3K/Akt and Mek/Erk pathways. In addition, to warrant that 
these pathway inhibitors can be safely administered to canine patients, future study 
should investigate the cytotoxic effects of these inhibitors, especially ZSTK474 and 
KP372-1, on normal canine cells and the side effects/toxicities in normal dogs.    
 It is observed that the Western Blot profiles of the five canine cell lines before 
and after the treatment of these PI3K pathway inhibitors are slightly different. This 
suggests that the molecular alterations and cellular contexts vary from one cell line to 
another line. Future work may investigate the genetic and epigenetic changes and the 
expression levels of the genes encoding components of the class I PI3K signaling 
network by utilizing molecular techniques such as polymerase chain reaction (PCR) - 
single strand conformation polymorphism (SSCP) analysis, methylated DNA 
immunoprecipitation (MeDIP), and Western Blotting (Hayashi 1991; Mohn et al. 2009).  
 Previous manuscripts demonstrated that Rapamycin at nanomolar concentrations 
specifically inhibited mTORC1 and exerted cytostatic effects on most cancer cell lines, 
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whereas this compound at micromolar concentrations inhibited both mTORC1 and 
mTORC2 and exerted cytotoxic effects on cells (Shor et al. 2008; Chen et al. 2010). 
Consistent with previous findings, the cell viability results show that the lower 
micromolar concentrations (20-40 µM) of Rapamycin drive all of the canine cell lines to 
death. This suggests that mTORC2 may play a role in maintaining cell viability in these 
canine cells. To investigate the role of mTORC2 and identify its downstream pathways 
or targets in these canine cells, one approach is to silence the genes which encode 
components of mTORC2, followed by compare the activated state of the cells with 
decreased mTORC2 activity with that of the control cells by using Western Blotting and 
Reverse-Phase Protein Array. Unraveling the role of mTORC2 in these canine cells may 
provide a better strategy to effectively treat canine cancer. 
 It is observed that chronic treatment of cells with KP372-1 often causes protein 
loss. Since it was reported that the protein leakage and DNA fragmentation often 
occurred in the apoptotic cells at the secondary necrosis stage when these apoptotic cells 
were cultured in the medium in the absence of phagocytes (Kelly et al. 2003; Krysko et 
al. 2008), it is speculated that the same scenario tends to occur in these KP372-1-treated 
cells. To know whether protein loss in the KP372-1-treated cells is due to protein 
leakage, collection of both cell lysates and growth medium in the KP372-1 treatment 
group are required for protein quantification and Western Blot analysis. 
In this study, Doxorubicin combined with the class I PI3K/Akt/mTOR pathway 
inhibitors do not exert synergistic or additive effects on most canine cell lines. One 
possible explanation for such results can be attributed to the actions of these inhibitors 
on G1/S cell cycle arrest, which prevents Doxorubicin from binding to proliferative 
cancer cells (Opel et al. 2008; McDonald et al. 2010; Bender et al. 2011). To improve 
the efficacy of Doxorubicin combined with PI3K pathway inhibitors, cells could be 
pretreated with Doxorubicin for 24 hours, and then concomitantly treated with 
Doxorubicin and the PI3K pathway inhibitors for a further ≥ 48 hours. This approach 
might prevent cells from accumulating at G0/G1 phase and allow Doxorubicin to 
interact with more cells at S phase (McDonald et al. 2010).  
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To investigate whether these class I PI3K pathway inhibitors induce autophagic 
resistance, future work may employ techniques such as transmission electron 
microscopy analysis, acridine orange staining, and autofluorescent 
monodansylcadaverine staining, to detect autophagic vacuoles in cells (Takeuchi et al. 
2005; Chiarini et al. 2010). In addition, to overcome the drug-induced autophagic 
resistance, concomitant treatment of these canine cells with the class I PI3K pathway 
inhibitors and an autophagic inhibitor such as Chloroquine may enhance the anti-cancer 
activity of these class I PI3K pathway inhibitors (Fan et al. 2010)  
 The study has successfully isolated the putative stem cells from canine glioma 
J3T cells by sphere formation assay. Further, several genes have been identified by using 
cDNA microarray analysis and have been implicated to be highly associated with the 
phenotype of the J3T spheres, due to their much higher or lower expression levels 
detected in the spheres than their parental cells To investigate the roles of these 
differentially expressed genes, particularly IGFBP2, FYN, DDIT4, PPP1R3C, NTRK2, 
FOS, PDGFRB, CBL, IGF2R, and CTNNB1, microarray data must be validated, for 
example, by using Western blotting or Northern blotting to check whether there is 
difference between protein and mRNA expression in both of the J3T spheres and their 
parental cells (Al Moustafa et al. 2002; Chuaqui et al. 2002). After the validation of the 
microarray data, several functional assays such as cell viability, apoptotic and motility 
assays are recommended to be performed on both of the J3T spheres with wild-type 
gene expression and with increased or decreased expression of a gene of interest. To 
alter the expression levels of genes of interest in the spheres, one approach is to transfect 
these spheres with siRNA and short hairpin RNA (shRNA) (to down-regulate gene 
expression) or with a vector which carries and up-regulates a gene of interest (to up-
regulate gene expression) (Doi et al. 2003; Li et al. 2012).   
 Although the data obtained from the cDNA microarray analysis indicate that 
several canonical pathways have a tendency to be up-regulated (e.g. Raf/Mek/Erk and 
Jak/Stat pathways) or down-regulated (e.g. class I PI3K/Akt/mTOR and IGF-1R 
pathways) in the J3T spheres, it should be borne in mind that the cDNA microarray is 
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used to quantify the transcriptional levels of genes of interest, instead of quantifying the 
active status (phosphoarylation levels) of components of these pathways. Further 
investigation of the activities, such as phosphorylation status, of these pathways by 
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Appendix 1: Statistic analysis of significance of the 
effects of Wortmannin (W) combined with Rapamycin 
(R) on cells 
1. Jurkat T (1) 
W 10 nMW 100 nMW 1 μMW 4 μMW 




1 μMW+1 μMR 4 μMW+1 μMR 
P-value 0.0304 0.0304 0.0304 0.168 
 
R 1 μMR 1 μMR 1 μMR 1 μMR 




1 μMW+1 μMR 4 μMW+1 μMR 
P-value 0.402 0.281 0.000 0.0304 
 
R 1 μMR 1 μMR 1 μMR 1 μMR 
W 10 nMW 100 nMW 1 μMW 4 μMW 
P-value 0.0304 0.0304 0.0304 0.002 
 
2. Jurkat T (2) 
W 4 μMW 4 μMW 4 μMW 4 μMW 












R 10 nMR 100 nMR 500 nMR 2.5 μMR 








P-value 0.0304 0.0304 0.0304 0.000 
 
R 10 nMR 100 nMR 500 nMR 2.5 μMR 
W 4 μMW 4 μMW 4 μMW 4 μMW 
P-value 0.001 0.002 0.004 0.065 
 
3. 3132 (1) 
W 10 nMW 100 nMW 1 µMW 10 µMW 








P-value 0.0304 0.0304 0.002 0.0304 
 
R 2.5 µMR 2.5 µMR 2.5 µMR 2.5 µMR 








P-value 0.104 0.113 0.003 0.000 
 
R 2.5 µMR 2.5 µMR 2.5 µMR 2.5 µMR 
W 10 nMW 100 nMW 1 µMW 10 µMW 
P-value 0.0304 0.0304 0.0304 0.001 
 
4. 3132 (2) 
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W 8 μMW 8 μMW 8 μMW 8 μMW 








P-value 0.0304 0.0304 0.0304 0.0304 
 
R 10 nMR 100 nMR 500 nMR 2.5 μMR 








P-value 0.0304 0.0304 0.001 0.000 
 
R 10 nMR 100 nMR 500 nMR 2.5 μMR 
W 8 μMW 8 μMW 8 μMW 8 μMW 
P-value 0.003 0.002 0.02 0.003 
 
5. J3T (1) 
W 100 nMW 1 μMW 10 μMW 20 μMW 








P-value 0.0304 0.0304 0.0304 0.0304 
 
R 10 μMR 10 μMR 10 μMR 10 μMR 












R 10 μMR 10 μMR 10 μMR 10 μMR 
W 100 nMW 1 μMW 10 μMW 20 μMW 
P-value 0.0304 0.0304 0.0304 0.000 
 
6. J3T (2) 
W 16 μMW 16 μMW 16 μMW 16 μMW 








P-value 0.0304 P=0.0304 P=0.000 P=0.0304 
 
R 10 nMR 100 nMR 1 μMR 10 μMR 








P-value 0.003 0.006 0.031 0.002 
 
R 10 nMR 100 nMR 1 μMR 10 μMR 
W 16 μMW 16 μMW 16 μMW 16 μMW 
P-value 0.001 0.000 0.000 0.0304 
 
7. SB (1) 
W 100 nMW 1 μMW 10 μMW 20 μMW 












R 10 μMR 10 μMR 10 μMR 10 μMR 








P-value 0.033 0.007 0.0304 0.0304 
 
R 10 μMR 10 μMR 10 μMR 10 μMR 
W 100 nMW 1 μMW 10 μMW 20 μMW 
P value 0.0304 0.0304 0.0304 0.004 
 
8. SB (2) 
W 16 μMW 16 μMW 16 μMW 16 μMW 








P-value 0.000 0.0304 0.000 0.0304 
 
R 10 nMR 100 nMR 1 μMR 10 μMR 








P-value 0.000 0.0304 0.001 0.0304 
 
R 10 nMR 100 nMR 1 μMR 10 μMR 
W 16 μMW 16 μMW 16 μMW 16 μMW 
P-value 0.020 0.037 0.039 0.193 
 
9. C2 (1) 
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W 10 nMW 100 nMW 1 μMW 4 μMW 




1 μMW+1 μMR 4 μMW+1 μMR 
P-value 0.000 0.000 0.001 0.001 
 
R 1 μMR 1 μMR 1 μMR 1 μMR 




1 μMW+1 μMR 4 μMW+1 μMR 
P-value 0.699 0.089 0.089 0.0304 
 
R 1 μMR 1 μMR 1 μMR 1 μMR 
W 10 nMW 100 nMW 1 μMW 4 μMW 
P-value 0.000 0.0304 0.0606 0.955 
 
10. C2 (2) 
W 4 μMW 4 μMW 4 μMW 4 μMW 








P-value 0.001 0.001 0.001 0.0304 
 
R 10 nMR 100 nMR 500 nMR 2.5 μMR 












R 10 nMR 100 nMR 500 nMR 2.5 μMR 
W 4 μMW 4 μMW 4 μMW 4 μMW 
P-value 0.003 0.001 0.205 0.059  
 
11. REM134 (1) 
W 100 nMW 1 μMW 10 μMW 20 μMW 
W+R 100 nMW+10 
μMR 




P-value 0.0304 0.0304 0.0304 0.0304 
 
R 10 μMR 10 μMR 10 μMR 10 μMR 
W+R 100 nMW+10 
μMR 




P-value 0.477 0.424 0.1124 0.080 
 
R 10 μMR 10 μMR 10 μMR 10 μMR 
W 100 nMW 1 μMW 10 μMW 20 μMW 
P-value 0.0304 0.000 0.0304 0.0304 
 
12. REM134 (2) 
W 16 μMW 16 μMW 16 μMW 16 μMW 




1 μMR+16 μMW 10 μMR+16 
μMW 




R 10 nMR 100 nMR 1 μMR 10 μMR 




1 μMR+16 μMW 10 μMR+16 
μMW 
P-value 0.994 0.634 0.295 0.053 
 
R 10 nMR 100 nMR 1 μMR 10 μMR 
W 16 μMW 16 μMW 16 μMW 16 μMW 





Appendix 2: Statistic analysis of significance of the 
effects of ZSTK474 (Z) combined with Rapamycin (R) on 
cells 
1.Jurkat T 
Z 50  nMZ 100 nMZ 250 nMZ 500 nMZ 








P-value 0.0809 0.006 0.001 0.0809 
 
R 25 nMR 25 nMR 25 nMR 25 nMR 








P value 0.017 0.003 0.000 0.0809 
 
R 25 nMR 25 nMR 25 nMR 25 nMR 
Z 50  nMZ 100 nMZ 250 nMZ 500 nMZ 
P-value 0.0809 0.028 0.234 0.0809 
 
2. 3132  
Z 250 nMZ 400 nMZ 600 nMZ 800 nMZ 
Z+R 250 nMZ+5 μMR 400 nMZ+5 
μMR 
600 nMZ+5 μMR 800 nMZ+5 
μMR 




R 5 μMR 5 μMR 5 μMR 5 μMR 
Z+R 250 nMZ+5 μMR 400 nMZ+5 
μMR 
600 nMZ+5 μMR 800 nMZ+5 
μMR 
P-value 0.001 0.000 0.0304 0.0304 
 
R 5 μMR 5 μMR 5 μMR 5 μMR 
Z 250 nMZ 400 nMZ 600 nMZ 800 nMZ 
P-value 0.000 0.003 0.962 0.281 
 
3. SB  
Z 50 nMZ 100 nMZ 250 nMZ 500 nMZ 
Z+R 50 nMZ+5 μMR 100 nMZ+5 
μMR 
250 nMZ+5 μMR 500 nMZ+5 
μMR 
P-value 0.0809 0.0809 0.0809 0.0809 
 
R 5 μMR 5 μMR 5 μMR 5 μMR 
Z+R 50 nMZ+5 μMR 100 nMZ+5 
μMR 
250 nMZ+5 μMR 500 nMZ+5 
μMR 
P-value 0.0809 0.017 0.001 0.000 
 
R 5 μMR 5 μMR 5 μMR 5 μMR 
Z 50 nMZ 100 nMZ 250 nMZ 500 nMZ 





Z 100 nMZ 500 nMZ 1 μMZ 4 μMZ 
Z+R 100 nMZ+1 μMR 500 nMZ+1 
μMR 
1 μMZ+1 μMR 4 μMZ+1 μMR 
P-value 0.0809 0.0809 0.0809  0.001 
 
R 1 μMR 1 μMR 1 μMR 1 μMR 
Z+R 100 nMZ+1 μMR 500 nMZ+1 
μMR 
1 μMZ+1 μMR 4 μMZ+1 μMR 
P-value 1.000 0.0809 0.0809 0.0809 
 
R 1 μMR 1 μMR 1 μMR 1 μMR 
Z 100 nMZ 500 nMZ 1 μMZ 4 μMZ 
P-value 0.0809 0.0809 0.0809 0.000 
 
5. J3T  
Z 250 nMZ 500 nMZ 750 nMZ 1 μMZ 
Z+R 250 nMZ+1 μMR 500 nMZ+1 
μMR 
750 nMZ+1 μMR 1 μMZ+1 μMR 
P-value 0.004 0.001  0.001 0.001 
 
R 1 μMR 1 μMR 1 μMR 1 μMR 
Z+R 250 nMZ+1 μMR 500 nMZ+1 
μMR 
750 nMZ+1 μMR 1 μMZ+1 μMR 




R 1 μMR 1 μMR 1 μMR 1 μMR 
Z 250 nMZ 500 nMZ 750 nMZ 1 μMZ 
P-value 0.099 0.664  0.034 0.001 
 
6. C2 
Z 250 nMZ 500 nMZ 750 nMZ 1 μMZ 








P-value 0.000 0.0304 0.000 0.0304 
 
R 500 nMR 500 nMR 500 nMR 500 nMR 








P-value 0.0304 0.0304 0.0304 0.0304 
 
R 500 nMR 500 nMR 500 nMR 500 nMR 
Z 250 nMZ 500 nMZ 750 nMZ 1 μMZ 





Appendix 3: Statistic analysis of significance of the 
effects of Doxorubicin (D) combined with Wortmannin 
(W), ZSTK474 (Z), KP372-1 (K), or Rapamycin (R) on 
cells 
 
1. SB: Doxorubicin (D) and Wortmannin (W) 
D 2.5 nMD 5 nMD 10 nMD 15 nMD 
D+W 2.5 nMD+20 
μMW 




P-value 0.0809 0.0809 0.000 0.0809 
 
W 20 μMW 20 μMW 20 μMW 20 μMW 
D+W 2.5 nMD+20 
μMW 




P-value 0.007 0.003 0.001 0.0809 
 
D 2.5 nMD 5 nMD 10 nMD 15 nMD 
W 20 μMW 20 μMW 20 μMW 20 μMW 
P-value 0.0809 0.000 0.008  0.41  
 
2. SB: Doxorubicin (D) and ZSTK474 (Z) 
D 2.5 nMD 5 nMD 10 nMD 15 nMD 
D+Z 2.5 nMD+100 
nMZ 








Z 100 nMZ 100 nMZ 100 nMZ 100 nMZ 
D+Z 2.5 nMD+100 
nMZ 




P-value 0.481 0.455  0.078  0.002 
 
D 2.5 nMD 5 nMD 10 nMD 15 nMD 
Z 100 nMZ 100 nMZ 100 nMZ 100 nMZ 
P-value 0.001 0.000 0.030 0.003 
 
3. SB: Doxorubicin (D) and KP372-1 (K) 
D 2.5 nMD 5 nMD 10 nMD 15 nMD 
D+K 2.5 nMD+80 
nMK 




P-value 0.0809 0.0809 0.0809 0.0809 
 
K 80nMK 80nMK 80nMK 80nMK 
D+K 2.5 nMD+80 
nMK 




P-value 0.008 0.0809 0.0809 0.0809 
 
D 2.5 nMD 5 nMD 10 nMD 15 nMD 
K 80 nMK 80 nMK 80 nMK 80 nMK 
P-value 0.000 0.000 0.001 0.000 
 
4. SB: Doxorubicin (D) and Rapamycin (R) 
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D 2.5 nMD 5 nMD 10 nMD 15 nMD 
D+R 2.5 nMD+5 
μMR 
5 nMD+5 μMR 10 nMD+5 μMR 15 nMD+5 μMR 
P-value 0.0809 0.001 0.0809 0.002 
 
R 5 μMR 5 μMR 5 μMR 5 μMR 
D+R 2.5 nMD+5 
μMR 
5 nMD+5 μMR 10 nMD+5 μMR 15 nMD+5 μMR 
P-value 0.0809 0.041 0.001 0.0809 
 
D 2.5 nMD 5 nMD 10 nMD 15 nMD 
R 5 μMR 5 μMR 5 μMR 5 μMR 
P-value 0.0809 0.002 0.001 0.637 
 
5. REM134: Doxorubicin (D) and Wortmannin (W) 
D 2.5 nMD 5 nMD 10 nMD 15 nMD 








P-value 0.539  0.782 0.450 0.096 
 
W 20 μMW 20 μMW 20 μMW 20 μMW 












D 2.5 nMD 5 nMD 10 nMD 15 nMD 
W 20 μMW 20 μMW 20 μMW 20 μMW 
P-value 0.018 0.065 0.069 0.322 
 
6. REM134: Doxorubicin (D) and ZSTK474 (Z) 
D 2.5 nMD 5 nMD 10 nMD 15 nMD 
D+Z 2.5 nMD+1 
μMZ 
5 nMD+1 μMZ 10 nMD+1 μMZ 15 nMD+1 μMZ 
P-value 0.001  0.001 0.001  0.008 
 
Z 1 μMZ 1 μMZ 1 μMZ 1 μMZ 
D+Z 2.5 nMD+1 
μMZ 
5 nMD+1 μMZ 10 nMD+1 μMZ 15 nMD+1 μMZ 
P-value 0.640 0.264 0.707 0.639  
 
D 2.5 nMD 5 nMD 10 nMD 15 nMD 
Z 1 μMZ 1 μMZ 1 μMZ 1 μMZ 
P-value 0.001 0.001  0.001 0.008 
 
7. REM: Doxorubicin (D) and KP372-1 (K) 
D 2.5 nMD 5 nMD 10 nMD 15 nMD 
D+K 2.5 nMD+5 
nMK 
5 nMD+5 nMK 10 nMD+5 nMK 15 nMD+5 nMK 




K 5 nMK 5 nMK 5 nMK 5 nMK 
D+K 2.5 nMD+5 
nMK 
5 nMD+5 nMK 10 nMD+5 nMK 15 nMD+5 nMK 
P-value 0.326 0.745 0.988 0.200  
 
D 2.5 nMD 5 nMD 10 nMD 15 nMD 
K 5 nMK 5 nMK 5 nMK 5 nMK 
P-value 0.002 0.004 0.036  0.3827 
 
8. REM134: Doxorubicin (D) and Rapamycin (R) 
D 2.5 nMD 5 nMD 10 nMD 15 nMD 
D+R 2.5 nMD+5 
μMR 
5 nMD+5 μMR 10 nMD+5 μMR 15 nMD+5 μMR 
P-value 0.001 0.001 0.0809 0.000  
 
R 5 μMR 5 μMR 5 μMR 5 μMR 
D+R 2.5 nMD+5 
μMR 
5 nMD+5 μMR 10 nMD+5 μMR 15 nMD+5 μMR 
P-value 0.756 0.593 0.073   0.015 
 
Doxo 2.5 nMD 5 nMD 10 nMD 15 nMD 
Rapa 5 μMR 5 μMR 5 μMR 5 μMR 
P-value 0.001 0.001 0.000 0.004 
 
9. 3132: Doxorubicin (D) + Wortmannin (W) 
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D 2 nMD 4 nMD  6 nMD 8 nMD 
D+W 2 nMD+8 μMW 4 nMD+8 μMW  6 nMD+8 μMW 8 nMD+8 μMW 
P-value 0.005 0.007  0.250 0.684 
 
W 8 μMW 8 μMW 8 μMW 8 μMW 
D+W 2 nMD+8 μMW 4 nMD+8 μMW  6 nMD+8 μMW 8 nMD+8 μMW 
P-value 0.049  0.001 0.0809 0.0809 
 
D 2 nMD 4 nMD  6 nMD 8 nMD 
W 8 μMW 8 μMW 8 μMW 8 μMW 
P-value 0.291 0.003  0.000  0.0809 
 
10. 3132: Doxorubicin (D) + ZSTK474 (Z) 
D 2 nMD 4 nMD  6 nMD 8 nMD 








P-value 0.0809 0.015 0.021 0.000  
 
Z 500 nMZ 500 nMZ 500 nMZ 500 nMZ 








P-value 0.013 0.006 0.001  0.000 
 
D 2 nMD 4 nMD  6 nMD 8 nMD 
Z 500 nMZ 500 nMZ 500 nMZ 500 nMZ 
346 
 
P-value 0.000 0.069 0.000 0.0809 
 
11. 3132: Doxorubicin (D) + Rapamycin (R) 
D 2 nMD 4 nMD  6 nMD 8 nMD 
D+R 2 nMD+40 nMR 4 nMD+40 nMR  6 nMD+40 
nMR 
8 nMD+40 nMR 
P-value 0.003 0.005 0.735 0.000 
 
R 40 nMR 40 nMR 40 nMR 40 nMR 
D+R 2 nMD+40 nMR 4 nMD+40 nMR  6 nMD+40 
nMR 
8 nMD+40 nMR 
P-value 0.565 0.081 0.013 0.011 
 
D 2 nMD 4 nMD  6 nMD 8 nMD 
R 40 nMR 40 nMR 40 nMR 40 nMR 
P-value 0.013 0.158 0.017 0.002 
 
12. C2: Doxorubicin (D) and Wortmannin (W) 
D 5 nMD 10 nMD  15 nMD 20 nMD 
D+W 
5 nMD+8 μMW 
10 nMD+8 
μMW 




P-value 0.013 0.158 0.591 0.003 
 
W 8 μMW 8 μMW 8 μMW 8 μMW 
D+W 
5 nMD+8 μMW 
10 nMD+8 
μMW 






P-value 0.434 0.020 0.008 0.002 
 
D 5 nMD 10 nMD  15 nMD 20 nMD 
W 8 μMW 8 μMW 8 μMW 8 μMW 
P-value 0.047 0.032 0.009 0.009 
 
13. C2: Doxorubicin (D) and ZSTK474 (Z) 
D 5 nMD 10 nMD  15 nMD 20 nMD 
D+Z 5 nMD+1 μMZ 10 nMD+1 μMZ  15 nMD+1 μMZ 20 nMD+1 μMZ 
P-value 0.0809 0.005 0.002 0.101 
 
Z 1 μMZ 1 μMZ 1 μMZ 1 μMZ 
D+Z 5 nMD+1 μMZ 10 nMD+1 μMZ  15 nMD+1 μMZ 20 nMD+1 μMZ 
P-value 0.423 0.015 0.006 0.007 
 
Doxo 5 nMD 10 nMD  15 nMD 20 nMD 
ZSTK 1 μMZ 1 μMZ 1 μMZ 1 μMZ 
P-value 0.0809 0.011  0.3827 0.543 
 
14. C2: Doxorubicin (D) and Rapamycin (R) 
D 5 nMD 10 nMD  15 nMD 20 nMD 
D+R 
5 nMD+8 μMR 10 nMD+8 μMR 
 15 nMD+8 
μMR 
20 nMD+8 μMR 




R 8 μMR 8 μMR 8 μMR 8 μMR 
D+R 5 nMD+8 μMR 10 nMD+8 μMR 15 nMD+8 μMR 20 nMD+8 μMR 
P-value 0.080 0.008 0.019 0.006 
 
Doxo 5 nMD 10 nMD 15 nMD 20 nMD 
Rapa 8 μMR 8 μMR 8 μMR 8 μMR 









Function Importance in gliomas 
Activator of class I PI3K 
DDR1 1.673 DDR1 encodes discoidin 
domain receptor-1 (DDR1), 
which is a type of RTK that can 
activate its downstream 
effectors, including class I PI3K 
and Raf MAPK pathways, in 
response to stimulation of 
growth factors (Marshall 1995; 
Lemmon and Schlessinger 
2010) 
DDR1 is commonly expressed 
in all malignant central 
nervous system (CNS) human 
brain tumours, including 
glioblastoma (Weiner et al. 
2000).  
DDR1 has a role in stimulate 
invasion and adhesion of 
human glioma cells (Ram et al. 
2006).  
FGFR1 1.920 FGFR1 encodes fibroblast 
growth factor receptor 1 
(FGFR1), which is a type of 
RTK that can activate its 
downstream effectors, including 
class I PI3K and Raf MAPK 
pathways, in response to 
stimulation of growth factors 
(Marshall 1995; Lemmon and 
Schlessinger 2010). 
FGFR1 plays a key role in 
promoting the growth and 
angiogenesis of glioma cells 
(Yamada et al. 1998; Yamada 




FGFR2 -2.200 FGFR2 encodes fibroblast 
growth factor receptor 2 
(FGFR2), which is a type of 
RTK that can activate its 
downstream effectors, including 
class I PI3K and Raf MAPK 
pathways, in response to 
stimulation of growth factors 
(Marshall 1995; Lemmon and 
Schlessinger 2010). 
FGFR2 was reported to 
promote growth and 
angiogenesis in C6 glioma 
cells (Auguste et al. 2001). 
Paradoxically, this RTK 
exerted no effect on the growth 
of other malignant glioma cell 
lines (Yamada et al. 1999). It 
is suggested that FGFR2-
modulated tumour progression 
is cell line-specific.   
FLT1 -2.106 FLT1 encodes Fms-like In human astrocytoma 
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tyrosine kinase 1 (Flt1), also 
named VEGFR1, which is a 
type of RTK that can activate 
its downstream effectors, 
including class I PI3K and Raf 
MAPK pathways, in response to 
stimulation of growth factors 
(Marshall 1995; Lemmon and 
Schlessinger 2010).  Flt1 acts to 
promote angiogenesis after 
binding to its ligand VEGF 
(Xiang et al. 2001).  
specimens, both tumour and 
endothelial cells expressed 
similar levels of Flt1. Besides, 
high grade astrocytomas 
expressed higher levels of Flt1 
than low-grade astrocytomas 
(Xiang et al. 2001). This 
protein acts to promote 
angiogenesis in astrocytoma 
(Xiang et al. 2001).  
 
FYN 9.334 FYN encodes protein-tyrosine 
kinase Fyn, which belongs to 
Src protein family.  Once RTK 
activates Fyn, it can 
subsequently activate class I 
PI3K  (Saito et al. 2010). 
Fyn promotes oligodendroglial 
cell differentiation and myelin 
formation in CNS in response to 
apotransferrin stimulation 
(Perez et al. 2009).  
Overexpression of Fyn was 
observed in many human 
cancers, such as glioma and 
leukemia, and was associated 
with promoting tumour 
invasion and migration (Yadav 
and Denning 2011).   
Fyn was reported to 
phosphorylate CD133 (a stem 
cell marker) in human 
medulloblastoma cells, 
suggesting playing a role in 
regulation of CD133 (Boivin et 
al. 2009).  
GAB1 2.444 GAB1 encodes Gab1, which is 
an adaptor protein. Gab1 can 
activate class I PI3K after Gab1 
is phosphorylated by activated 
RTK (Rodrigues et al. 2000).  
Down-regulation of Gab1 
expression was reported in low 
grade human astrocytoma 
specimens (Huang et al. 2000).  
In high grade glioblastoma 
cells, the Shp-2 
phosphatase/Gab1 complex 
activates class I PI3K/Akt/NF-
кB signaling after EGFR 
activation (Kapoor et al. 
2004). 
GHR 1.426 GHR encodes growth hormone 
receptor (GHR), which can 
activate class I PI3K through 
activation of GHR/JAK2/IRS-1 
signaling (Herrington and 
Expression of GHR was 
detected in human CNS tissue 
and the human gliomblastoma 




Carter-Su 2001).    
GRB2 -1.190 GRB2 encodes growth factor 
receptor-bound protein 2 
(Grb2), which acts as an 
adaptor protein of RTK. The 
interaction between active RTK 
and Grb2 promotes Grb2 to 
activate class I PI3K through 
Gab1 or Ras (Cully et al. 2006). 
Grb2, along with Ras and Shc, 
played a role in up-regulating 
tumourigeneity in human 
glioblastoma cells expressing 
mutant DeltaEGFR expression 
(Prigent et al. 1996).  
IGF1R -1.554 IGF1R encodes IGF-1R, which 
is a type of RTK. The IGF-1R 
is often activated by its ligands, 
IGF-1 and IGF-2. The IGF-1R 
exerts the growth effect on 
normal and cancer cells by 
activation of its downstream 
class I PI3K/Akt and Raf1 
MAPK signaling (Pollak 2012). 
IGF1R was reported to 
positively regulate the growth 
of glioblastoma (Hagerstrand 
et al. 2010). Besides, genetic 
variation in IGF1R was 
reported to be correlated with 
low grade glioma but not high 
grade glioblastoma (Lonn et al. 
2008).  
INSR 1.747 INSR encodes IR, which is a 
type of RTK. IR contains A 
isoform (IR-A) and B isoform 
(IR-B). IR is activated by its 
ligand insulin. IR-A can also be 
activated by IGF-2.  The main 
downstream pathways of IR are 
class I PI3K/Akt and Raf 
MAPK pathways.  IR plays a 
key role in regulate 
carbohydrate metabolism in 
both normal and tumour cells 
(Marshall 1995; Lemmon and 
Schlessinger 2010; Belfiore and 
Malaguarnera 2011).  
Insulin was reported to up-
regulate proliferation of low 
grade gliomas, promote 
differentiation of high grade 
glioblastoma, and increase 
glucose uptake of glioma cells 
(Grunberger et al. 1986; Glick 
et al. 1989). 
IRS1 1.292 IRS1 encodes IRS-1, a RTK 
adaptor protein. IRS-1 acts to 
activate PI3K after the 
interaction of IRS-1 and RTK 
(Wymann and Pirola 1998). 
The level of IRS-1 was 
positively correlated with 
higher grade of human gliomas 
(Qian et al. 2008).  
JAK2 2.405 JAK2 encodes Jak2 which 
activates Stat, Grb2/Erk and 
IRS-1/class I PI3K pathways 
after Jak2 is activated by its 
Constitutive activation of 
Jak2/Stat3 was observed to 
contribute to overgrowth of the 
human GL15 glioblastoma cell 
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regulators, such as growth 
hormone and cytokine receptors 
(VanderKuur et al. 1995; 
Leonard and O'Shea 1998; 
Herrington and Carter-Su 
2001). 
line (Sciaccaluga et al. 2007). 
A recent study showed that 
Jak2/Stat3 pathway positively 
regulated invasion and 
migration of human 
glioblastoma (Senft et al. 
2011). 
Jak2/Stat3 pathway has a role 
in up-regulating proliferation 
and survival of glioblastoma 
stem cells (Sai et al. 2012).  
KDR 1.764 KDR encodes vascular 
endothelial growth factor 
receptor 2 (VEGFR2), which is 
a type of RTK that can activate 
its downstream effectors, 
including class I PI3K and Raf 
MAPK pathways, in response to 
stimulation of growth factors 
(Marshall 1995; Lemmon and 
Schlessinger 2010). 
Constitutive activation of 
VEGFR2 was frequently 
observed in high grade 
astrocytomas but not in low 
grade gliomas (Carroll et al. 
1999). Autocrine regulation 
and expression of VEGFR2 
and its ligand VEGF was 
positively correlated with the 
radioresistance of glioblastoma 
cells (Geng et al. 2001; 
Knizetova et al. 2008). 
However, there is a debate on 
the roles of VEGFR2 and 
VEGF in regulation of the 
proliferation of glioma cells 
(Hong et al. 2007; Knizetova 
et al. 2008).   
KRAS -2.151 KRAS encodes K-Ras GTPase, 
which acts as an upstream 
activator of both class I PI3K 
and Raf MAPK pathways 
(Castellano and Downward 
2011). 
Expression of K-ras or 
constitutive activation of 
mutant K-Ras was observed to 
promote gliomagenesis in 
human patient and mouse 
model (Holmen and Williams 
2005; Janzarik et al. 2007).  
NRAS -1.288 NRAS encodes N-Ras GTPase, 
which acts as an upstream 
activator of both class I PI3K 
and Raf MAPK pathways 
(Castellano and Downward 
2011). 
N-Ras with acting mutation is 
responsible for  initiating  
certain human glioblastomas 
(Knobbe et al. 2004).  
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NTRK2 7.805 NTRK2 encoding TrkB RTK, 
which activates its downstream 
pathways, including Ras/Raf, 
class I PI3K/Akt, PLCγ, NF-кB, 
atypical PKC (ζ and ι) in 
response to BDNF, and 
neurotrophin 4 and 5 (NT4 and 
NT5) (Marshall 1995; Huang 
and Reichardt 2003; Lemmon 
and Schlessinger 2010). 
TrkB is ubiquitously expressed 
on all the cells of nervous 
system. An in vivo experiment 
showed that TrkB receptor was 
critical for the viability of 
sensory and motor neurons in 
mouse model (Barbacid 1994).  
Expression of NTRK2 was 
frequently detected in human 
astrocytic gliomas (Wang et al. 
1998). Expression of truncated 
NTRK2 was reported to 
regulate RhoA-modulated cell 
morphology and cytoskeletal 
rearrangement in rat C6 glioma 
cell line in response to BDNF 
(Ohira et al. 2006).  
NTRK2 expressed two forms 
of TrkB, truncated and full-
length TrkB. The truncated 
TrkB was frequently expressed 
in neural stem cells and glial 
cells whereas full-length TrkB 
was expressed in mature 
neurons (Islam et al. 2009).  
The BDNF/TrkB signaling 
plays a role in promoting 
proliferation, differentiation 
and migration and guiding 
direction of embryonic and 
adult neural stem 
cells/progenitors (Tervonen et 
al. 2006; Bartkowska et al. 
2007; Islam et al. 2009; 
Bagley and Belluscio 2010). 
NTRK3 3.138 NTRK3encodes TrkC RTK, 
which activates its downstream 
pathways, including Ras/Raf, 
class I PI3K/Akt, PLCγ, NF-кB, 
atypical PKC (ζ and ι) in 
response to NT3 (Huang and 
Reichardt 2003). 
TrkC is ubiquitously expressed 
on all the cells of nervous 
system and some non-nerve 
system structures, such as tooth 
and diaphram. TrkC-null mouse 
model resulted in completely 
loss of la muscle afferents at 
spinal cord and partially loss of 
Expression of NTRK3 was 
frequent in human astrocytic 
gliomas (Wang et al. 1998). 
NT3/TrkC signaling regulates 
neural cell development and 
differentiation (Klopotowska 
and Strzadala 2005; Wang et 
al. 2007).    
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neurons, axons and nerve fiber  
(Barbacid 1994). 
PDGFC 1.743 PDGFC encodes platelet 
derived growth factor C 
(PDGF-C). The PDGF-C 
frequently forms a homodimer, 
thus becoming PDGF-CC. The 
PDGF-CC can activate class I 
PI3K signaling through binding 
to PDGF receptor (PDGFR) αα 
(PDGFR αα) or PDGFR αβ 
(Calzolari and Malatesta 2010). 
PDGF-C is abundantly 
expressed in gliomas but is 
rarely found in normal brain 
tissue (Lokker et al. 2002). 
PDFG-C functioned in 
promoting vascular maturation 
in gliomas (di Tomaso et al. 
2009).     
PDGFRA 2.371 PDGFRA encodes PDGF 
receptor α (PDGFRα). The 
PDGFRα can either 
homodimerze with another 
PDGFRα to form PDGFRαα, or 
heterodimerize with PDGFβ to 
form PDGFR αβ. The PDGFR 
αα and PDGFR αβ belongs to 
RTK kinase family, which can 
activates class I PI3K in 
response to PDGF-AA, AB, BB 
or CC (Calzolari and Malatesta 
2010; Lemmon and 
Schlessinger 2010).  
PDGFRA is commonly 
expressed in glioma, especially 
in malignant glioblastomas 
(Furnari et al. 2007). The 
established autocrine/paracrine 
regulation of PDGFRs and 
their ligands may contribute to 
gliomagenesis (Calzolari and 
Malatesta 2010).   
PDGF-A/PDGFRα signaling 
regulates proliferation and 
survival of glial progenitors, 
the differentiation from glial 
progenitors into 
oligodendrocytes, and 
generation of myelin in CNS 
(Calzolari and Malatesta 
2010). 
PDGFRB 7.251 PDGFRB encodes PDGF 
receptor β (PDGFR β). The 
PDGFR β can either 
homodimerze with another 
PDGFR β to form PDGFR ββ, 
or heterodimerize with PDGFα 
to form P signaling is associated 
with PDGFR αβ. The PDGFR 
ββ and PDGFR αβ belongs to 
RTK kinase family, which can 
activates class I PI3K in 
response to PDGF- AB, BB or 
DD (Calzolari and Malatesta 
PDGFRB is abundantly 
expressed in endothelial cells 
in high grade glioblastoma 




2010; Lemmon and 
Schlessinger 2010).   
PTK2 -2.200 PTK2 encodes FAK, a 
cytoplasmic tyrosine kinase. 
FAK can activate class I PI3K 
after FAK is associated with its 
main upstream activator β-
integrin. The β-integrin/FAK 
signaling regulates cell-cell 
adhesion and cell movement  
(Guan 2010).  
FAK was abundantly 
expressed in high-grade human 
glioblastomas and is involved 
in positively regulating 
proliferation, survival, motility 
and invasion in gliomas 
(Natarajan et al. 2003).      
RRAS2 -1.403 Oncogene RRAS2 encodes 
TC21 (also named R-Ras2). 
TC21 induces transformation 
and maintains survival through 
activation of its downstream 
pathways including class I PI3K 
and NF-кB (Rong et al. 2002).   
N/A 
SHC1 1.098 SHC1 encodes ShcA which 
mainly activates MAPK and c-
Myc pathways and cell survival. 
Alternatively, ShcA associates 
with Grb2 and subsequently 
activates class I PI3K in 
response to IGF-1 stimulation 
(Ravichandran 2001; 
Radhakrishnan et al. 2008).  
Mutant DeltaEGFR was 
reported to up-regulate 
tumourigenesis of human 
glioblastomas through 
constitutive phosphorylation of 
its adaptor proteins Shc and 
Grb2. The phosphorylayed Shc 
and Grb2 by DeltaEGFR 
frequently resulted in 
activation of Ras pathway 
(Prigent et al. 1996).  
CBL 5.566 CBL encodes c-Cbl which acts 
as an adaptor protein and an E3 
ubiquitin ligase. c-Cbl can bind 
to p85 subunit of class IA PI3K 
and subsequently activate class 
IA PI3K after tyrosine 
phosphorylation of c-Cbl by 
Fyn or Bcr/Abl (Jain et al. 
1997; Hunter et al. 1999).  
Wild-type c-Cbl promotes 
glioma invasion through 
increasing expression of matrix 
matrix metalloprotease 2 
(MMP2) (Lee and Tsygankov 
2010).  
PTPN11 -2.548 PTPN11 encodes Shp-2, which 
positively regulates class I PI3K 
activation (Wu et al. 2001).  
Shp-2 acts as a dual regulator 
of gliomagenesis. On one 




inhibiting cell aging or 
relaying signals from RTKs to 
their downstream pathways 
such as class I PI3K and Erk 
(Zhan and O'Rourke 2004; 
Charest et al. 2006; Zhan et al. 
2009; Liu et al. 2011; Sturla et 
al. 2011). On the other hand, 
this protein binds to the 
SIRPα1 receptor, which results 
in inhibiting wild –type EGFR 
and mutant EGFRvIII-
mediated transformation and 
migration of glioma  (Wu et al. 
2000; Kapoor and O'Rourke 
2010).  
Inhibitor of class I PI3K 
IGFBP2 27.128 IGFBP2 encodes IGF-binding 
protein (IGFBP)-2 (IGFBP2), 
which binds to IGF and 
subsequently prevents the 
interaction of IGF with IGF 
receptor, leading to inhibition of 
class I PI3K pathway (Rajaram 
et al. 1997).  
Expression of IGFBP2 mRNA 
was detected in rat brain at both 
young age and adulthood. Its 
expression level was increased 
with age (Chernausek et al. 
1993).     
High frequency of IGFBP2 
overexpression was detected in 
glioma, especially in high 
grade human and canine 
glioblastoma (Becher et al. 
2008; Lin et al. 2009; Stoica et 
al. 2011). The presence of 
higher IGFBP2 expression 
levels in blood is positively 
correlated with poor prognosis 
(Lin et al. 2009). Although 
IGFBP2 protein in normal 
cells acts as inhibitor of 
IGF/class I PI3K signaling, 
this protein has been reported 
to be a positive regulator of 
Akt signaling in PDGFB-
induced glioma (Rajaram et al. 
1997; Dunlap et al. 2007). 
IGFBP2 protein was 
demonstrated to up-regulate 
invasion and motility of human 
GBM cell lines through 
interacting with integrin-α5 
and up-regulating expression 
of MMP-2 gene. Besides, this 




regulating CD24 gene 
expression (Wang et al. 2003; 
Wang et al. 2006; Fukushima 
et al. 2007).  In pediatric high 
grade astrocytomas, IGFBP2 
promotes malignant phenotype 
through up-regulating 
expression of genes encoding 
several DNA repair enzymes, 
but not through promoting the 
invasion and growth of tumour 
cells (Becher et al. 2008).  
IGFBP2 was demonstrated to 
induce proliferation, maintain 
survival and drug resistance of 
GSCs, in part through Akt 
signaling (Hsieh et al. 2010).   
IGFBP4 2.852 IGFBP4 encodes IGFBP4 
protein, which binds to IGF and 
subsequently prevents the 
interaction of IGF with IGF 
receptor, leading to inhibition of 
class I PI3K pathway (Rajaram 
et al. 1997).  
Expression of IGFBP4 mRNA 
was detected in rat brain at both 
young age and adulthood. Its 
expression level was decreased 
with age (Chernausek et al. 
1993).  
IGFBP4 has been detected in 
high-grade human 
glioblastoma (Schlenska-
Lange et al. 2008) IGFBP4 
was reported to act as tumour 
suppressor in glioblastoma 
through down-regulating 
angiogenesis and 
tumourigenesis (Moreno et al. 
2006).  
IGFBP6 1.807 IGFBP6 encodes IGFBP6 
protein, which binds to IGF and 
subsequently prevents the 
interaction of IGF with IGF 
receptor, leading to inhibition of 
class I PI3K pathway (Rajaram 
et al. 1997). 
IGFBP6 transcript was 
detected in high grade human 
glioblastoma (Schlenska-
Lange et al. 2008).  
 
 
IGFBP7 2.991 IGFBP7 encodes IGFBP7 
protein, which binds to IGF 
with low affinity and is 
speculated to negatively 
IGFBP7 was specifically 
expressed in blood vessels of 
GBM, particularly in 
endothelial cells and vascular 
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regulate IGF/IGF receptor/class 
I PI3K signaling, based on the 
findings of lower IGFBP7 
levels in cancers than that in 
normal tissue (Oh et al. 1996).  
 
 
membrane. Conversely, no 
expression of IGFBP7 was 
detected in normal brain (Pen 
et al. 2007). Up-regulation of 
IGFBP7 gene in GBM vessels 
was found to be stimulated by 
TGF-β/ALK5/Smad-2 pathway 
(Pen et al. 2008). 
It was reported that IGFBP7 
protein acted as a tumour 
suppressor in GBM cells 
through inhibiting cell growth 
and promoting cell aging. But 
this protein promoted vascular 
stabilization in GBM by 
recruiting smooth muscle cells 
and inducing trans-
differentiation from 
endothelial cells into vascular 
smooth muscle cells (Pen et al. 
2011).  
IGF2R 4.862 IGF2R encoding 
IGFII/mannose-6-phosphate 
receptor which acts to attenuate 
IGF-II signaling (Furstenberger 
and Senn 2002) 
Deletion of IGF2R, as a result 
of chromosomal translocation, 
was detected in primary human 
GBM tumours and human 




1.473 INPPL1 encodes Ship-2, which 
functions in conversion of 
PtdIns(3,4,5)P3 back to 
PtdIns(3,4)P2 through 
dephosphorylation of 
PtdIns(3,4,5)P3 on the 5’ 
position (Damen et al. 1996).  
Ship2 inhibited G1/S phase 
transition and inactivated Akt 
in glioma cells whereas this 
positively regulated RhoA-
modulated migration and 
polarization (Taylor et al. 
2000; Kato et al. 2012).   
RASA1 1.921 RASA1 encodes RAS p21 
protein activator 1 (p120 
RasGAP), which has GAP 
activity toward Ras, leading to 
inhibition of Ras signaling 
(Vogel et al. 1988; Woodcock 
and Hughes 2004).  
N/A 
  
SOCS2 1.705 SOCS2 encodes suppressor of SOCS2 expression was 
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cytokine signaling (SOCS)-2 
(SOCS2), which belongs to 
SOCS protein family. SOCS 
family serves as a subunit of E3 
ubiquitin ligase which degrades 
target proteins. In addition, 
SOCS family functions in 
inactivation of Jak/Stat pathway 
(Akhtar and Benveniste 2011).  
SOCS2 acts as the negative 
regulator of cytokine/Jak/Stat, 
growth hormone and IGF-1 
pathways (Rico-Bautista et al. 
2006).  
reported to be a key factor for 
the response of GBM cells to a 
chemotherapeutic agent 
Semustine (Zhao et al. 2011).  
SOCS5 2.045 SOCS5 encodes SOCS5 
protein, which belongs to SOCS 
protein family. SOCS family 
serves as a subunit of E3 
ubiquitin ligase which degrades 
target proteins. In addition, 
SOCS family functions in 
inactivation of Jak/Stat pathway 
(Akhtar and Benveniste 2011). 
SOCS5 protein inhibits 
cytokine IL-4/Jak/Stat and 
EGFR signaling pathways (Seki 
et al. 2002; Kario et al. 2005).  
N/A 
Activator of Akt 
CSNK2A
2 
1.357 CSNK2A2 encodes α catalytic 
subunit of CK2, which is a 
constitutively active 
serine/threonine kinase and can 
phosphorylate its substrates 
through transferring a 
phosphate group from ATP and 
GTP to its substrates. CK2 can 
activate class I PI3K/Akt 
signaling pathway through 
inhibitory phosphorylation of 
PTEN and active 
phosphorylation of Akt (Hanif 
et al. 2010). CK2 is associated 
CK2 promotes survival and 
invasion of glioma cells 
through down-regulation of 
p53-modulated cell cycle 
arrest, TNFα-modulated 
apoptosis and PTEN activity, 
up-regulation of DNA repair 
and trans-activation of 
EGF/Erk signaling-stimulated 
β-catenin-dependent invasion 
(Maccario et al. 2007; Ji et al. 
2009; Olsen et al. 2010; Dixit 
et al. 2012).  
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with promoting proliferation 
and maintaining survival of 
tumour cells (Kaminska et al. 
2009).   
CSNK2A
1 
-1.226 CSNK2A2 encodes α prime 
catalytic subunit of CK2 (Hanif 
et al. 2010).   
CK2 promotes survival and 
invasion of glioma cells 
through down-regulation of 
p53-modulated cell cycle 
arrest, TNFα-modulated 
apoptosis and PTEN activity, 
up-regulation of DNA repair 
and trans-activation of 
EGF/Erk signaling-stimulated 
β-catenin-dependent invasion 
(Maccario et al. 2007; Ji et al. 
2009; Olsen et al. 2010; Dixit 
et al. 2012). 
HSP90B
1 
-1.393 HSP90B1 encodes heat shock 
protein 90 kDa (HSP90) beta 
member 1. The HSP90 acts to 
assist around 200 proteins to 
have correct conformation for 
performing their biological 
activities, such as cell growth 
and survival (Messaoudi et al. 
2008). Among HSP90 client 
proteins, HSP90 was reported to 
positively regulate Akt-
dependent cell survival and 
Akt/eNOS signaling-induced 
angiogenesis (Sato et al. 2000; 
Miyauchi et al. 2012).  
 
HSP90 is ubiquitously 
expressed in gliomas, 
particularly high-grade 
glioblastoma, and endothelial 
cells in glioma vessels (Strik et 
al. 2000).   
The HSP90 was found to be 
correlated with tumour 
progression, including 
angiogenesis, unlimited DNA 
replication, invasion, 
migration, proliferation and 
survival, via its client proteins  
(Messaoudi et al. 2008).  
Studies of HSP90 inhibitors 
highlighted HSP90 played a 
critical role in G2/M phase 
transition and maintaining 
survival in gliomas and the 
growth of glioma stem cells 
(Garcia-Morales et al. 2007; 
Sauvageot et al. 2009).  
MRAS -1.459 MRAS encodes M-Ras, which 
belongs to Ras GTPase protein 




expressed in CNS brain tissue 
and is involved in activation of 
Akt survival pathway, MAPK-
induced neuronal 
differentiation, integrin pathway 
and actin cytoskeletal 
rearrangement (Matsumoto et 
al. 1997; Kimmelman et al. 
2000; Kimmelman et al. 2002; 
Yoshikawa et al. 2007).  
Inhibitor of Akt 
PRKAR1
A 
1.749 PRKAR1A encodes type 1α 
regulatory subunit of PKA, 
which keeps PKA at inactive 
state (Howe 2004). PKA 
activates Akt through class I 
PI3K-independent pathway 
(Filippa et al. 1999).  
Dibutyryl cAMP-stimulated 
PKA activity preferentially 
increased expression of the 
type I regulatory subunit but 
not other subunits of PKA in 
neuroblastoma-glioma hybrid 
cells (Lohmann et al. 1983).  
Up-regulation of PKA kinase 
cascades was found to promote 
differentiation, induce 
apoptosis and inhibit growth of 
high-grade glioblastoma (Chen 
et al. 1998). Type 1α 
regulatory subunit of PKA 




-1.790 PRKAR2A encodes type 2α 
regulatory subunit of PKA 
which keeps PKA at inactive 
state (Howe 2004). PKA 
activates Akt through class I 
PI3K-independent pathway 
(Filippa et al. 1999). 
Up-regulation of PKA kinase 
cascades was found to promote 
differentiation and apoptosis 
and growth arrest of high-
grade glioblastoma (Chen et al. 
1998). Type 2α regulatory 
subunit of PKA counteracts 
PKA activity (Howe 2004).  
The type 2 regulatory subunit 
of PKA is one component of 
cAMP-stabilizing region 
(CSR)-protein complex which 
plays a critical role in mRNA 
stabilization in rat glioma cells 




THEM4 -2.129 THEM encodes carboxyl-
terminal modulator protein 
(CTMP). The CTMP acts as the 
negative regulator of Akt 
(Knobbe et al. 2004). 
Hypermethylation of CTMP 
promoter resulting in down-
regulation of CTMP mRNA 
levels is common in 
glioblastoma (Knobbe et al. 
2004). 
PLD3 3.925 PLD3 encodes phospholipase D 
(PLD)-3 (PLD3). Unlike the 
classical PLD1 and PLD2 
which produce phosphatidic 
acid for mTORC1 activation, 
the function of PLD3 remains 
unclear (Xu et al. 2011). PLD3 
was reported to promote 
cellular differentiation in brain 
and muscle (Pedersen et al. 
1998; Osisami et al. 2012). 
Overexpression of PLD3 was 
found to inactivate Akt 
signaling in muscle cells 
(Zhang et al. 2009).      
N/A 
Activator of mTORC1 
PIK3C3 1.619 PIK3C3 encodes class III PI3K 
which can activate mTORC1 in 
response to both amino acid and 
glucose stimulation (Byfield et 
al. 2005; Nobukuni et al. 2007).  
N/A 
Inhibitor of mTORC1 
STK11 1.320 STK11 gene encodes LKB1 
which cooperates with AMPK 
to inhibit mTORC1 signaling 
when the ratio of intracellular 
ATP: AMP is low (Oakhill et 
al. 2011). 
LKB1/AMPK pathway 
promotes the migration and 
survival of glioma cells but 
arrests tumour cell growth in 
response to metabolic stress, 
such as glucose deprivation 
(Godlewski et al. 2010). 
DDIT4 8.506 DDIT4 encodes REDD1 which 
acts as negatively regulates 
mTORC1 activity in the 
presence of stress inputs such as 




2004; Sofer et al. 2005).  
PRKAB2 -1.413 PRKAB2 encodes β2 subunit of 
AMPK which acts as an energy 
sensor and negatively regulates 
mTORC1 signaling (Hardie et 
al. 2006).  
 
AMPK attenuates the pro-
apoptotic or cytotoxic effect of 
anti-cancer drugs through 
induction of autophagy in 
cancers, including gliomas 
(Harhaji-Trajkovic et al. 2009; 
Misirkic et al. 2012). Another 
function of AMPK is to 
promote migration of glioma 
cells in the presence of gherlin, 
a gastric peptide (Chen et al. 
2011).  
In glioblastomas expressing 
mutant EGFRVIII, AMPK acts 
as a tumour suppressor through 
inhibiting lipogenesis (Guo et 
al. 2009). 
Components of class I PI3K/Akt/mTOR axis pathway 
PIK3CD -2.243 PIK3CD encodes p110δ 
catalytic subunit of class IA 
PI3K (Wymann and Pirola 
1998) 
Overexpression of p110δ was 
detected in many gliomas in 
vitro and the role of p110δ in 
glioma was to promote cell 
migration and invasiveness.  
Either PIK3CD gene 
amplification or 
overexpression of its mRNA in 
glioblastoma has been 
documented (Knobbe and 
Reifenberger 2003; Mizoguchi 
et al. 2004).   
PIK3R5 -1.289 PIK3R5 encodes p101 
regulatory subunit of class IB 
PI3K (Voigt et al. 2005).  
N/A 
AKT1 -1.760 AKT1 encodes Akt1 kinase 
which acts to promote both 
cellular growth and survival in 
mouse model (Chen et al. 2001; 
Cho et al. 2001). Akt1 was 
reported to promote motility in 
normal cells but arrest 
Amplification and 
overexpression of Akt1 gene 
rarely occurs in glioblastoma 
(Knobbe and Reifenberger 
2003).  
Although Akt1 kinase 
contributes to the growth and 
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migration in cancer cells.   survival of normal cells in 
mouse model and the tumour 
types other than glioma, it has 
been reported that this protein 
exerts no effect on the growth 
and survival of glioma cells in 
vitro (Chen et al. 2001; Cho et 
al. 2001; Altomare and Testa 
2005; Mure et al. 2010).   
EIF4E -1.654 EIF4E encodes eIF4E. This 
protein participates in triggering 
translation of capped mRNAs 
(Mamane et al. 2004).  
In normal brain tissue, eIF4E 
was only expressed in pyramid 
neurons. However, high 
expression level of eIF4E was 
detected in malignant 
glioblastomas (Gu et al. 2005).  
Two reports showed that 
eIF4E promoted glioma cell 
growth under normaxia. But 
this protein sensitized glioma 
cell to radiation therapy under 
hypoxic condition, due to 
increased hypoxia-induced cell 
death (Dubois et al. 2009; 
Rouschop et al. 2011).  
Substrates of class I PI3K/Akt/mTOR axis pathway 
ACLY 1.592 ACLY encodes ACL enzyme 
which participates in glucose-
dependent lypogenesis process 
and is responsible for 
generation of acetyl- CoA from 
citrate. The activity of ACL is 
activated by Akt in response to 
insulin or growth factor 
stimulation. The mRNA level of 
ACL can be up-regulated in 
response to insulin and is class I 
PI3K/Akt signaling-dependent 
(Hatzivassiliou et al. 2005).   
The migration and 
invasiveness of glioblastoma 
cells was reported to depend 
on ACL-induced glycolysis. 
High level of ACL was found 
to be accumulated in 
pseudopodia (Beckner et al. 
2010).   
 
CHUK  -1.349 CHUK encodes IKK-α, which 
acts to dissociate of NF-кB 
from inhibitors of NF-кB (IкB) 
through phosphorylation of IкB. 
IKK-α is involved in 
regulation of Notch1/Akt-
induced cell migration and 
invasion (Zhang et al. 2012).   
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This results in activation of NF-
кB transcription factor, which  
targets genes associated with 
regulation of immune system, 
cellular survival, proliferation 
and differentiation (Hayden and 
Ghosh 2012). 
FOXO1 2.116 FOXO1 encodes FoxO1, a 
transcription factor. The 
FoxO1a can up-regulate or 
down-regulate its target genes, 
depending on its binding 
partner. Akt acts as the negative 
regulator of FoxO1a in response 
to the stimulation of growth 
factors, hormone and cytokines 
(van der Vos and Coffer 2011).  
FoxO1a acts as a tumour 
suppressor and its activity is 
often abrogated by active class 
I PI3K/Akt signaling in 
gliomas (Ramaswamy et al. 
2002; Choe et al. 2003). 
GSK3B 1.381 GSK3B encodes GSK-3β. The 
GSK-3β maintains neural 
progenitor at undifferentiated 
state, inhibits migration and 
polarization of neurons, and 
abrogates axon outgrowth 
through regulation of its 
downstream targets such as 
transcription factors and 
microtubule-associated 
proteins, and ubiquitin-protease 
system. Akt and p38MAPK act 
as negative regulators of GSK-
3β (Hur and Zhou 2010).       
   
Phosphorylated GSK-3β on 
Ser9, indicating inactivation of 
GSK-3β, was moderately to 
strongly expressed in a high 
percentage (71%) of GBM 
(Otero and Tihan 2011).  
GSK-3β was reported to 
induce differentiation of 
glioblastoma cells (Li et al. 
2010). In addition, this protein 
promotes proliferation and 
maintains survival in glioma 
through inhibition of Rb and 
p53 pathways (Miyashita et al. 
2009).   
There is conflicting data 
regarding the role of GSK-3β 
in glioblastoma stem cells. On 
one hand, active EGFR/Akt 
signaling-mediated inhibitory 
phosphorylation of GSK-3β 
was found to promote 
proliferation of neurosphere 
cells (Howard et al. 2010). On 
the other hand, down-
regulation of GSK3B 
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expression or GSK-3β activity 
reduced GBM stem cell pool 
and induced differentiation and 
apoptosis (Korur et al. 2009). 
PRKCI -1.822 PRKCI encodes atypical protein 
kinase C iota (PKCι), which 
promotes cell polarity, 
proliferation and survival. This 
protein kinase is activated by 
PtdIns(3,4,5)P3 and PDK1 
(Fields and Regala 2007).  
PKCι was reported to promote 
proliferation, survival and 
invasion of glioma cells 
(Baldwin et al. 2010; Desai et 
al. 2011; Desai et al. 2012).  
RAC1 1.465 RAC1 encodes Rac1, which 
belongs to Rho GTPase family 
and acts to promote cytoskeletal 
rearrangement and hypoxia-
induced angiogenesis (Kaibuchi 
et al. 1999; Cantley 2002; Xue 
et al. 2011)   
Decreased Rac1 expression 
was observed in astrocytic 
gliomas (Khalil and El-Sibai 
2012).  
The functions of Rac1 are 
involved in enhancing 
tumourigenesis, altering 
cellular morphology, 
promoting cell migration and 
invasion (Salhia et al. 2005; 
Nakada et al. 2006; Feng et al. 
2011).    
Rac1 activity is positively 
correlated with self-renewal, 
proliferation, invasion, and 
migration of glioma stem cells 
(Yoon et al. 2011).   
RHOA 1.300 RHOA encodes RhoA GTPase 
which is involved in regulation 
of cell morphology and 
cytoskeletal rearrangement, 
such as stress fiber induction, 
focal adhesion, cellular division 
and movement, smooth muscle 
contraction and neurite 
retraction. With regard to the 
regulators of RhoA, guanine 
nucleotide exchange factors 
(GEFs) activator of RhoA 
whereas GAPs and GDP 
dissociation inhibitor (GDI) act 
The expression level of RhoA 
is positively correlated with 
the pathological grades of 
astrocytomas (Yan et al. 
2006).  
Although RhoA promotes cell 
migration in normal cells, this 
protein impairs cell motility in 
gliomas (Cachero et al. 1998). 
In addition RhoA is involved 
in regulation of radioresistant 
phenotype in glioblastoma 
(McLaughlin et al. 2006).   
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as inhibitors of RhoA (Kaibuchi 
et al. 1999). Class I PI3K 
negatively regulates RhoA 
through its downstream 
PtdIns(3,4,5)P3/ASAP3 
signaling (Krugmann et al. 
2002).     
 
  
STAT3 1.603 STAT3 encodes Stat3 
transcription factor, which 
regulates many cellular 
activities, including 
proliferation, differentiation, 
survival and inflammation.  
Many proteins, including RTKs, 
cytokine receptor, Src proteins, 
Jak2, mTOR and p38MAPK, 
were reported to regulate Stat3 
in response to stimulation of 
growth factors, cytokinases and 
hormones (Yokogami et al. 
2000; Xu et al. 2003; Yue and 
Turkson 2009).   
   
 
Constitutive activation of Stat3 
protein in high-grade 
glioblastoma in the absence of 
molecular alteration was 
reported. The functions of 
Stat3 in glioma and 
glioblastoma are promoting 
cell proliferation and survival, 
and probably involved in 
angiogenesis (Liu et al. 2010).    
Stat3 activation played a 
critical role in the maintenance 
of GBM stem cell properties, 
including proliferation, self-
renewal and multipotency. In 
addition, Stat3 in stem cells 
derived from GBM was found 
to inhibit immune response, 
particularly T cell-associated 
activities (Liu et al. 2010; Sai 
et al. 2012).  
Class I PI3K signaling network 
FKBP1A 1.172 FKBP1A encodes FK506 
binding protein (FKBP) 1A, 
12kDa (FKBP12), which 
belongs to FKBP protein 
family. FKBP12 can bind to 
some immunosuppressive drugs 
such as Rapamycin and FK506. 
FKBP12 also binds to 
ryanodine receptors (RyRs), 
which are intracellular calcium 
release channels in muscle, for 
enhancing RyRs stability and 
promoting channel gating. 
FKBP12 inhibits TGF-β 
Up-regulation of genes 
encoding components of 
EGFR/FKBP12/HIF-2α core 
signaling was common in 
malignant childhood 





signaling through interacting 
with TGF-β receptor type I 
(Kang et al. 2008).  
Translation initiation factor 
EIF1 1.442 EIF1 encodes eIF1, serving as a 
subunit of 43S pre-initiation 
complex which binds to 5’ 
capped mRNA and is  required 
for translation initiation  (Preiss 
and Hentze 2003).  
N/A 
EIF1AX -1.714 EIF1AX  encodes X 
chromosome-linked eIF1A, 
serving as a subunit of 43S pre-
initiation complex which binds 
to 5’ capped mRNA and is  
required for translation 
initiation  (Preiss and Hentze 
2003).  
N/A 





onto 40S ribosome. eIF2A is 
suggested to participates in 
initiating translation of a small 
subset of mRNAs (Zoll et al. 
2002).   
N/A 
EIF2B1 -2.190 EIF2B1 encodes the α subunit 
of eIF2B, a GEF. eIF2B acts to 
convert inactive state of GDP 
bound eIF2 into active state  of 
GTP-bound eIF2, which is a 
subunit of 43S pre-initiation 
complex (Preiss and Hentze 
2003; Mohammad-Qureshi et 
al. 2008).  
N/A 
EIF2B2 -2.551 EIF2B2 encodes the β subunit 
of eIF2B. The function of 
eIF2B is described as 
aforementioned (see EIF2B1). 
N/A 
EIF2B3 -1.926 EIF2B3 encodes the γ subunit 




eIF2B is described as 
aforementioned (see EIF2B1). 
EIF2B4 -1.459 EIF2B4 encodes the δ subunit 
of eIF2B The function of eIF2B 
is described as aforementioned 
(see EIF2B1). 
N/A 
EIF2C1 1.763 EIF2C1 encodes eIF2C, 
isoform 1, which plays a critical 
role in RNA interference and 
inhibit mRNA translation (Doi 
et al. 2003).   
N/A 
EIF2C3 1.438 EIF2C3 encodes eIF2C3, 
isoform 3, which plays a critical 
role in RNA interference and 
acts to inhibit mRNA 
translation (Meister et al. 2004).  
N/A 
EIF2S1 -2.288 EIF2S1 encodes the α subunit 
of eIF2 (eIF2α), which is a 
heterotrimeric protein and 
serves as a subunit of 43S pre-
initiation complex which is 
required for translation 
initiation (Preiss and Hentze 
2003).  
eIF2α was reported to promote 
the growth of malignant 
glioma cells (Kambara et al. 
2005). Some drugs, such as 
Candidaspongiolide and 
Cannabioid, were reported to 
induce apoptosis of glioma 
cells in vitro through eIF2α-
dependent ER stress or 
caspase12 pathway 
(Trisciuoglio et al. 2008; 
Salazar et al. 2009).  
EIF2S2 -1.365 EIF2S2 encodes the β subunit 
of eIF2 (eIF2β). The eIF2β is 




the γ subunit of eIF2 (eIF2γ)  
initiation (Preiss and Hentze 
2003).   
N/A 
EIF2S3 -1.363 EIF2S2 encodes eIF2γ, which  
interacts with both GTP and 
Met-tRNAi
Met
 (Preiss and 
Hentze 2003).   
N/A 
EIF3A -1.572 EIF3A encodes the a subunit of 




subunits comprising eIF3 
(Hershey 2010). eIF3 is a 
subunit of 43S pre-initiation 
complex which is required for 
translation initiation (Preiss and 
Hentze 2003). eIF3a is 
dispensible for eIF3-based 
translation initiation. eIF3a is 
involved in regulation of G1/S 
phase transition through 
regulation of a small number of 
specific mRNAs, such as 
p27
kip1
 (Saletta et al. 2010).   
EIF3B -2.253 EIF3B encodes the b subunit of 
eIF3. The eIF3 is a subunit of 
43S pre-initiation complex 
which is required for translation 
initiation (Preiss and Hentze 
2003; Hershey 2010). 
It was reported that inhibition 
of EIF3B expression 
accumulated human 
glioblastoma cells at G0/G1 
phase and induced apoptosis 
(Liang et al. 2012).  
EIF3D -1.696 EIF3D encodes the d subunit of 
eIF3. The eIF3 is a subunit of 
43S pre-initiation complex 
which is required for translation 
initiation (Preiss and Hentze 
2003; Hershey 2010). 
N/A 
EIF3E -1.672 EIF3E encodes the e subunit of 
eIF3 (eIF3e). The eIF3e subunit 
was reported to arrest mRNA 
translation through binding to 
p56 interferon-induced protein 
(Hershey 2010).   
N/A 
EIF3G -1.215 EIF3G encodes the g subunit of 
eIF3 (eIF3g). The eIF3g subunit 
promotes translation by 
interaction with poly(A)-
binding protein-interacting 
protein 1 (PAIP-1) that acts to 
enhance translation initiation 
(Martineau et al. 2008).   
N/A 
EIF3H -1.347 EIF3H encodes the h subunit of 
eIF3 (eIF3h). The function of 




malignancy phenotype and 
acceleration of mRNA 
translation in cancer (Hershey 
2010).    
EIF3I -1.515 EIF3I encodes the i subunit of 
eIF3 (eIF3i). Like eIF3h, eIF3i 
is also involved in malignancy 
phenotype and acceleration of 
mRNA translation in cancer 
(Hershey 2010). Besides, eIF3i 
was reported to inhibit TGFβ 
signaling through interaction 
with type II TGFβ receptor 
(Choy and Derynck 1998).  
N/A 
EIF3J -2.040 EIF3I encodes the j subunit of 
eIF3 (eIF3j). eIF3j acts to 
transfer eIF3 to 40S ribosome, 
stabilize the interaction between 
eIF3 and 40S ribosome, and 
regulate the binding of mRNA 
to 40S ribosome (Fraser et al. 
2004; Fraser et al. 2007).  
N/A 
EIF4A1 -1.871 EIF4A1 encodes eIF4A isoform 
1 (eIF4AI). There are three 
eIF4A isoforms, including 
eIF4AI, eIF4AII and eIF4AIII. 
eIF4A displays RNA-dependent 
ATPase activity and serves as a 
helicase to unwind secondary 
structure of 5’capped mRNA in 
an ATP-dependent manner. The 
helicase activity of eIF4A is 
activated by eIF4B. eIF4A is 
often in complex with eIF4E 
and eIF4G to form eIF4F 
complex, which is required for 
cap-dependent translation 
(Gingras et al. 1999; Rogers et 
al. 2002).  
N/A 
EIF4A3 -1.255 EIF4A3 encodes eIF4A isoform 
3 (eIF4AIII). The functions of 




aforementioned (see EIF4A1).   
PABPC1 -1.228 PABPC1 encodes PABP1, 
which acts to enhance the 
initiation step of cap-dependent 
translation by binding to the 3’ 
end poly(A) tail of capped 
mRNA (Sachs and Varani 
2000; Khaleghpour et al. 2001).  
N/A 
PAIP1 1.345 PAIP1 encodes PAIP-1, which 
acts to enhance initiation step of 
cap-dependent translation by 
binding to PABP-1 
(Khaleghpour et al. 2001). 
N/A 
PAIP2 1.764 PAIP2 encodes PAIP-2, which 
acts to abrogate initiation step 
of cap-dependent translation by 
competing with PAIP1 for 
binding to PABP1 
(Khaleghpour et al. 2001). 
N/A 
Pro-survival or anti-apoptosis 
BCL2 1.918 BCL2 encodes Bcl-2 pro-
survival factor which serves as 
a regulator of mitochondrial 
change during cell death 
(Skommer et al. 2007).  
 
Bcl-2-dependent pro-survival 
activity plays a key role in the 
resistance of glioma cells to 
chemotherapy and radiation 
therapy. In addition, Bcl-2 
promotes the proliferation and 
progression of gliomas. 
However, up-regulation of 
Bcl-2 is more common in 
benign gliomas than malignant 
glioblastomas, presumably due 
to its up-regulation of p27
kip1
 
cell cycle inhibitor, inhibition 
of phosphorylated Rb and pro-
apoptotic activity when 
binding to Nur77/TR3 protein 
(Kouri et al. 2012).  
BCL2L1 1.536 BCL2L1 encodes Bcl-xL pro-
survival factor, which belongs 
to Bcl-2 protein family. Bcl-xL 
serves as a regulator of 
mitochondrial change during 
Bcl-xL was reported to 
promote survival and 
invasiveness of high-grade 
gliomas (Weiler et al. 2006).   
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cell death (Skommer et al. 
2007).   
MCL1 1.734 MCL1 encodes myeloid cell 
leukemia sequence 1 (Mcl-1) 
pro-survival factor which 
belongs to Bcl-2 protein family. 
Mcl-1 serves as a regulator of 
mitochondrial change during 
cell death (Skommer et al. 
2007). Transcription of MCL1 
gene is stimulated by class I 
PI3K/Akt signaling (Wang et 
al. 1999). PKC, Erk and GSK3 
have been reported to be the 
regulators of Mcl-1 at post-
translational level. The former 
two kinases acted as activator of 
Mcl-1 whereas the latter one 
acted as inhibitor of Mcl-1 
(Domina et al. 2004; Maurer et 
al. 2006).   
Mcl-1 was reported to 
maintain survival of high-
grade gliomas (Sheng et al. 
2010).  
Bone morphogenetic receptor IB/Smad signaling 
BMPR1B -1.320 BMPR1B encodes type IB 
BMP receptor, which belongs to 
TGFβ superfamily. BMP exerts 
its cellular effect through 
binding to both type I and II 
BMP receptors. The activated 
BMP receptors transduce 
signals to, or activate, 
Smad1/5/8 pathway-regulated 
transcription of genes. BMP 
signaling is involved in 
regulation of early embryonic 
development, cytoskeletal 
rearrangements, quiescence and 
angiogenesis (Sieber et al. 
2009).   
Higher expression level of type 
IB BMP receptor was detected 
in high-grade glioblastomas 
than that in low-grade gliomas, 
suggesting that this protein 
might contribute to malignant 
phenotype of gliomas (Yamada 
et al. 1996).   
BMP signaling pathway was 
reported to promote 
differentiation of CSCs derived 
from a subgroup of 
glioblastomas (Lee et al. 
2008).  
Wnt/beta-catennin 
CTNNB1 4.145 CTNNB1 encodes β-catenin, 
which serves as an important 
component of Wnt core 
Overexpression of β-catenin 
and other member proteins of 




signaling was reported to exert 
dual effects on stem cells. On 
one hand, this pathway acted to 
maintain self-renewal and 
pluripotent properties of ES 
cells and somatic SCs. On the 
other hand, Wnt//β-catenin 
signaling triggered 
differentiation and regulated 
lineage commitment of ES cells 
(Miki et al. 2011).   
 
detected in GBM (Nager et al. 
2012).  
Wnt/β-catenin was reported to 
contribute to promoting 
proliferation and the resistance 
mechanism of glioma cells to 
chemotherapy and radiation 
therapy. Besides, active β-
catenin may up-regulate 
invasiveness and EMT in 
response to growth factor 
stimulation (Nager et al. 2012; 
Shi et al. 2012).   
Activation of Wnt/ β-catenin 
signaling was found to 
promote self-renewal and 
proliferation, and prevent 
differentiation of glioma CSCs 
(Nager et al. 2012).  
MAPK pathway 
MAP2K1  1.308 MAP2K1 encodes Mek1 
kinase, which serves as an 
important component of 
Raf/Mek/Erk axis pathway. 
RTKs and GPCRs often serve 
as activator of Raf/Mek/Erk 
pathway through Ras.  
This pathway is involved in 
regulation of  transcription, 
proliferation, survival and cap-
dependent mRNA translation 
(Roux and Blenis 2004). 
However, excessive activation 
of Raf/Mek/Erk signaling was 
reported to cause senescence-
like growth inhibition in normal 
human fibroblasts and 
astrocytes. This senescence-like 
growth arrest was mediated by 
activation of either Mek1 or 
Raf1 (Fanton et al. 2001).  
Active B-Raf/Mek/Erk 
signaling, which contributes to 
promoting proliferation and 
survival of tumour cells, is 
much more common in 
paediatric benign glioma than 








MAPK1 1.461 MAPK1 encodes Erk2 kinase, 
which serves as an important 
component of Raf/Mek/Erk axis 
pathway. RTKs and GPCRs 
often serve as activator of 
Raf/Mek/Erk pathway through 
Ras.  
This pathway is involved in 
regulation of  transcription, 
proliferation, survival and cap-
dependent mRNA translation 
(Roux and Blenis 2004).   
Activation of Erk contributes 
to proliferation, survival, 
radioresistance, invasion and 
migration of glioma cells 
(Pelloski et al. 2006; Song and 
Moon 2006; Hargrave 2009; 
Das et al. 2011).  
 
 
MAPK14 -1.335 MAPK14 encodes p38 MAPK 
protein, which is frequently 
activated by cytokines and 
various stresses such as hypoxia 
and UV irradiation. P38 MAPK 
is involved in regulation of 
inflammatory and immune 
responses, transcription and 
cap-dependent mRNA 
translation (Roux and Blenis 
2004) .  
p38 MAPK exerts dual effects 
on glioma. On one hand, 
p38MAPK was reported to 
antagonize activities against 
glioma progression by 
enhancement of 
chemosensitivity and 
inhibition of growth and 
proliferation, and induction of 
apoptosis (Amantini et al. 
2007; Yao et al. 2008; Yao et 
al. 2008; Lou et al. 2009). On 
the other hand, this protein was 
reported to reduce patients’ 
survival time, promote 
invasion/migration, and up-
regulate VEGF secretion (Song 
and Moon 2006; Yoshino et al. 
2006; Demuth et al. 2007).    
RAF1 1.659 RAF1 encodes Raf1 (also 
termed c-Raf) kinase, which 
serves as an important 
component of Raf/Mek/Erk axis 
pathway. RTKs and GPCRs 
often serve as activator of 
Raf/Mek/Erk pathway through 
Ras. This pathway is involved 
in regulation of  transcription, 
proliferation, survival and cap-
dependent mRNA translation 
(Roux and Blenis 2004). 
The level of Raf1 expression is 
associated with the poor 
outcome of patients with 
malignant glioblastomas 
(Hagemann et al. 2009).   
Active Raf1 was reported to 
positively regulate invasion 
and tumourigenesis of gliomas. 
But paradoxically, Raf1 could 
arrest cell cycle though up-






However, excessive activation 
of Raf/Mek/Erk signaling was 
reported to cause senescence-
like growth inhibition in normal 
human fibroblasts and 
astrocytes. This senescence-like 
growth arrest was mediated by 
activation of either Mek1 or 
Raf1 (Fanton et al. 2001). 
p16
Ink4a
/pRb pathways (Fanton 
et al. 2001; Lyustikman et al. 
2008; Hagemann et al. 2009; 
Das et al. 2011).  
RPS6KA
1 
-1.333 RPS6KA1 encodes RSK, 
isoform 1 (RSK1).  There are 
four isoforms of RSKs, 
including RSK1, RSK2, RSK3 
and RSK4. RSKs promote 
cellular proliferation and 
survival, and regulate 
transcription. Erk and PDK1 
were identified to be the 
activators of RSKs (Roux and 




-1.589 RPS6KA2 encodes RSK2.  
RSKs promote cellular 
proliferation and survival, and 
regulate transcription. Erk and 
PDK1 were identified to be the 
activators of RSKs (Roux and 
Blenis 2004). 
N/A 
FOS 7.450 FOS encodes c-Fos which 
belongs to Fos protein family. 
Fos family is a subunit of AP-1 
heterodimer. Another subunit of 
AP-1 is Jun protein family. AP-
1 regulates differentiation, 
proliferation, survival and 
apoptosis through up-regulating 
or down-regulating 
transcription of its target genes 
after AP-1 receives stimuli such 
as cytokines, growth factors and 
stress  (Hess et al. 2004). c-Fos 
was reported to be activated by 
Ras and components of MAPK 
pathway, including RSK, Erk 
The expression level of c-Fos 
was found to be positively 
correlated with the malignant 
degree of glioma (Yu et al. 
1999; Assimakopoulou and 
Varakis 2001).  
Abberent methylation of FOS 
in glioma has been observed 
and supposed to promote 
glioma progession (Uyeno et 
al. 1996).  
c-Fos plays a role in positively 
regulating proliferation of 
glioma cells (Koul et al. 2007).  
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and Jnk (Deng and Karin 1994; 
Roux and Blenis 2004) .   
JUN 1.395 JUN encodes c-Jun, which 
serves as a subunit of AP-1 
heterodimer. AP-1 regulates 
differentiation, proliferation, 
survival and apoptosis through 
up-regulating or down-
regulating transcription of its 
target genes after AP-1 receives 
stimuli such as cytokines, 
growth factors and stress  (Hess 
et al. 2004). C-Jun was reported 
to be regulated by Jnk and RSK 
(Roux and Blenis 2004). The 
functions of c-Jun are involved 
in regulation of survival, 
apoptosis, regeneration and 
proliferation of cells (Herdegen 
et al. 1997; Behrens et al. 
1999).   
High expression level of 
phosphorylated c-Jun was 
commonly detected in high-
grade glioblastomas but rarely 
in low-grade gliomas, 
indicating that phosphorylated 
c-Jun was positively correlated 
with malignant degree of 
gliomas (Assimakopoulou and 
Varakis 2001).   
SOCS6 1.319 SOCS6 encodes SOCS6 
protein, which belongs to SOCS 
protein family. SOCS family 
serves as a subunit of E3 
ubiquitin ligase which degrades 
target proteins. In addition, 
SOCS family functions in 
inactivation of Jak/Stat pathway 
(Akhtar and Benveniste 2011) 
However, SOCS6 was reported 
to inhibit KIT-mediated Erk and 
p38 MAPK pathways, but not 
Akt and Stat pathways (Bayle et 
al. 2004; Zadjali et al. 2011).  
N/A 
Sodium channel 
ACCN1 2.253 ACCN1 encodes acid-sensing 
ion channel-2 (ASIC2) which 
belongs to degenerin/epithelial 
sodium channel (DEG/ENaC) 
superfamily. ASIC2 serves as a 




acts to sense sour in taste buds 
and regulates acid-dependent 
nociception in central and 
peripheral nervous system 
(Shimada et al. 2004).  
CNKSR3 1.555 CNKSR3 encodes CNKSR 
family member 3, which is 
responsible for ENaC-
dependent transepithelial 
sodium transport and is 
involved in regulation of Mek 
activity. Expression of 
CNKSR3 gene is modulated by 
mineralocorticoid receptor in 
kidney in response to 
aldosterone stimulation (Ziera 
et al. 2009). 
N/A 
NEDD4 1.750 NEDD4 encodes neural 
precursor cell expressed, 
developmentally down-
regulated 4 (NEDD4) protein. 
NEDD4 acts to inhibit the 
activity of sodium channel in 
epithelial and neural cells in 
response to elevated sodium 
concentration within cells. In 
addition, NEDD4   serves as an 
ubiquitin ligase for 
ubiquitylation and degradation 
of the targeted proteins, such as 
TGFβ-sepcific Smad2 
(Dinudom et al. 1998; Goulet et 
al. 1998; Kuratomi et al. 2005).   
N/A 
Erk or Jun MAPK; AP-1 activity for proliferation, differentiation and neuronal 
transduction 
PRKCD 1.835 PRKCD encodes novel PKCδ 
serine/threonine kinase. PKCδ 
acts to arrest growth, promote 
differentiation and apoptosis, 
abrogate epithelial chloride 
secretion, inhibit Stat signaling, 
and activate AP-1 transcription 
and Mek/Erk pathway. Src and 
Previous studies showed that 
PKCδ induced apoptosis, 
inhibited migration, but 
promoted invasion of glioma 
(Lu et al. 2007; Reyland 2007; 
Kim et al. 2008; Sarkar and 
Yong 2010; Ziv-Av et al. 
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Abl were identified as 
activators of PKCδ (Gschwendt 
1999; Tang et al. 2010).  
 
2011).  
PKCδ played a role in 
expanding glioma stem cell 
pool and up-regulating 
expression levels of self-
renewal-related proteins upon 
radiation treatment (Kim et al. 
2011).  
PRKD3 1.265 PRKD3 encodes PKD3, which 
is a member of PKD protein 
family. PKDs act to inhibit cell 
motility, regulate transcription, 
maintain oxidative stress-
regulated cell survival, 
modulate immune responses of 
T and B cells, and Golgi 
vesicle-associated activities. 
Many extrcellular substances 
such as hormones, growth 
factors and neurotransmitters 
can activate PKDs through 
receptor/PLC/PtdIns(4,5)P2/dia
cylglycerol (DAG)/PKC 
pathway (Fu and Rubin 2011).  
N/A 
Integrin pathway 
ITGA5 1.573 ITGA5 encodes the α5 subunit 
of integrin receptor, which is a 
heterodimer composed of 
multiple α and β subunits. The 
main function of integrin 
receptors is to regulate the cell-
cell or cell-ECM (extracellular 
matrix) adhesion, migration, 
invasion and actin-based 
cytoskeletal rearrangement 
(Miyamoto et al. 1995). 
Besides, integrin receptors are 
involved in regulation of cell 
growth, embryonic 
development and angiogenesis 
through their downstream 
adaptor proteins (Cox et al. 
High expression levels of 
integrin receptors α5β3 and 
α5β5 in tumour cells and blood 
vessels in gliomas have been 
described. These integrin 
receptors have been reported to 
positively regulate adhesion, 
migration and angiogenesis  of 
malignant glioblastomas and 
contribute to radioresistant 






ITGB1 1.334 ITGB1 encodes β1 subunit of 
integrin receptor, which is a 
heterodimer composed of 
multiple α and β subunits. The 
main function of integrin 
receptors is to regulate the cell-
cell or cell-ECM adhesion, 
migration, invasion and actin-
based cytoskeletal 
rearrangement (Miyamoto et al. 
1995). Besides, integrin 
receptors are involved in 
regulation of cell growth, 
embryonic development and 
angiogenesis through their 
downstream adaptor proteins 
(Cox et al. 2010).  
Recently, integrin receptor 
α6β1 has found to be 
abundantly expressed in 
glioma stem cells and be 
involved in up-regulation of 
self-renewal, proliferation and 
tumourigenic capabilities 
(Lathia et al. 2010).      
IGFBP10  1.171 IGFBP10 encodes IGFBP10 
protein, also named Cyr61, 
which promotes cell 
proliferation in response to 
growth factor stimulation and 
cell adhesion through 
interaction with integrin 
receptors. Other actions exerted 
by Cyr61 include cartilage cell 
differentiation, angiogenesis, 
survival and apoptosis. 
Expression of IGFBP10 gene is 
predominantly activated in 
response to growth factors and 
TGF-β and is through RhoA 
GTPase and p38 MAPK 
pathways (Chen and Du 2007).   
High expression level of Cyr61 
was detected in gliomas (Xie et 
al. 2004). Cyr61 was reported 
to promote growth, invasion, 
migration, progression and 
perhaps chemoresistant 
mechanism of gliomas (Xie et 
al. 2004; Young and Van 
Brocklyn 2007; Le Mercier et 
al. 2008; Young et al. 2009; 
Goodwin et al. 2010).   
RRAS 1.770 RRAS encodes ras-related 
protein (RRAS), which is a 
member of Ras GTPase family. 
RRAS acts to activate integrin 
receptor and regulate actin-
based cytoskeletal arrangement, 
such as cell spreading, 




phagocytosis, in part through its 
substrate phospholipase C 
epsilon type (PLC-ε) (Ada-
Nguema et al. 2006).  
Serine/threonine phosphatase 
PPP1CC -1.266 PPP1CC encodes the catalytic 
subunit of protein phosphatase 
1 (PP1), γ isoform (PP1γ).  
PP1 is a heterodimer composed 
of a catalytic and a regulatory 
subunit. The catalytic subunit of 
PP1 acts to dephosphorylate its 
target kinases from 
serine/threonine residues. PP1 
is involved in regulation of 
various cellular processes, such 
as glycogen synthesis, 
cytoskeletal organization and 
cell proliferation, by its 
catalytic subunit-dependent 
dephosphorylation of its target 
proteins and the location of its 
regulatory subunit (Cohen 
2002).   
PP1 was report to promote 
progression of glioma by 
degradation of glycogen into 
glucose under glucose 
deprivation condition (Kelsall 
et al. 2011).  
PPP1R10 -1.337 PPP1R10 encodes the 
regulatory subunit 10 of PP1, 
which is distributed in nucleus 
of all cell types. PP1 that 
contains the regulatory subunit 
10 exerts its action in specific 
RNA-binding (Cohen 2002; 




-1.398 PPP1R12A encodes the 
regulatory subunit 12A of PP1, 
which is distributed in smooth 
muscle and regulates smooth 
muscle relaxation through 
dephosphorylation of myosin 




-2.333 PPP1R14B encodes the 
regulatory subunit 14B of PP1, 




and acts to inhibit PP1 activity 
(Cohen 2002).  
PPP1R3
C 
7.969 PPP1R3C encodes the 3C 
regulatory subunit of PP1, 
which is ubiquitously expressed 
in all types of cells, particularly 
in liver and muscle cells and 
functions in promoting 
glycogen synthesis (Cohen 
2002).  
N/A 
PPP1R7 -1.575 PPP1R7 encodes the regulatory 
subunit 7 of PP1, which is 
ubiquitously expressed in 
nucleus of all types of cells and 
promotes cell progression from 
metaphase to anaphase (Cohen 
2002).  
N/A 
PPP2CB 1.235 PPP2CB encodes protein 
phosphatase 2, catalytic subunit, 
beta isoform (PP2Ac-β), which 
is widely distributed, 
particularly in brain and heart. 
PP2A acts to arrest G2/M phase 
transition, and inhibit cap-
dependent translation and signal 
transductions, promote 
apoptosis through 
dephosphorylation of protein 
kinases (such as mTOR, Erk 
and caspase-3) on 
serine/threonine residues 
(Janssens and Goris 2001).  
Evidence suggested that PP2A 
might induce differentiation 
and/or death of GSCs through 
decreasing Akt 
phosphorylation and increasing 
the expression level of nuclear 
receptor corepressor (N-CoR) 
(Lu et al. 2010).  
PPP2R3
B 
-1.583 PPP2R3B encodes protein 
phosphatase 2, regulatory 
subunit B'', β isoform (also 
named PR48). PR48 is 
distributed in nucleus in 
mammalian cells and acts to 
arrest G1/S transition (Yan et 
al. 2000).  
 
Evidence suggested that PP2A 
played a role in decreasing Akt 
phosphorylation and increasing 
the expression level of N-CoR 
which is overexpressed in 
CSCs derived from GBM (Lu 
et al. 2010). In addition, PP2A 
or PP1 might be involved in 
regulation of ethanol-inhibited 
the import of adenosine into 
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glioma cells (Coe et al. 1996).   
PPM1J -1.418 PPM1J encodes protein 
phosphatase 2C, zeta isoform 
(PP2C-ζ), which is a member of 
PP2C serine/threonine protein 
phosphatase family. PPM1J is 
involved in degradation of 
proteins through binding to 
ubiquitin conjugating enzyme 9 
(Kashiwaba et al. 2003).  
N/A 
Cytoskeletal rearrangement for cell migration, cell division and intracellular 
trafficking 
FNBP1 1.874 FNBP1 encodes formin binding 
protein 17 (FBP17) protein, 
which is a member of CIP4 
subfamily of F-BAR protein 
family. FBP17 is the binding 
partner of three fomin proteins, 
which are mDia1, mDia2 and 
DAAM1. FBP17 is required for 
regulation of formin-based actin 
polymerization and is involved 
in many cellular processes, such 
as motility, division and 
endocytosis/phagocytosis 
(Aspenstrom 2010).   
N/A 
RHOC 1.477 RHOC encodes ras homolog 
gene family (Rho), member C 
(RhoC), which is a member of 
Rho GTPase protein family. 
RhoC is widely distributed in 
cytosol and acts to promote cell 
motility (Wennerberg and Der 
2004; Wheeler and Ridley 
2004).   
A study suggested that RhoC 
was involved in regulation of 
microRNA-10b-induced 
invasion of glioma (Sasayama 
et al. 2009).   
RHOJ -1.559 RHOJ encodes Rho, member J 
(RhoJ), which is a member of 
Rho GTPase family.  RhoJ 
mediates migration, tubule 
generation and actomyosin 
contractility of endothelial cells 





endocytosis, and adipocyte 
differentiation in response to 
peroxisome proliferator-
activated receptor γ (PPARγ) 
stimulation (de Toledo et al. 
2003; Nishizuka et al. 2003; 
Kaur et al. 2011).   
RHOQ 2.132 RHOQ encodes Rho, member Q 
(RhoQ, also named TC10), 
which is a member of Rho 
GTPase family. TC10 is 
involved in actin-based 
cytoskeletal arrangement and 
GLUT4 transportation in 
adipocytes in response to 
insulin stimulation. TC10 also 
plays a role in regulation of 
neural development and 
plasticity (Chiang et al. 2002; 
Wennerberg and Der 2004).   
N/A 
RHOT1 1.540 RHOT1 encodes Rho, member 
T1 (RhoT1, also named Miro-
1), an atypical Rho GTPase. 
Miro-1 is involved in apoptosis 
induction and mitochondrial 
homeostasis and trafficking 
(Fransson et al. 2003; Fransson 
et al. 2006).    
N/A 
RND3 1.863 RND3 encodes Rho family 
GTPase 3 (Rnd3), also termed 
RhoE. Rnd3/RhoE was reported 
to inhibit RhoA-modulated 
cellular events such as motility, 
focal adhesion and cell 
morphology, and down-regulate 
cyclinD1-dependent cell cycle 
progression, and act as a tumour 
suppressor (Riento et al. 2005).   
RhoE was found to act as 
tumour suppressor in 
glioblastoma by disruption of 
cytoskeletal arrangement, 
apoptosis induction, and 
growth arrest (through 
RhoE/Erk/cycln D1/Rb 
pathway) (Poch et al. 2007).  
SRF -1.219 SRF encodes serum response 
factor (SRF) transcription 
factor, which regulates several 
cellular functions including 
SRF was found to regulate 
migration of glioma, in part, by 
binding to RTVP-1 promoter 
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contractility, motility, survival, 
synaptic activity and immune 
response through transcription 
of its target genes. There are 
two pathways which regulate 
SRF transcription activity, 
which are RTK/MAPK/ELK1 
and Rho pathways (Miano 
2010).   
(Ziv-Av et al. 2011).    
TRIP10 1.703 TRIP10 encodes thyroid 
hormone receptor interactor 10 
(Trip10). The functions of 
Trip10 are involved in 
translocation of GLUT4 glucose 
transporter, endocytosis, 
cytoskeletal rearrangement, cell 
cycle progression and survival, 
all of which is cell-specific 
(Hsu et al. 2011).    
N/A 
Insulin-related glucose uptake 
STX4 1.974 STX4 encodes syntaxin 4. The 
syntaxin 4 promotes exocytosis 
or secretion of insulin from 
pancreatic β islet cells and 
insulin-induced translocation of 
the glucose transporter GLUT4 
which is attached on vesicles 
from cytosol to cell surface, 
which allows glucose uptake in 
skeletal muscle cells and 
adipocytes (Jewell et al. 2010). 
N/A 
STXBP4 -1.855 STXBP4 encodes synip, which 
functions as a negative 
regulator of syntaxin4 through 
binding to syntaxin 4. The 
insulin/class I PI3K/Akt-
mediated phosphorylation of 
synip results in dissociation of 
synip from syntaxin 4. 
Subsequently, the free syntaxin 
can recruit the glucose 
transporter GLUT4 attached on 




surface, which allows glucose 
uptake in adipocytes (Yamada 
et al. 2005).  
TGFBR2 -1.495 TGFBR2 encodes TGFβ 
receptor type II (TβRII). The 
TGFβ-RII activates its 
downstream Smad2/3 signaling 
through phosphorylation of 
TGFβ receptor type I (TβRI). 
The TGFβ signaling functions 
in inhibition of G1/S phase 
transition and promotion of 
EMT for cell migration. The 
TGFβ signaling can either 
promote or inhibit tumour 
progression, depending on 
tumour types (Hata 2001).  
 
TGFβ signaling positively 
regulates glioma invasiveness 
and metastasis through up-
regulation of matrix 
metalloprotease (MMP) 
expression and EMT. Besides, 
TGFβ signaling down-
regulates MHC class II 
expression in immunocytes, 
endothelial cells and tumour 
cells within glioma. This 
inhibits the migration of 
immunocytes to glioma, which 
allows glioma to escape 
immune response. TGFβ 
signaling generally acted to 
arrest the growth of glioma 
cells in vivo (Wick et al. 
2006).   
TGFβ signaling was reported 
to maintain stemness and 
tumour-initiating ability of 
glioma stem cells through up-
regulating transcription of 
SOX4 and LIF genes 
(Miyazono et al. 2012). 
14-3-3 protein family  
YWHAB  -1.223 YWHAB encodes 14-3-3β, 
which belongs to 14-3-3 
phosphoserine/phosphothreonin
e-binding protein family. Over 
100 proteins, such as 
transcription factors, 
cytoskeletal components and 
proteins involved in signaling 
pathways, have been identified 
as the binding partners of 14-3-
3 protein family. The functions 
of 14-3-3 proteins are involved 
in regulating transportation, 
Increased expression of 14-3-
3β protein was detected in 
human gliomas as compared 
with the surrounding normal 
tissue (Liang et al. 2009). 
Up-regulation of 14-3-3β gene 
and its protein level was 
positively correlated with 
malignancy degree of 
astrocytomas (Cao et al. 2008; 
Yang et al. 2009).    
14-3-3 family proteins are 
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stabilization, interaction and 
phosphorylated state of their 
protein substrates. 
14-3-3β positively regulates 
Raf/Erk pathway through 
interaction with Ras. 14-3-3β 
induces cellular motility, 
spreading and integrin-
associated signaling through 
interaction with integrins 
(Wilker and Yaffe 2004).   
involved in maintaining 
survival and proliferation of 
xenograft of human glioma 
cell lines in mouse model (Cao 
et al. 2010).  
 
YWHAG -3.020 YWHAG encodes 14-3-3γ, 
which belongs to 14-3-3 
phosphoserine/phosphothreonin
e-binding protein family 
(Wilker and Yaffe 2004). The 
general functions of 14-3-3 
protein family were described 
as aformationed (in YWHAB).  
14-3-3 family proteins are 
involved in maintaining 
survival and proliferation of 
xenograft of human glioma 
cell lines in mouse model (Cao 
et al. 2010).  
 
YWHAQ -1.255 YWHAQ encodes 14-3-3θ, 
which belongs to 14-3-3 
phosphoserine/phosphothreonin
e-binding protein family 
(Wilker and Yaffe 2004). The 
general functions of 14-3-3 
protein family were described 
as aformationed (in YWHAB). 
The immunohistochemical 
intensity of 14-3-3θ protein 
was positively correlated with 
malignancy degree of 
gliomas(Cao et al. 2008).     
14-3-3 family proteins are 
involved in maintaining 
survival and proliferation of 
xenograft of human glioma 
cell lines in mouse model (Cao 
et al. 2010).  
N/A represents information not available. 
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